The official news source of the only global association dedicated to the multidisciplinary study of lung cancer
IASLC 2022-23
MEETINGS SCHEDULE

IASLC 2022 North America Conference on Lung Cancer
September 23-25, 2022
Chicago, Illinois
#NACL22

IASLC 2022 Asia Conference on Lung Cancer
October 27-29, 2022
Nara, Japan
#ACL22

IASLC 2023 Latin America Conference on Lung Cancer
January 25-27, 2023
Montevideo, Uruguay
#LALCA23

IASLC 2023 Targeted Therapies of Lung Cancer
February 22-25, 2023
Santa Monica, California
#TTLC23

IASLC 2023 World Conference on Lung Cancer
September 9-12, 2023
Singapore
#WCLC23

IASLC.org/Meetings-Webinars
Scan the QR code for information on upcoming meetings and webinars

CONNECT WITH US
@IASLC
facebook.com/IASLC
@iaslungcancer
linkedin.com/IASLC
youtube.com/IASLC

*Location and dates subject to change
# TABLE OF CONTENTS

## 1. Welcome

- Welcome Messages 7
- Conference Summary 10

## 2. IASLC & WCLC Committees

- International Association for the Study of Lung Cancer (IASLC) 13
- IASLC Board of Directors 2021 – 2023 14
- WCLC Program Committees 14
- International Abstract Review Committees 18

## 3. General Conference Information

- Health & Safety Measures at WCLC 2022 23
- Registration 25
- Virtual Platform and Mobile App 26
- Press and Media 26
- Information for Invited Faculty and Abstract Presenters 28
- Oral Abstract Presenters 29
- Mini Oral Presenters 29
- Poster Presenters 29
- Poster Display Time 30
- Presenters in Attendance 30
- Poster Setup Time 30
- Poster Takedown Time 30
ePosters 30
- Invited Speakers and Discussants 30
- Onsite Services and General Information 31

## 4. Continuing Medical Education

- Continuing Medical Education 37

## 5. IASLC & Conference Awards

- IASLC Distinguished Service Award Winners 41
- IASLC Lectureship Award Winners 44
- WCLC 2022 Early Career Education Award Winners 45
- WCLC 2022 Developing Nation Education Award Winners 46
- IASLC Patient Advocacy Award Winners 47
- IASLC Nurse and Allied Health Professional Award Winners 47
- Cancer Care Team Award Winners 47

## 6. Conference Program

- Program at a Glance 49
- Friday, August 5 51
- Saturday, August 6 52
- Sunday, August 7 53
- Monday, August 8 57
- Tuesday, August 9 61
- On-Demand Sessions 65
- Program by Track 67

## 7. Daily Scientific Program

- Friday, August 5 81
- Saturday, August 6 83
- Sunday, August 7 87
- Monday, August 8 99
- Tuesday, August 9 112
- On-Demand Sessions 122

## 8. Poster Sessions

- Sunday, August 7 125
- Monday, August 8 130
# TABLE OF CONTENTS

## 9. ePosters

| ePosters | 137 |

## 10. Author Index

| Author Index | 171 |

## 11. Maps & Floor Plans

| Messe Wien Exhibition and Congress Center | 219 |
| Foyer D & Hall C | 220 |
| Congress Center | 221 |

## 12. Exhibit & Sponsor Information

| Conference Supporters | 223 |
| Exhibit Floor Plan | 225 |
| Exhibitors Listings | 226 |
| Exhibitor & Supporter Descriptions | 227 |

## 13. Industry Symposia

| Saturday, August 6 | 237 |
| Sunday, August 7 | 240 |
| Monday, August 8 | 241 |

---

**CONFERECE SECRETARIAT**

International Conference Services Ltd. (ICS)

Suite 710, 1201 West Pender Street,
Vancouver, BC, Canada, V6E 2V2

Phone: +1 604 681 2153
Fax: +1 604 681 1049

www.icsevents.com

---

**GLOBAL OFFICES**

Vancouver, Toronto, Denver,
London, Barcelona, Vienna,
Tokyo, Singapore
1 WELCOME
MESSAGES
Sehr geehrte Kongressteilnehmerinnen und -teilnehmer!


Ich bin überzeugt davon, dass Sie sich in Wien wohlfühlen werden. Nicht umsonst wurde unsere Millionenstadt erst jüngst wieder von der International Congress and Convention Association (ICCA) zur beliebtesten Kongressstadt der Welt gewählt.


In diesem Sinne wünsche ich Ihnen einen informativen Kongress und einen abwechslungsreichen Aufenthalt in Wien!

Dear Conference Participants,

As Mayor and Governor of Vienna, it is a great honour and pleasure for me to welcome you to the Austrian capital on occasion of the 2022 World Conference on Lung Cancer.

This large and important network meeting provides thousands of experts from all around the world with an opportunity to exchange and deepen the latest knowledge in the area of thoracic oncology in the interest of the patients.

I am sure that you will enjoy your stay in Vienna as our city has recently been renamed the world’s leading meeting destination in the ranking of the International Congress and Convention Association (ICCA).

There are several reasons for this: with its numerous parks and leisure opportunities Vienna is one of the greenest city in the world but also provides vast cultural offerings such as the current film festival in front of Vienna City Hall.

On this note, I would like to wish you an informative congress and an enjoyable stay in Vienna!

Dr. Michael Ludwig
Bürgermeister und Landeshauptmann von Wien
Mayor and Governor of Vienna
Dear Colleagues from around the World,
Welcome! Willkommen!

The International Association for the Study of Lung Cancer (IASLC) and the WCLC 2022 Conference Chairs take great pleasure to welcome you to the IASLC 2022 World Conference on Lung Cancer (WCLC 2022) in Vienna. In 2016, the WCLC took place in Vienna for the first time, and much has changed since then. The IASLC now has more than 6,000 members from over 100 countries, and the WCLC has become the premier Conference devoted to all aspects of the management of lung cancer and other thoracic malignancies.

The IASLC 2022 WCLC offers four days of intense scientific activity bringing together more than 4,000 delegates from all fields in basic and clinical sciences related to thoracic malignancies. We are proud to have received 1,474 abstracts which are organized in oral, mini oral, and poster sessions. More than 380 invited lectures, 60 oral and 84 mini oral presentations as well as almost 1,000 posters and ePosters will contribute to the exchange of new information among delegates.

We encourage you to participate actively in the discussions, and also to enjoy the beauty of Vienna – its music, architecture, culture, gastronomy – and to immerse yourself in the ancient imperial traditions along with the modern lifestyle.

To facilitate discussions and networking opportunities we have a mobile app (available in App and Google Play Store), that will allow delegates to ask questions and chat with other participants during the sessions.

Don’t miss the opportunity to visit our Poster Viewing reception on Sunday and Monday evening and note that all posters (including ePosters) are available for viewing during networking breaks in the Exhibit Hall.

We also would like to extend our gratitude and thanks to all sponsors and exhibitors for their continued support to WCLC and IASLC. Without them this Conference would not be possible.

Thank you for joining us in Vienna or online. We wish all delegates an enjoyable and productive Conference in this historic and significant region of the world.

Yours sincerely,

Robert Pirker, MD
Austria

Eric Lim, MD
United Kingdom

Françoise Mornex, MD, PhD
France

Silvia Novello, MD, PhD
Italy

Helmut Prosch, MD
Austria
Dear WCLC Participants,

As the President and the CEO of the IASLC, we are thrilled to welcome you to the IASLC 2022 World Conference on Lung Cancer (WCLC 2022) in beautiful Vienna. We are honored that you have chosen to join us for what is sure to be a rigorous, fascinating and collaborative meeting.

This year marks the 23rd WCLC, serving as a unique moment to pause and reflect on how this meeting and the thoracic oncology field have evolved over the past four decades. During that time, we’ve seen extraordinary progress in the field of lung cancer diagnosis and treatment, with the discovery of new biomarkers, new screening techniques and the rise of precision medicine leading to improvements in overall mortality and quality of life for patients.

Throughout its long history, the WCLC has played a strong role in facilitating that progress – providing a platform for sharing cutting-edge research, creating space for new collaborations and partnerships, connecting established researchers with young investigators and serving as a foundational meeting for health care professionals (representing the full spectrum of the multidisciplinary team), patients and advocates who have dedicated their lives to conquering these challenging diseases. This enduring importance is illustrated in how the WCLC has evolved over time – growing from a gathering of approximately 100 colleagues in the late-1970s to an expansive conference that regularly attracts over 7,500 international participants. Such growth in size, impact and relevance did not happen by accident. We are grateful to our previous WCLC conference presidents, organizers and participants. Additionally, we want to honor our past and current board members, as well as former CEOs Heine H. Hansen, Paul A. Bunn Jr. and Fred R. Hirsch for their leadership of the IASLC – from its formative years to the present day.

But while the story of the WCLC is well-established, we know that we must always be looking to the future if we are to continue making inroads in the treatment of thoracic cancers. That is why for WCLC 2022 we are proud to announce that the conference organizers have put together an incredible scientific program that includes almost 1,480 abstracts. We want to thank them for their hard work, and we are especially grateful for the dedication and leadership of our Conference Chairs: Drs. Robert Pirker, Eric Lim, Françoise Mornex, Silvia Novello, and Helmut Prosch. The program is organized in to 17+ specialized tracks and covers the latest advances in biology, prevention, screening, staging and treatment. With its ground-breaking plenaries, interactive breakfast sessions, research abstracts and specialized sessions, we have no doubt that you will find WCLC 2022 to be an exceptional educational experience.

Thank you for attending WCLC 2022 and thank you for your engagement with the IASLC. We hope you enjoy the meeting; have the opportunity to explore Vienna and the surrounding countryside; find opportunities to develop new relationships and collaborations; and, finally gain novel skills and insights that can be applied to improving the lives of thoracic cancer patients – both in your local communities and worldwide. Like so much of what the IASLC does, the success of the WCLC hinges on the passion, commitment and engagement of those who attend it. In short, your participation is one of the main reasons for why the event has remained the world’s leading thoracic cancer conference for over 40 years. We also encourage you to participate in the IASLC Steps Challenge, which is a seven-day virtual walk-a-thon that will raise money to support Research Grants. We appreciate you being a part of our ongoing story.

Heather Wakelee, MD
President, International Association for the Study of Lung Cancer (IASLC)

Karen Kelly, MD
Chief Executive Officer, International Association for the Study of Lung Cancer (IASLC)
ONSITE REGISTRATION

**Foyer D**, Ground Level, (U2 Station Krieau)
Messe Wien Exhibition & Congress Center

**Closest Metro Station**: U2 Station Krieau

<table>
<thead>
<tr>
<th>Day</th>
<th>August 5, 2022</th>
<th>August 6, 2022</th>
<th>August 7, 2022</th>
<th>August 8, 2022</th>
<th>August 9, 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Friday</strong></td>
<td>07:30 - 18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Saturday</strong></td>
<td></td>
<td>07:00 - 20:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sunday</strong></td>
<td></td>
<td></td>
<td>06:30 - 19:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Monday</strong></td>
<td></td>
<td></td>
<td></td>
<td>07:00 - 19:00</td>
<td></td>
</tr>
<tr>
<td><strong>Tuesday</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>07:00 - 16:00</td>
</tr>
<tr>
<td>Event</td>
<td>Location</td>
<td>Dates</td>
<td>Hours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>----------------------------</td>
<td>------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SPEAKER PREVIEW</strong></td>
<td><strong>VIP Lounge D</strong> Messe Wien Exhibition &amp; Congress Center</td>
<td>Friday, August 5, 2022</td>
<td>14:00 - 18:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Saturday, August 6, 2022</td>
<td>07:00 - 19:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sunday, August 7, 2022</td>
<td>07:00 - 16:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monday, August 8, 2022</td>
<td>07:00 - 16:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tuesday, August 9, 2022</td>
<td>07:00 - 15:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EXHIBITION HALL</strong></td>
<td><strong>Hall B</strong> Messe Wien Exhibition &amp; Congress Center</td>
<td>Saturday, August 6, 2022</td>
<td>19:45 - 21:00 (Welcome Reception)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sunday, August 7, 2022</td>
<td>09:45 - 19:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monday, August 8, 2022</td>
<td>09:45 - 19:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tuesday, August 9, 2022</td>
<td>09:45 - 14:15</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COAT &amp; BAGGAGE CHECK</strong></td>
<td><strong>Foyer D</strong> Messe Wien Exhibition &amp; Congress Center</td>
<td>Friday, August 5, 2022</td>
<td>08:00 - 17:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Saturday, August 6, 2022</td>
<td>07:00 - 22:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sunday, August 7, 2022</td>
<td>06:30 - 20:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monday, August 8, 2022</td>
<td>07:00 - 20:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tuesday, August 9, 2022</td>
<td>07:00 - 17:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MEDIA WORK ROOM</strong></td>
<td><strong>Piazza</strong> Messe Wien Exhibition &amp; Congress Center</td>
<td>Saturday, August 6, 2022</td>
<td>08:00 - 18:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sunday, August 7, 2022</td>
<td>08:00 - 18:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monday, August 8, 2022</td>
<td>08:00 - 18:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tuesday, August 9, 2022</td>
<td>08:00 - 18:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IASLC BUSINESS MEETING</strong></td>
<td><strong>Strauss 3</strong> Messe Wien Exhibition &amp; Congress Center</td>
<td>Tuesday, August 9, 2022</td>
<td>10:00 - 10:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IASLC AWARD CEREMONY</strong></td>
<td><strong>Lehar 1</strong> Messe Wien Exhibition &amp; Congress Center</td>
<td>Saturday, August 6, 2022</td>
<td>17:00 - 17:45</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
International Association for the Study of Lung Cancer (IASLC)

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes nearly 8,000 lung cancer specialists in over 100 countries.

IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. IASLC publishes the Journal of Thoracic Oncology, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.

The IASLC mission is:

» To embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies.
» To provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public
» To use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world.

IASLC & WCLC COMMITTEES

Karen Kelly
Chief Executive Officer

John Skadow
Chief Financial Officer

Matt Yeingst
Chief Development Officer

Tessa Baxter
ILC Foundation Coordinator / Project Manager

Becky Bunn
Senior Advisor, Scientific Relations

Mya Burns
Associate Director, Conferences

Casey Connolly
Scientific Affairs Specialist

Bailey Creamer
Editorial Assistant

Kathy Doherty
Director, Human Resources

Ken Harrell
Database Administrator

O’Ryan Jackson
Administrative Assistant

Vun Sin Lim
Editorial Consultant JTO Clinical and Research Reports

Sara Lindsey Patton
Patient Advocacy Specialist

Katie Maher
Member Experience Specialist

Sunhee Malinowski
Account Manager

Jan Mazotti
Associate Director, Marketing and Communications

Karen Muth
Executive Assistant and Board Liaison

Rodrigo Sagastegui
Marketing Specialist

Mary Todd
Managing Editor, JTO & JTO CRR

Kelsey Wood
Associate Director, Member Experience

Kelly Wright
Member Experience Coordinator

Murry Wynes, PhD
Senior Advisor, Scientific Affairs

Kexin Yu
Accountant

Flavia Zarcula
Corporate Relations Manager
IASLC BOARD OF DIRECTORS 2021 – 2023

OFFICERS:

President
Heather Wakelee, United States

Past-President
Tetsuya Mitsudomi, Japan

President-Elect
Paul Van Schil, Belgium

Secretary
Andrea Bezjak, Canada

Treasurer
Erik Thunnissen, Netherlands

Chief Executive Officer
Karen Kelly, United States

BOARD OF DIRECTORS:

Joachim Aerts, Netherlands
Carlos Gil Moreira Ferreira, Brazil
Jhanelle Gray, United States
Roy Herbst, United States
Young Tae Kim, South Korea
Morten Quist, Denmark
Lecia Sequist, United States
Ming-Sound Tsao, Canada
Paula Ugalde, United States
Caicun Zhou, China

WCLC PROGRAM COMMITTEES

WCLC CONFERENCE CHAIRS:
Robert Pirker, Austria
Eric Lim, United Kingdom
Françoise Mornex, France
Silvia Novello, Italy
Helmut Prosch, Austria

EARLY DETECTION AND SCREENING:
Mario Silva, Chair, Italy
Monica Castro, Co-Chair, Argentina
Ivy Elkins, United States
John Field, United Kingdom
Anna Kerpel-Fronius, Hungary
Annette McWilliams, Australia
Ugo Pastorino, Italy
Nir Peled, Israel
Ricardo Sales Santos, Brazil

EARLY STAGE NON-SMALL CELL LUNG CANCER – NEOADJUVANT AND ADJUVANT SYSTEMIC THERAPY (MULTI-MODALITY TREATMENT, IMMUNOTHERAPY, MOLECULAR TARGETED TREATMENTS):
Mariano Provencio, Chair, Spain

EARLY STAGE NON-SMALL CELL LUNG CANCER – RADIOTherapy AND OTHER ABLATIVE TECHNIQUES:
Natasha Leighl, Co-Chair, Canada
Jamie Chaft, United States
Rafal Dzidziusko, Poland
Enriqueta Felip, Spain
Nicolas Girard, France
Stephanie Saw, Singapore
Yi Long Wu, China
Caicun Zhou, China

EARLY STAGE NON-SMALL CELL LUNG CANCER – RADIOTHERAPY AND OTHER ABLATIVE TECHNIQUES:
Lizza Hendriks, Chair, Netherlands
Shankar Siva, Co-Chair, Australia
Yong Chan Ahn, South Korea
Kevin Chua Lee Min, Singapore
Yasushi Nagata, Japan
Umberto Ricardi, Italy
Rocco Trisolini, Italy
Maria Werner-Wasik, United States
EARLY STAGE NON-SMALL CELL LUNG CANCER – SURGERY:
Masahiro Tsuboi, Chair, Japan
Giulia Veronesi, Co-Chair, Italy
Alessandro Brunelli, United Kingdom
Jessica Donington, United States
Mir Ali Reza Hoda, Austria
Young Tae Kim, South Korea
Katherine Kuhns, United States
Valerie Rusch, United States
Alan Sihoe, Hong Kong
Jonathan Spicer, Canada
Ricardo Terra, Brazil
Wen-Zhao Zhong, China
Jie Wang, China

EPIDEMIOLOGY:
Paolo Boffetta, Chair, Italy
Christine Berg, Co-Chair, United States
Hermann Brenner, Germany
David Christiani, United States
Rayjean Hung, Canada
Mattias Johansson, France
Qing Lan, United States
Adonina Tardón, Spain

GLOBAL HEALTH, HEALTH SERVICES RESEARCH, AND HEALTH ECONOMICS:
Clarissa Mathias, Chair, Brazil
Suresh Senan, Co-Chair, Netherlands
Fabrice Barlesi, France
Digambar Behera, India
Peter Berzince, Slovakia
Caleb Egwuenu, Nigeria
Tewodros Haile, Ethiopia
Mohana Roy, United States
Martin Sebastian, Germany
Chunxia Su, China

LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER – CHEMORADIOThERAPY AND RadioTherAPY:
Andrea Bezjak, Chair, Canada
Matthias Guckenberger, Co-Chair, Switzerland
Dirk de Ruysscher, Netherlands
Wilfried Eberhardt, Germany
Ken Harada, Japan
Ross Soo, Singapore
Anna Wrona, Poland
Milada Zemanova, Czech Republic
Zheng-Fei Zhu, China

LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER – NEOADJUVANT AND ADJUVANT THERAPY:
Luis Paz-Ares, Chair, Spain
Virginie Westeel, Co-Chair, France
Oscar Arrieta, Mexico
Christophe Dooms, Germany
Maximilian Hochmair, Austria
Julia Judd, United States
Thomas Newsom-Davis, United Kingdom
Qing Zhou, China

LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER - SURGERY:
Shanda Blackmon, Chair, United States
Andrea Bille, Co-Chair, United Kingdom
Margaret Blair Marshall, United States
Oleg Pikin, Russia
Geatano Rocco, United States
Brendon Stiles, United States
Hauke Winter, Germany

MANAGEMENT OF LUNG CANCER IN THE ERA OF COVID-19:
Marina Garassino, Chair, United States
Christian Grohe, Co-Chair, Germany
Alfredo Addeo, Switzerland
Leanne Ashrafian, United Kingdom
Jackie Fenemore, United Kingdom
Abdul Rahman Jazieh, Saudi Arabia
Eldsmir Mascarenhas, Brazil

MESOTHELIOMA, THYMOMA, AND OTHER THORACIC MALIGNANCIES:
Paul Baas, Chair, Netherlands
Dean Fennell, Co-Chair, United Kingdom
Leah Backhus, United States
WCLC PROGRAM COMMITTEES

Paolo Bironzo, Italy
Joseph Friedberg, United States
Ritu Gill, United States
Raffit Hassan, United States
Marko Jakopovic, Croatia
Anna Nowak, Australia
Jordi Remon, Spain
Enrico Ruffini, Italy
Arnaud Scherpereel, France
Leah Taylor, United Kingdom
David Waller, United Kingdom

METASTATIC NON-SMALL CELL LUNG CANCER – IMMUNOTHERAPY:
Pilar Garrido, Chair, Spain
Sanjay Popat, Co-Chair, United Kingdom
Charu Aggarwal, United States
Michael Boyer, Australia
Federico Cappuzzo, Italy
Shun Lu, China
Martin Reck, Germany
Kostas Syrigos, Greece
Daniel Tan, Singapore

METASTATIC NON-SMALL CELL LUNG CANCER – MOLECULAR TARGETED TREATMENTS:
Benjamin Besse, Chair, France
Lorenza Landi, Co-Chair, Italy
Joachim Aerts, Netherlands
Odd Terje Brustugun, Norway
Andrew Ciupek, United States
Baohui Han, China
Pasi Jänne, United States
Helena Linardou, Greece
Laura Mezquita, Spain
Amanda Tufman, Germany
Saulius Cicenas, Lithuania
Simon Ekman, Sweden
Yesim Eralp, Turkey
Jorge Gomez, United States
Hans Hoffmann, Germany
Isabelle Opitz, Switzerland
Ben Slotman, Netherlands

METASTATIC NON-SMALL CELL LUNG CANCER – PALLIATIVE CHEMOTHERAPY:
Giorgio Scagliotti, Chair, Italy
Navneet Singh, Co-Chair, India
Antonio Araujo, Portugal
Sofia Baka, Greece
Khaled Kamal, Egypt

METASTATIC NON-SMALL CELL LUNG CANCER – PALLIATIVE RADIOTHERAPY:
Fiona Hegi-Johnson, Chair, Australia
Sara Ramella, Co-Chair, Italy
Jeff Bradley, United States
Karim Dieckmann, Austria
Jill Feldman, United States
Andrea Filippi, Italy
Kristin Higgins, United States
Billy Loo, United States
Alexandra Louie, Canada

NURSING AND ALLIED HEALTH PROFESSIONALS:
Maria Ftanou, Chair, Australia
Michelle Turner, Co-Chair, United States
Somaya Abou-Abdou, Egypt
Melissa Culligan, United States
Jacqui Frowen, Australia
Nazanin Nouriany, Canada
Morten Quist, Denmark
Alison Homes Tisch, United States

PALLIATIVE AND SUPPORTIVE CARE:
Alberto Chiappori, Chair, United States
Jose Belderbos, Co-Chair, Netherlands
PATIENT ADVOCACY:
Christina Sit, Chair, Canada
Stefania Vallone, Co-Chair, Spain
Anne-Marie Baird, Ireland
Lorraine Dallas, United Kingdom
Merel Hennink, Netherlands
Shani Shilo, Israel
Ewelina Szmytke, Poland

PATHOLOGY:
Sylvia Lantuejoul, Chair, France
Keith Kerr, Co-Chair, United Kingdom
Sanja Dacic, United States
Patrick Micke, Sweden
Yuko Minami, Japan
Andrew Nicholson, United Kingdom
Masayuki Noguchi, Japan
Helmut Popper, Austria
Fernando Lopez Rios, Spain
Ales Ryska, Czech Republic
Erik Thunnissen, Netherlands

PULMONOLOGY, RADIOLOGY AND STAGING:
Jin Mo Goo, Chair, South Korea
Daniele Gompelmann, Co-Chair, Austria
Hisao Asamura, Japan
Wentao Fang, China
Kwun Meng Fong, Australia
Rudolf Huber, Germany
Ankush Jajodia, India
Edith Marom, Israel
Lucia Viola, Colombia

SMALL CELL LUNG CANCER AND NEURO-ENDOCRINE TUMOURS:
Raffaele Califano, Chair, United Kingdom
Melissa L. Johnson, Co-Chair, United States
Andrea Ardizzoni, Italy
Corinne Favre-Finn, United Kingdom
Guyla Ostoros, Hungary
Upal Basu Roy, United States
Miyako Satouchi, Japan
Egbert Smit, Netherlands
Jens Benn Sorensen, Denmark
Sumitra Thongprasert, Thailand

TOBACCO CONTROL AND RISK REDUCTION:
Jacek Jassem, Chair, Poland
Bill Evans, Co-Chair, Canada
May Myat Cho, Thailand
Nagla Abdel Karim, United States
Judith (Jodi) Prochaska, United States
Matthew Steliga, United States
Emily Stone, Australia
Ning Wu, China
Xiuyi Zhi, China

TUMOUR BIOLOGY AND BIOMARKERS:
Caroline Dive, Chair, United Kingdom
Kurt Schalper, Co-Chair, United States
Prasad Adusumilli, United States
Martin Filipits, Austria
Philippe Joubert, Canada
Umberto Malapelle, Italy
Amy Moore, United States
Kenneth O’Byrne, Australia
Sandra Ortiz-Cuaran, France
Christian Rolfo, United States
Jie Wang, China
### INTERNATIONAL ABSTRACT REVIEW COMMITTEES

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nagla Abdel Karim</td>
<td>United States</td>
</tr>
<tr>
<td>Somaya Abou-Abdou</td>
<td>Egypt</td>
</tr>
<tr>
<td>Alfredo Addeo</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Prasad Adusumilli</td>
<td>United States</td>
</tr>
<tr>
<td>Joachim Aerts</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Charu Aggarwal</td>
<td>United States</td>
</tr>
<tr>
<td>Yong Chan Ahn</td>
<td>South Korea</td>
</tr>
<tr>
<td>Mara Antonoff</td>
<td>United States</td>
</tr>
<tr>
<td>Antonio Araujo</td>
<td>Portugal</td>
</tr>
<tr>
<td>Andrea Ardizzoni</td>
<td>Italy</td>
</tr>
<tr>
<td>Oscar Arrieta</td>
<td>Mexico</td>
</tr>
<tr>
<td>Hisao Asamura</td>
<td>Japan</td>
</tr>
<tr>
<td>Leanne Ashrafian</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Fredrick Asirwa</td>
<td>Kenya</td>
</tr>
<tr>
<td>Paul Baas</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Leah Backhus</td>
<td>United States</td>
</tr>
<tr>
<td>Anne-Marie Baird</td>
<td>Ireland</td>
</tr>
<tr>
<td>Haval Balata</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>David Baldwin</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Upal Basu Roy</td>
<td>United States</td>
</tr>
<tr>
<td>Mary Beth Beasley</td>
<td>United States</td>
</tr>
<tr>
<td>Digambar Behera</td>
<td>India</td>
</tr>
<tr>
<td>Jose Belderbos</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Sabina Berezsowska</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Christine Berg</td>
<td>United States</td>
</tr>
<tr>
<td>Eric Bernicker</td>
<td>United States</td>
</tr>
<tr>
<td>Pietro Bertoglio</td>
<td>Italy</td>
</tr>
<tr>
<td>Peter Berzinec</td>
<td>Slovakia</td>
</tr>
<tr>
<td>Ricardo Beyruti</td>
<td>Brazil</td>
</tr>
<tr>
<td>Semra Bilaceroglu</td>
<td>Turkey</td>
</tr>
<tr>
<td>Andrea Bille</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Paolo Bironzo</td>
<td>Italy</td>
</tr>
<tr>
<td>Paolo Boffetta</td>
<td>Italy</td>
</tr>
<tr>
<td>Alain Borczuk</td>
<td>United States</td>
</tr>
<tr>
<td>Andrea Borondy Kitts</td>
<td>United States</td>
</tr>
<tr>
<td>Souheil Boubia</td>
<td>France</td>
</tr>
<tr>
<td>Michael Boyer</td>
<td>Australia</td>
</tr>
<tr>
<td>Jeff Bradley</td>
<td>United States</td>
</tr>
<tr>
<td>Luka Bric</td>
<td>Austria</td>
</tr>
<tr>
<td>Emilio Bria</td>
<td>Italy</td>
</tr>
<tr>
<td>Caitlin Broderick</td>
<td>Australia</td>
</tr>
<tr>
<td>Alessandro Brunelli</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Odd Terje Brustugun</td>
<td>Norway</td>
</tr>
<tr>
<td>Lukas Bubendorf</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Guoping Cai</td>
<td>United States</td>
</tr>
<tr>
<td>Raffaele Califano</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Federico Cappuzzo</td>
<td>Italy</td>
</tr>
<tr>
<td>Giuseppe Cardillo</td>
<td>Italy</td>
</tr>
<tr>
<td>Monica Castro</td>
<td>Argentina</td>
</tr>
<tr>
<td>Milena Cavic</td>
<td>Serbia</td>
</tr>
<tr>
<td>Joe Y. Chang</td>
<td>United States</td>
</tr>
<tr>
<td>Andreas Charalambous</td>
<td>Cyprus</td>
</tr>
<tr>
<td>Alberto Chiappori</td>
<td>United States</td>
</tr>
<tr>
<td>May Myat Cho</td>
<td>Thailand</td>
</tr>
<tr>
<td>Ricardo Terra</td>
<td>United States</td>
</tr>
<tr>
<td>Teh-Ying Chou</td>
<td>Taiwan</td>
</tr>
<tr>
<td>Kevin Chua Lee Min</td>
<td>Singapore</td>
</tr>
<tr>
<td>Jin-Haeng Chung</td>
<td>South Korea</td>
</tr>
<tr>
<td>Saulius Cicenas</td>
<td>Lithuania</td>
</tr>
<tr>
<td>Andrew Ciupeck</td>
<td>United States</td>
</tr>
<tr>
<td>Wendy Cooper</td>
<td>Australia</td>
</tr>
<tr>
<td>Sanja Dacic</td>
<td>United States</td>
</tr>
<tr>
<td>Roselle De Guzman</td>
<td>Philippines</td>
</tr>
<tr>
<td>Marc de Perrot</td>
<td>Canada</td>
</tr>
<tr>
<td>Dirk de Ruysscher</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Karin Dieckmann</td>
<td>Austria</td>
</tr>
<tr>
<td>Anne-Marie Dingemans</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Caroline Dive</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Jessica Donington</td>
<td>United States</td>
</tr>
<tr>
<td>Christophe Dooms</td>
<td>Germany</td>
</tr>
<tr>
<td>Carolyn Dresler</td>
<td>United States</td>
</tr>
<tr>
<td>Elizabeth Dudnik</td>
<td>Israel</td>
</tr>
<tr>
<td>Mary Duffy</td>
<td>Australia</td>
</tr>
<tr>
<td>Wilfried Eberhardt</td>
<td>Germany</td>
</tr>
<tr>
<td>Simon Ekman</td>
<td>Sweden</td>
</tr>
<tr>
<td>Ivy Elkins</td>
<td>United States</td>
</tr>
<tr>
<td>Yesim Eralp</td>
<td>Turkey</td>
</tr>
<tr>
<td>Jeremy John Erasmus</td>
<td>United States</td>
</tr>
<tr>
<td>Bill Evans</td>
<td>Canada</td>
</tr>
<tr>
<td>Wentao Fang</td>
<td>China</td>
</tr>
<tr>
<td>Nicholas Faris</td>
<td>United States</td>
</tr>
<tr>
<td>Babalola Faseru</td>
<td>United States</td>
</tr>
</tbody>
</table>
Program | IASLC 2022 World Conference on Lung Cancer

Margaret Blair Marshall, United States
Eldsamira Mascarenhas, Brazil
Clarissa Mathias, Brazil
José Matilla, Spain
Daisuke Matsubara, Japan
Fiona McDonald, United Kingdom
Sara McLaughlin-Barrett, Australia
Annette McWilliams, Australia
Laura Mezquita, Spain
Patrick Micke, Sweden
Andrzej Milewski, Poland
Yuko Minami, Japan
Mari Mino-Kenudson, United States
Deebya Mishra, Nepal
Tetsuya Mitsudomi, Japan
Drew Moghanaki, United States
Luis Montuenga, Spain
Amy Moore, United States
Carlos Gil Moreira Ferreira, Brazil
Merel Nissenberg Mountain, United States
Sudish Murthy, United States
Yasushi Nagata, Japan
Ursula Nestle, Switzerland
Thomas Newsom-Davis, United Kingdom
Andrew Nicholson, United Kingdom
Kim Norris, United States
Nazanin Nouriany, Canada
Junichi Soh, Japan
Anna Nowak, Australia
Kenneth O’Byrne, Australia
Emma O’Dowd, United Kingdom
Sandra Ortiz-Cuaron, France
Raymond U. Osarogiabon, United States
Gyula Ostoros, Hungary
Marcin Ostrowski, Poland
Harvey Pass, United States
Manali Patel, United States
Hofman Paul, France
Luis Paz Ares, Spain
Tobias Peikert, United States
Nir Peled, Israel
Oleg Pikin, Russia
Claudia Poleri, Argentina
Sanjay Popat, United Kingdom
Helmut Popper, Austria
Helmut Prosch, Austria
Mariano Provencio, Spain
Paul Martin Putora, Switzerland
Morten Quist, Denmark
Kavitha Ramchandran, United States
Sara Ramella, Italy
Ramón Rami-Porta, Spain
Martin Reck, Germany
Natasha Rekhtman, United States
Jordi Remon, Spain
Joshua Reuss, United States
Umberto Ricardi, Italy
Maureen Rigney, United States
Andreas Rimner, United States
Geatano Rocco, United States
Anja Roden, United States
Christian Rolfo, United States
Mohana Roy, United States
John Ruckdeschel, United States
Enrico Ruffini, Italy
Valerie Rusch, United States
Ales Ryska, Czech Republic
Witold Rzyman, Poland
Ricardino Sales Santos, Brazil
Rachel Sanborn, United States
Jacob Sands, United States
Beth Sandy, United States
Edgardo Santos, United States
Anjali Saqi, United States
Miyako Satouchi, Japan
Stephanie Saw, Singapore
Giorgio Scagliotti, Italy
Kurt Schalper, United States
Arnaud Scherpereel, France
Jun Nakajima, Italy
Martin Sebastian, Germany
Yoshitaka Sekido, Japan
Suresh Senan, Netherlands
Claudia Henschke, Spain
Anant Mohan, United States
Abhishek Shankar, India
Shani Shilo, Israel
Hyo Sup Shim, South Korea
Lynette Sholl, United States
Elaine Shum, United States
Alan Siho, Hong Kong
Mario Silva, Italy
Navneet Singh, India
Christina Sit, Canada
Shankar Siva, Australia
Ben Slotman, Netherlands
Matthew Smeltzer, United States
Egbert Smit, Netherlands
Ross Soo, Singapore
Jonathan Spicer, Canada
Matthew Steliga, United States
Daniel Sterman, United States
Conor Steuer, United States
Brendon Stiles, United States
Emily Stone, Australia
Chunxia Su, China
Francisco Suarez, Chile
J. Marie Suga, United States
Kostas Syrigos, Greece
Adonina Tardon, Spain
Erik Thunnissen, Netherlands
Betty Tong, United States
William Travis, United States
Rocco Trisolini, Italy
Ming Tsao, Canada
Yasuhiro Tsutani, Japan
Amanda Tufman, Germany
Akif Turna, Turkey
James Huang, United States
Michelle Turner, United States
Paula Ugalde, Canada
Stefania Vallone, Italy
Jan Van Meerbeeck, Belgium
Paul Van Schil, Belgium
Luigi Ventura, Italy
Giulia Veronesi, Italy
Lucia Viola, Colombia
Jan Von Der Thussen, Netherlands
David Waller, United Kingdom
Jie Wang, China
Shun-ichi Watanabe, Japan
Stefan Watzka, Austria

Annikka Weissferdt, United States
Virginie Westeel, France
Paul Wheatley-Price, Canada
Kahren White, Australia
Hauke Winter, Germany
Ignacio Wistuba, United States
Ning Wu, China
Yi Long Wu, China
Chi-Fu Yang, United States
Gail Darling, United States
Dawei Yang, China
David Yankelevitz, United States
Yasushi Yatabe, Japan
Sonam Puri, United States
Milada Zemanova, Czech Republic
Caicun Zhou, China
Qing Zhou, China
Zheng-fei Zhu, China
GENERAL INFORMATION
HEALTH & SAFETY MEASURES AT WCLC 2022

WCLC 2022 will be hosted as an in-person meeting in Vienna, Austria at the Messe Wien Convention & Exhibition Center. The health and safety of all our stakeholders are of the utmost importance. Although we are excited to welcome you to Vienna, all necessary precautions will be taken to ensure a safe environment throughout the Conference.

The following measures are in place and enforced on-site to achieve this commitment (applicable to all staff, delegates, exhibitors, sponsors, and guests):

Vaccination
All in-person attendees at WCLC 2022 must be fully vaccinated against COVID-19 by the time of the Conference. Fully vaccinated refers to completing the approved first 2 vaccines, as per the guidelines of their country of residence.

All participants, including attendees, speakers, staff, and suppliers will be asked to present proof of full vaccination and photo ID with a matching name prior to entry into the Conference Venue.

Access will be denied if proper proof of full vaccination is not provided. Proof of a negative test will NOT be a substitute for vaccination. Accepted Forms of Proof: (Note: Proof of vaccination must match the Attendee’s name)
• Copy of an official certificate from your Country/State/Province
• Photo of the official certificate
• Digital PDF or document of the official certificate on a mobile device
• Accepted Vaccines: as per approved guidelines from the country of residence

If you cannot or choose not to comply with the IASLC health and safety protocols, or if you are unable to come to Vienna, please join us virtually for live-streamed sessions, Q&A, and other interactive features.

If you will not be fully vaccinated by the time of the Conference and are registered for the in-person meeting, you may change your registration to virtual-only by sending an email request to WCLC2022-registration@icsevents.com.

Mask Requirement
Masks will be required to be worn at all times in all WCLC 2022 session rooms and at networking events.

The only time masks may be removed is when you are eating, drinking, taking medication, or presenting. The mask mandate will be strictly enforced by security. There will be masks available at the Registration Desk, located in Foyer D of the Messe Convention Centre & Exhibition Center for the convenience of attendees.

We strongly recommend all participants administer self-tests at least 24 hours prior to coming on-site to the venue. An onsite testing facility will be available free of charge to all delegates.

By registering to attend, you agree that:
• You will not attend if you have any COVID-19 symptoms
• If during your attendance you develop any COVID-19 symptoms, you will immediately:
  • Self-isolate;
    ○ Comply with all local/national government restrictions; and
    ○ Inform the WCLC 2022 Conference Secretariat by email (WCLC2022-Registration@icsevents.com).

IASLC and their suppliers will in their best effort, provide a safe environment to meet. It is expected that all participants will follow the measures to help reduce the risk.
THE BiTE® UNIVERSE IS EXPANDING
WITH THE GOAL OF TARGETING MULTIPLE TUMOR TYPES

Amgen is contributing to the advancement of cancer treatment with the investigational BiTE® immuno-oncology platform. This versatile technology is engineered to deliver off-the-shelf therapies that direct patients' own T cells to target tumor-associated antigens, activating their cytotoxic potential.1,2 Currently being investigated in multiple tumor types and extended half-life therapies, BiTE® technology is designed to close the space between patients' T cells and tumors.1,3

Learn more about the BiTE® platform by visiting the Amgen medical booth

BCMA, B-cell maturation antigen; CD, cluster of differentiation; DLL3, delta-like ligand 3; FLT3, FMS-like tyrosine kinase 3; MUC17, mucin 17; PSMA, prostate-specific membrane antigen.

References:
REGISTRATION LOCATION

**Foyer D, Ground Level, Messe Wien Exhibition & Congress Center**

REGISTRATION MATERIALS:

Registration Materials Include:

- Name Badge
- Ribbons (if applicable)
- Mini Pocket Program
- Printed Conference Program (only if printed version selected during registration)
- Public Transportation Ticket

NAME BADGES:

Delegates and guests are requested to wear their name badge at all times in order to participate in the Scientific Sessions, Networking Events and Exhibition.

DELEGATE HELP AND VISIT VIENNA DESK

**Foyer D, Ground Level, Messe Wien Exhibition & Congress Center**

Visit the Help Desk for Information on the scientific sessions and networking events. Information on Vienna tours and attractions, restaurant reservations and general information can be found at the Visit Vienna Desk.

HOURS OF OPERATION

<table>
<thead>
<tr>
<th>Day, Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, August 5</td>
<td>07:30 - 18:00</td>
</tr>
<tr>
<td>Saturday, August 6</td>
<td>07:00 - 20:30</td>
</tr>
<tr>
<td>Sunday, August 7</td>
<td>06:30 - 19:00</td>
</tr>
<tr>
<td>Monday, August 8</td>
<td>07:00 - 19:00</td>
</tr>
<tr>
<td>Tuesday, August 9</td>
<td>07:00 - 16:00</td>
</tr>
</tbody>
</table>
### VIRTUAL PLATFORM / MOBILE APP HELP DESK

- **Foyer D**, Ground Level, Messe Wien Exhibition & Congress Center

Visit the Virtual Platform and Mobile App Help Desk for information on watching sessions online, asking questions, sending connection requests, or downloading conference resources.

If you have log-in related questions, you can get help here as well.

### HOURS OF OPERATION

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Friday</strong></td>
<td>07:30 - 18:00</td>
</tr>
<tr>
<td>August 5, 2022</td>
<td></td>
</tr>
<tr>
<td><strong>Saturday</strong></td>
<td>07:00 - 20:30</td>
</tr>
<tr>
<td>August 6, 2022</td>
<td></td>
</tr>
<tr>
<td><strong>Sunday</strong></td>
<td>06:30 - 19:00</td>
</tr>
<tr>
<td>August 7, 2022</td>
<td></td>
</tr>
<tr>
<td><strong>Monday</strong></td>
<td>07:00 - 19:00</td>
</tr>
<tr>
<td>August 8, 2022</td>
<td></td>
</tr>
<tr>
<td><strong>Tuesday</strong></td>
<td>07:00 - 16:00</td>
</tr>
<tr>
<td>August 9, 2022</td>
<td></td>
</tr>
</tbody>
</table>

### PRESS AND MEDIA / MEDIA WORK ROOM

- **Piazza**, Upper Level, Messe Wien Exhibition & Congress Center

### HOURS OF OPERATION

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Saturday</strong></td>
<td>08:00 - 18:00</td>
</tr>
<tr>
<td>August 6, 2022</td>
<td></td>
</tr>
<tr>
<td><strong>Sunday</strong></td>
<td>08:00 - 18:00</td>
</tr>
<tr>
<td>August 7, 2022</td>
<td></td>
</tr>
<tr>
<td><strong>Monday</strong></td>
<td>08:00 - 18:00</td>
</tr>
<tr>
<td>August 8, 2022</td>
<td></td>
</tr>
<tr>
<td><strong>Tuesday</strong></td>
<td>08:00 - 18:00</td>
</tr>
<tr>
<td>August 9, 2022</td>
<td></td>
</tr>
</tbody>
</table>

### PRESS CONFERENCES

- **Schubert 5/6**, Upper Level, Messe Wien Exhibition & Congress Center

### SCHEDULE TIME

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sunday</strong></td>
<td>10:05 - 10:45</td>
</tr>
<tr>
<td>August 7, 2022</td>
<td></td>
</tr>
<tr>
<td><strong>Monday</strong></td>
<td>10:25 - 11:00</td>
</tr>
<tr>
<td>August 8, 2022</td>
<td></td>
</tr>
<tr>
<td><strong>Tuesday</strong></td>
<td>10:05 - 10:45</td>
</tr>
<tr>
<td>August 9, 2022</td>
<td></td>
</tr>
</tbody>
</table>

Press releases will be posted on the Conference website at the conclusion of each Conference day. The Press Conferences will be live streamed. The link will be made available to all registered Press & Media Representatives.
PRESS AND MEDIA REGISTRATION AND ACCESS
Press and Media passes are issued to journalists, including photographers and freelance journalists, after providing proof of accreditation. Pre-registration form and proof of accreditation must be submitted prior to the Conference. Press and Media representatives are required to check in at the regular Registration Counters when they arrive on-site.

PRESS RELEASE POLICY
Press releases that feature data or events involving the WCLC should include the full name of the meeting, specifically: IASLC 2022 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer. Further, we respectfully request that the release include the official conference hashtag: #WCLC22. To learn more, please visit www.iaslc.org.

Abstracts selected for inclusion in the WCLC press program will be kept under embargo until either the time of the presentation or the beginning of the WCLC press conference in which it is presented, whichever comes first. All abstracts covered in the WCLC press program will receive a press release.

All other abstracts have been available since Tuesday, July 12, 2022 on the Conference website at wclc2022.iaslc.org

All abstracts, including those presented in the press program, will be published as an online supplement to the Journal of Thoracic Oncology (JTO).

SOCIAL MEDIA POLICY
Organizations may use social media to disseminate news and information regarding abstracts being presented at the WCLC. All information distributed through social media channels must adhere to the IASLC’s embargo policy. Please use the IASLC’s World Conference hashtag, #WCLC22 in any social media posts. Members of the media are permitted to photograph and transmit/share on any social media platform any presentation’s slides without approval from the presenter and/or the IASLC unless explicitly forbidden. However, authors retain the copyright to their full slide presentations and all copyright laws.

INTERVIEW POLICY
For an in-person meeting, all interviews outside of press conferences must be arranged in advance with interviewees and must take place in IASLC approved and designated rooms, with an IASLC meeting backdrop. No last-minute or hallway interviews are permitted inside the conference facility, IASLC staff are available to help schedule interviews and a limited number of designated interview rooms are available, complimentary to credentialed media and may be scheduled for up to two hours. Sign up is required.

For questions, please see the IASLC staff in the Media Room.

Media organizations filming a large amount of video content must contact the IASLC in advance CMartin@DavidJamesGroup.com and must meet the following requirements:
1. All filming must take place in one designated spot (contact the IASLC for that location).
2. No filming of sessions is allowed.
3. All filming must be done in front of backdrop which includes any of the below linked images of the IASLC logo. This may be co-branded to have your logo as well, as long as the IASLC logo is visible in the final footage.
4. All filming must include the official name of the Conference “IASLC 2022 World Conference on Lung Cancer” in the questions asked of the interviewees, and acknowledgement must be given to the fact that the interview was conducted at the WCLC.
5. Any footage placed on your website must include a reference to the IASLC World Conference on Lung Cancer.
6. If possible, you may also include the Conference hashtag: #WCLC22
VIDEO, PHOTOGRAPHY AND AUDIO RECORDING POLICY
Photography, videotaping and audio recording are allowed for news coverage only in the following area/events:
• Press Conference / Media Availability
• Interview rooms
• Other designated locations (with IASLC approval)
• Recording in common areas requires permission and/or an IASLC staff escort

LIVE COVERAGE POLICY
We welcome the coverage of the event. Please contact us ahead of time to arrange this. An authorized representative of any press vehicle requiring electrical service or external cabling must be available to coordinate logistical details with the IASLC. Live coverage is restricted to designated areas or an area approved by IASLC staff and is on a first-come, first-served basis.

PRESENTATION SLIDES AND POSTER RELEASE POLICY
All presentation slides including audio or video recordings as well as the electronic poster files will be released on the virtual platform within 24 hours after the presentation, but only after the talk or the poster has been presented at the Conference.

MEDIA LIST POLICY
The IASLC does not release media lists for the IASLC World Conference on Lung Cancer.

INFORMATION FOR INVITED FACULTY AND ABSTRACT PRESENTERS

DISCLOSURE INFORMATION
All invited speakers as well as oral and mini oral abstract presenters must include a slide with their financial disclosure information. Without a disclosure slide you will not be allowed to present!

PRESENTATION SLIDE TEMPLATE
All invited speakers as well as oral and mini oral abstract presenters are strongly encouraged to use the IASLC/WCLC presentation slide template for their presentation.

LANGUAGE GUIDE
Please review the IASLC Language Guide and ASCO Language of Respect to review guidelines on presentation best practices to promote the use of language that respects the dignity of people diagnosed with lung cancer.

To review the guideline, please visit at https://wclc2022.iaslc.org/presenter-resources/

REGISTRATION
Invited Faculty
‘Invited Faculty’ Registration Counter
(Session Chairs, Invited Speakers, Abstract Discussants)

Abstract Presenters
Pre-Registered Delegates Counter
All invited speakers as well as oral and mini oral abstract presenters are encouraged to report to the Speaker Preview Room & Lounge at least 24 hours prior to their scheduled presentation to preview their slides and ensure all fonts appear as expected and all sound/video clips are working properly.

Due to CME regulations, changes to previously submitted and reviewed slides can only be allowed in exceptional circumstances.

**NO FILE SUBMISSIONS WILL BE ACCEPTED IN THE SESSION ROOMS.**

**ORAL ABSTRACT PRESENTERS**

- You will have a total of 10 minutes; 8 minutes of presentation, followed by 2 minutes time for questions from the audience. Time limits will be strictly enforced.

**MINI ORAL ABSTRACT PRESENTERS**

- You will have a total of 5 minutes. Time limits will be strictly enforced.
- You are asked to prepare a PPT Presentation with maximum 5 slides in 16:9 format (not including title, author and disclosure slide).
- Please be in room for your session 10 minutes before the start time of the session. The session Chairs will start and end strictly on time.
- The presenting author must control all content.
- Slides, abstracts, and handouts cannot contain advertising, QR codes, corporate logos, trade names, or product-group messages of an ACCME-defined ineligible company.
- All presenters MUST include statement disclosing any conflict of interest related to your abstract as the first slide of your presentation.

**POSTER PRESENTERS**

Poster Presenters are asked to prepare and print their poster(s) for display at the Conference (double sided cohesive tapes will be provided in the Exhibit Hall). The maximum poster size is: 1900mm (wide) x 1040mm (high) – landscape format. Poster Presentations/Boards are located in the Exhibit Hall (Hall B), Ground Level, and each Poster Board is identified by a professionally lettered sign with the assigned Poster Number. The Poster Board Number corresponds with the pre-assigned Poster Number provided in your confirmation letter and printed in the Abstract Book and this Conference Program.

- You are asked to prepare a PPT Presentation with maximum 10 slides in 16:9 format (not including title, author and disclosure slide).
- Please be in room for your session 10 minutes before the start time of the session. The session Chairs will start and end strictly on time.
- The presenting author must control all content.
- Slides, abstracts, and handouts cannot contain advertising, QR codes, corporate logos, trade names, or product-group messages of an ACCME-defined ineligible company.
- All presenters MUST include statement disclosing any conflict of interest related to your abstract as the first slide of your presentation.
**POSTER DISPLAY TIME**

Posters for both Poster Sessions (P1 and P2) will be on display for the entire duration of the Conference.

- **Sunday, August 7, 2022** 09:45 - 19:00
- **Monday, August 8, 2022** 09:45 - 19:00
- **Tuesday, August 9, 2022** 09:45 - 14:15

Poster Presenters **MUST** place their poster(s) and be present during their assigned Poster Viewing Session. Presenting authors who do not comply may be at risk of having their abstract(s) rejected at future WCLC conferences.

**POSTER SETUP TIME**

**Sunday, August 7, 2022** 07:00 - 08:30

**POSTER TAKEDOWN TIME**

**Tuesday, August 9, 2022** 13:30 - 14:15

Any posters not removed by the end of Poster Takedown time will be discarded by management.

**ePOSTERS**

ePosters will be available for delegates to view in the exhibit hall during exhibit hall opening hours.
- You are asked to prepare a PPT Presentation with one (1) slide in 16:9 format.
- All e-Posters will be displayed on a 60-inch digital screen.

**INVITED SPEAKERS AND DISCUSSANTS**

- Employees of ACCME-defined **ineligible companies** are prohibited from presenting educational content for Continuing Medical Education.
- You are asked to prepare a PPT Presentation in **16:9 format**.
- Please be in room for your session 10 minutes before the start time of the session. The session Chairs will start and end strictly on time.
- The presenting author must control all content.
- Slides, abstracts, and handouts cannot contain advertising, QR codes, corporate logos, trade names, or product-group messages of an ACCME-defined **ineligible company**.
- All presenters **MUST** include statement disclosing any conflict of interest as the first slide of your presentation.
- The duration of presentation was provided in your invitation letter. If you are unsure of the length of your presentation, please contact **wclc2022-speakers@icsevents.com**.
ONSITE SERVICES AND GENERAL INFORMATION

IASLC MEETINGS & CONFERENCES MOBILE APP
Download the free IASLC Meetings and Conferences mobile app for a convenient way to stay up-to-date via your phone or tablet. View the full scientific schedule, abstracts, exhibit information including floor plan and exhibitor biographies, and general Conference and venue information on our easy-to-use app!

The app is compatible with all iOS devices and all Android mobile devices. Timely updates on program or room changes will be distributed through the mobile app via notification alerts.

Search for: IASLC Meetings & Conferences

IASLC WCLC 2022 VIRTUAL PLATFORM
All sessions will be audio recorded and made available on the Virtual Platform and the Mobile App within 24 hours. The Virtual Platform and Mobile App also include presentation slides, abstracts and posters.

Log-in details are sent to your registered email. If you need assistance, you can visit the Virtual Platform / Mobile App Help Desk in Foyer D, Ground Level or send an email to wclc2022-registration@icsevents.com.

GET THE WCLC 2022 VIRTUAL PLATFORM AT MEETINGSAPP.IASLC.ORG/EVENT/WCLC2022
All accepted abstracts are also included in the IASLC Meetings & Conferences Mobile App.

IASLC SOCIAL MEDIA ACCOUNTS
facebook.com/IASLC
@IASLC
IASLC
iaslungcancer

ABSTRACTS
Abstracts selected for IASLC WCLC are presented in Oral, Mini Oral and Poster Sessions. The top rated abstracts featuring groundbreaking trials will be presented in the Presidential Symposium on Monday, August 8, 08:30 – 10:20.

All accepted and confirmed abstracts are published in a supplement of the Journal of Thoracic Oncology and on the Conference Website prior to IASLC 2022 WCLC.

ABSTRACTS ONLINE
Attendees are invited to view the abstracts available on the Conference website, the Mobile App and the Virtual Platform. You may search for abstracts, topics, presenters, and keywords. You can bookmark presentations and sessions building your own personal conference calendar.
ACCREDITATION
Please refer to CME Information on page 36 (CME Page) in this book for further information.

ATTIRE
Business casual is appropriate for all sessions and networking events. Room temperature can vary in session rooms. We encourage attendees to dress in layers for their personal comfort.

ATM
There are two ATM machines located in the Mall Area – One is located between Hall C and Foyer D, the other is close to the café between Hall A and Hall B.

BADGES AND ACCESS CONTROL
You will be required to wear your badge at all times within the venue.

BREAKFAST
The Conference does NOT provide breakfast except for the Interactive Breakfast Sessions (ticketed sessions) from Sunday – Tuesday from 07:30 – 08:15 or as otherwise indicated in the program.

CELL PHONES
As a courtesy to fellow attendees, please turn off cell phones during scientific sessions.

CERTIFICATE OF ATTENDANCE
International attendees can request a ‘Certificate of Attendance’ by completing the Conference evaluation form available on the Conference website at the conclusion of the Conference. After completing the evaluation form you will be able to download your Certificate of Attendance.

CHARGING STATION
Charging Station is located in the Exhibit Hall (Hall B) allowing delegates to power up their cell phones, tablets, and other electronic devices for free.

COAT AND BAGGAGE CHECK
Foyer D, Ground Level, Messe Wien Exhibition & Congress Center

OPENING HOURS
<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday</td>
<td>August 5, 2022</td>
<td>08:00 - 17:00</td>
</tr>
<tr>
<td>Saturday</td>
<td>August 6, 2022</td>
<td>07:00 - 22:00</td>
</tr>
<tr>
<td>Sunday</td>
<td>August 7, 2022</td>
<td>06:30 - 20:00</td>
</tr>
<tr>
<td>Monday</td>
<td>August 8, 2022</td>
<td>07:00 - 20:00</td>
</tr>
<tr>
<td>Tuesday</td>
<td>August 9, 2022</td>
<td>07:00 - 17:30</td>
</tr>
</tbody>
</table>

DELEGATE LOUNGES
Exhibit Hall, Hall B, Ground Level, Messe Wien Exhibition & Congress Center
Delegate Lounges are available and located in the Exhibit Hall (Hall B). These lounges are specifically designed to provide a comfortable seating area for delegates to rest, conduct brief meetings or network with colleagues.

IASLC Membership Lounge
Reserved for IASLC Members

Patient Advocacy Lounge
Reserved for Patients, Survivors, Caregivers/Partners, and Patient Advocates

Collaborative Meeting Space
Public space for a quick meeting for all delegates

EMERGENCY SERVICES AND FIRST AID
Dial 133 for police, 122 for Fire, and 144 for Ambulance service. Please have the number of your embassy with you when travelling. In case of fire at the Messe Wien, use the stairs and NOT the elevator for exit. Please follow the Messe Wien’s instructions in case of emergency.

The first aid room is located in ARZT Room in Foyer CC, Ground Floor.

INTERNET CAFÉ
Exhibit Hall, Hall B, Ground Level, Messe Wien Exhibition & Congress Center
Keep in touch with home and office! Computers with internet and printers are available to delegates on a complimentary basis. The Internet Café is open during Exhibit Hall Hours. Internet sessions are limited to 15 minutes per delegate.
**MOTHERS / PRAYER ROOM**
**Mothers / Prayer Room**, Ground Level, Messe Wien Exhibition & Congress Center

IASLC is offering delegates the use of a private nursing room and the use of a multifaith prayer room located on the ground level next to Strauss 3.

**LOST AND FOUND**
The lost and found collection point is at the Registration Counter. Every object found around the Conference premises (by security, cleaning staff or attendees) is eventually delivered and centralized to the Registration Counter at the end of the day.

**MEDIA WORK ROOM**
**Piazza**, Upper Level, Messe Wien Exhibition & Congress Center

Workstations with internet access and copy machine will be available to press and media representatives. Support staff will also take reservations for the use of Interview Room 1 & 2.

**OVERFLOW ROOMS**
An overflow viewing area has been set up in Lehar 2, 3 & 4.

**PARKING**
Public car parking is available at multi-storey car park D / access via Trabrennstraße 3, 1020 Wien/ GPS-Coordinates: 48.212802, 16.412057 / entrance height on the ground floor: 3 meters; first floor: 2,10 meters. The parking fee is € 3.00 for the first hour and € 3.50 for every additional hour (incl VAT).

**POSTERS ONLINE**
All abstracts accepted for poster presentation will be presented as traditional printed posters to be displayed on poster boards in the Exhibit Hall (Hall B). In addition to the printed poster, each presenter is required to submit an electronic version of their poster to be made available in the Virtual Platform at MEETINGSAPP.IASLC.ORG/EVENT/WCLC2022 and the Mobile App (available in the App and Google Play Store), which, is free of charge to all delegates.

**PUBLIC TRANSPORTATION**
We strongly recommend that you take public transportation whenever possible. Vienna offers efficient public transportation networks. For assistance, please visit the Delegate Help and Visit Vienna Desk in Foyer D, Ground Level, Messe Wien Exhibition & Congress Center.

All in-person delegates will receive a ticket for complimentary use of the public transportation system for the duration of the Conference with their registration materials.

**RESTAURANTS**
There are plenty of restaurant choices in Vienna and within walking distance from the Messe Wien Exhibition & Congress Center. The staff at the Delegate Help Desk will be happy to assist with recommendations and bookings.

**SMOKING**
The Messe Wien Exhibition & Congress Center is a smoke-free environment. All public areas, rental space, corridors, loading docks, exhibit halls, and parking lots are designated non-smoking. The Messe Wien Exhibition & Congress Center is required to enforce the no-smoking rules.

**SPEAKER PREVIEW ROOM & LOUNGE**
**VIP Lounge D**, Upper Level, Messe Wien Exhibition & Congress Center

All presenters are required to preview their slides at least 24 hours prior to their scheduled presentation to ensure compatibility with the Conference AV Equipment.

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday</td>
<td>August 5, 2022</td>
<td>14:00 - 18:00</td>
</tr>
<tr>
<td>Saturday</td>
<td>August 6, 2022</td>
<td>07:00 - 19:30</td>
</tr>
<tr>
<td>Sunday</td>
<td>August 7, 2022</td>
<td>07:00 - 16:30</td>
</tr>
<tr>
<td>Monday</td>
<td>August 8, 2022</td>
<td>07:00 - 16:30</td>
</tr>
<tr>
<td>Tuesday</td>
<td>August 9, 2022</td>
<td>07:00 - 15:45</td>
</tr>
</tbody>
</table>
VIRTUAL PLATFORM
The WCLC 2022 Virtual Platform is included in your registration and can be accessed through MEETINGSAPP.IASLC.ORG/EVENT/WCLC2022

Your personal Virtual Platform Log-in information will be sent to your registered email prior to the Conference. Should you need assistance to Log-in to the Virtual Platform, please contact wclc2022-registration@icsevents.com

WIRELESS INTERNET
Premium Attendee Wireless Internet Access is provided throughout the Messe Wien Exhibition & Congress Center. This service is suited for attendee general usage such as checking email social media, and web surfing. Users are restricted from Virtual Private Networks (VPN), Remote Desktop Protocols (RDP) and peer to peer protocols.

Wireless network is optimized to be used by devised operation in the 5GHz radio band (802.11 a/n ac). Although the service will be offered in the 2.4GHz radio band (802.11 g/n) the service is provided best effort due to the high levels of contention and interference present on the radio band.

DISCLAIMER
The organizers have made every attempt to ensure that all information in this publication is correct. The organizers take no responsibility for changes to the program or any loss that may occur as a result of changes to the program. Some of the information provided in this publication has been provided by external sources. Although every effort has been made to ensure the accuracy, currency and reliability of the content, the organizers accept no responsibility in that regard.

Join the IASLC Today!

Scan the QR code & enter WCLCNewMember2022 to receive half off membership dues for one year.
CONTINUING MEDICAL EDUCATION (CME)

The International Association for the Study of Lung Cancer (IASLC) complies with the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). IASLC applies these Standards throughout the educational planning process to ensure independence, balance, objectivity and scientific rigor for all Continuing Medical Education (CME) activities.

In compliance with the ACCME Standards, each individual in a position to control the content of a CME activity is required to disclose all financial relationships with ACCME defined ineligible companies. All disclosures are reviewed to identify relevant financial relationships and any conflicts of interest which are mitigated before the individual can assume their role in the activity.

ACCREDITATION AND CREDIT STATEMENT
The International Association for the Study of Lung Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IASLC designates this “other activity” (a live conference offered in a hybrid format including recorded virtual participation) for a maximum of 57.25 AMA PRA Category 1 Credit(s)™.

GOAL & PURPOSE
The IASLC 2022 World Conference on Lung Cancer (WCLC 2022) is the world’s largest international conference for clinicians, researchers, and scientists in the field of lung cancer and thoracic oncology. Bringing together lung cancer specialists from around the world and across disciplines, the conference offers opportunities for learning and sharing the latest developments in lung cancer and thoracic malignancy research, prevention, diagnosis, treatment and management. With 20 educational tracks and over 300 global experts as invited speakers, WCLC 2022 provides a robust, comprehensive scientific program encompassing cutting edge knowledge on subjects such as tumour biomarkers, clinical trials, targeted therapies, liquid biopsy, lung cancer screening, immunotherapy, tobacco control and patient advocacy. Sessions include plenaries with live Q&A, expert lectures, panel discussions, oral abstracts, and posters.

TARGET AUDIENCE
The 2022 World Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, and physician assistants.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
1. Examine scientific advances in thoracic cancer including the pathogenesis, biology, and mechanisms of drug interactions that can be used to make evidence-based diagnosis and treatment decisions.
2. Synthesize cutting edge research from clinical trials and translational studies conducted around the world to deepen knowledge within primary specialty area(s) and broaden knowledge of other specialties.
3. Advocate for lung cancer prevention strategies including tobacco control, smoking cessation, reducing environmental risks, addressing the quality and value of healthcare, and implementing early screening.
4. Apply evidence-based recommendations and clinical practice guidelines to diagnose and manage patients.
5. Collaborate on multidisciplinary teams to improve patient outcomes through patient-centered diagnostic, therapeutic and palliative care.
6. Engage and empower patients to become active participants in their treatment.

OFFICIAL LANGUAGE
The official language of the IASLC 2022 World Conference on Lung Cancer is English.

DISCLAIMER
The information presented at the IASLC 2022 World Conference on Lung Cancer is that of the contributing faculty and does not necessarily
represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

HOW TO RECEIVE A CME CERTIFICATION (PHYSICIANS ONLY)

Physicians are entitled to receive a CME certificate after completing the Conference evaluation survey. A link to this survey will be emailed to all attendees at the conclusion of the Conference; the survey can also be accessed from the Conference website. After submitting the survey, physicians have the option to print or save their CME certificate.

CME certificates will reflect the number of accredited sessions attended. CME accredited activities are designated in the program guide. The deadline for claiming CME credit is December 31, 2022.

Please direct any certificate inquiries to: cme@iaslc.org

HOW TO RECEIVE A CERTIFICATE OF ATTENDANCE (NON-PHYSICIANS)

Non-physicians are entitled to receive a “Certificate of Attendance”. To claim a Certificate of Attendance, non-physicians must first complete the Conference evaluation survey. A survey link will be emailed to all attendees at the conclusion of the Conference; the survey can also be accessed from the Conference website. After submitting the survey, attendees may print or save their Certificate of Attendance. The deadline for receiving a Certificate of Attendance is December 31, 2022.

Please direct any certificate inquiries to: cme@iaslc.org
LUNG CANCER CONSIDERED
with Dr. Stephen Liu and Dr. Narjust Florez

The official podcast of the IASLC.
Tune in each month for conversations with the researchers, healthcare professionals, patients and advocates from around the world who are making a difference in the treatment of thoracic cancers.

Find new podcast episodes at IASLC.org/Lung-Cancer-Considered
Simply scan the QR Code and start listening today.

Lung Cancer Considered is funded in part by: AstraZeneca, Bristol Myers Squibb, Lilly Oncology, and Merck KGaA.
Dr. Edward Patz is a thoracic radiologist with a long-standing interest in early lung cancer detection, molecular diagnostics, and novel therapeutic strategies. Dr. Patz has been studying lung cancer for over 25 years, and has been involved with numerous clinical trials including the National Lung Cancer Screening Trial (NLST). Dr. Patz was on the ACRIN-NLST Executive Committee, helped design and was the Chair of the ACRIN-NLST Biomarker Committee, and have been involved with many other lung cancer initiatives, including the IASLC staging project.

Dr. Patz has also been the principal investigator of a basic science laboratory that currently has projects on clonal evolution of tumours, cell-free plasma DNA as biomarkers for early detection, and the role of inflammation in cancer. While remaining focused on early cancer detection and treatment, his out-of-the-box type of approach has required him to explore and integrate a broad spectrum of different disciplines. As below, this work has resulted in a number of seminal publications and impact on patient care, but this is an amazingly complex challenge that requires innovative strategies. His experience as both a clinical and basic science researcher, particularly in lung cancer biology, provides a unique perspective to help move these innovative types of translational projects forward with the ultimate goal to improve patient care and outcomes.

Dr. Rafael Rosell is Director of the Cancer Biology and Precision Medicine Program at the Catalan Institute of Oncology, Hospital Germans Trias i Pujol (Badalona, Barcelona, Spain), Chief Scientific Officer, Chairman and Founder of Pangaea Oncology SL (Barcelona), Chief Medical Officer and President of the Dr Rosell Oncology Institute (IOR), Quirón Dexeus, General de Catalunya & Sagrat Cor Univ. Hospitals (Barcelona), and Founder and President of the Molecular Oncology Research Foundation (Barcelona). He is Founder and Director of International Relations and Projects, Spanish Lung Cancer Group (SLCG), member of the Foundation Council and Steering Committee of the European Thoracic Oncology Platform (ETOP) and on the Foundation Board of the ETOP- International Breast Cancer Study Group (IBCSG). He is also a Panel member of the ASCO Clinical Practice Living Guidelines- Systemic Therapy for Stage IV NSCLC.

Dr. Rosell’s contributions to translational medical oncology, with particular emphasis in the field of non-small-cell lung cancer with EGFR mutations, have earned him international renown. Dr. Rosell is fully dedicated to the improvement of lung cancer therapy. His current research programs include continued investigation in translational/preclinical research, liquid biopsy, and novel technologies with NGS. In 2018, he was selected to participate in The European Liquid Biopsy Academy (ELBA).
James Chih-Hsin Yang, MD, PhD, received his MD from National Taiwan University (NTU) in Taipei in 1986 and completed his PhD degree at the Graduate Institute of Clinical Medicine, NTU, in 2000. He completed his internal medicine residency at the NTU Hospital. Between 1992 and 1995, he undertook medical oncology fellowship training for early phase cancer trials and new cancer drug development at the National Cancer Institute at Bethesda, Maryland. He has been a staff member in the Department of Oncology at the NTU Hospital since 1995 and chair the Department of Oncology between 2015-2020. He was appointed as the superintendent (Director) of the NTU Cancer Center hospital in Aug 2020, Director of NTU Cancer Research Center in Aug 2021. He is the President of Taiwan Oncology Society since Sep 2021, the President of Taiwan Association for the Study of Lung Cancer since April 2022.

Dr Yang’s research focuses on lung cancer treatment and the mechanism of resistance of chemotherapy, targeted therapy and immunotherapy. Dr Yang is a leader in lung cancer new drug development. He and other Asian investigators have established EGFR TKI as the front-line treatment for lung cancer patients with EGFR mutation (IPASS study). He is also the principal investigator of several studies that led to the global approval of the 2nd-generation irreversible EGFR TKI, afatinib, and contributed to the development of 3rd-generation EGFR TKI, osimertinib. His studies were highly focused on various approach to improve the treatment outcome of EGFR mutation positive patients. He contributed and established the standards for the treatment of uncommon EGFR mutations patients and leptomeningeal metastasis patients. His clinical research included EGFR TKI combination with chemotherapy, targeted therapies and immunotherapy. He has published more than 300 papers in peer-reviewed journals such as New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, Lancet Respiratory Medicine, Cancer Discovery and Journal of Thoracic Oncology etc. He served more than 15 years as associate editor of Journal of Thoracic Oncology. He received many awards such as the 2nd Kobayashi Foundation Cancer Research Award from the Asian Clinical Oncology Society in 2012, the distinguished research award of the Taiwan National Science Council 2012-2015, the TECO award for biotechnology in 2015, distinguished research award of the Ministry of Science and Technology, Taiwan, from 2016-2018 and Academic Award from Taiwan Ministry of Education in 2018; Outstanding Scholar Award, Foundation For the Advancement of Outstanding Scholarship 2019 Aug -2021 Jan. Chair Professor Award, Taiwan Ministry of Education, 2021 Feb to 2024 Jan and Chair Professor of National Taiwan University in 2021. He is also the highly cited researcher of 2019, 2020, 2021 in Clinical Medicine category awarded by Clarivate Analytics (Web of Science Group). He gave numerous speech in international conferences, including many oral presentations of study reports in ASCO, ESMO and World Conference on Lung Cancer.
Dr. Valerie W. Rusch is Attending Thoracic Surgeon, Vice Chair of Clinical Research, Department of Surgery and Member, Memorial Sloan-Kettering Cancer Center in New York, where she holds the Miner Family Chair in Intrathoracic Cancers. After residencies in general and cardiothoracic surgery at the University of Washington, she was a Faculty Associate at the MD Anderson Cancer Center, then a faculty member at the University of Washington. She moved to MSKCC in 1989, where she served as Chief of Thoracic Surgery from 2000 to 2013. Dr. Rusch’s career has been devoted to thoracic surgical oncology, to clinical and translational research, and she has been PI for multiple NCI-sponsored Cooperative Group clinical trials. Dr. Rusch is a Past President of the American College of Surgeons, and has held leadership positions in ASCO, the Society for Thoracic Surgeons, the American Association for Thoracic Surgery, and the International Association for the Study of Lung Cancer. She has served as a Director and Chair of the American Board of Thoracic Surgery. Dr. Rusch is the recipient of multiple teaching awards, is author on more than 450 peer-reviewed publications, holds more than 50 visiting professorships and has delivered more than 400 invited lectures.

### DISTINGUISHED SERVICE AWARD WINNERS

<table>
<thead>
<tr>
<th>Year</th>
<th>Adi F. Gazdar IASLC Merit Award</th>
<th>IASLC Mary J. Matthews Pathology/Translational Research Award</th>
<th>IASLC Joseph W. Cullen Prevention/Early Detection Award</th>
<th>IASLC Paul A. Bunn, Jr. Scientific Award</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>Michael Boyer</td>
<td>Deepali Jain</td>
<td>Gabriella Sozzi</td>
<td>David P. Carbone</td>
</tr>
<tr>
<td>2020</td>
<td>Alex A. Adjei</td>
<td>Caroline Dive</td>
<td>Pan-Chyr Yang</td>
<td>Joan H. Schiller</td>
</tr>
<tr>
<td>2019</td>
<td>Hisao Asamura</td>
<td>Andrew Nicholson</td>
<td>Denise R. Aberle</td>
<td>Charles Rudin</td>
</tr>
<tr>
<td>2018</td>
<td>Françoise Mornex</td>
<td>Ignacio I. Wistuba</td>
<td>Fadlo Khuri</td>
<td>Charles Swanton</td>
</tr>
<tr>
<td>2017</td>
<td>Ramon Rami-Porta</td>
<td>Yasushi Yatabe</td>
<td>Carolyn Dresley</td>
<td>Tony Mok</td>
</tr>
<tr>
<td>2016</td>
<td>Sumitra Thongprasert Keunchil Park</td>
<td>Keith Kerr</td>
<td>Ugo Pastorino</td>
<td>Roy Herbst</td>
</tr>
<tr>
<td>2015</td>
<td>Harvey Pass</td>
<td>Ming Tsao</td>
<td>Jacek Jassem</td>
<td>Yi-Long Wu</td>
</tr>
<tr>
<td>2013</td>
<td>James Jett</td>
<td>Tetsuya Mitsudomi</td>
<td>Pieter Postmus</td>
<td>David R. Gandara</td>
</tr>
<tr>
<td>2011</td>
<td>David Ball</td>
<td>Philip Hasleton</td>
<td>John Field</td>
<td>Nagahiro Saijo</td>
</tr>
<tr>
<td>2009</td>
<td>Giorgio V. Scaglotti</td>
<td>Masayuki Noguchi</td>
<td>Stephen Lam</td>
<td>Bruce Johnson</td>
</tr>
<tr>
<td>2008</td>
<td></td>
<td></td>
<td></td>
<td>Tom Lynch</td>
</tr>
<tr>
<td>2007</td>
<td>Peter Goldstraw</td>
<td>Fred R. Hirsch</td>
<td>James Mulshine</td>
<td>Frances Shepherd</td>
</tr>
<tr>
<td>2005</td>
<td>Harubumi Kato</td>
<td>Elisabeth Brambilla</td>
<td>Nigel Gray</td>
<td>Thierry LeChevalier</td>
</tr>
<tr>
<td>2003</td>
<td>Paul A. Bunn, Jr.</td>
<td>Adi Gazdar</td>
<td></td>
<td>Paul Van Houte</td>
</tr>
<tr>
<td>2000</td>
<td>Desmond Carney</td>
<td>Yokio Shimosato</td>
<td></td>
<td>Daniel C. Ihde</td>
</tr>
<tr>
<td>1997</td>
<td>Heine H. Hansen</td>
<td>William Travis</td>
<td>Clifford Douglas</td>
<td>John D. Minna</td>
</tr>
<tr>
<td>1994</td>
<td>Y. Shimosato</td>
<td>Geno Saccamanno</td>
<td></td>
<td>Jesse Steinfeld</td>
</tr>
<tr>
<td>1991</td>
<td>Clifton F. Mountain</td>
<td></td>
<td></td>
<td>Robert J. Ginsberg</td>
</tr>
</tbody>
</table>
The IASLC International Lectureship Award Winners will receive their award at the IASLC Award Ceremony on Saturday, August 6, 17:00 – 17:45, at Lehar 1, Congress Center, Ground Level, Messe Wien Exhibition & Congress Center. Each award winner will give their presentation at the following assigned Lectureship Award Sessions:

**IASLC LECTURESHIP AWARD WINNERS**

**LA01 – Lectureship Award Session 1**  
Sunday, August 7, 13:15 – 14:15  
Hall C1, Ground Level  
IASLC Lectureship Award for Tobacco Control and Smoking Cessation  
RAY OSAROGIAGBON, UNITED STATES  
Medical Oncology  
Tsuguo Naruke Lectureship Award for Surgery  
WENZHAO ZHONG, CHINA  
Thoracic Surgery  
Daniel C. Ihde Lectureship Award for Medical Oncology  
PATRICK FORDE, UNITED STATES  
Medical Oncology

**LA02 – Lectureship Award Session 2**  
Monday, August 8, 13:30 – 14:30  
Hall C1, Ground Level  
Robert J. Ginsberg Lectureship Award for Surgery  
ISABELLE OPITZ, SWITZERLAND  
Thoracic Surgery  
James D. Cox Lectureship Award for Radiation Oncology  
YUKO NAKAYAMA, JAPAN  
Radiation Oncology  
Heine H. Hansen Lectureship Award for Small Cell Lung Cancer  
STEPHEN V LIU, UNITED STATES  
Medical Oncology

**LA03 – Lectureship Award Session 3**  
Tuesday, August 9, 13:15 – 14:15  
Hall C1, Ground Level  
Fred R. Hirsch Lectureship Award for Translational Research  
LUKAS BUBENDORF, SWITZERLAND  
Pathologist  
IASLC Lectureship Award for Nurses and Allied Health Professionals (NAHP)  
ANNE FRASER, NEW ZEALAND  
Nursing  
Clifton F. Mountain Lectureship Award for Staging  
CLARISSA MATHIAS, BRAZIL  
Medical Oncology
IASLC ACADEMY PARTICIPANTS

The IASLC Academy Participants will be acknowledged and honored during the IASLC Award Ceremony on Saturday, August 6, 17:00 – 17:45, at Lehar 1, Congress Center, Ground Level, Messe Wien Exhibition & Congress Center.

MIHAELA ALDEA
Gustave Roussy, France

HASHIM ISMAIL
Travancore Medical College, India

CARLOS CABRERA
UOMi Cancer Center, Spain

CORAL OLAZAGASTI
University of Miami Health System, United States

NICOLE CARRIEL
Hospital Dr. Gustavo Fricke, Chile

KEIGO KOBAYASHI
National Cancer Centre Singapore, Singapore

GUILHERME HARADA
Memorial Sloan-Kettering Cancer Center, United States

MANGLIO RIZZO
Hospital Universitario Austral, Argentina

BRIAN S HENICK
Herbert Irving Comprehensive Cancer Center, United States

GIOVANNI ROSSI
IRCCS Ospedale Policlinico San Martino, Italy

HASHIM ISMAIL
Travancore Medical College, India

KONSTANTINOS LEVENTAKOS
Mayo Clinic, United States

BRIAN S HENICK
Herbert Irving Comprehensive Cancer Center, United States

JOSEPH MURRAY
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, United States

STEPHANIE PEI LI SAW
National Cancer Centre Singapore, Singapore

WCLC 2022 EARLY CAREER EDUCATION AWARD WINNERS

The WCLC 2022 Early Career Education Award Winners will receive their award during the IASLC Award Ceremony on Saturday, August 6, 17:00 – 17:45, at Lehar 1, Congress Center, Ground Level, Messe Wien Exhibition & Congress Center.

NICOLAS ALCALA
International Agency for Research on Cancer / World Health Organization, France
MA02.03: The Evolution of Lung Neuro-endocrine Tumors

MARTA CASARRUBIOS
Hospital Puerta de Hierro Majadahonda, Spain
OA02.03: Tumor Bulk-RNA Seq Identifies Patients at High Risk Of Progression in Non-Complete Pathological Responders from NADIM Trial

KEVIN CHUA
National Cancer Centre Singapore, Singapore
P2.13-02: Dynamic Tracking of Bespoke Circulating Tumour DNA During Multi-Modality Therapy for Locally Advanced NSCLC (LA-NSCLC)

LAURENT DERCLE
Columbia University Medical Center / Herbert Irving Cancer Center (CUMC / HICCC), United States
P2.12-03: External Validation of A Novel CT-Based Prognostic Radiomic Signature in Patients with Metastatic NSCLC in SWOG S0819 Phase III Randomized Trial

ALBERTO TRAVERSO
Maastro Clinic, Netherlands
P1.15-01: Differential Diagnosis of Pneumonitis in Metastatic NSCLC (Non-Small Cell Lung Cancer) Patients Receiving Immunotherapy with Radiomics

ARVIND KUMAR
Icahn School of Medicine at Mount Sinai, United States
OA02.04: Multimodal Management of T4 N2 Non-Small-Cell Lung Cancer with Additional Ipsilateral Pulmonary Nodules

JENNIFER MARKS
Georgetown University, United States
MA05.08: MET Exon 14 Skipping Mutation in Non-Small Cell Lung Cancer (NSCLC) by Specific Mutation, Histology, and Smoking History

ÉMILIE MATHIAN
International Agency for Research on Cancer (IARC-WHO), France
MA01.07: From Molecular to Histological Characterization of Lung Carcinoids via Computer Vision and Spatial Genomics

SIMON HEEKE
UT MD Anderson Cancer Center, United States
MA01.03: Exploiting DNA Methylation for Classification of SCLC Subtypes from Liquid Biopsies Using A Robust Machine Learning Approach

HANA ZAHED
International Agency for Research on Cancer (IARC / WHO), France
MA11.05: The Blood Proteome of Imminent Lung Cancer
The WCLC 2022 Developing Nation Education Award Winners will receive their award during the IASLC Award Ceremony on Saturday, August 6, 17:00 – 17:45, at Lehar 1, Congress Center, Ground Level, Messe Wien Exhibition & Congress Center.

AMIYA AGRAWAL
Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India
MA09.03: Response of Palliative Radiotherapy in Bone Metastases of Lung Cancer - Results of Prospective Longitudinal Study from India

LEEN AL-KRAIMEEN
Jordan University of Science and Technology, Jordan
EP16.01-008: The Effect of Cytochrome P450 Family 4 Subfamily B Member 1 (CYP4B1) on Lung Adenocarcinoma (LUAD) Immune Microenvironment

RUI FU
School of Medicine, South China University of Technology, Guangdong Lung Cancer Institute, China
EP16.02-024: Plasma ctDNA Organ-Specific Genomic Patterns and Origination Analysis in Advanced Non-Small Cell Lung Cancer

CHENCHEN GUO
Cas Center for Excellence in Molecular Cell Science, Shanghai, China
EP14.02-005: Therapeutic targeting Mevalonate-Geranylgeranyl Diphosphate Pathway with Statins Overcomes Chemotherapy-resistance in SCLC

CHINMAY HARIDAS
Shri Vasantrao Naik Government Medical College, Yavatmal, India
EP14.05-003: Recent Stage Shifts and Changes in the Treatment of Stage I Small Cell Lung Cancer in the United States

DEBPRIYA MONDAL
Tata Medical Center, India
EP08.02-040: Dacomitinib Induced Febrile Neutropenia: a Rare Serious Adverse Event
EP16.02-006: Evaluation of Carcinoembryonic Antigen (CEA) as Predictive Marker in Patients with Metastatic Non-small Cell Lung Cancer

AMBER RATHOR
All India Institute of Medical Sciences, India
EP11.01-011: Clinical Application of Liquid Biopsy for assessing Early EGFR mutation detection in Non-Small Cell Lung Carcinoma

SEBAWE SYAJ
Jordan University of Science and Technology, Jordan
EP02.04-008: Efficacy and Safety of Neoadjuvant Chemoimmunotherapy in Resectable Non-small Cell Lung Cancer (NSCLC): a Systematic Review and Meta-analysis
EP05.03-010: Extended Resection of Non-small Cell Lung Cancer with Superior Vena Cava Involvement: a Systematic Review and Meta-analysis

SAURAV VERMA
Vardhman Mahavir Medical College and Safdarjung Hospital, India
P2.02-03: A Phase II Study of Metformin with Pemetrexed/Carboplatin in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer
The IASLC Patient Advocacy Award Winner will receive their award during the IASLC Award Ceremony on **Saturday, August 6, 17:00 – 17:45**, at Lehar 1, Congress Center, Ground Level, Messe Wien Exhibition & Congress Center.

**IASLC PATIENT ADVOCACY AWARD WINNERS**

- MaryAnn Bradley
  Canada
- Seamus Cotter
  Ireland
- Dusty Joy Donaldson
  United States

The IASLC Nurse and Allied Health Professional Award Winners will receive their award during the IASLC Award Ceremony on **Saturday, August 6, 17:00 – 17:45**, at Lehar 1, Congress Center, Ground Level, Messe Wien Exhibition & Congress Center.

**IASLC NURSE AND ALLIED HEALTH PROFESSIONAL AWARD WINNERS**

**LAKEDIA BANKS**
Va Palo Alto Health Care System, United States
**EP04.02-003**: Improving Supportive Care for Patients with Thoracic Cancer

**IMANUELY BORCHARDT**
Grupo Oncoclinicas, Brazil
**OA08.03**: Do in Screening-Calf Circumference and Muscle Strength is Predictive of Outcomes in Lung Cancer Treatment

**AMANDA MOORE**
The University of Texas at Austin, United States
**EP05.02-013**: Immune-Related Adverse Effects and Durvalumab Treatment Patterns in VHA Patients with Unresectable Stage III NSCLC

**ANDREJA SAJNIĆ**
Department for Respiratory Diseases Jordanovac, University Hospital Center, Croatia
**P02.04-01**: Lung Cancer Patient Experience Survey from Twelfth Central and Eastern Europe Countries

**CANCER CARE TEAM AWARD WINNERS**

**Latin America Regional Winner**
Instituto Nacional del Tórax in Providencia, Chile

**North America Regional Winner**
Baptist Cancer Center in Memphis, TN

**Asia / Rest of the World Regional Winner**
Shanghai Pulmonary Hospital Affiliated to Tonji University, Shanghai, China
PROGRAM AT A GLANCE

Friday
August 5, 2022

07:00 - 09:00: CT Screening Workshop (05:00 - 16:00)
09:00 - 12:00: Joint IASLC/NSCLC Rechtshelfer Training Workshop (08:00 - 12:00)
12:00 - 13:00: Lunch Break
13:00 - 14:00: Concurrent Industry Symposium (13:00 - 14:00)
14:00 - 15:00: Concurrent Industry Symposium (14:00 - 15:00)
15:00 - 16:30: Opening Plenary Session (15:45 - 16:45)

Saturday
August 6, 2022

07:30 - 08:00: Break (08:00 - 10:45)
08:00 - 12:00: Plenary Session 2 (08:30 - 11:45)
12:00 - 13:00: Concurrent Abstract Sessions (12:00 - 13:00)
13:00 - 14:15: Concurrent Industry Symposium (13:00 - 14:15)
14:30 - 15:30: Lunch Break (13:45 - 14:15)
15:45 - 16:45: Concurrent Industry Symposium (15:45 - 16:45)

Sunday
August 7, 2022

07:15 - 08:15: Break (07:30 - 08:15)
08:15 - 09:00: Welcome Reception (10:30 - 10:45)
09:00 - 10:30: Concurrent Industry Symposium (09:00 - 10:30)
10:45 - 11:45: Concurrent Abstract Sessions (10:45 - 11:45)
12:00 - 13:00: Concurrent Abstract Sessions (12:00 - 13:00)
13:30 - 14:30: Concurrent Abstract Sessions (13:30 - 14:30)

Ticketed Event
IASLC CME Accredited
**SESSION OVERVIEW**

**Friday, August 5, 2022**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 16:00</td>
<td>WS02: IASLC CT Screening Symposium: Forefront Advances in Lung Cancer Screening</td>
</tr>
</tbody>
</table>

*Official ticketed session*

**Location:** Strauss 3
SESSION OVERVIEW

Saturday, August 6, 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 11:30</td>
<td>WS03 Early Career &amp; First Time Attendee Session</td>
<td>Lehar 1</td>
</tr>
<tr>
<td></td>
<td><strong>LIGHT BREAKFAST PROVIDED</strong></td>
<td></td>
</tr>
<tr>
<td>08:00 - 12:00</td>
<td>WS04 IASLC/IMIG Workshop - The Future of Mesothelioma Treatment</td>
<td>Lehar 4</td>
</tr>
<tr>
<td>09:00 - 11:00</td>
<td>WS05 Social Media + Communications Workshop</td>
<td>Lehar 2</td>
</tr>
<tr>
<td>12:00 - 17:00</td>
<td>WS06 Nurse &amp; AHP + ITONF Joint Workshop</td>
<td>Lehar 3</td>
</tr>
<tr>
<td></td>
<td><strong>LIGHT LUNCH REFRESHMENTS PROVIDED</strong></td>
<td></td>
</tr>
<tr>
<td>15:00 - 16:30</td>
<td>WS07 LATAM Workshop</td>
<td>Lehar 2</td>
</tr>
<tr>
<td>17:00 - 17:45</td>
<td>AC01 IASLC Awards Ceremony</td>
<td>Lehar 1</td>
</tr>
<tr>
<td>18:15 - 19:45</td>
<td>PL01 Opening Plenary 1: Immunotherapy &amp; Vaccines</td>
<td>Hall C1</td>
</tr>
<tr>
<td></td>
<td><strong>LIVE-STREAM</strong></td>
<td></td>
</tr>
<tr>
<td>19:45 - 21:00</td>
<td>Welcome Reception</td>
<td>Hall B, Exhibit Hall</td>
</tr>
</tbody>
</table>

**Abbreviations:**
- EP: ePosters
- ES: Educational Session
- IBS: Interactive Breakfast Session (Ticketed Session)
- IS: Industry Symposium
- LA: Lectureship Awards
- MA: Mini Oral Session
- OA: Oral Session
- P: Posters
- PL: Plenary Session
- WS: Workshop
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30 - 08:15</td>
<td><strong>IBS01 Lung Cancer Screening: From Lung Cancer to Multiple Comorbidities</strong></td>
<td>Lehar 1, Track: Early Detection and Screening</td>
</tr>
<tr>
<td>07:30 - 08:15</td>
<td><strong>IBS02 SABR versus Surgery for Operable Lung Cancer</strong></td>
<td>Hall C8, Track: Early Stage Non-Small Cell Lung Cancer - Radiotherapy and Other Ablative Techniques</td>
</tr>
<tr>
<td>07:30 - 08:15</td>
<td><strong>IBS03 Real World Discussion about Testing in Low Income Countries</strong></td>
<td>Lehar 2, Track: Global Health, Health Services Research, and Health Economics</td>
</tr>
<tr>
<td>07:30 - 08:15</td>
<td><strong>IBS04 The Survivorship Experience for People Treated with Immunotherapy or Targeted Therapy</strong></td>
<td>Strauss 3, Track: Nursing and Allied Health Professionals</td>
</tr>
<tr>
<td>07:30 - 08:15</td>
<td><strong>IBS05 Controversies in Management of Locally Advanced NSCLC</strong></td>
<td>Lehar 3, Track: Locally Advanced Non-Small Cell Lung Cancer</td>
</tr>
<tr>
<td>07:30 - 08:15</td>
<td><strong>IBS06 Which Therapy for Which MPM Patient?</strong></td>
<td>Lehar 4, Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies</td>
</tr>
<tr>
<td>08:30 - 10:00</td>
<td><strong>PL02 Plenary 2: Multidisciplinary Approach to the Oligo Paradigm</strong></td>
<td>Hall C1</td>
</tr>
<tr>
<td>10:00 - 10:45</td>
<td><strong>Networking Break</strong></td>
<td>Hall B, Exhibit Hall</td>
</tr>
<tr>
<td>10:05 - 10:45</td>
<td><strong>PC02 Press Conference</strong></td>
<td>Schubert 5/6</td>
</tr>
<tr>
<td>10:45 - 11:45</td>
<td><strong>ES01 Implementation and Continuous Optimization of Lung Cancer Screening</strong></td>
<td>Hall C1, Track: Early Detection and Screening</td>
</tr>
</tbody>
</table>
### Session Overview

#### Sunday, August 7, 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Track</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 - 11:45</td>
<td><strong>ES03 Synchronous Oligometastatic NSCLC: Practical Implications</strong></td>
<td>Strauss 1/2</td>
<td>Metastatic Non-small Cell Lung Cancer - Oligometastatic Disease</td>
</tr>
<tr>
<td>10:45 - 11:45</td>
<td><strong>MA01 Molecular Subtypes and Prognostic Factors for SCLC and Neuro-endocrine Tumours</strong></td>
<td>Hall C7</td>
<td>Small Cell Lung Cancer and Neuro-endocrine Tumours</td>
</tr>
<tr>
<td>10:45 - 11:45</td>
<td><strong>MA02 Molecular Underpinnings of Lung Cancer Histological Differentiation and Targeted Therapeutics</strong></td>
<td>Hall C8</td>
<td>Tumour Biology and Biomarkers</td>
</tr>
<tr>
<td>10:45 - 11:45</td>
<td><strong>OA01 Real World Data to Guide Our Daily Needs</strong></td>
<td>Strauss 3</td>
<td>Global Health, Health Services Research, and Health Economics</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td><strong>ES04 Current Status of Lung Cancer Screening Worldwide</strong></td>
<td>Hall C1</td>
<td>Early Detection and Screening</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td><strong>ES05 Oncogenic Alterations and Beyond - Novel Treatments</strong></td>
<td>Hall C2</td>
<td>Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td><strong>ES06 Symptom Management in Lung Cancer</strong></td>
<td>Lehár 1</td>
<td>Palliative and Supportive Care</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td><strong>ES07 Impact of Tumour Plasticity and Molecular/Immune Adaptations in Treatment Sensitivity and Resistance</strong></td>
<td>Strauss 1/2</td>
<td>Tumour Biology and Biomarkers</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td><strong>MA03 Predicting Outcome in Patients with Early Disease NSCLC</strong></td>
<td>Hall C8</td>
<td>Early Stage Stage Non-small Cell Lung Cancer</td>
</tr>
</tbody>
</table>
**Sunday, August 7, 2022**

**12:00 - 13:00**  
OA02 From Locally Advanced to Unresectable NSCLC: Improvement of Multimodality Treatment  
Hall C7  
Track: Locally Advanced Non-small Lung Cancer

**13:15 - 14:15**  
LA01 Lectureship Awards - Sunday  
Hall C1

**13:15 - 14:45**  
Networking Lunch  
Hall B, Exhibit Hall

**14:00 - 15:30**  
MTE01 Meet the Editor  
Committee Room 1

**14:30 - 15:30**  
ES08 Sublobar Resection: Oncological Outcome and Advantages  
Hall C1  
Track: Early Stage Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments - Surgery

**14:30 - 15:30**  
ES09 Technology Innovations  
Hall C2

**14:30 - 15:30**  
ES10 Problems and Controversies in Thoracic Tumours  
Strauss 1/2  
Track: Pathology

**14:30 - 15:30**  
ES11 Joint ESTRO Session - Integration of Radiotherapy for Optimal Patient Outcomes  
Lehar 1

**14:30 - 15:30**  
MA04 Pulmonology, Radiology, and Staging  
Strauss 3  
Track: Pulmonology, Radiology, and Staging

**14:30 - 15:30**  
OA03 Molecular Targeted Treatments  
Hall C7  
Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

**14:30 - 15:30**  
OA04 Mesothelioma Under the Looking Glass  
Hall C8  
Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies
**Sunday, August 7, 2022**

15:45 - 16:45  **ES12 Surgical Issues in Multimodality Treatments for Early Stage NSCLC**
- **IASLC CME ACCREDITED**
- Hall C1
- Track: Early Stage Non-small Cell Lung Cancer - Surgery

15:45 - 16:45  **ES13 Mesothelioma**
- **IASLC CME ACCREDITED**
- Hall C2
- Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies

15:45 - 16:45  **ES14 Think, Think, Think…..The Importance of Thinking Holistically When Caring for Lung Cancer Patients**
- **IASLC CME ACCREDITED**
- Lehar 1
- Track: Nursing and Allied Health Professionals

15:45 - 16:45  **ES15 Is Cytotoxic Chemotherapy in NSCLC Management Only Palliative?**
- **IASLC CME ACCREDITED**
- Strauss 1/2
- Track: Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy

15:45 - 16:45  **MA05 Immune Landscape and Molecular Profiling of Lung Cancer**
- Hall C8
- Track: Tumour Biology and Biomarkers

15:45 - 16:45  **OA05 The Granularity of Lung Cancer Screening Implementation**
- Hall C7
- Track: Early Detection and Screening

17:00 - 19:00  **Poster Viewing Reception - Poster Session P1 Presenters in Attendance (Stand By Their Posters)**
- **LIGHT REFRESHMENTS PROVIDED**
- Hall B, Exhibit Hall

18:00 - 18:30  **Editorial Reception (By Invitation Only)**
- Messe Wien, Ground Floor, Pavilion Restaurant

19:30 - 22:30  **International Lung Cancer Foundation Benefit Supporting Early Career Researchers**
- **TICKETED NETWORKING EVENT**

Please refer to the ILCF Benefit Supporting Early Career Researchers Ticket for more information.

<table>
<thead>
<tr>
<th>EP</th>
<th>ePosters</th>
<th>MA</th>
<th>Mini Oral Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>ES</td>
<td>Educational Session</td>
<td>OA</td>
<td>Oral Session</td>
</tr>
<tr>
<td>IBS</td>
<td>Interactive Breakfast Session (Ticketed Session)</td>
<td>P</td>
<td>Posters</td>
</tr>
<tr>
<td>IS</td>
<td>Industry Symposium</td>
<td>PL</td>
<td>Plenary Session</td>
</tr>
<tr>
<td>LA</td>
<td>Lectureship Awards</td>
<td>WS</td>
<td>Workshop</td>
</tr>
</tbody>
</table>
Monday, August 8, 2022

07:30 - 08:15  IBS07 Interactive Multidisciplinary Thoracic Tumour Board
(IAASLC CME ACCREDITED) (TICKETED SESSION) (LIGHT BREAKFAST PROVIDED)
Lehar 1
Track: Early Stage Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Systemic Therapy (Multi-Modality Treatment, Immunotherapy, Molecular Targeted Treatments)

07:30 - 08:15  IBS08 Chemotherapy Still Remains a Key Component of Treatment for Majority of Patients with Metastatic NSCLC in the Era of Immune-Oncology
(IAASLC CME ACCREDITED) (TICKETED SESSION) (LIGHT BREAKFAST PROVIDED)
Hall C8
Track: Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy

07:30 - 08:15  IBS09 Inequities in Access to Lung Cancer Care across the World
(IAASLC CME ACCREDITED) (TICKETED SESSION) (LIGHT BREAKFAST PROVIDED)
Struass 3
Track: Patient Advocacy

07:30 - 08:15  IBS10 In Situ IO Biomarkers
(IAASLC CME ACCREDITED) (TICKETED SESSION) (LIGHT BREAKFAST PROVIDED)
Lehar 2
Track: Pathology

07:30 - 08:15  IBS11 E-Cigarettes Are an Effective Smoking Cessation Aid
(IAASLC CME ACCREDITED) (TICKETED SESSION) (LIGHT BREAKFAST PROVIDED)
Lehar 3
Track: Tobacco Control and Risk Reduction

07:30 - 08:15  IBS12 Mediastinal Staging
(IAASLC CME ACCREDITED) (TICKETED SESSION) (LIGHT BREAKFAST PROVIDED)
Lehar 4
Track: Pulmonology, Radiology, and Staging

08:30 - 10:20  PL03 Plenary 3: Presidential Symposium – Top Rated Abstracts
(IAASLC CME ACCREDITED) (LIVE-STREAM)
Hall C1

10:20 - 11:00  Networking Break
(LIGHT REFRESHMENTS PROVIDED)
Hall B, Exhibit Hall

10:25 - 11:00  PC03: Press Conference
Schubert 5/6

11:00 - 12:00  ES16 Pushing the Boundaries in Lung Ablative Therapies
(IAASLC CME ACCREDITED)
Hall C1
Track: Early Stage Non-Small Cell Lung Cancer - Radiotherapy and Other Ablative Techniques
**SESSION OVERVIEW**

**Monday, August 8, 2022**

**11:00 - 12:00**  
**ES17 Cost and Accessibility to Lung Cancer Drugs - Pathways to Improvement**  
IASLC CME ACCREDITED  
Hall C2  
Track: Global Health, Health Services Research, and Health Economics

**11:00 - 12:00**  
**ES18 Management of Pulmonary Nodules**  
IASLC CME ACCREDITED  
Strauss 1/2  
Track: Pulmonology, Radiology, and Staging

**11:00 - 12:00**  
**OA06 Impact of COVID-19 on Cancer Management and Protection from Vaccines**  
Lehar 1  
Track: Management of Lung Cancer in the Era of COVID-19

**11:00 - 12:00**  
**OA07 Is There Still a Role for Chemotherapy Alone in the Management of NSCLC?**  
Hall C7  
Track: Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy

**11:00 - 12:00**  
**OA08 Multidisciplinary Care of the Lung Cancer Patient**  
Strauss 3  
Track: Nursing and Allied Health Professionals

**12:15 - 13:15**  
**ES19 Toxicity Avoidance in SABR for Early Stage NSCLC**  
IASLC CME ACCREDITED  
Hall C1  
Track: Early Stage Non-Small Cell Lung Cancer - Radiotherapy and Other Ablative Techniques

**12:15 - 13:15**  
**ES20 Management of Lung Cancer in the Era of COVID-19 II**  
IASLC CME ACCREDITED  
Hall C2  
Track: Management of Lung Cancer in the Era of COVID-19

**12:15 - 13:15**  
**ES21 Problems and Controversies in Lung Tumours**  
IASLC CME ACCREDITED  
Strauss 1/2  
Track: Pathology

**12:15 - 13:15**  
**MA06 Resectable and Unresectable Locally Advanced Lung Cancer**  
Lehar 1  
Track: Locally Advanced Non-small Cell Lung Cancer

**12:15 - 13:15**  
**MA07 Overcoming Resistance to EGFR Inhibitors**  
Hall C7  
Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
### Monday 8 August, 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:15 - 13:15 | MA08 Patient Advocacy and Patient Preferences  
**Strauss 3**  
Track: Patient Advocacy |
| 13:30 - 14:30 | LA02 Lectureship Awards - Monday  
**Hall C1**  
**LIVE-STREAM** |
| 13:30 - 14:30 | Networking Lunch  
**Hall B, Exhibit Hall** |
| 14:45 - 15:45 | ES22 Lung Cancer in Individuals Without A Smoking History  
**Hall C1**  
Track: Epidemiology |
| 14:45 - 15:45 | ES23 Optimizing Radio-Chemo-Immunotherapy for Locally Advanced NSCLC  
**Hall C2**  
Track: Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy |
| 14:45 - 15:45 | ES24 Palliative Care Integration and QOL in Advanced Lung Cancer  
**Strauss 1/2**  
Track: Palliative and Supportive Care |
| 14:45 - 15:45 | MA09 Palliative Radiotherapy: The Changing Landscape with Immunotherapy and Targeted Therapies  
**Hall C7**  
Track: Metastatic Non-small Cell Lung Cancer - Palliative Radiotherapy |
| 14:45 - 15:45 | MA10 Updates in Thymoma  
**Hall C8**  
Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies |
| 14:45 - 15:45 | OA09 Precision Immunotherapy via Modulation of the Tumour Microenvironment  
**Lehar 1**  
Track: Tumour Biology and Biomarkers |
| 14:45 - 15:45 | OA10 Strategies to Integrate Smoking Cessation and Cancer Care  
**Strauss 3**  
Track: Tobacco Control and Risk Reduction |
Monday, August 8, 2022

16:00 – 17:00  ES25 Clinical Issues with Immunotherapy in Non-small Cell Lung Cancer
  Hall C1
  Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy

16:00 – 17:00  ES26 Thymoma
  Hall C2
  Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies

16:00 – 17:00  ES27 Joint Global Lung Cancer Coalition and International Association for the Study of Lung Cancer Session - Breaking Down Roadblocks to Lung Cancer Care in 2022
  Strauss 1/2
  Track: Patient Advocacy incl. Joint Session with GLCC

16:00 – 17:00  MA11 Optimization of Technologies for Lung Cancer Screening: Population Selection and Nodule Handling
  Lehar 1
  Track: Early Detection and Screening

16:00 – 17:00  OA11 Optimal Patient Selection for Local Therapy in Stage IV NSCLC
  Hall C7
  Track: Metastatic Non-small Cell Lung Cancer - Oligometastatic Disease

16:00 – 17:00  OA12 Novel Combination Strategies for SCLC
  Hall C8
  Track: Small Cell Lung Cancer and Neuro-endocrine Tumours

17:15 - 19:00  Poster Viewing Reception
  Hall B, Exhibit Hall

19:30 - 22:30  Faculty Dinner (By Invitation Only)
  Please refer to the Faculty Dinner Ticket for more information

---

<table>
<thead>
<tr>
<th>EP</th>
<th>ePosters</th>
<th>MA</th>
<th>Mini Oral Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>ES</td>
<td>Educational Session</td>
<td>OA</td>
<td>Oral Session</td>
</tr>
<tr>
<td>IBS</td>
<td>Interactive Breakfast Session (Ticketed Session)</td>
<td>P</td>
<td>Posters</td>
</tr>
<tr>
<td>IS</td>
<td>Industry Symposium</td>
<td>PL</td>
<td>Plenary Session</td>
</tr>
<tr>
<td>LA</td>
<td>Lectureship Awards</td>
<td>WS</td>
<td>Workshop</td>
</tr>
</tbody>
</table>
Tuesday, August 9, 2022

07:30 - 08:15  IBS13 CNS Involvement in Oncogene-Driven and Not-Oncogene-Driven Disease: Optimal Management
Lehar 1
Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

07:30 - 08:15  IBS14 Supportive Care in Lung Cancer: Improving Value in the Era of Modern Therapies
Strauss 3
Track: Palliative and Supportive Care

07:30 - 08:15  IBS15 Should We Offer PCI and Consolidation Thoracic RT to Patients Treated with First-Line Chemo-Immunotherapy?
Hall C8
Track: Small Cell Lung Cancer and Neuro-endocrine Tumours

07:30 - 08:15  IBS16 A Guide for the Perplexed: How to Use Lung Cancer Risk Models Efficiently for Screening
Lehar 2
Track: Early Detection and Screening

07:30 - 08:15  IBS17 Interactive Debate: Predictive Biomarkers for Immunotherapy: Which Biomarker to Use across Histologies and Clinical Settings?
Lehar 3
Track: Tumour Biology and Biomarkers

07:30 - 08:15  IBS18 Women in Thoracic Oncology
Lehar 4

08:30 - 10:00  PLO4 Plenary 4: Artificial Intelligence in Lung Cancer
Hall C1

10:00 - 10:45  IASLC Business Meeting
Strauss 3

10:00 - 10:45  Networking Break
Hall B, Exhibit Hall

10:05 - 10:45  PC04 - Press Conference
Schubert 5/6
## SESSION OVERVIEW

### Tuesday, August 9, 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Track</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 - 11:45</td>
<td>ES28 Neoadjuvant and Adjuvant Treatment of NSCLC in 2022</td>
<td>Hall C1</td>
<td>Early Stage Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Systemic Therapy (Multi-Modality Treatment, Immunotherapy, Molecular Targeted Treatments)</td>
</tr>
<tr>
<td>10:45 - 11:45</td>
<td>ES29 Palliative Radiotherapy in Metastatic NSCLC: State of the Art in an Era of New Hope</td>
<td>Hall C2</td>
<td>Metastatic Non-small Cell Lung Cancer - Palliative Radiotherapy</td>
</tr>
<tr>
<td>10:45 - 11:45</td>
<td>ES30 Leveraging the Power of Immunotherapy for SCLC</td>
<td>Strauss 1/2</td>
<td>Small Cell Lung Cancer and Neuro-endocrine Tumours</td>
</tr>
<tr>
<td>10:45 - 11:45</td>
<td>ES31 Survivorship across the Cancer Continuum for Patients Treated with Immunotherapies and Targeted Therapies</td>
<td>Lehar 1</td>
<td></td>
</tr>
<tr>
<td>10:45 - 11:45</td>
<td>MA12 Pathology: Tumour Diagnostics</td>
<td>Hall C7</td>
<td></td>
</tr>
<tr>
<td>10:45 - 11:45</td>
<td>OA13 Evolving Epidemiology of Lung Cancer Beyond Tobacco</td>
<td>Hall C8</td>
<td></td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td>ES32 Beyond Tobacco: Environmental Risk Factors for Lung Cancer</td>
<td>Hall C1</td>
<td>Epidemiology</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td>ES33 Management of Oligometastatic and Multi-Focal Lung Cancer</td>
<td>Hall C2</td>
<td>Locally Advanced Non-small Cell Lung Cancer - Oligometastatic</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td>ES34 Updates in Radiology, Pulmonology, and Staging</td>
<td>Strauss 1/2</td>
<td>Pulmonology, Radiology, and Staging</td>
</tr>
</tbody>
</table>
**SESSION OVERVIEW**

**Tuesday, 9 August, 2022**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Track</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 - 13:00</td>
<td><strong>ES35 High-Plex Spatial Technologies for Molecular Tumour Analysis and Single-Cell Studies</strong></td>
<td>Hall C7</td>
<td>Lehar 1 Track: Tumour Biology and Biomarkers</td>
</tr>
<tr>
<td></td>
<td>in Thoracic Oncology Research and Future Clinical Uses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td><strong>MA13 Update on ROS1 Inhibitors and New Pathways</strong></td>
<td>Hall C7</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td><strong>OA14 New Techniques to Improve Outcome in Early Stage NSCLC Patients</strong></td>
<td>Hall C8</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Treated with Surgery or Radiotherapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:15 - 14:15</td>
<td><strong>LA03 Lectureship Awards - Tuesday</strong></td>
<td>Hall C1</td>
<td></td>
</tr>
<tr>
<td>13:15 - 14:15</td>
<td><strong>Networking Lunch</strong></td>
<td>Hall B, Exhibit Hall</td>
<td></td>
</tr>
<tr>
<td>14:30 - 15:30</td>
<td><strong>ES36 Revisiting the Perioperative Management of NSCLC</strong></td>
<td>Hall C1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30 - 15:30</td>
<td><strong>ES37 What Lung Cancer Clinicians Need to Know about Tobacco</strong></td>
<td>Hall C2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30 - 15:30</td>
<td><strong>ES38 Optimising the Management of SCLC and Neuro-endocrine Tumours</strong></td>
<td>Strauss 1/2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30 - 15:30</td>
<td><strong>ES39 Role of Novel Biomarkers and Technologies in Optimal Diagnosis and Disease Management:</strong></td>
<td>Lehar 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Focus on Liquid Biopsies and Advanced Tissue Diagnostics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30 - 15:30</td>
<td><strong>MA14 Palliative and Supportive Care - The Forgotten Trade</strong></td>
<td>Strauss 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Tuesday, 9 August, 2022

14:30 - 15:30 OA15 Patient Selection in Advanced NSCLC Immunotherapy
Hall C7
Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy

15:45 - 16:45 PL05 Closing Plenary 5: Access to Drugs
Hall C1
These on-demand sessions are available exclusively on the virtual platform.

WS08  Joint IASLC-CSCO-CAALC Session: Liquid Biopsy in Oncogene Driven NSCLC
HOD01  Highlights of the Day - Sunday
HOD02  Highlights of the Day - Monday
HOD03  Highlights of the Day - Tuesday
Immunohistochemistry is an extremely valuable and powerful technique for pathologic diagnosis.

Published by the IASLC and its Pathology Committee, the IHC Atlas takes a comprehensive look at diagnostic IHC and its role in thoracic pathology.

The IHC Atlas is a useful reference for anyone interested in thoracic tumor diagnostics, from basic researchers to practicing oncologists. All pathologists should have access to these best practices. The Atlas is available in multiple languages.

Visit the IASLC booth or scan the QR code to order your copy today!

Coming Soon!
IASLC Atlas on Molecular Biomarker Testing for Targeted Therapy
Available at #TTLC23
## Early Detection and Screening

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, August 7, 2022</td>
<td>07:30 - 08:15</td>
<td>Interactive Breakfast Session</td>
<td>IBS01</td>
<td>Lung Cancer Screening: From Lung Cancer to Multiple Comorbidities</td>
<td>Lehar 1</td>
</tr>
<tr>
<td>Sunday, August 7, 2022</td>
<td>10:45 - 11:45</td>
<td>Education Session</td>
<td>ES01</td>
<td>Implementation and Continuous Optimization of Lung Cancer Screening</td>
<td>Hall C1</td>
</tr>
<tr>
<td>Sunday, August 7, 2022</td>
<td>12:00 - 13:00</td>
<td>Education Session</td>
<td>ES04</td>
<td>Current Status of Lung Cancer Screening Worldwide</td>
<td>Hall C1</td>
</tr>
<tr>
<td>Sunday, August 7, 2022</td>
<td>15:45 - 16:45</td>
<td>Oral Session</td>
<td>OA05</td>
<td>The Granularity of Lung Cancer Screening Implementation</td>
<td>Hall C7</td>
</tr>
<tr>
<td>Monday, August 8, 2022</td>
<td>16:00 - 17:00</td>
<td>Mini Oral Session</td>
<td>MA11</td>
<td>Optimization of Technologies for Lung Cancer Screening: Population Selection and Nodule Handling</td>
<td>Lehar 1</td>
</tr>
<tr>
<td>Tuesday, August 9, 2022</td>
<td>07:30 - 08:15</td>
<td>Interactive Breakfast Session</td>
<td>IBS16</td>
<td>A Guide for the Perplexed: How to Use Lung Cancer Risk Models Efficiently for Screening</td>
<td>Lehar 2</td>
</tr>
</tbody>
</table>

## Early Stage Non-small Cell Lung Cancer

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, August 7, 2022</td>
<td>12:00 - 13:00</td>
<td>Mini Oral Session</td>
<td>MA03</td>
<td>Predicting Outcome in Patients with Early Disease NSCLC</td>
<td>Hall C8</td>
</tr>
<tr>
<td>Tuesday, August 9, 2022</td>
<td>12:00 - 13:00</td>
<td>Oral Session</td>
<td>OA14</td>
<td>New Techniques to Improve Outcome in Early Stage NSCLC Patients Treated with Surgery or Radiotherapy</td>
<td>Hall C8</td>
</tr>
</tbody>
</table>
**Early Stage Non-small Cell Lung Cancer – Neoadjuvant and Adjuvant Systemic Therapy (Multi-Modality Treatment, Immunotherapy, Molecular Targeted Treatments)**

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, August 8, 2022</td>
<td>07:30 - 08:15</td>
<td>Interactive Breakfast Session</td>
<td>IBS07</td>
<td>Interactive Multidisciplinary Thoracic Tumour Board</td>
<td>Lehar 1</td>
</tr>
<tr>
<td>Tuesday, August 9, 2022</td>
<td>10:45 - 11:45</td>
<td>Education Session</td>
<td>ES28</td>
<td>Neoadjuvant and Adjuvant Treatment of NSCLC in 2022</td>
<td>Hall C1</td>
</tr>
</tbody>
</table>

**Early Stage Non-small Cell Lung Cancer – Radiotherapy and Other Ablative Techniques**

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, August 7, 2022</td>
<td>07:30 - 08:15</td>
<td>Interactive Breakfast Session</td>
<td>IBS02</td>
<td>SABR versus Surgery for Operable Lung Cancer</td>
<td>Hall C8</td>
</tr>
<tr>
<td>Monday, August 8, 2022</td>
<td>11:00 – 12:00</td>
<td>Education Session</td>
<td>ES16</td>
<td>Pushing the Boundaries in Lung Ablative Therapies</td>
<td>Hall C1</td>
</tr>
<tr>
<td>Monday, August 8, 2022</td>
<td>12:15 – 13:15</td>
<td>Education Session</td>
<td>ES19</td>
<td>Toxicity Avoidance in SABR for Early Stage NSCLC</td>
<td>Hall C1</td>
</tr>
</tbody>
</table>

**Early Stage Non-small Cell Lung Cancer – Surgery**

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, August 7, 2022</td>
<td>14:30 - 15:30</td>
<td>Education Session</td>
<td>ES08</td>
<td>Sublobar Resection: Oncological Outcome and Advantages</td>
<td>Hall C1</td>
</tr>
<tr>
<td>Sunday, August 7, 2022</td>
<td>15:45 - 16:45</td>
<td>Education Session</td>
<td>ES12</td>
<td>Surgical Issues in Multimodality Treatments for Early Stage NSCLC</td>
<td>Hall C1</td>
</tr>
</tbody>
</table>
## Epidemiology

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, August 8, 2022</td>
<td>14:45 – 15:45</td>
<td>Education Session</td>
<td>ES22</td>
<td>Lung Cancer in Individuals Without A Smoking History</td>
<td>Hall C1</td>
</tr>
<tr>
<td>Tuesday, August 9, 2022</td>
<td>10:45 - 11:45</td>
<td>Oral Session</td>
<td>OA13</td>
<td>Evolving Epidemiology of Lung Cancer Beyond Tobacco</td>
<td>Hall C8</td>
</tr>
<tr>
<td>Tuesday, August 9, 2022</td>
<td>12:00 - 13:00</td>
<td>Education Session</td>
<td>ES32</td>
<td>Beyond Tobacco: Environmental Risk Factors for Lung Cancer</td>
<td>Hall C1</td>
</tr>
</tbody>
</table>

## Global Health, Health Services Research, and Health Economics

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, August 7, 2022</td>
<td>07:30 - 08:15</td>
<td>Interactive Breakfast Session</td>
<td>IBS03</td>
<td>Real World Discussion about Testing in Low Income Countries</td>
<td>Lehar 2</td>
</tr>
<tr>
<td>Sunday, August 7, 2022</td>
<td>10:45 - 11:45</td>
<td>Oral Session</td>
<td>OA01</td>
<td>Real World Data to Guide Our Daily Needs</td>
<td>Strauss 3</td>
</tr>
<tr>
<td>Monday, August 8, 2022</td>
<td>11:00 – 12:00</td>
<td>Education Session</td>
<td>ES17</td>
<td>Cost and Accessibility to Lung Cancer Drugs - Pathways to Improvement</td>
<td>Hall C2</td>
</tr>
</tbody>
</table>

## Locally Advanced Non-small Cell Lung Cancer

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, August 7, 2022</td>
<td>07:30 - 08:15</td>
<td>Interactive Breakfast Session</td>
<td>IBS05</td>
<td>Controversies in Management of Locally Advanced NSCLC</td>
<td>Hall C8</td>
</tr>
<tr>
<td>Sunday, August 7, 2022</td>
<td>12:00 - 13:00</td>
<td>Oral Session</td>
<td>OA02</td>
<td>From Locally Advanced to Unresectable NSCLC: Improvement of Multimodality Treatment</td>
<td>Hall C8</td>
</tr>
<tr>
<td>Monday, August 8, 2022</td>
<td>12:15 – 13:15</td>
<td>Mini Oral Session</td>
<td>MA06</td>
<td>Resectable and Unresectable Locally Advanced Lung Cancer</td>
<td>Lehar 1</td>
</tr>
</tbody>
</table>
# Locally Advanced Non-small Cell Lung Cancer – Chemoradiotherapy and Radiotherapy

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, August 8, 2022</td>
<td>14:45 – 15:45</td>
<td>Education Session</td>
<td>ES23</td>
<td>Optimizing Radio-Chemo-Immunotherapy for Locally Advanced NSCLC</td>
<td>Hall C2</td>
</tr>
</tbody>
</table>

# Locally Advanced Non-small Cell Lung Cancer – Neoadjuvant and Adjuvant Therapy

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday, August 9, 2022</td>
<td>14:30 - 15:30</td>
<td>Education Session</td>
<td>ES36</td>
<td>Revisiting the Perioperative Management of NSCLC</td>
<td>Hall C1</td>
</tr>
</tbody>
</table>

# Locally Advanced Non-small Cell Lung Cancer – Oligometastatic

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday, August 9, 2022</td>
<td>12:00 - 13:00</td>
<td>Education Session</td>
<td>ES33</td>
<td>Management of Oligometastatic and Multi-Focal Lung Cancer</td>
<td>Hall C2</td>
</tr>
</tbody>
</table>

# Management of Lung Cancer in the Era of COVID-19

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, August 7, 2022</td>
<td>10:45 - 11:45</td>
<td>Education Session</td>
<td>ES02</td>
<td>Management of Lung Cancer in the Era of COVID-19</td>
<td>Hall C2</td>
</tr>
<tr>
<td>Monday, August 8, 2022</td>
<td>11:00 – 12:00</td>
<td>Oral Session</td>
<td>OA06</td>
<td>Impact of COVID-19 on Cancer Management and Protection from Vaccines</td>
<td>Lehar 1</td>
</tr>
</tbody>
</table>
### Mesothelioma, Thymoma, and Other Thoracic Malignancies

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, August 7, 2022</td>
<td>07:30 - 08:15</td>
<td>Interactive Breakfast Session</td>
<td>IBS06</td>
<td>Which Therapy for Which MPM Patient?</td>
<td>Lehar 4</td>
</tr>
<tr>
<td>Sunday, August 7, 2022</td>
<td>14:30 - 15:30</td>
<td>Oral Session</td>
<td>OA04</td>
<td>Mesothelioma Under the Looking Glass</td>
<td>Hall C8</td>
</tr>
<tr>
<td>Sunday, August 7, 2022</td>
<td>15:45 - 16:45</td>
<td>Education Session</td>
<td>ES13</td>
<td>Mesothelioma</td>
<td>Hall C2</td>
</tr>
<tr>
<td>Monday, August 8, 2022</td>
<td>14:45 – 15:45</td>
<td>Mini Oral Session</td>
<td>MA10</td>
<td>Updates in Thymoma</td>
<td>Hall C8</td>
</tr>
<tr>
<td>Monday, August 8, 2022</td>
<td>16:00 – 17:00</td>
<td>Education Session</td>
<td>ES26</td>
<td>Thymoma</td>
<td>Hall C2</td>
</tr>
</tbody>
</table>

### Metastatic Non-small Cell Lung Cancer - Immunotherapy

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, August 8, 2022</td>
<td>16:00 – 17:00</td>
<td>Education Session</td>
<td>ES25</td>
<td>Clinical Issues with Immunotherapy in Non-small Cell Lung Cancer</td>
<td>Hall C1</td>
</tr>
<tr>
<td>Tuesday, August 9, 2022</td>
<td>14:30 - 15:30</td>
<td>Mini Oral Session</td>
<td>OA15</td>
<td>Patient Selection in Advanced NSCLC Immunotherapy</td>
<td>Hall C7</td>
</tr>
</tbody>
</table>

### Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, August 7, 2022</td>
<td>12:00 - 13:00</td>
<td>Education Session</td>
<td>ES05</td>
<td>Oncogenic Alterations and Beyond - Novel Treatments</td>
<td>Hall C7</td>
</tr>
<tr>
<td>Sunday, August 7, 2022</td>
<td>14:30 - 15:30</td>
<td>Oral Session</td>
<td>OA03</td>
<td>Molecular Targeted Treatments</td>
<td>Hall C7</td>
</tr>
<tr>
<td>Monday, August 8, 2022</td>
<td>12:15 – 13:15</td>
<td>Mini Oral Session</td>
<td>MA07</td>
<td>Overcoming Resistance to EGFR Inhibitors</td>
<td>Hall C7</td>
</tr>
<tr>
<td>Tuesday, August 9, 2022</td>
<td>07:30 - 08:15</td>
<td>Interactive Breakfast Session</td>
<td>IBS13</td>
<td>CNS Involvement in Oncogene-Driven and Not-Oncogene-Driven Disease: Optimal Management</td>
<td>Lehar 1</td>
</tr>
<tr>
<td>Tuesday, August 9, 2022</td>
<td>12:00 - 13:00</td>
<td>Mini Oral Session</td>
<td>MA13</td>
<td>Update on ROS1 Inhibitors and New Pathways</td>
<td>Hall C7</td>
</tr>
</tbody>
</table>
## Metastatic Non-small Cell Lung Cancer – Oligometastatic Disease

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, August 7, 2022</td>
<td>10:45 - 11:45</td>
<td>Education Session</td>
<td>ES03</td>
<td>Synchronous Oligometastatic NSCLC: Practical Implications</td>
<td>Strauss 1/2</td>
</tr>
<tr>
<td>Monday, August 8, 2022</td>
<td>16:00 – 17:00</td>
<td>Oral Session</td>
<td>OA11</td>
<td>Optimal Patient Selection for Local Therapy in Stage IV NSCLC</td>
<td>Hall C7</td>
</tr>
</tbody>
</table>

## Metastatic Non-small Cell Lung Cancer – Palliative Chemotherapy

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, August 7, 2022</td>
<td>15:45 - 16:45</td>
<td>Education Session</td>
<td>ES15</td>
<td>Is Cytotoxic Chemotherapy in NSCLC Management Only Palliative?</td>
<td>Strauss 1/2</td>
</tr>
<tr>
<td>Monday, August 8, 2022</td>
<td>07:30 - 08:15</td>
<td>Interactive Breakfast Session</td>
<td>IBS08</td>
<td>Chemotherapy Still Remains a Key Component of Treatment for Majority of Patients with Metastatic NSCLC in the Era of Immune-Oncology</td>
<td>Hall C8</td>
</tr>
<tr>
<td>Monday, August 8, 2022</td>
<td>11:00 – 12:00</td>
<td>Oral Session</td>
<td>OA07</td>
<td>Is There Still a Role for Chemotherapy Alone in the Management of NSCLC?</td>
<td>Hall C7</td>
</tr>
</tbody>
</table>

## Metastatic Non-small Cell Lung Cancer – Palliative Radiotherapy

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, August 8, 2022</td>
<td>14:45 – 15:45</td>
<td>Mini Oral Session</td>
<td>MA09</td>
<td>Palliative Radiotherapy: The Changing Landscape with Immunotherapy and Targeted Therapies</td>
<td>Hall C7</td>
</tr>
<tr>
<td>Tuesday, August 9, 2022</td>
<td>10:45 - 11:45</td>
<td>Education Session</td>
<td>ES29</td>
<td>Palliative Radiotherapy in Metastatic NSCLC: State of the Art in an Era of New Hope</td>
<td>Hall C2</td>
</tr>
</tbody>
</table>
### Nursing and Allied Health Professionals

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, August 7, 2022</td>
<td>07:30 - 08:15</td>
<td>Interactive Breakfast Session</td>
<td>IBS04</td>
<td>The Survivorship Experience for People Treated with Immunotherapy or Targeted Therapy</td>
<td>Strauss 3</td>
</tr>
<tr>
<td>Sunday, August 7, 2022</td>
<td>15:45 - 16:45</td>
<td>Education Session</td>
<td>ES14</td>
<td>Think, Think, Think.....The Importance of Thinking Holistically When Caring for Lung Cancer Patients</td>
<td>Lehar 1</td>
</tr>
<tr>
<td>Monday, August 8, 2022</td>
<td>11:00 – 12:00</td>
<td>Oral Session</td>
<td>OA08</td>
<td>Multidisciplinary Care of the Lung Cancer Patient</td>
<td>Strauss 3</td>
</tr>
<tr>
<td>Tuesday, August 9, 2022</td>
<td>10:45 - 11:45</td>
<td>Education Session</td>
<td>ES31</td>
<td>Survivorship across the Cancer Continuum for Patients Treated with Immunotherapies and Targeted Therapies</td>
<td>Lehar 1</td>
</tr>
</tbody>
</table>

### Palliative and Supportive Care

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, August 7, 2022</td>
<td>12:00 - 13:00</td>
<td>Education Session</td>
<td>ES06</td>
<td>Symptom Management in Lung Cancer</td>
<td>Lehar 1</td>
</tr>
<tr>
<td>Monday, August 8, 2022</td>
<td>14:45- 15:45</td>
<td>Education Session</td>
<td>ES24</td>
<td>Palliative Care Integration and QOL in Advanced Lung Cancer</td>
<td>Strauss 1/2</td>
</tr>
<tr>
<td>Tuesday, August 9, 2022</td>
<td>07:30 - 08:15</td>
<td>Interactive Breakfast Session</td>
<td>IBS14</td>
<td>Supportive Care in Lung Cancer: Improving Value in the Era of Modern Therapies</td>
<td>Strauss 3</td>
</tr>
<tr>
<td>Tuesday, August 9, 2022</td>
<td>14:30 - 15:30</td>
<td>Mini Oral Session</td>
<td>MA14</td>
<td>Palliative and Supportive Care - The Forgotten Trade</td>
<td>Strauss 3</td>
</tr>
</tbody>
</table>
## Pathology

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, August 6, 2022</td>
<td>14:30 - 15:30</td>
<td>Education Session</td>
<td>ES10</td>
<td>Problems and Controversies in Thoracic Tumours</td>
<td>Strauss 1/2</td>
</tr>
<tr>
<td>Monday, August 8, 2022</td>
<td>07:30 - 08:15</td>
<td>Interactive Breakfast Session</td>
<td>IBS10</td>
<td>In Situ IO Biomarkers</td>
<td>Lehar 2</td>
</tr>
<tr>
<td>Monday, August 8, 2022</td>
<td>12:15 - 13:15</td>
<td>Education Session</td>
<td>ES21</td>
<td>Problems and Controversies in Lung Tumours</td>
<td>Strauss 1/2</td>
</tr>
<tr>
<td>Tuesday, August 9, 2022</td>
<td>10:45 - 11:45</td>
<td>Mini Oral Session</td>
<td>MA12</td>
<td>Pathology: Tumour Diagnostics</td>
<td>Hall C7</td>
</tr>
</tbody>
</table>

## Patient Advocacy

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, August 8, 2022</td>
<td>07:30 - 08:15</td>
<td>Interactive Breakfast Session</td>
<td>IBS09</td>
<td>Inequities in Access to Lung Cancer Care across the World</td>
<td>Strauss 3</td>
</tr>
<tr>
<td>Monday, August 8, 2022</td>
<td>16:00 - 17:00</td>
<td>Education Session</td>
<td>ES27</td>
<td>Joint Global Lung Cancer Coalition and International Association for the Study of Lung Cancer Session - Breaking Down Roadblocks to Lung Cancer Care in 2022</td>
<td>Strauss 1/2</td>
</tr>
</tbody>
</table>

## Pulmonology, Radiology, and Staging

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, August 7, 2022</td>
<td>14:30 - 15:30</td>
<td>Mini Oral Session</td>
<td>MA04</td>
<td>Pulmonology, Radiology, and Staging</td>
<td>Strauss 3</td>
</tr>
<tr>
<td>Monday, August 8, 2022</td>
<td>07:30 - 08:15</td>
<td>Interactive Breakfast Session</td>
<td>IBS12</td>
<td>Mediastinal Staging</td>
<td>Lehar 4</td>
</tr>
<tr>
<td>Monday, August 8, 2022</td>
<td>10:45 - 11:45</td>
<td>Education Session</td>
<td>ES18</td>
<td>Management of Pulmonary Nodules</td>
<td>Strauss 1/2</td>
</tr>
<tr>
<td>Tuesday, August 9, 2022</td>
<td>12:00 - 13:00</td>
<td>Education Session</td>
<td>ES34</td>
<td>Updates in Radiology, Pulmonology, and Staging</td>
<td>Strauss 1/2</td>
</tr>
</tbody>
</table>
# Small Cell Lung Cancer and Neuro-endocrine Tumours

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, August 7,</td>
<td>10:45 - 11:45</td>
<td>Mini Oral Session</td>
<td>MA01</td>
<td>Molecular Subtypes and Prognostic Factors for SCLC and Neuro-endocrine Tumors</td>
<td>Hall C7</td>
</tr>
<tr>
<td>2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monday, August 8,</td>
<td>16:00 – 17:00</td>
<td>Oral Session</td>
<td>OA12</td>
<td>Novel Combination Strategies for SCLC</td>
<td>Hall C8</td>
</tr>
<tr>
<td>2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuesday, August 9,</td>
<td>07:30 - 08:15</td>
<td>Interactive Breakfast Session</td>
<td>IBS15</td>
<td>Should We Offer PCI and Consolidation Thoracic RT to Patients Treated with First-Line Chemo-Immunotherapy?</td>
<td>Hall C8</td>
</tr>
<tr>
<td>2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuesday, August 9,</td>
<td>10:45 - 11:45</td>
<td>Education Session</td>
<td>ES30</td>
<td>Leveraging the Power of Immunotherapy for SCLC</td>
<td>Strauss 1/2</td>
</tr>
<tr>
<td>2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuesday, August 9,</td>
<td>14:30 - 15:30</td>
<td>Education Session</td>
<td>ES38</td>
<td>Optimising the Management of SCLC and Neuro-endocrine Tumours</td>
<td>Strauss 1/2</td>
</tr>
<tr>
<td>2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

# Tobacco Control and Risk Reduction

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, August 7,</td>
<td>07:30 - 08:15</td>
<td>Interactive Breakfast Session</td>
<td>IBS11</td>
<td>E-Cigarettes Are an Effective Smoking Cessation Aid</td>
<td>Lehar 3</td>
</tr>
<tr>
<td>2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monday, August 8,</td>
<td>14:45 – 15:45</td>
<td>Oral Session</td>
<td>OA10</td>
<td>Strategies to Integrate Smoking Cessation and Cancer Care</td>
<td>Strauss 3</td>
</tr>
<tr>
<td>2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuesday, August 9,</td>
<td>14:30 - 15:30</td>
<td>Education Session</td>
<td>ES37</td>
<td>What Lung Cancer Clinicians Need to Know about Tobacco</td>
<td>Hall C2</td>
</tr>
<tr>
<td>2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# Tumour Biology and Biomarkers

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, August 7,</td>
<td>10:45 - 11:45</td>
<td>Mini Oral Session</td>
<td>MA02</td>
<td>Molecular Underpinnings of Lung Cancer Histological Differentiation and Targeted Therapeutics</td>
<td>Hall C8</td>
</tr>
<tr>
<td>2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunday, August 7,</td>
<td>12:00 - 13:00</td>
<td>Education Session</td>
<td>ES07</td>
<td>Impact of Tumor Plasticity and Molecular/Immune Adaptations in Treatment Sensitivity and Resistance</td>
<td>Strauss 1/2</td>
</tr>
<tr>
<td>2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunday, August 7,</td>
<td>15:45 - 16:45</td>
<td>Oral Session</td>
<td>MA05</td>
<td>Immune Landscape and Molecular Profiling of Lung Cancer</td>
<td>Hall C8</td>
</tr>
<tr>
<td>2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monday, August 8,</td>
<td>14:45 - 15:45</td>
<td>Oral Session</td>
<td>OA09</td>
<td>Precision Immunotherapy via Modulation of the Tumor Microenvironment</td>
<td>Lehar 1</td>
</tr>
<tr>
<td>2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuesday, August 9,</td>
<td>07:30 - 08:15</td>
<td>Interactive Breakfast Session</td>
<td>IBS17</td>
<td>Interactive Debate: Predictive Biomarkers for Immunotherapy: Which Biomarker to Use across Histologies and Clinical Settings?</td>
<td>Lehar 3</td>
</tr>
<tr>
<td>2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuesday, August 9,</td>
<td>12:00 - 13:00</td>
<td>Education Session</td>
<td>ES35</td>
<td>High-Plex Spatial Technologies for Molecular Tumor Analysis and Single-Cell Studies in Thoracic Oncology Research and Future Clinical Uses</td>
<td>Lehar 1</td>
</tr>
<tr>
<td>2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuesday, August 9,</td>
<td>14:30 - 15:30</td>
<td>Education Session</td>
<td>ES39</td>
<td>Role of Novel Biomarkers and Technologies in Optimal Diagnosis and Disease Management: Focus on Liquid Biopsies and Advanced Tissue Diagnostics</td>
<td>Lehar 1</td>
</tr>
<tr>
<td>2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Others

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, August 7, 2022</td>
<td>14:30 - 15:30</td>
<td>Education Session</td>
<td>ES09</td>
<td>Technology Innovations</td>
<td>Hall C2</td>
</tr>
<tr>
<td>Sunday, August 7, 2022</td>
<td>14:30 - 15:30</td>
<td>Education Session</td>
<td>ES11</td>
<td>Joint IASLC-ESTRO Session - Integration of Radiotherapy for Optimal Patient Outcomes</td>
<td>Lehar 1</td>
</tr>
<tr>
<td>Tuesday, August 8, 2022</td>
<td>07:30 - 08:15</td>
<td>Interactive Breakfast Session</td>
<td>IBS18</td>
<td>Women in Thoracic Oncology</td>
<td>Lehar 4</td>
</tr>
</tbody>
</table>

## Workshops

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, August 5, 2022</td>
<td>09:00 - 16:00</td>
<td>Workshop</td>
<td>WS02</td>
<td>IASLC CT Screening Symposium: Forefront Advances in Lung Cancer Screening</td>
<td>Strauss 3</td>
</tr>
<tr>
<td>Saturday, August 6, 2022</td>
<td>08:00 - 11:30</td>
<td>Workshop</td>
<td>WS03</td>
<td>Early Career &amp; First Time Attendee Session</td>
<td>Lehar 1</td>
</tr>
<tr>
<td>Saturday, August 6, 2022</td>
<td>08:00 - 12:00</td>
<td>Workshop</td>
<td>WS04</td>
<td>IASLC/IMIG Workshop - The Future of Mesothelioma Treatment</td>
<td>Lehar 4</td>
</tr>
<tr>
<td>Saturday, August 6, 2022</td>
<td>09:00 - 11:00</td>
<td>Workshop</td>
<td>WS05</td>
<td>Social Media + Communications Workshop</td>
<td>Lehar 2</td>
</tr>
<tr>
<td>Saturday, August 6, 2022</td>
<td>12:00 - 17:00</td>
<td>Workshop</td>
<td>WS06</td>
<td>Nurse &amp; AHP + ITONF Joint Workshop</td>
<td>Lehar 3</td>
</tr>
<tr>
<td>Saturday, August 6, 2022</td>
<td>15:00 - 16:30</td>
<td>Workshop</td>
<td>WS07</td>
<td>LATAM Workshop</td>
<td>Lehar 2</td>
</tr>
<tr>
<td>On-Demand</td>
<td></td>
<td>Workshop</td>
<td>WS08</td>
<td>Joint IASLC-CSCO-CAALC Session (On-Demand)</td>
<td>On-Demand</td>
</tr>
</tbody>
</table>
# Plenary Sessions

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Aug 6</td>
<td>18:15 - 19:45</td>
<td>Plenary</td>
<td>PL01</td>
<td>Opening Plenary 1: Immunotherapy &amp; Vaccines</td>
<td>Hall C1</td>
</tr>
<tr>
<td>Sunday, Aug 7</td>
<td>08:30 - 10:00</td>
<td>Plenary</td>
<td>PL02</td>
<td>Plenary 2: Multidisciplinary Approach to the Oligo Paradigm</td>
<td>Hall C1</td>
</tr>
<tr>
<td>Monday, Aug 8</td>
<td>08:30 - 10:20</td>
<td>Plenary</td>
<td>PL03</td>
<td>Plenary 3: Presidential Symposium – Top Rated Abstracts</td>
<td>Hall C1</td>
</tr>
<tr>
<td>Tuesday, Aug 9</td>
<td>08:30 - 10:00</td>
<td>Plenary</td>
<td>PL04</td>
<td>Plenary 4: Artificial Intelligence in Lung Cancer</td>
<td>Hall C1</td>
</tr>
<tr>
<td>Tuesday, Aug 9</td>
<td>15:45 - 16:45</td>
<td>Plenary</td>
<td>PL05</td>
<td>Closing Plenary 5: Access to Drugs</td>
<td>Hall C1</td>
</tr>
</tbody>
</table>

# Lectureship Awards

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, Aug 7</td>
<td>13:15 - 14:15</td>
<td>Lectureship Awards</td>
<td>LA01</td>
<td>Lectureship Awards - Sunday</td>
<td>Hall C1</td>
</tr>
<tr>
<td>Monday, Aug 8</td>
<td>13:30 - 14:30</td>
<td>Lectureship Awards</td>
<td>LA02</td>
<td>Lectureship Awards - Monday</td>
<td>Hall C1</td>
</tr>
<tr>
<td>Tuesday, Aug 9</td>
<td>13:15 - 14:15</td>
<td>Lectureship Awards</td>
<td>LA03</td>
<td>Lectureship Awards - Tuesday</td>
<td>Hall C1</td>
</tr>
</tbody>
</table>

# IASLC Awards Ceremony

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Aug 6</td>
<td>17:00 - 17:45</td>
<td>Awards Ceremony</td>
<td>AC01</td>
<td>IASLC Awards Ceremony</td>
<td>Lehar 1</td>
</tr>
</tbody>
</table>

# IASLC Business Meeting

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday, Aug 9</td>
<td>10:00 - 10:45</td>
<td>Business Meeting</td>
<td></td>
<td>IASLC Business Meeting</td>
<td>Strauss 3</td>
</tr>
</tbody>
</table>

# Meet the Editor

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Type</th>
<th>#</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, Aug 7</td>
<td>14:00 - 15:30</td>
<td>Meet the Editor</td>
<td>MTE01</td>
<td>Meet the Editor</td>
<td>Committee Room 1</td>
</tr>
</tbody>
</table>
Remaking medicine, starting in lung cancer

EQRx™

Clinical OLYMPICS

A GAMIFIED SATELLITE SYMPOSIUM DURING THE IASLC 2022 WORLD CONFERENCE ON LUNG CANCER

HARNESSING THE FULL POTENTIAL OF FRONTLINE IMMUNOTHERAPY IN ADVANCED NSCLC

SUNDAY, 7 AUGUST 2022 | 18:00 – 19:00

Mess Wien Exhibition & Congress Center Hall C7

EVENT #1: Use of Biomarker Testing in Advanced NSCLC
EVENT #2: Selecting Frontline Immunotherapy in Advanced NSCLC
EVENT #3: Managing Immunotherapy-Related Adverse Events in NSCLC

Register Now!
RMEI.com/WCLC2022

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

This educational activity was independently developed by RMEI Medical Education, LLC. All faculty and planner relevant financial relationships were identified and mitigated and RMEI Medical Education, LLC has reviewed the content and determined it to be fair, balanced, and without commercial bias.
09:00 - 16:00
WS02: IASLC CT Screening Symposium: Forefront Advances in Lung Cancer Screening

Chairs: Chunxue Bai, China, David Baldwin, United Kingdom, Ella Kazerooni, United States, Stephen Lam, Canada, Annette McWilliams, Australia, Harry de Koning, Netherlands

09:00 – 09:12
WS02.01 / WS02.02 / WS02.03 / WS02.04 / WS02.05 / WS02.06 Session Introduction
Chunxue Bai, China, David Baldwin, United Kingdom, Ella Kazerooni, United States, Stephen Lam, Canada, Annette Mcwilliams, Australia, Harry de Koning, Netherlands

09:12 – 09:15
WS02.07 / WS02.08 Session 1 Welcome
Ella Kazerooni, United States, Stephen Lam, Canada

09:15 – 09:25
WS02.09 Key Elements for Successful Implementation of a National Screening Program - The Taiwan Experience
Pan Chyr Yang, Taiwan

09:25 – 09:35
WS02.10 LungPlan (Financial Modeling to Secure Resources for Lung Screening and Nodule Management Program)
Ella Kazerooni, United States

09:35 – 09:45
WS02.11 LungPlan (Financial Modeling to Secure Resources for Lung Screening and Nodule Management Program)
Robert Smith, United States

09:45 – 09:55
WS02.12 Optimal Smoking Cessation Strategy
Matthew Peters, Australia

09:55 – 10:25
WS02.13 Panel Discussion & Live Q&A

10:25 – 10:40 WS02.14 Break

10:40 – 10:45
WS02.15 / WS02.16 Session 2 Welcome
David Baldwin, United Kingdom, Annette Mcwilliams, Australia

10:45 – 10:55
WS02.17 Training, Assessment and Standardized Cad-Based Reporting - The British Columbia Lung Screening Program
Stephen Lam, Canada

10:55 – 11:05
WS02.18 IASLC Education Resource Initiative
Natthaya Triphuridet, Thailand

11:05 – 11:15
WS02.19 Quality Assurance of Radiology Reporting: PERFECTS
Yan Chen, United Kingdom

11:15 – 11:25
WS02.20 CAD/AI in Screening Interpretation: From Detection through Management
Mathijs Oudkerk, Netherlands

11:25 – 11:55
WS02.21 Panel Discussion & Live Q&A

11:55 – 12:55
WS02.22 Lunch Break

12:55 – 13:10
WS02.23 / WS02.24 Welcome Back/Q&A from Morning Sessions
Stephen Lam, Canada, Harry de Koning, Netherlands

13:10 – 13:20
WS02.25 Assessing Lung Cancer Risk from a Single Chest CT
Marjolein Heuvelmans, Netherlands

13:20 – 13:30
WS02.26 Personalized Risk Assessment Using Blood and Imaging Biomarkers
Hilary Robbins, France

13:30 – 13:40
WS02.27 Deep Learning Approach to Optimize the Lung Cancer Screening Interval
Ping Hu, United States

13:40 – 13:50
WS02.28 Future Directions Using AI Technologies for Early Lung Cancer Detection
Georg Langs, Austria

13:50 – 14:20
WS02.29 Panel Discussion & Live Q&A

14:20 – 14:30
WS02.30 Break

14:30 – 14:35
WS02.31 / WS02.32 Session 4 Welcome
Ella Kazerooni, United States, Harry de Koning, Netherlands

14:35 – 14:45
WS02.33 Mass Screening Using AI and Liquid Biopsy in China
Chunxue Bai, China
14:45 – 14:55
WS02.34 Incidental Lung Nodules - An Opportunity to Advance Early Lung Cancer Detection
Raymond Osarogiagbon, United States

14:55 – 15:05
WS02.35 Benchmarks for Diagnostic Workup of Early Lung Cancer
Annette McWilliams, Australia

15:05 – 15:15
WS02.36 Additional Findings in Lung Cancer Screening
David Baldwin, United Kingdom

15:15 – 15:40
WS02.37 Panel Discussion & Live Q&A

15:40 – 15:50
WS02.38 Workshop Summary/Conclusion
John Field, United Kingdom
WS03: Early Career & First Time Attendee Session

Chairs: Karen Kelly, United States, Heather Wakelee, United States

07:30 - 08:00
WS03.01 / WS03.02 Session Introduction
Karen Kelly, United States, Heather Wakelee, United States

08:10 - 08:25
WS03.03 Introduction to the IASLC - Why You Should Be a Member
Karen Kelly, United States

08:25 - 08:40
WS03.04 Making the Most of WCLC: A Guide for First Time Attendees
Jarushka Naidoo, Ireland

08:40 - 08:55
WS03.05 Planning a Career in Lung Cancer - Bench to Bedside and Educational
Anne-Marie Dingemans, Netherlands

08:55 - 09:10
WS03.06 Planning a Career in Lung Cancer - Sponsored and Academic Trials
Ross Soo, Singapore

09:10 - 09:25
WS03.07 Planning a Career in Lung Cancer - A New Era of Trial Designs
Simon Ekman, Sweden

09:25 - 09:55
WS03.08 Break

09:55 - 10:10
WS03.09 Principles to Get Your Paper Published
Alex Adjei, United States

10:10 - 10:25
WS03.10 How to Give a Great Presentation
Pasi Janne, United States

10:25 - 10:40
WS03.11 Role of IASLC in Developing Countries
Clarissa Mathias, Brazil

10:40 - 10:55
WS03.12 Early Career Researcher Experience
Alessandro Russo, Italy

10:55 - 11:30
WS03.13 Live Q&A
09:00 – 10:00
WS05: Social Media + Communications Workshop

LEHAR 2
Chair(s): Brendon Stiles, United States, Jarushka Naidoo, Ireland

09:00 - 09:05
WS05.01 / WS05.02 Introduction & Live Tweeting Session
Brendon Stiles, United States, Jarushka Naidoo, Ireland

09:05 - 09:10
WS05.03 How to Work with Hospital, Institution, Communications Staff Members. Or Oncology Trade Journal Editor Perspectives
Chris Martin, United States

09:10 - 09:15
WS05.04 Building a Personal Brand on Social Media
Stephen Liu, United States

09:15 - 09:20
WS05.05 Promoting Your Research through Traditional and Social Media Networks
Matthew Smeltzer, United States

09:20 - 09:25
WS05.06 Engaging in Latin America
Jose Corona-Cruz, Mexico

09:25 - 09:30
WS05.07 Engaging in Asia
Vun-Sin Lim, Hong Kong

09:30 - 09:35
WS05.08 How to Give the Perfect Interview (Traditional Approach to Media/Trade Interviews)
Karen Reckamp, United States

09:35 - 09:40
WS05.09 Using Podcast to Promote Your Message and Disseminate Research
Narjust Florez, United States

09:40 - 09:45
WS05.10 Use of Social Media and Communications Channels for Patient Advocacy
Janet Freeman-Daily, United States

09:45 - 09:50
WS05.11 Wrap Up

09:50 - 10:10
WS05.12 Networking

12:00 – 17:00
WS06: Nurse & AHP + ITONF Joint Workshop

LEHAR 3
Chair(s): Mary Duffy, Australia, Maria Ftanou, Australia, Jacqui Frowen, Australia

12:00 - 12:30
WS06.01 ITONF AGM - ITONF Membership
Mary Duffy, Australia

12:30 - 13:00
WS06.02 Lunch/Networking/Poster Viewing

13:00 - 13:10
WS06.03 / WS06.04 Welcome
Mary Duffy, Australia, Maria Ftanou, Australia

13:10 - 13:15
WS06.05 Session Introduction
Jacqui Frowen, Australia

13:15 - 13:30 WS06.06
Targeted Therapy in NSCLC - New Frontiers
Marianne Davies, United States

13:30 - 13:45
WS06.07 Beyond Treating the Disease, Addressing the Person We Care For - Symptom Management, Palliative Care, Survivorship
Polly Dufton, Australia

13:45 - 14:00
WS06.08 Unlocking the Secrets of Immunotherapy - What Clinicians Need to Know
Michelle Turner, United States

14:00 - 14:10
WS06.09 Live Q&A

14:10 - 14:30
WS06.10 Refreshment Break/Networking/Poster Viewing

14:30 - 14:35
WS06.11 Session Introduction
Melanie Rabbets, Australia

14:35 - 14:50
WS06.12 Stigma & Shame Still an Issue in Lung Cancer?
Maria Ftanou, Australia

14:50 - 15:05
WS06.13 Enhancing Health Literacy Amongst Care Givers of People with Lung Cancer
Simon Dunne, Ireland

15:05 - 15:20
WS06.14 Supporting Children of Parents & Grandparents with Lung Cancer
Elena Schiena, Australia
15:20 - 15:30
WS06.15 / WS07.02 Live Q&A

15:30 - 15:50
WS06.16 Networking Break/Poster Viewing

15:50 - 15:55
WS06.17 Session Introduction
Andreas Charalambous, Cyprus

15:55 - 16:10
WS06.18 Working across Borders, Egypt & ITONF's Educational Modules
Mary Duffy, Australia

16:10 - 16:20
WS06.19 Clinician Professional & Academic Development - From Bedside to Bench: Getting Involved in Research - A Practical Approach
Morten Quist, Denmark

16:20 - 16:30
WS06.20 Clinician Professional & Academic Development - From Bedside to Bench: The Grant Application Process
Jacqui Frowen, Australia

16:30 - 16:40
WS06.21 Clinician Professional & Academic Development - From Bedside to Bench: Getting Published
Marianne Davies, United States

16:40 - 16:50
WS06.22 Clinician Professional & Academic Development - From Bedside to Bench: Getting Involved in Clinical Practice Guidelines Development
Marianne Davies, United States

16:50 - 17:00
WS06.23 Successfully Navigating the WCLC2022 Program Summary & Close
Morten Quist, Denmark

15:00 - 16:30
WS07: LATAM Workshop

15:12 - 15:22
WS07.04 KRAS Alterations, Clinicopathological Features and Co-occurring Drivers Associated with Prognosis in Advanced NSCLC Patients
Maritza Ramos-Ramirez, Mexico

15:22 - 15:32
WS07.05 Artificial Intelligence in Lung Cancer Screening: Accuracy and Predictive Value
Ricardo Santos, Brazil

15:32 - 15:42
WS07.06 Real-world Evidence of Durvalumab for Stage III NSCLC: Survival Outcomes and Patterns of Care Post-progression
Pedro Aguiar Jr, Brazil

15:42 - 15:52
WS07.07 Discussant
Andres Cardona, Colombia

15:52 – 16:02
WS07.08 Ancestry and Somatic Mutations in Lung Cancer in Latin America
Ticiana Leal, United States

16:02 – 16:12
WS07.09 Challenges of Implementing Lung Cancer Screening in Latin Countries
Ricardo Sales Santos, Brazil

16:12 – 16:22
WS07.10 Lung Cancer Disparities in Molecular Testing and Therapy Outcome in Hispanics in LATAM
Luis Raez, United States

16:22 – 16:30
WS07.11 Live Q&A

17:00 – 17:45
AC01: IASLC Awards Ceremony

18:15 – 19:45
PL01: Opening Plenary 1: Immunotherapy & Vaccines

Chair(s): Silvia Novello, Italy, Robert Pirker, Austria, Eric Lim, United Kingdom, Françoise Mornex, France, Helmut Prosch, Austria
18:20 - 18:25  
PL01.06 Welcome Address - IASLC President  
Heather Wakelee, United States

18:25 - 18:27  
PL01.07 Welcome Address - IASLC Past President  
Tetsuya Mitsudomi, Japan

18:30 – 18:55  
PL01.09 IASLC Distinguished Service Award Presentations

18:55 – 19:10  
PL01.10 “We'll Do the Best We Can for as Long as We Can” and Other Assumptions I Hope We'll Make Obsolete in My Lifetime  
Annabelle Gurwitch, United States

19:10 – 19:25  
PL01.11 Immune Checkpoint Inhibitors  
Julie Brahmer, United States

19:25 – 19:45  
PL01.12 mRNA Vaccines for Prevention or Treatment of Disease  
Christoph Huber, Austria

19:45 – 21:00  
Welcome Reception

HALL B, EXHIBIT HALL

Light refreshments and beverages will be served.
07:30 – 08:15
IBS01: Lung Cancer Screening: From Lung Cancer to Multiple Comorbidities

Track: Early Detection and Screening

07:30 - 08:15
IBS01.01 Net Benefit of Lung Cancer Screening: Much More Than Lung Cancer
John K. Field, United Kingdom

07:30 – 08:15
IBS02: SABR versus Surgery for Operable Lung Cancer

Track: Early Stage Non-small Cell Lung Cancer - Radiotherapy and Other Ablative Techniques

07:30 - 08:15
IBS02.01 / IBS02.02 SABR versus Surgery for Operable Lung Cancer
Famke Schneiders, Netherlands, Hiran Chrishantha Fernando, United States

08:10 - 08:15
IBS02.03 Live Q&A

07:30 – 08:15
IBS03: Real World Discussion about Testing in Low Income Countries

Track: Global Health, Health Services Research, and Health Economics

07:30 – 08:00
IBS03.01 / IBS03.02 Real World Discussion about Testing in Low Income Countries
Rodrigo Dientsmann, Brazil, Thanyanan Baisamut, Thailand

08:00 - 08:15
IBS03.03 Live Q&A

07:30 – 08:15
IBS04: The Survivorship Experience for People Treated with Immunotherapy or Targeted Therapy

Track: Nursing and Allied Health Professionals

07:30 - 07:45
IBS04.01 The Survivorship Experience for People Treated with Immunotherapy or Targeted Therapy - Shared Presentation Nurse and Patient Advocate
Jennifer King, United States

07:45 - 08:00
IBS04.02 The Survivorship Experience for People Treated with Immunotherapy or Targeted Therapy - Shared Presentation Nurse and Consumer
Anne Fraser, New Zealand

08:00 - 08:15
IBS04.03 Live Q&A

07:30 – 08:15
IBS05: Controversies in Management of Locally Advanced NSCLC

Track: Locally Advanced Non-small Cell Lung Cancer

07:30 - 07:45
IBS05.01 Controversies in Management of Locally Advanced NSCLC
Gerry Hanna, United Kingdom

07:45 - 08:00
IBS05.02 Defining Resectability in Locally Advanced Lung Cancer
Clemens Aigner, Germany

08:00 - 08:15
IBS05.03 Live Q&A
07:30 – 08:15 IBS06: Which Therapy for Which MPM Patient?

Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies

LEHAR 4

07:30 - 07:45
IBS06.02 Local Treatments for Meso - Surgery
Marc De Perrot, Canada

07:45 - 08:00
IBS06.03 Local Treatments for Meso - Radiotherapy
Andreas Rimner, United States

08:00 - 08:15
IBS06.04 Live Q&A

08:30 – 10:00
PL02: Plenary 2: Multidisciplinary Approach to the Oligo Paradigm

HALL C1

Chair(s): Francoise Mornex, France, Hisao Asamura, Japan

08:30 - 08:32
PL02.01 / PL02.02 Session Introduction
Francoise Mornex, France, Hisao Asamura, Japan

08:32 - 08:40
PL02.03 Definitions of Oligometastatic Disease - Concept, Definitions, Different Clinical Situations
Anne-Marie Dingemans, Netherlands

08:40 - 08:48
PL02.04 Definitions of Oligometastatic Disease - Concept, Definitions, Different Clinical Situations
Mathias Guckenberger, Switzerland

08:48 - 08:56
PL02.05 Definitions of Oligometastatic Disease - Biological Bases and Specificities
John Heymach, United States

08:56 - 09:06
PL02.06 Radical Modalities for De Novo Oligometastatic Disease - Role and Timing of Systemic Therapy
Delphine Antoni, France

09:06 - 09:16
PL02.07 Radical Modalities for De Novo Oligometastatic Disease - Local Consolidation - Surgery
Mara Antonoff, United States

09:16 - 09:26
PL02.08 Radical Modalities for De Novo Oligometastatic Disease - Local Consolidation - Radiation Oncology
Daniel Gomez, United States

09:26 - 09:36
PL02.09 Radical Modalities for De Novo Oligometastatic Disease - Local Consolidation - Interventional Radiology
Miltiadis Krokidis, Greece

09:36 - 09:43
PL02.10 Radical Management of Induced Oligometastatic Disease - Multi-modality Management
Eric Lim, United Kingdom

09:43 - 09:53
PL02.11 Patient Perspectives for Radical Management of Advanced Disease: When is it Enough/Too Much?
Lavina Magee, United Kingdom

09:53 - 10:00
PL02.12 Round Table

10:00 – 10:45
Networking Break

10:05 – 10:45
PC02: Press Conference

SCHUBERT 5/6

10:45 – 11:45
ES01: Implementation and Continuous Optimization of Lung Cancer Screening

Track: Early Detection and Screening

HALL C1

Chair(s): Mario Silva, Italy, Marjolein Heuvelmans, Netherlands

10:45 – 10:47
ES01.01 / ES01.02 Session Introduction
Mario Silva, Italy, Marjolein Heuvelmans, Netherlands

10:47 – 10:59
ES01.03 Scalability of Excellence: Continuous Refinement of Screening Scheme
Annette McWilliams, Australia
10:59 – 11:11
ES01.04 Strategies for Recruitment: Risk Profile, Engagement, Adherence
Hilary Robbins, France

11:11 - 11:23
ES01.05 LCS: Pulmonary and Extrapulmonary Findings
Sam Janes, United Kingdom

11:23 - 11:35
ES01.06 US-Preventive Services Task Force LCS Recommendations in Community Based Health Care Systems
Katharine Rendle, United States

11:35 - 11:45
ES01.07 Live Q&A

10:45 – 11:45
ES02: Management of Lung Cancer in the Era of COVID-19

Track: Management of Lung Cancer in the Era of COVID-19

HALL C2
Chair(s): Marina Garassino, United States, Christian Grohe, Germany

10:45 - 10:47
ES02.01 / ES02.02 Session Introduction
Marina Garassino, United States, Christian Grohe, Germany

10:47 - 10:59
ES02.03 Impact of the COVID-19 Pandemic on Lung Cancer Diagnosis and Screening
Betty Tong, United States

10:59 -11:11
ES02.04 Impact of the COVID-19 Pandemic on Surgery
Leanne Ashrafian, United Kingdom

11:11 - 11:23
ES02.05 Impact of the COVID-19 Pandemic on Radiotherapy
Umberto Ricardi, Italy

11:23 – 11:35
ES02.06 Impact of the COVID-19 Pandemic on Systemic Treatment
Wilfried Eberhardt, Germany

11:35 - 11:45
ES02.07 Live Q&A

10:45 – 11:45
ES03: Synchronous Oligometastatic NSCLC: Practical Implications

Track: Metastatic Non-small Cell Lung Cancer - Oligometastatic Disease

STRAUSS 1/2
Chair(s): Daniel Tan, Singapore, Hans Hoffmann, Germany

10:45 - 10:47
ES03.01 / ES03.02 Session Introduction
Daniel Tan, Singapore, Hans Hoffmann, Germany

10:47 - 10:59
ES03.03 Synchronous Oligometastatic NSCLC 2022 Where Are We Now
Jeffrey Bradley, United States

10:59 -11:11
ES03.04 Concept 1: Brain Only Disease
Paul Martin Putora, Switzerland

11:11 - 11:23
ES03.05 Concept 2: Bulky Thoracic Disease
Ben Solomon, Australia

11:23 – 11:35
ES03.06 Concept 3: cT1bN0, Single Adrenal Met: Surgery or Radiotherapy; Sequencing with Systemic Treatment
Isabelle Opitz, Switzerland

11:35 - 11:45
ES03.07 Live Q&A

10:45 – 11:45
MA01: Molecular Subtypes and Prognostic Factors for SCLC and Neuro-endocrine Tumours

Track: Small Cell Lung Cancer and Neuro-endocrine Tumours

HALL C7
Chair(s): Fabio Pagni, Italy, Ferdinando Skoulidis, United States

10:45 - 10:47
MA01.01 / MA01.02 Session Introduction
Fabio Pagni, Italy, Ferdinando Skoulidis, United States

10:47 - 10:52
MA01.03 Exploiting DNA Methylation for Classification of SCLC Subtypes from Liquid Biopsies Using a Robust Machine Learning Approach
Simon Heeke, United States
MA01.04 Molecular Subtypes of Surgically Resected Small Cell Lung Cancer: Expression Pattern and Prognostic Relevance
Zsolt Megyesfalvi, Hungary

MA01.05 Immuno-microenvironment (TIME) Heterogeneity of Small Cell Lung Cancer (SCLC) Stratified by Molecular Subtypes
Jiyan Dong, China

MA01.06 Discussant
Kenneth O’Byrne, Australia

MA01.07 From Molecular to Histological Characterization of Lung Carcinoids via Computer Vision and Spatial Genomics
Émilie Mathian, France

MA01.08 Impact of [18F]FDG PET/CT-derived Metabolic Parameters on Outcomes in Extensive-stage SCLC
Giuseppe Lamberti, Italy

MA02.01 / MA02.02 Session Introduction
Erik Thunnissen, Netherlands, Rafael Rosell, Spain

MA02.03 The Evolution of Lung Neuro-endocrine Tumours
Nicolas Alcala, France

MA02.04 Molecular Drivers and Therapeutic Targets for Neuro-endocrine Transformation in Lung Cancer
Triparna Sen, United States

MA02.05 Dynamic Mutation Profiles of SCLC Transformation in NSCLC Patients Harboring Concurrent EGFR/TP53/RB1 Mutations
Jie Huang, China

MA02.06 Discussant
Yuko Minami, Japan

MA02.07 Aurora A Kinase Inhibition with VIC-1911 Potentiates KRASG12C Inhibitor and Overcomes Resistance to Sotorasib in Lung Cancer
Jong Woo Lee, United States

MA02.08 Trametinib Inhibition of MEK1/2 Upregulates PD-L1 Expression in KRAS-Mutant NSCLC Through ID1 Downregulation
Ander Puyalto, Spain

MA02.09 Impact of Baseline Clinicopathologic and Genomic Features on Outcomes to KRAS G12C Inhibitors in Patients with NSCLC
Giuseppe Lamberti, United States

MA02.10 Discussant
Sally Lau, United States

OA01.03 Lung Cancer in Victoria: Association Between Stage-Specific Receipt of Guideline-Concordant Treatment and Survival
Sanuki Tissera, Australia
10:57 - 11:07
OA01.04 Persisting Gaps in Optimal Care of Stage III Non-Small Cell Lung Cancer: An Australian Patterns of Care Analysis
Robert Stirling, Australia

11:07 - 11:17
OA01.05 Socio-economic Inequalities in NSCLC Treatment During the Era of Tumour Biomarker Guided Therapy: A Population-based Study
Ruth Norris, United Kingdom

11:17 - 11:27
OA01.06 Project PEER: A Longitudinal Real-World Study to Understand the Experience of Patients With Lung Cancer and Their Caregivers
Upal Basu Roy, United States

11:17 - 11:27
OA01.07 Discussant
Tatiane Montella, Brazil

11:37 - 11:55
OA01.08 Live Q&A

12:00 – 13:00
ES04: Current Status of Lung Cancer Screening Worldwide

Track: Early Detection and Screening

Chair(s): Torsten Blum, Germany, Ricardo Sales Santos, Brazil, Mónica Castro, Argentina

12:02 - 12:14
ES05.03 Targeting Rarer Events in Known Targets: EGFR Exon20 (EGFR, HER2)
Giannis Mountzios, Greece

12:14 - 12:26
ES05.04 All You Need to Know About KRAS
Odd Terje Brustugun, Norway

12:26 - 12:38
ES05.05 Antibody-Drug Conjugates - Where We Stand Today?
Bob T. Li, United States

12:38 - 12:50
ES05.06 HRD/DDR in Lung Cancer: Role and Therapeutic Implications
Lauren Byers, United States

12:50 - 13:00
ES05.07 Live Q&A

12:00 – 13:00
ES06: Symptom Management in Lung Cancer

Track: Palliative and Supportive Care

Chair(s): Alberto Chiapponni, United States, Sara Ramella, Italy

12:00 - 12:02
ES06.01 / ES06.02 Session Introduction
Alberto Chiappori, United States, Sara Ramella, Italy
12:02 – 12:14
ES06.03 The Management of Symptoms with Patients Reported Outcome
Emilio Bria, Italy

12:14 - 12:26
ES06.04 Interventional Pulmonology for Managing Dyspnea in Lung Cancer
Semra Bilaceroglu, Turkey

12:26 - 12:38
ES06.05 Palliative Radiotherapy in the Era of Targeted and Immunotherapy
Lucyna Kepka, Poland

12:38 - 12:50
ES06.06 Self-Care for the Clinician Caring for Advanced Cancer Patients: Compassion Fatigue and Burnout
Maria Ftanou, Australia

12:50 - 12:55
ES06.07 Innovative Technology/Tools for Smoking Cessation
Lawson Eng, Canada

12:00 – 13:00
MA03: Predicting Outcomes in Patients with Early Disease NSCLC
Track: Early Stage Non-small Cell Lung Cancer

12:02 – 12:07
MA03.03 Predicting Occult Lymph Node Metastasis in Patients With Clinical Stage IA Non-small Cell Lung Cancer: A Prospective Cohort Study
Junghee Lee, South Korea

12:07 – 12:12
MA03.04 An Integrated Deep Learning Method to Predict Lung Cancer Recurrence Risk for Resected Stage IA NSCLC
Peng Huang, United States

12:12 - 12:17
MA03.05 EGFR mutation Is Not a Risk Factor for Postoperative Recurrence of Lung Adenocarcinoma on Long Follow-up of a Multi-Institutional Cohort
Yuki Matsumura, Japan

12:17 - 12:27
MA03.06 Discussant
Betty Tong, United States

12:27 - 12:32
MA03.07 Accurate Intraoperative Diagnosis of Spread Through Air Spaces (STAS) Using a Cryo Embedding Medium Inflation Method
Takashi Eguchi, Japan
13:15 – 14:15
LA01: Lectureship Awards - Sunday

Chair(s): Keunchil Park, South Korea, Paul A. Bunn, Jr., United States

13:15 – 13:17
LA01.01 / L01.02 Session Introduction
Keunchil Park, South Korea, Paul A. Bunn, Jr., United States

13:17 - 13:32
LA01.03 IASLC Lectureship Award for Smoking Cessation and Tobacco Control
Raymond Osarogiagbon, United States

13:32 - 13:47
LA01.04 Tsuguo Naruke Lectureship Award for Surgery
Wenzhao Zhong, China

13:47 - 14:02
LA01.05 Daniel C. Ihde Lectureship Award for Medical Oncology
Patrick Forde, United States

14:02 – 14:15
LA01.06 Live Q&A

13:15 – 14:15 Networking Lunch

Complimentary food and beverages will be served.

14:00 – 15:30
MTE01: Meet the Editor

COMMITTEE ROOM 1

14:00 - 15:30
MTE01.01 Meet the Editor
Alex Adjei, United States

14:30 – 15:30
ES08: Sublobar Resection: Oncological Outcome and Advantages

Track: Early Stage Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments - Surgery

Chair(s): Masahiro Tsuboi, Japan, Monica Casiraghi, Italy
**Program | IASLC 2022 World Conference on Lung Cancer**

14:30 – 14:32
ES08.01 / ES08.02 Session Introduction
Masahiro Tsuboi, Japan, Monica Casiraghi, Italy

14:32 - 14:44
ES08.03 Patients Selection for Segmentectomy
Hisao Asamura, Japan

14:44 - 14:56
ES08.04 Occult Lymph Nodes Metastasis During Segmentectomy: What to Do
Keiju Aokage, Japan

14:56 - 15:08
ES08.05 Are There Benefits of Sublobar Resection Including Lung Function
Nasser Khaled Altorki, United States

14:30 – 15:30
ES09: Technology Innovations

**HALL C2 | IASLC CME ACCREDITED**

Chair(s): Joe Chang, United States, Wieland Voigt, Germany

14:30 – 14:32
ES09.01 / ES09.02 Session Introduction
Joe Chang, United States, Wieland Voigt, Germany

14:32 - 14:44
ES09.03 New Radiotherapy Machines, Techniques and Results
Suresh Senan, Netherlands

14:44 - 14:56
ES09.04 How to Improve Lung Tolerance to Radiation in the Setting of Combined Modality Treatment
Andrea Bezjak, Canada

14:56 - 15:08
ES09.05 Machine Learning in Cancer Imaging: The Power of Pooling Data
Philippe Lambin, Netherlands

15:08 - 15:20
ES09.06 Robotic Surgery
Diego Gonzalez Rivas, Spain

15:20 – 15:30
ES09.07 Live Q&A

14:30 – 15:30
ES10: Problems and Controversies in Thoracic Tumours

**STRAUSS 1/2 | IASLC CME ACCREDITED**

Chair(s): Keith Kerr, United Kingdom, Wendy Cooper, Australia

14:30 – 14:32
ES10.01 / ES10.02 Session Introduction
Keith Kerr, United Kingdom, Wendy Cooper, Australia

14:32 - 14:44
ES10.03 Undifferentiated Epithelioid Tumour in a Biopsy
Andrew Nicholson, United Kingdom

14:44 - 14:56
ES10.04 Undifferentiated Spindle Tumour in a Biopsy
Sabina Berezowska, Switzerland

14:56 - 15:08
ES10.05 How To Maximize Biomarker Information From a Small Sample
Kuniko Sunami, Japan

15:08 - 15:20
ES10.06 Grading Lung Cancer - Where Are We Now
Andre Moreira, United States

15:20 - 15:30
ES10.07 Live Q&A

14:30 – 15:30
ES11: Joint IASLC-ESTRO Session - Integration of Radiotherapy for Optimal Patient Outcomes

**LEHAR 1 | IASLC CME ACCREDITED**

Chair(s): Alexander Louie, Canada, Corinne Faivre-Finn, United Kingdom

14:30 – 14:32
ES11.01 / ES11.02 Session Introduction
Alexander Louie, Canada, Corinne Faivre-Finn, United Kingdom

14:30 – 14:56
ES11.03 What Is the Role of Radiotherapy in the Immunotherapy Era for Resectable NSCLC?
Shankar Siva, Australia

14:56 - 15:08
ES11.05 How Do We Address the Challenge of Pneumonitis in the Multimodality Radical Treatment Era?
Andrew Bang, Canada

15:08 - 15:20
ES11.06 Grading Lung Cancer - Where Are We Now
Andre Moreira, United States

15:20 - 15:30
ES11.07 Live Q&A

**SUNDAY, AUGUST 7, 2022**

WCLC 2022 | DAILY SCIENTIFIC PROGRAM
14:56 - 15:08
ES11.06 The Increasing Role of Re-Irradiation: How Do We Keep It Safe?
Sara Ramella, Italy

15:08 - 15:30
ES11.07 Live Q&A

14:30 – 15:30
MA04: Pulmonology, Radiology, and Staging

Track: Pulmonology, Radiology, and Staging

STRAUSS 3

Chair(s): Mir Ali Reza Hoda, Austria, Pieter Postmus, Netherlands

14:30 – 14:32
MA04.01 / MA04.02 Session Introduction
Mir Alireza Hoda, Austria, Pieter Postmus, Netherlands

14:32 – 14:37
MA04.03 Reconsidering T Classification for T3/T4 Non-small Cell Lung Cancer with Additional Nodule(s)
Fang Wang, China

14:37 – 14:42
MA04.04 The Ground-Glass Component Status Combined with the Clinical T Descriptor Predicts Prognosis and Genomic Alterations in NSCLC
Yukihiro Yoshida, Japan

14:42 - 14:47
MA04.05 T3 Defining Features Influence Long Term Survival after Resection of T3N0M0 NSCLC
Paula Ugalde Figueroa, United States

14:31 - 14:57
MA04.06 Discussant
Frank Detterbeck, United States

14:57 - 15:02
MA04.07 A Controlled Study of Pathological T-staging and Imaging T-staging of NSCLC Based on Artificial Intelligence
Yuanyong Wang, China

15:02 - 15:07
MA04.08 Navigation Bronchoscopy Mediated Sentinel Lymph Node Procedure: an Explorative Study in Ex-vivo Lung Cancer Specimens
Desi Ter Woerds, Netherlands

15:07 - 15:12
MA04.09 The Incidence and Predictors of Unsuspected Brain Metastases in Patients with Stage IA NSCLC
Camille Mathey-Andrews, United States

15:12 - 15:22
MA04.10 Discussant
Rudolf Huber, Germany

15:22 - 15:30
MA04.11 Live Q&A

14:30 – 15:40
OA03: Molecular Targeted Treatments

Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

HALL C7

Chair(s): Andrew Ciupek, United States, David Gandara, United States

14:30 – 14:32
OA03.01 / OA03.02 Session Introduction
Andrew Ciupek, United States, David Gandara, United States

14:32 – 14:42
OA03.03 Sotorasib in Combination with RMC-4630, a SHP2 Inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumours
Gerald Falchook, United States

14:42 - 14:52
OA03.04 Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation
Adrian Sacher, Canada

14:52 - 15:02
OA03.05 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C
Michael Thomas, Germany

15:02 - 15:12
OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC
Bob Li, United States

15:12 - 15:22
OA03.07 Safety and Efficacy of D-1553 in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C
Shun Lu, China

15:22 – 15:32
OA03.08 Discussant
Helena Linardou, Greece

15:32 - 15:40
OA03.09 Live Q&A
14:30 – 15:40
OA04: Mesothelioma Under the Looking Glass

Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies

HALL C8

Chair(s): Joachim Aerts, Netherlands, Anne Tsao, United States

14:30 – 14:32
OA04.01 / OA04.02 Session Introduction
Joachim Aerts, Netherlands, Anne Tsao, United States

14:32 – 14:42
OA04.03 Multi-omic Analysis of Malignant Pleural Mesothelioma PDXs Reveal Pathway Alterations and Therapeutic Targets
Triparna Sen, United States

14:42 – 14:52
OA04.04 Association of Novel microRNAs With Diagnosis and Histology of Malignant Pleural Mesothelioma
Michaela Kirschner, Switzerland

14:52 – 15:02
OA04.05 MESOMICS Project: Using Whole-Genome Sequencing Data to Fill the Gaps in Malignant Pleural Mesothelioma Molecular Studies
Nicolas Alcala, France

15:02 – 15:12
OA04.06 PEMbrolizumab Plus Lenvatinib In Second And Third Line Malignant Pleural MEsotheLiomA Patients: A Single Arm Phase II Study (PEMMELA)
Li-Anne Douma, Netherlands

15:12 – 15:22
OA04.07 Discussant
Giovanni Ceresoli, Italy

15:22 – 15:40
OA04.08 Live Q&A

15:45 – 16:45
ES12: Surgical Issues in Multimodality Treatments for Early Stage NSCLC

Track: Early Stage Non-small Cell Lung Cancer - Surgery

HALL C1

Chair(s): Tomaz Stupnik, Slovenia, Mir Ali Reza Hoda, Austria

15:45 – 15:47
ES12.01 / ES12.02 Session Introduction
Tomaz Stupnik, Slovenia, Mir Ali Reza Hoda, Austria
15:45 – 16:45
ES14: Think, Think, Think?..The Importance of Thinking Holistically When Caring for Lung Cancer Patients

**Track:** Nursing and Allied Health Professionals

**Chair(s):** Anne Fraser, New Zealand, Andreas Charalambous, Cyprus

15:45 – 15:47
ES14.01 / ES14.02 Session Introduction
Anne Fraser, New Zealand, Andreas Charalambous, Cyprus

15:47 – 15:59
ES14.03 Information Needs of Carers of People with Lung Cancer
Simon Dunne, Ireland

15:59 - 16:11
ES14.04 Interventions to Improve Cancer Survivorship among Indigenous Peoples and Communities
Marianne Davies, United States

16:11 - 16:23
ES14.05 Interventions to Limit the Impacts of Parental Lung Cancer Impact on Children
Elena Schiena, Australia

16:23 - 16:35
ES14.06 Treating People with Comorbid Dementia: Implications for Cancer Care
Lorna McWilliams, United Kingdom

16:35 – 16:45
ES14.07 Live Q&A

15:45 – 16:45
ES15: Is Cytotoxic Chemotherapy in NSCLC Management Only Palliative?

**Track:** Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy

**Chair(s):** Navneet Singh, India, Khaled Kamal, Egypt

15:45 – 15:47
ES15.01 / ES15.02 Session Introduction
Navneet Singh, India, Khaled Kamal, Egypt

15:52 - 16:04
ES15.03 Can Chemotherapy Agents Be Personalized in NSCLC?
David Planchard, France

16:04 - 16:16
ES15.04 Second-Line Chemotherapy Following First-Line Mono-Immunotherapy in High PD-L1 (TPS≥50%) Advanced/Metastatic NSCLC
Sara Pilotto, Italy

16:16 – 16:28
ES15.05 The Future of Cytotoxics in the Management of NSCLC
Sofia Baka, Greece

16:28 - 16:40
ES15.06 Chemotherapy in Elderly NSCLC Patients: How to Play It Safe?
Rajwanth Veluswamy, United States

16:40 - 16:45
ES15.08 Live Q&A

15:45 – 16:45
MA05: Immune Landscape and Molecular Profiling of Lung Cancer

**Track:** Tumour Biology and Biomarkers

**Chair(s):** Luis Paz-Ares, Spain, Tina Cascone, United States

15:45 - 15:47
MA05.01 / MA05.02 Session Introduction
Luis Paz-Ares, Spain, Tina Cascone, United States

15:47 - 15:52
MA05.03 Utilization of Genomic Mutation Signature to Predict the Immunotherapy Response in Non-small Cell Lung Cancer
Wenbin Li, China

16:12 - 16:17
MA05.05 Analysis of CREBBP as a Potential Biomarker for Immune Checkpoint Therapy in Solid Tumours and Its Correlation With Immune Microenvironment
Xiaoli Liu, China

15:52 - 15:57
MA05.04 Multiplex Phenotyping Reveals Spatial Immune Patterns in NSCLC
Max Backman, Sweden

16:02 - 16:12
MA05.06 Discussant
Fabio Pagni, Italy
MA05.07 Intertumoural Molecular Heterogeneity of Non-small Cell Lung Cancer With MET Exon 14 Skipping
Yuchen Han, China

MA05.08 MET Exon 14 Skipping Mutation in Non-Small Cell Lung Cancer (NSCLC) by Specific Mutation, Histology, and Smoking History
Jennifer Marks, United States

MA05.09 Genomic Mapping of Metastatic Organotropism: Analysis of 2326 Primary and Organ-Specific Metastases in Lung Adenocarcinoma
Harry Lengel, United States

MA05.10 Discussant
Giulia Pasello, Italy

MA05.11 Live Q&A

OA05.01 / OA05.02 Session Introduction
Arjun Nair, United Kingdom, Ella Kazerooni, United States

OA05.03 Incidence, Timing, and Survival of Second Primary Lung Cancer in Patients in the National Lung Screening Trial
Alexandra Potter, United States

OA05.04 A Comparison of Stage- and Histology-Specific CT Sensitivity in the NELSON Trial and the NLST
Koen de Nijs, Netherlands

OA05.05 China Lung Cancer Screening (CLUS) Version 1.0: Mortality, Survival and Incidence Rates with Long-Term Follow-up
Fangfei Qian, China

OA05.06 Early Diagnosis of Lung Cancer Among Younger vs. Older Adults: Widening Disparities in the Era of Lung Cancer Screening
Alexandra Potter, United States

OA05.07 The Granularity of Lung Cancer Screening Implementation
Anand Devaraj, United Kingdom

OA05.08 Live Q&A

OA05: The Granularity of Lung Cancer Screening Implementation

Track: Early Detection and Screening

Chair(s): Arjun Nair, United Kingdom, Ella Kazerooni, United States

OA05.01 / OA05.02 Session Introduction
Arjun Nair, United Kingdom, Ella Kazerooni, United States

OA05.03 Incidence, Timing, and Survival of Second Primary Lung Cancer in Patients in the National Lung Screening Trial
Alexandra Potter, United States

OA05.04 A Comparison of Stage- and Histology-Specific CT Sensitivity in the NELSON Trial and the NLST
Koen de Nijs, Netherlands

OA05.05 China Lung Cancer Screening (CLUS) Version 1.0: Mortality, Survival and Incidence Rates with Long-Term Follow-up
Fangfei Qian, China

OA05.06 Early Diagnosis of Lung Cancer Among Younger vs. Older Adults: Widening Disparities in the Era of Lung Cancer Screening
Alexandra Potter, United States

OA05.07 The Granularity of Lung Cancer Screening Implementation
Anand Devaraj, United Kingdom

OA05.08 Live Q&A

17:00 – 19:00
Poster Viewing Reception
Poster Session P1 Presenters in Attendance

18:00 – 18:30
Editorial Reception (By Invitation Only)

19:30 – 22:30
International Lung Cancer Foundation Benefit Supporting Early Career Researchers

Please refer to your International Lung Cancer Foundation Benefit Supporting Early Career Researchers ticket for more information.
07:30 – 08:15
IBS07: Interactive Multidisciplinary Thoracic Tumour Board

Track: Early Stage Non-small Cell Lung Cancer? Neoadjuvant and Adjuvant Systemic Therapy (Multi-Modality Treatment, Immunotherapy, Molecular Targeted Treatments)

LEHAR 1

07:30 - 08:15
IBS07.01 Interactive Multidisciplinary Thoracic Tumour Board
Stephen Liu, United States

07:30 – 08:15
IBS08: Chemotherapy Still Remains a Key Component of Treatment for Majority of Patients with Metastatic NSCLC in the Era of Immune-Oncology

Track: Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy

HALL C8

07:30 - 07:45
IBS08.01 In Favor
Takayuki Takahama, Japan

07:45 - 08:00
IBS08.02 Against
Mirjana Rajer, Slovenia

08:00 - 08:15
IBS08.03 Live Q&A

07:30 – 08:15
IBS09: Inequities in Access to Lung Cancer Care across the World

Track: Patient Advocacy

STRAUSS 3

Chair(s): Stefania Vallone, Italy, Merel Hennink, Netherlands

07:30 - 07:32
IBS09.01 / IBS09.02 Session Introduction
Stefania Vallone, Italy, Merel Hennink, Netherlands

07:32 - 07:56
IBS09.03 / IBS09.04 / IBS09.05 Growing Inequality: Care and Access to New Treatments
Ebele Mbanugo, United States, Karla Ruiz de Castilla, Peru, Nabanita Mandal, India

07:56 - 08:06
IBS09.06 Opportunities to Equalize Access to Treatment: Cost, Health Technology Assessment (HTA) And Logistics
Christina Sit, Canada

08:06 - 08:15
IBS09.07 Live Q&A

07:30 – 08:15
IBS10: In Situ IO Biomarkers

Track: Pathology

LEHAR 2

07:30 – 08:00
IBS10.01 / IBS10.02 Pathology, Immunotherapy and the TME
Sanja Dacic, United States, Patrick Micke, Sweden

08:00 - 08:15
IBS10.03 Live Q&A

07:30 – 08:15
IBS11: E-Cigarettes Are an Effective Smoking Cessation Aid

Track: Tobacco Control and Risk Reduction

LEHAR 3

07:30 - 07:45
IBS11.01 Pro
Matt Evison, United Kingdom

07:45 - 08:00
IBS11.02 Con
Emily Stone, Australia

08:00 - 08:15
IBS11.03 Live Q&A
07:30 – 08:15
IBS12: Mediastinal Staging

Track: Pulmonology, Radiology, and Staging

07:30 - 07:42
IBS12.01 Mediastinal Staging: Pulmonologist’s Perspective
Sylvia Guetz, Germany

07:42 - 07:54
IBS12.02 Mediastinal Staging: Surgeon’s Perspective
Joshua Sonett, United States

07:54 - 08:15
IBS12.03 Live Q&A

08:30 – 10:20
PL03: Plenary 3: Presidential Symposium - Top Rated Abstracts

HALL C1  IASLC CME ACCREDITED  LIVE-STREAM

Chair(s): Heather Wakelee, United States, Eric Lim, United Kingdom

08:30 - 08:30
PL03.01 / PL03.02 Session Introduction
Heather Wakelee, United States, Eric Lim, United Kingdom

08:30 - 08:40
PL03.03 Personalised Smoking Cessation Support in a Lung Cancer Screening Programme: The Yorkshire Enhanced Stop Smoking Study (YESS)
Rachael Murray, United Kingdom

08:40 - 08:50
PL03.04 Discussant
Jacek Jassem, Poland

08:50 - 08:55
PL03.05 Live Q&A

08:55 - 09:05
PL03.06 Lobar or Sub-lobar Resection for Peripheral Clinical Stage IA = 2 cm Non-small Cell Lung Cancer (NSCLC): Results From an International Randomized Phase III Trial (CALGB 140503 [Alliance])
Nasser Khaled Altorki, United States

09:05 - 09:15
PL03.07 Discussant
Hisashi Saji, Japan

09:15 - 09:20
PL03.08 Live Q&A

09:20 - 09:30
PL03.09 IMpower010: Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC
Enriqueta Felip, Spain

09:30 - 09:40
PL03.10 Discussant
Benjamin Besse, France

09:40 - 09:45
PL03.11 Live Q&A

09:45 - 09:55
PL03.12 Progression Free Survival and Overall Survival in NADIM II Study
Mariano Provencio, Spain

09:55 - 10:05
PL03.13 Discussant
Masahiro Tsuboi, Japan

10:05 - 10:15
PL03.14 Discussant
Corinne Faivre-Finn, United Kingdom

10:20 – 11:00
Networking Break

HALL B, EXHIBIT HALL
Light refreshments and beverages will be served.

10:25 – 11:00
PC03: Press Conference

SCHUBERT 5/6

11:00 – 12:00
ES16: Pushing the Boundaries in Lung Ablative Therapies

Track: Early Stage Non-small Cell Lung Cancer Radiotherapy and Other Ablative Techniques

HALL C1  IASLC CME ACCREDITED

Chair(s): Yasushi Nagata, Japan, Ursula Nestle, Germany

11:00 - 11:14
ES16.01 / ES16.02 Session Introduction
Yasushi Nagata, Japan, Ursula Nestle, Germany

11:00 - 11:14
ES16.03 SABR and ICI Combinations
Stephanie Kroeze, Switzerland
11:00 – 12:00
ES16: New Radiotherapy Approaches (MRI-Linac, Protons, Single Fraction)
Yong Chan Ahn, South Korea

11:26 – 11:38
ES16.05 Thermal Ablation: Stand-Alone or Prior to Lung SBRT?
Percy Lee, United States

11:38 – 11:50
ES16.06 Re-Irradiation: Which Are the Possibilities? A Practical Guide
Kevin Chua, Singapore

11:50 – 12:00
ES16.07 Live Q&A

11:00 – 12:00
ES17: Cost and Accessibility to Lung Cancer Drugs - Pathways to Improvement

Track: Global Health, Health Services Research, and Health Economics

Chair(s): David R. Gandara, United States

11:00 - 11:02
ES17.02 Session Introduction
David R. Gandara, United States

11:07 - 11:19
ES17.03 WHO Essential List: Is This a Possible Road to Follow?
Gilberto Lopes, United States

11:19 - 11:31
ES17.04 Bringing Research to the Forefront of Care? Lessons Learned
Clarissa Mathias, Brazil

11:31 - 11:43
ES17.05 Incorporation of China Innovative Anti-cancer Drugs - What Have We Learned?
Yuankai Shi, China

11:43 - 11:55
ES17.06 Role of Advocacies and Scientific Societies in Improving Cancer Care in Low Income Countries
Alina Comanescu, Romania

11:55 - 12:00
ES17.08 Live Q&A

11:00 – 12:00
ES18: Management of Pulmonary Nodules

Track: Pulmonology, Radiology, and Staging

Chair(s): Edith Marom, Israel, Wentao Fang, China

11:00 - 11:02
ES18.01 / ES18.02 Session Introduction
Edith Marom, Israel, Wentao Fang, China

11:02 - 11:14
ES18.03 Preneoplasia Management Strategies
Seung Hun Jang, South Korea

11:14 - 11:26
ES18.04 Nodule Measurements: Diameter vs. Volume
Ritu Gill, United States

11:26 - 11:38
ES18.05 Biopsy and Localization of Nodules
Yeun-Chung Chang, Taiwan

11:38 - 11:50
ES18.06 Managing Indeterminate Pulmonary Nodules: Current Best Practice
Hans-Ulrich Kauczor, Germany

11:50 - 12:00
ES18.07 Live Q&A

11:00 – 12:00
OA06: Impact of COVID-19 on Cancer Management and Protection from Vaccines

Track: Management of Lung Cancer in the Era of COVID-19

Chair(s): Marina Garassino, United States, Christian Grohe, Germany

11:00 - 11:02
OA06.01 / OA06.02 Session Introduction
Marina Garassino, United States, Christian Grohe, Germany

11:02 - 11:12
OA06.03 Serological Response to SARS-CoV-2 Vaccination in Patients Lung Cancer: A Mount Sinai-Led Prospective Matched Controlled Study
Philip Mack, United States
11:12 - 11:22
OA06.04 Immune Response after SARS-CoV-2 Vaccination in Lung Cancer Patients. Update of the Covid Lung Vaccine Cohort
Ainhoa Hernandez, Spain

11:22 - 11:32
OA06.05 Impact of COVID-19 Pandemic on Proportion and Treatment Patterns for Stage I Non-small Cell Lung Cancer in the Netherlands
Nienke Wolfhagen, Netherlands

11:32 - 11:42
OA06.06 Impact of Systemic Anti-cancer Treatments on Outcomes of COVID-19 in Patients with Thoracic Cancers: CCC19 Registry Analysis
Amit Kulkarni, United States

11:42 - 11:52
OA06.07 Stereotactic Ablative Radiotherapy Before Resection to Avoid Delay for Early-Stage Lung Cancer or Oligometastases
Biniam Kidane, Canada

11:52 - 12:02
OA06.08 Discussant
Marina Garassino, United States

12:02 - 12:10
OA06.09 Live Q&A

11:00 – 12:00
OA07: Is There Still a Role for Chemotherapy Alone in the Management of NSCLC?

Track: Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy

HALL C7
Chair(s): Lubos Petruzelka, Czech Republic, Pilar Garrido, Spain

11:00 - 11:02
OA07.01 / OA07.02 Session Introduction
Lubos Petruzelka, Czech Republic, Pilar Garrido, Spain

11:02 - 11:12
OA07.03 Association Between Genetic Variation in the ATP-binding Cassette Transporter ABCC10 and nab-PTX Treatment in Japanese Cohort
Minoru Horiuchi, Japan

11:12 - 11:22
OA07.04 Overall Survival in Patients With Advanced NSCLC Receiving Taxane-Containing Regimen After Exposure to Immunotherapy and Platinum-Doubléet
Stephen Liu, United States

11:22 - 11:32
OA07.05 Gemcitabine Plus Platinum Chemotherapy Re-challenge in Metastatic Pulmonary Lymphoepithelioma-like Carcinoma
Gavin Cheung, Hong Kong

11:32 - 11:42
OA07.06 Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) in Advanced Non-small Cell Lung Cancer (aNSCLC)
Edouard Auclin, France

11:42 - 11:52
OA07.07 Discussant
Navneet Singh, India

11:52 - 12:00
OA07.08 Live Q&A

11:00 – 12:00
OA08: Multidisciplinary Care of the Lung Cancer Patient

Track: Nursing and Allied Health Professionals

STRAUSS 3
Chair(s): Shankar Siva, Australia, Sun Min Lim, South Korea

11:00 - 11:02
OA08.01 / OA08.02 Session Introduction
Shankar Siva, Australia, Sun Min Lim, South Korea

11:02 - 11:12
OA08.03 Do in Screening - Calf Circumference and Muscle Strength is Predictive of Outcomes in Lung Cancer Treatment.
Imanuely Borchardt Borchardt, Brazil

11:12 - 11:22
OA08.04 The Impact of Video-fluoroscopic Swallow Assessment on Dysphagia Management in Lung Cancer
Ashton Brower, United Kingdom

11:22 - 11:32
OA08.05 A Quality Improvement Project Determining if Dietitian Input with the UHS Lung Oncology Team Improved Patient Outcomes.
Ann-Marie Jones, United Kingdom

11:32 - 11:42
OA08.06 Implementation of a Nurse-led Geriatric Oncology Assessment Model in the Lung Cancer Care Pathway
Polly Dufton, Australia
11:42 - 11:52
OA08.07 Discussant
Jacqui Frowen, Australia

11:52 - 12:00
OA08.08 Live Q&A

12:15 – 13:15
ES19: Toxicity Avoidance in SABR for Early Stage NSCLC

Track: Early Stage Non-small Cell Lung Cancer? - Radiotherapy and Other Ablative Techniques

HALL C1  IASLC CME ACCREDITED

Chair(s): Lizza Hendriks, Netherlands, Shankar Siva, Australia

12:15 - 12:17
ES19.01 / ES19.02 Session Introduction
Lizza Hendriks, Netherlands, Shankar Siva, Australia

12:17 - 12:29
ES19.03 SABR in the Ultracentral Lesions
Kevin Franks, United Kingdom

12:29 - 12:41
ES19.04 Heart Matters in Lung SABR
Pamela Samson, United States

12:41 - 12:53
ES19.05 SABR in Patients with Interstitial Lung Disease
Yeon Sil Kim, South Korea

12:53 - 13:05
ES19.06 Chest Wall Myositis, Pleuritis and Rib Fracture
Maria Werner-Wasik, United States

13:05 - 13:15
ES19.07 Live Q&A

12:15 – 13:15
ES20: Management of Lung Cancer in the Era of COVID-19 II

Track: Management of Lung Cancer in the Era of COVID-19

HALL C2  IASLC CME ACCREDITED

Chair(s): Andrea Bezjak, Canada, Milena Cavic, Serbia

12:15 - 12:17
ES20.01 / ES20.02 Session Introduction
Andrea Bezjak, Canada, Milena Cavic, Serbia

12:17 - 12:29
ES20.03 COVID-19 and Its Complications in Patients With Lung Cancer
Kwun Fong, Australia

12:29 - 12:41
ES20.04 Impact of COVID-19 on Lung Cancer and Mesothelioma Specialist Nurses
Sarah Hargreaves, United Kingdom

12:41 - 12:53
ES20.05 Intensive Care for Lung Cancer Patients
Erwin GrasmUnited Kingdom-Siegl, Austria

12:53 - 13:05
ES20.06 Telemedicine in 2021: Pros and Cons
Howard (Jack) West, United States

13:05 - 13:15
ES20.07 Live Q&A

12:15 – 13:15
ES21: Problems and Controversies in Lung Tumours

Track: Pathology

STRAUSS 1/2  IASLC CME ACCREDITED

Chair(s): Jin-Haeng Chung, South Korea, Sylvie Lantuejoul, France

12:15 - 12:17
ES21.01 / ES21.02 Session Introduction
Jin-Haeng Chung, South Korea, Sylvie Lantuejoul, France

12:17 - 12:29
ES21.03 G3NET/Supracarcinoids
Mauro Papotti, Italy

12:29 - 12:41
ES21.04 SCLC Subtypes
Natasha Rekhtman, United States

12:41 - 12:53
ES21.05 LCNEC: Where Are We with Diagnosis?
Teodora Radonic, Netherlands

12:53 - 13:05
ES21.06 Molecular Profiling and Biomarkers in Lung NET. Any Closer?
Alexandra Sexton-Oates, France

13:05 - 13:15
ES21.07 Live Q&A
12:15 – 13:15
**MA06: Resectable and Unresectable Locally Advanced Lung Cancer**

**Track: Locally Advanced Non-small Cell Lung Cancer**

**LEHAR 1**

Chair(s): Saulius Cicenas, Lithuania, Celine Mascaux, France

12:15 - 12:17
**MA06.01 / MA06.02 Session Introduction**
Saulius Cicenas, Lithuania, Celine Mascaux, France

12:17 - 12:22
**MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial**
Atocha Romero, Spain

12:22 - 12:27
**MA06.04 Phase II Study of Durvalumab Plus Concurrent Radiotherapy in Unresectable Locally Advanced NSCLC: DOLPHIN Study (WJOG11619L)**
Motoko Tachihara, Japan

12:27 - 12:32
**MA06.05 Consolidation Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiation for Patients with Unresectable Stage III NSCLC**
Greg Durm, United States

12:32 - 12:42
**MA06.06 Discussant**
Andrea Bille, United Kingdom

12:42 - 12:47
**MA06.07 Molecular Typing of pN2 Lung Adenocarcinoma: A Retrospective Study Based on Transcriptome Sequencing**
Jianfei Zhu, China

12:47 - 12:52
**MA06.08 Long-term Survival and Competing Risks of Death in the ESPATUE Randomized Phase-III Trial in Stage III NSCLC**
Wilfried Eberhardt, Germany

12:52 - 12:57
**MA06.09 Deep Learning for Predicting MPR to Neoadjuvant Immunotherapy in NSCLC**
Yifan Zhong, China

12:57 - 13:07
**MA06.10 Discussant**
Dawn Owen, United States

13:07 - 13:15
**MA06.11 Live Q&A**

12:15 – 13:15
**MA07: Overcoming Resistance to EGFR Inhibitors**

**Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments**

**HALL C7**

Chair(s): Dana Lucia Stanculeanu, Romania, Ross Soo, Singapore

12:15 - 12:17
**MA07.01 / MA07.02 Session Introduction**
Dana Lucia Stanculeanu, Romania, Ross Soo, Singapore

12:17 - 12:22
**MA07.03 Real-world Landscape of EGFR C797X Mutation as a Resistance Mechanism to Osimertinib in Non-small Cell Lung Cancer**
Suresh Ramalingam, United States

12:22 - 12:27
**MA07.04 Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC**
Melina Marmarelis, United States

12:27 - 12:32
**MA07.05 Phase 1b/2 Study of Combined HER Inhibition in Refractory EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)**
Jonathan Goldman, United States

12:32 - 12:42
**MA07.06 Discussant**
Laura Mezquita, Spain

12:42 - 12:47
**MA07.07 Clinical/Molecular Profile of Patients with Non-small Cell Lung Cancer (NSCLC) with Incidental Pathogenic Germline Variants Detected in cfDNA**
Laura Mezquita, Spain

12:47 - 12:52
**MA07.08 JIN-A02, a Highly Effective 4th Generation EGFR-TKI, Targeting EGFR C797S Triple Mutation in NSCLC**
Byoung Chul Cho, South Korea

12:52 - 12:57
**MA07.09 BBT-176, a 4th generation EGFR TKI, for Progressed NSCLC after EGFR TKI Therapy: PK, Safety and Efficacy from Phase 1 Study**
Sun Min Lim, South Korea

12:57 - 13:07
**MA07.10 Discussant**
Pasi Jänne, United States

13:07 - 13:15
**MA07.11 Live Q&A**
12:15 – 13:15
MA08: Patient Advocacy and Patient Preferences

Track: Patient Advocacy

STRAUSS 3

Chair(s): Merel Hennink, Netherlands, Ewelina Szmytke, Poland

12:15 - 12:17
MA08.01 / MA08.02 Session Introduction
Merel Hennink, Netherlands, Ewelina Szmytke, Poland

12:17 - 12:22
MA08.03 Breathe Anew: Designing and Testing the Feasibility of a Novel Intervention for Lung Cancer Survivorship
Yogita S. Patel, Canada

12:22 - 12:27
MA08.04 Initial Steps in Creating a Patient-Centric Addendum to Clinical Trial Informed Consent Forms
Bellinda King-Kallimanis, United States

12:27 - 12:32
MA08.05 Advancing Education and Advocacy for the Small Cell Lung Cancer Community
Jennifer King, United States

12:32 - 12:42
MA08.06 Discussant
Lorraine Dallas, United Kingdom

12:42 - 12:47
MA08.07 Understanding Lung Cancer Patients’ Preferences in Speaking to Their Treatment Team: Insights from a Global Patient Experience Survey
Jackie Fenemore, United Kingdom

12:47 - 12:52
MA08.08 Impact of Lung Cancer on Quality of Life - A European Perspective
Anne-Marie Baird, Ireland

12:52 - 12:57
MA08.09 The Role of Social Media as a Platform for Patient-Led Support Groups
Maryann Bradley, Canada

12:57 - 13:07
MA08.10 Discussant
Hiroaki Akamatsu, Japan

13:07 - 13:15
MA08.11 Live Q&A

13:30 – 14:30
LA02: Lectureship Awards - Monday

HALL C1

Chair(s): Frances Shepherd, Canada, Giorgio Scagliotti, Italy

13:30 - 13:32
LA02.01 / LA02.02 Session Introduction
Frances Shepherd, Canada, Giorgio Scagliotti, Italy

13:32 - 13:47
LA02.03 Robert J. Ginsberg Lectureship Award for Surgery
Isabelle Opitz, Switzerland

13:47 - 14:02
LA02.04 James D. Cox Lectureship Award for Radiation Oncology
Yuko Nakayama, Japan

14:02 - 14:17
LA02.05 Heine H. Hansen Lectureship Award for Small Cell Lung Cancer
Stephen Liu, United States

14:17 - 14:30
LA02.06 Live Q&A

13:30 – 14:30
Networking Lunch

HALL B, EXHIBIT HALL

Complimentary food and beverages will be served.

14:45 – 15:45
ES22: Lung Cancer in Individuals Without A Smoking History

Track: Epidemiology

HALL C1

Chair(s): Rayjean Hung, Canada, Mattias Johansson, France

14:45 - 14:47
ES22.01 / ES22.02 Session Introduction
Rayjean Hung, Canada, Mattias Johansson, France

14:47 - 14:59
ES22.03 Epidemiological Risk Factors for Lung Cancer Beyond Smoking History
Michelle C. Turner, Spain

14:59 - 15:11
ES22.04 Radon and Lung Cancer
Alberto Ruano Ravina, Spain
14:45 – 15:45
ES23: Optimizing Radio-Chemo-Immunotherapy for Locally Advanced NSCLC

Track: Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy

HALL C2  IASLC CME ACCREDITED

Chair(s): Billy Loo, United States, Jose Belderbos, Netherlands

14:45 - 14:47
ES23.01 / ES23.02 Session Introduction
Billy Loo, United States, Jose Belderbos, Netherlands

14:47 - 14:59
ES23.03 Early Integration of Immune Checkpoint Inhibition into Radio-Chemotherapy
Willemijn Theelen, Netherlands

14:59 - 15:11
ES23.04 Management of Patients with Oncogenic Driver Mutations
Ross Soo, Singapore

15:11 - 15:23
ES23.05 Next-Generation Radiotherapy in the Era of Immunotherapy
Ken Harada, Japan

15:23 - 15:35
ES23.06 Diagnosis and Management of Pneumonitis after Radio-Chemo-Immunotherapy
Alexander Louie, Canada

15:35 - 15:45
ES23.07 Live Q&A

14:45 – 15:45
ES24: Palliative Care Integration and QOL in Advanced Lung Cancer

Track: Palliative and Supportive Care

STRAUSS 1/2

Chair(s): Charu Aggarwal, United States, Karin Dieckmann, Austria

14:45 - 14:47
ES24.01 / ES24.02 Session Introduction
Charu Aggarwal, United States, Karin Dieckmann, Austria

14:47 - 14:59
ES24.03 Early Palliative Care in Advanced Non-small-Cell Lung Cancer
Jennifer Temel, United States

14:59 - 15:11
ES24.04 Treatment Decision-Making for Patients with Complicated Bone Metastases
Thanyanan Baisamut, Thailand

15:11 - 15:23
ES24.05 What Is the Role of Supporting Care to Improve Checkpoint Inhibitor Tolerance?
Mirjana Rajer, Slovenia

15:23 - 15:35
ES24.06 The Management of Pain in Lung Cancer: Pharmacological Interventions
Marliese Alexander, Australia

15:35 - 15:45
ES24.07 Live Q&A

14:45 – 15:45
MA09: Palliative Radiotherapy: The Changing Landscape with Immunotherapy and Targeted Therapies

Track: Metastatic Non-small Cell Lung Cancer - Palliative Radiotherapy

HALL C7

Chair(s): Milada Zemanova, Czech Republic, David Ball, Australia

14:45 - 14:47
MA09.01 / MA09.02 Session Introduction
Milada Zemanova, Czech Republic, David Ball, Australia

14:47 - 14:52
MA09.03 Response of Palliative Radiotherapy in Bone Metastases of Lung Cancer - Results of Prospective Longitudinal Study from India
Amiya Agrawal, India
14:52 - 14:57
MA09.04 First-line PD-1 Inhibitors and Chemotherapy Combined with or without Radiotherapy in Advanced Non-small-cell Lung Cancer
Xiaorong Dong, China

14:57 - 15:02
MA09.05 Increased PD-L1 Tracer Uptake in Recently-irradiated Lesions in NSCLC: Preliminary Results of a Phase 0 Trial (ImmonoPET) of a Novel PET Tracer
Michael Macmanus, Australia

15:02 - 15:12
MA09.06 Discussant
Kristin Higgins, United States

15:12 - 15:17
MA09.07 Understanding Outcomes of Patients with Metastatic Non-Small Cell Lung Carcinoma Undergoing Whole Brain vs Stereotactic Radiotherapy
Dhruv Abhi, United Kingdom

15:17 - 15:22
MA09.08 Radiotherapy Improves Outcomes to Immunotherapy in Patients with Stage III and IV NSCLC
Haihua Yang, China

15:22 - 15:27
MA09.09 Perilesional Edema and Size of Brain Metastases as Prognostic and Predictive Factors to Local Therapy in Advanced Non-small-Cell Lung Cancer
Oscar Arrieta, Mexico

15:27 - 15:27
MA09.10 Discussant
Ursula Nestle, Germany

15:27 - 15:35
MA09.11 Live Q&A

14:45 - 15:45
MA10: Updates in Thymoma

Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies

Chair(s): Noboru Yamamoto, Japan, Paul van Houtte, Belgium

14:45 - 14:47
MA10.01 / MA10.02 Session Introduction
Noboru Yamamoto, Japan, Paul van Houtte, Belgium

14:47 - 14:52
MA10.03 Is Thoracoscopic Thymectomy Safe and Oncologically Sound in Large Thymic Tumours?
Venkata Ramani Karthik, India

14:52 - 14:57
MA10.04 Long-term Follow-up Study of Thymic Epithelial Tumours. Report of the Updated Nationwide Database in Japan
Meinoshin Okumura, Japan

14:57 - 15:02
MA10.05 High Levels of CD47 Expression in Thymic Epithelial Tumours
Thomas Yang Sun, United States

15:02 - 15:12
MA10.06 Discussant
Joachim Aerts, Netherlands

15:12 - 15:17
MA10.07 Phase II Trial of Sunitinib in Patients with Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines - STYLE Trial (NCT03449173)
Claudia Proto, Italy

15:17 - 15:22
MA10.08 Activated Pathways of Myastenia Gravis in Thymic Epithelial (TETs)
Jose Benitez, France

15:22 - 15:27
MA10.09 Outcomes of Induction Therapy Followed by Surgical Resection for Advanced Thymic Tumour
Sumin Shin, South Korea

15:27 - 15:37
MA10.10 Discussant
Alessandra Curioni-Fontecedro, Switzerland

15:37 - 15:45
MA10.11 Live Q&A

14:45 – 15:45
OA09: Precision Immunotherapy via Modulation of the Tumour Microenvironment

Track: Tumour Biology and Biomarkers

Chair(s): Kurt Schalper, United States, Umberto Malapelle, Italy

14:45 - 14:47
OA09.01 / OA09.02 Session Introduction
Kurt Schalper, United States, Umberto Malapelle, Italy
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:47 - 14:57</td>
<td>OA09.03 Single Cell Analyses Reveal Effects of Immunosenescence Cells in Neoadjuvant Immunotherapy of Lung Squamous cell Carcinoma Patients Tao Wang, China</td>
</tr>
<tr>
<td>14:57 - 15:07</td>
<td>OA09.04 Spatial Mapping and Clinical Significance of the LAG-3/FGL1 Pathway in Non-small Cell Lung Cancer Using High-Dimensional Tissue Imaging Shruti Desai, United States</td>
</tr>
<tr>
<td>15:07 - 15:17</td>
<td>OA09.05 Neoadjuvant IL-15-PDL1 Antibody Promotes T cell Memory and Decreases Metastatic Recurrence in Resectable NSCLC Jonathan Villena-Vargas, United States</td>
</tr>
<tr>
<td>15:17 - 15:27</td>
<td>OA09.06 Vascular Leakage Promotes Immunosuppression and is Associated with Reduced Patient Survival in Non-Small Cell Lung Cancer Emmanuel Nwadozi, Sweden</td>
</tr>
<tr>
<td>15:27 - 15:37</td>
<td>OA09.07 Discussant Umberto Malapelle, Italy</td>
</tr>
<tr>
<td>15:37 - 15:45</td>
<td>OA09.08 Live Q&amp;A</td>
</tr>
<tr>
<td>14:45 - 14:54</td>
<td>OA10: Strategies to Integrate Smoking Cessation and Cancer Care</td>
</tr>
<tr>
<td>14:45 - 14:47</td>
<td>OA10.01 / OA10.02 Session Introduction Enrica Capelletto, Italy, Manfred Neuberger, Austria</td>
</tr>
<tr>
<td>14:47 - 14:57</td>
<td>OA10.03 A Randomized Trial of Telephone-Based Smoking Cessation Treatment in the Lung Cancer Screening Setting Randi Williams, United States</td>
</tr>
<tr>
<td>14:57 - 15:07</td>
<td>OA10.04 Opt-out Outperforms Opt-in Smoking Cessation Treatment One-month Post Randomization Babalola Faseru, United States</td>
</tr>
<tr>
<td>15:07 - 15:17</td>
<td>OA10.05 Integrating Smoking Cessation into LDCT Lung Cancer Screening. Results of the Ontario, Canada, Pilot Bill Evans, Canada</td>
</tr>
<tr>
<td>15:17 - 15:27</td>
<td>OA10.06 An Unconventional Financial Incentive Based Feasibility Trial for Smoking Cessation Gregory Holt, United States</td>
</tr>
<tr>
<td>15:27 - 15:37</td>
<td>OA10.07 Discussant Patrizia Froesch, Switzerland</td>
</tr>
<tr>
<td>15:37 - 15:55</td>
<td>OA10.08 Live Q&amp;A</td>
</tr>
<tr>
<td>16:00 - 17:00</td>
<td>ES25: Clinical Issues with Immunotherapy in Non-small Cell Lung Cancer</td>
</tr>
<tr>
<td>16:00 - 16:02</td>
<td>ES25.01 / ES25.02 Session Introduction Martin Reck, Germany, Sanjay Popat, United Kingdom</td>
</tr>
<tr>
<td>16:02 - 16:14</td>
<td>ES25.03 First-Line Choice in PD-L1 Positive Patients Filiz Oezkan, Germany</td>
</tr>
<tr>
<td>16:14 - 16:26</td>
<td>ES25.04 First-Line Choice in PD-L1 Negative Patients Delvys Rodriguez-Abreu, Spain</td>
</tr>
<tr>
<td>16:26 - 16:38</td>
<td>ES25.05 Second-Line Options in Immune-Pretreated Patients Keunchil Park, South Korea</td>
</tr>
<tr>
<td>16:38 - 16:50</td>
<td>ES25.06 Immunotherapy in Oncogene-Addicted NSCLC Francesco Passiglia, Italy</td>
</tr>
<tr>
<td>16:50 - 17:00</td>
<td>ES25.07 Live Q&amp;A</td>
</tr>
</tbody>
</table>
16:00 – 17:00
ES26: Thymoma

**Track:** Mesothelioma, Thymoma, and Other Thoracic Malignancies

**HALL C2**  
IASLC CME ACCREDITED

Chair(s): Joachim Aerts, Netherlands, David Waller, United Kingdom

16:00 - 16:02  
ES26.01 / ES26.02 Session Introduction  
Joachim Aerts, Netherlands, David Waller, United Kingdom

16:02 - 16:14  
ES26.03 Pathological Staging of Thymic Epithelial Tumours  
Anja Roden, United States

16:14 - 16:26  
ES26.04 How to Implement Surgery in the Multimodality Therapy of Thymic Epithelial Tumours  
Enrico Ruffini, Italy

16:26 - 16:38  
ES26.05 Risks and Options of IO Therapy in Thymic Epithelial Tumours  
Chen Zhao, United States

16:38 - 16:50  
ES26.06 Indications for Radiation Therapy  
Anna Wrona, Poland

16:50 - 17:00  
ES26.07 Live Q&A

16:00 – 17:00
ES27: Joint Global Lung Cancer Coalition and International Association for the Study of Lung Cancer Session - Breaking Down Roadblocks to Lung Cancer Care in 2022

**Track:** Patient Advocacy

**HALL C2**  
IASLC CME ACCREDITED

Chair(s): Carolyn Aldige, United States, David Baldwin, United Kingdom

16:00 - 16:02  
ES27.01 / ES27.02 Session Introduction  
Carolyn Aldige, United States, David Baldwin, United Kingdom

16:02 - 16:12  
ES27.03 Mitigating the Effects of COVID - How Does Lung Cancer Recover?  
David Baldwin, United Kingdom

16:12 - 16:22  
ES27.04 Lung Cancer Screening - From Pilots to Programs and the Effects of Patient Advocacy  
Shani Shilo, Israel

16:22 - 16:32  
ES27.05 Lung Cancer Screening - From Pilots to Programs  
Matthew Peters, Australia

16:32 - 16:42  
ES27.06 Lung Cancer Patient Experience - The Impact of COVID  
Merel Hennink, Netherlands

16:42 - 16:52  
ES27.07 Optimising Telehealth for the Lung Cancer Patient  
Lauren Pretorius, South Africa

16:52 - 17:00  
ES27.08 Live Q&A

16:00 – 17:00
MA11: Optimization of Technologies for Lung Cancer Screening: Population Selection and Nodule Handling

**Track:** Early Detection and Screening

**LEHAR 1**  
IASLC CME ACCREDITED

Chair(s): Anna Kerpel-Fronius, Hungary, Annemiek Snoeckx, Belgium

16:00 - 16:02  
MA11.01 / MA11.02 Session Introduction  
Anna Kerpel-Fronius, Hungary, Annemiek Snoeckx, Belgium

16:02 - 16:07  
MA11.03 Updated Cost-Effectiveness Analysis of Lung Cancer Screening for Australia, Capturing Differences in the Impact of NELSON and NLST Outcomes  
Preston Ngo, Australia

16:07 - 16:12  
MA11.04 Genetic Variants of HUNT Lung Cancer Model Improve Lung Cancer Risk Assessment Over Clinical Models  
Olav Toai Duc Nguyen, Norway

16:12 - 16:17  
MA11.05 The Blood Proteome of Imminent Lung Cancer  
Hana Zahed, France

16:17 - 16:27  
MA11.06 Discussant  
Carole Ridge, United Kingdom
16:27 - 16:32
MA11.07 The ELIC Distributed Database and Computation Environment for Analyses of Lung Cancer Screening LDCTs Across the World
Stephen Lam, Canada

16:32 - 16:37
MA11.08 Value of Computer Aided Diagnosis on Radiologists' Workflow and Recommendation for Reporting Lung Cancer Screening LDCT
Ren Yuan, Canada

16:37 - 16:42
MA11.09 Artificial Intelligence in Lung Cancer Screening: Accuracy and Predictive Value
Ricardo Santos, Brazil

16:42 - 16:52
MA11.10 Discussant
Arjun Nair, United Kingdom

16:52 - 17:00
MA11.11 Live Q&A

16:00 – 16:02
OA11.01 / OA11.02 Session Introduction
Pablo Munoz-Schuffenegger, Chile, Mariana Brandao, Belgium

16:02 - 16:12
OA11.03 Nonregional Lymph Nodes as the Only Metastatic Site in Stage IV Non-Small Cell Lung Cancer: A Marker of Better Prognosis
Peter Zhan, United States

16:12 - 16:22 OA11.04
The Factors Associated With Reduced Risk of Progression in Patients With Oligometastatic NSCLC Treated With Local Ablative Radiotherapy
Gowoon Yang, South Korea

16:22 - 16:32
OA11.05 Treatment Strategies Based on Different Oligoprogressive Patterns after Immunotherapy Resistance in Advanced NSCLC
Shun Lu, China

16:32 - 16:42
OA11.06 Sequencing of ctDNA Revealed Radiotherapeutic Efficacy and Prognosis in Non-small Cell Lung Cancer Patients with Brain Metastasis
Xiaorong Dong, China

16:42 - 16:52
OA11.07 Discussant
Digambar Behera, India

16:52 - 17:00
OA11.08 Live Q&A

16:00 – 17:00
OA12: Novel and Combination Strategies for SCLC

Track: Small Cell Lung Cancer and Neuro-endocrine Tumours

16:00 - 16:02
OA12.01 / OA12.02 Session Introduction
Alessandra Curioni-Fontecedro, Switzerland, Kostas Syrigos, Greece

16:02 - 16:12
OA12.03 Phase 2 Study Analysis of Talazoparib (TALA) Plus Temozolomide (TMZ) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Jonathan Goldman, United States

16:12 - 16:22
OA12.04 Efficacy of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer after Chemo-Immunotherapy: A Phase 2 Trial.
Dwight Owen, United States

16:22 - 16:32
OA12.05 Phase 1 Updated Exploration and First Expansion Data for DLL3-targeted T-cell Engager Tarlatamab in Small Cell Lung Cancer
Hossein Borghaei, United States

16:32 - 16:42
OA12.06 First-Line Pembrolizumab or Placebo Combined With Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results
Charles Rudin, United States

16:42 - 16:52
OA12.07 Discussant
Virginie Westeel, France

16:52 - 17:00
OA12.08 Live Q&A
17:15 – 19:00
Poster Viewing Reception
Poster Session P2 Presenters in Attendance

**HALL B, EXHIBIT HALL**

Complimentary food and beverage will be served.

19:30 – 22:30
Faculty Dinner (By Invitation Only)

Please refer to your Faculty Dinner ticket for more information.
**DAILY SCIENTIFIC PROGRAM - TUESDAY, AUGUST 9**

**07:30 – 08:15**
IBS13: CNS Involvement in Oncogene-Driven and Not-Oncogene-Driven Disease: Optimal Management

*Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments*

**LEHAR 1**

- **07:30 - 08:00**
  IBS13.01 CNS Involvement in Oncogene-Driven and Not-Oncogene-Driven Disease: Optimal Management
  Rifaquat Rahman, United States

- **08:00 - 08:15**
  IBS13.02 Live Q&A

**07:30 – 08:15**
IBS14: Supportive Care in Lung Cancer: Improving Value in the Era of Modern Therapies

*Track: Palliative and Supportive Care*

**STRAUSS 3**

- **07:30 - 08:00**
  IBS14.01 Supportive Care in Lung Cancer: Improving Value in the Era of Modern Therapies
  Krisztina Bogos, Hungary

- **08:00 - 08:15**
  IBS14.02 Live Q&A

**07:30 – 08:15**
IBS15: Should We Offer PCI and Consolidation Thoracic RT to Patients Treated with First-Line Chemo-Immunotherapy?

*Track: Small Cell Lung Cancer and Neuro-endocrine Tumours*

**HALL C8**

- **07:30 - 07:45**
  IBS15.01 No
  Gyula Ostoros, Hungary

- **07:45 - 08:00**
  IBS15.02 Yes
  Corinne Faivre-Finn, United Kingdom

**08:00 - 08:15**
IBS15.03 Live Q&A

**07:30 – 08:15**

*Track: Early Detection and Screening*

**LEHAR 2**

- **07:30 - 08:00**
  IBS16.01 A Guide for the Perplexed: How to Use Lung Cancer Risk Models Efficiently for Screening
  Martin Tammemagi, Canada

- **08:00 - 08:15**
  IBS16.02 Live Q&A

**07:30 – 08:15**
IBS17: Interactive Debate: Predictive Biomarkers for Immunotherapy: Which Biomarker to Use across Histologies and Clinical Settings?

*Track: Tumour Biology and Biomarkers*

**LEHAR 3**

- **07:30 – 08:00**
  IBS17.01 / IBS17.02 Interactive Debate: Predictive Biomarkers for Immunotherapy: Which Biomarker to Use across Histologies and Clinical Settings?
  Fred R. Hirsch, United States, Solange Peters, Switzerland

- **08:00 - 08:15**
  IBS17.03 Live Q&A

**07:30 – 08:15**
IBS18: Women in Thoracic Oncology

*Chair(s): Françoise Mornex, France, Silvia Novello, Italy, Narjust Florez, United States*

**LEHAR 4**

- **07:30 – 07:33**
  IBS18.01 / IBS18.02 / IBS18.03 Session Introduction
  Francoise Mornex, France, Silvia Novello, Italy, Narjust Florez, United States

- **07:33 – 07:35**
  IBS18.04 President Welcome
  Heather Wakelee, United States
07:35 – 07:45
IBS18.05 / IBS18.06 / IBS18.07 / IBS18.08 / IBS18.09 / IBS18.11 / IBS18.12 / IBS18.13 / IBS18.14 Panel Discussion - Thriving during a Global Crisis
Narjust Florez, United States, Heather Wakelee, United States, Silvia Novello, Italy, Clarissa Mathias, Brazil, Françoise Mornex, France, Karen Kelly, United States, Enriqueta Felip, Spain, Roselle De Guzman, Philippines, Feng-Ming Spring Kong, Hong Kong

07:45 – 08:15
Round Table
Moderators: Anne-Marie Dingemans, Netherlands, Deepali Jain, India, Aki Kobayashi, Japan, Vun-Sin Lim, Hong Kong, Natasha Leighl, Canada

Topics:
1. Career Transitions - Finding a New Job
2. Negotiating Salary and Beyond (Vacation, Rooms in Clinic, Days of Clinic, RVU Target)
3. Finding Mentors beyond Your Institution / How to Identify Suitable Mentors in General
4. Systematic Approaches to Wellness (Changing the Work Environment)
5. Building a Career beyond Clinical Care and Research - Admin, Education, etc
6. Finding Your Niche - What Fills Your Cup?
7. Social Media - How to Get Involved

08:30 – 10:00
PL04: Plenary 4: Artificial Intelligence in Lung Cancer

Chair(s): Andrea Bezjak, Canada, Helmut Prosch, Austria

08:30 - 08:32
PL04.01 / PL04.02 Session Introduction
Andrea Bezjak, Canada, Helmut Prosch, Austria

08:32 - 08:52
PL04.03 AI in Pathology
Douglas Hartman, United States

08:52 - 09:12
PL04.04 AI in Radiology
Fergus Gleeson, United Kingdom

09:12 - 09:32
PL04.05 AI in Radiotherapy
Jean-Emmanuel Bibault, France

09:32 - 09:52
PL04.06 The Promise of Big Data
Georg Langs, Austria

09:52 - 10:00
PL04.07 Live Q&A

10:00 – 10:45
IASLC Business Meeting

10:45 – 11:45
ES28: Neoadjuvant and Adjuvant Treatment of NSCLC in 2022

Track: Early Stage Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Systemic Therapy (Multi-Modality Treatment, Immunotherapy, Molecular Targeted Treatments)

Chair(s): Tina Cascone, United States, Mariano Provencio, Spain

10:45 - 10:47
ES28.01 / ES28.02 Session Introduction
Tina Cascone, United States, Mariano Provencio, Spain

10:47 - 10:59
ES28.03 Surgical Techniques to Optimize Uptake of Adjuvant Treatment
Thomas D’Amico, United States

10:59 - 11:11
ES28.04 Standardisation of Pathological Assessment with Novel Neoadjuvant Therapies
Yasushi Yatabe, Japan

11:11 - 11:23
ES28.05 How Does MRD Status Affect Decisions on Adjuvant Therapy?
Federico Cappuzzo, Italy
11:23 - 11:35
ES28.06 Neoadjuvant EGFR TKI Trials
Julia Rotow, United States

11:35 - 11:45
ES28.07 Live Q&A

10:45 – 11:45
ES29: Palliative Radiotherapy in Metastatic NSCLC: State of the Art in an Era of New Hope

Track: Metastatic Non-small Cell Lung Cancer - Palliative Radiotherapy

Chair(s): Fiona Hegi-Johnson, Australia, Joachim Widder, Austria

10:45 – 11:45
ES30: Leveraging the Power of Immunotherapy for SCLC

Track: Small Cell Lung Cancer and Neuro-endocrine Tumours

Chair(s): Giorgio Scagliotti, Italy, Raffaele Califano, United Kingdom

11:40 – 11:45
ES30.07 Live Q&A

10:45 – 11:45
ES31: Survivorship across the Cancer Continuum for Patients Treated with Immunotherapies and Targeted Therapies

Track: Nursing and Allied Health Professionals

Chair(s): Nazanin Nouriany, Canada, Morten Quist, Denmark

11:40 – 11:45
ES31.07 Live Q&A
10:47 - 10:59
ES31.03 Long-Term Immunotherapy Survivors of Advanced Non-small Cell Lung Cancer: The Survivorship Experience
Michelle Turner, United States

10:59 - 11:11
ES31.04 Survivorship and Financial Toxicity in Lung Cancer
Paula Shepherd, United Kingdom

11:11 - 11:23
ES31.05 Fear of Cancer Progression in Patients Treated with Novel Therapies
Fiona Lynch, Australia

11:23 - 11:35
ES31.06 Impact of Body Composition, Nutritional and Inflammatory Status on Outcome of Non-small Cell Lung Cancer Patients Treated with Immunotherapy
Ilaria Trestini, Italy

11:35 - 11:45
ES31.07 Live Q&A

10:45 – 11:45
MA12: Pathology: Tumour Diagnostics

Track: Pathology

HALL C7
Chair(s): Aleks Ryska, Czech Republic, Deepali Jain, India

10:45 - 10:47
MA12.01 / MA12.02 Session Introduction
Aleks Ryska, Czech Republic, Deepali Jain, India

10:47 - 10:52
MA12.03 Mechanisms of Immune Evasion in Patients With KRAS-Mutant Lung Adenocarcinoma: A Role of MAPK Pathway Activation
Dwayne Naves, Netherlands

10:52 - 10:57
MA12.04 SAKK 16/14: CD8 T Cell Positioning Correlates with Survival in Stage IIIA(N2) NSCLC After Neoadjuvant Immunotherapy
Sacha Rothschild, Switzerland

10:57 - 11:02
MA12.05 Economic Impact of Delaying Care With Single-Gene Testing Versus Next-Generation Sequencing in Non-small Cell Lung Cancer
Brandon Sheffield, Canada

11:02 - 11:12
MA12.06 Discussant
Ming-Sound Tsao, Canada

11:12 - 11:17
MA12.07 Defining Morphologic Features of Invasion in Pulmonarynon-MucinousUnited Statesadenocarcinoma With Lepidic Growth
Erik Thunnissen, Netherlands

11:17 - 11:22
MA12.08 Pagetoid Growth of Squamous Cell Carcinoma with a Subsolid Component
Federica Filipello, Italy

11:22 - 11:27
MA12.09 Frequency and Detectability of Uncommon EGFR Mutations in NSCLC
Hazel O’Sullivan, United Kingdom

11:27 - 11:37
MA12.10 Discussant
Mari Mino-Kenudson, United States

11:37 - 11:45
MA12.11 Live Q&A

10:45 – 11:45
OA13: Evolving Epidemiology of Lung Cancer Beyond Tobacco

Track: Epidemiology

HALL C8
Chair(s): Matthew Warkentin, Canada, Hilary Robbins, France

10:45 - 10:47
OA13.01 / OA13.02 Session Introduction
Matthew Warkentin, Canada, Hilary Robbins, France

10:47 - 10:57
OA13.03 Evaluation of Outdoor Air Pollution Exposure (PM2.5) In Female Non-smoking Lung Cancer Patients
Renelle Myers, Canada

11:07 - 11:17
OA13.06 Changing Patterns of Lung Cancer Histology in an Asbestos Exposed Population
Chellan Kumarasamy, Australia
11:27 - 11:37
OA13.07 Discussant
Chang-Chuan Chan, Taiwan

11:37 - 11:45
OA13.08 Live Q&A

12:00 – 13:00
ES32: Beyond Tobacco: Environmental Risk Factors for Lung Cancer

Track: Epidemiology

HALL C1

Chair(s): Christine D Berg, United States, Paolo Boffetta, United Kingdom

12:00 - 12:02
ES32.01 / ES32.02 Session Introduction
Christine Berg, United States, Paolo Boffetta, United States

12:02 - 12:14
ES32.03 Outdoor Particulate Air Pollution
Pawan Kumar Singh, India

12:14 - 12:26
ES32.04 What Changes Are Needed to Reach WHO Particulate Matter Standards: Particular Emphasis on Power Generation and Transportation
Paolo Boffetta, United States

12:26 - 12:38
ES32.05 Indoor Air Pollution, Genetic Susceptibility, and Lung Cancer among Women in Asia Without a Smoking History
Chunxia Su, China

12:38 - 12:50
ES32.06 Effects of Climate Change: Treatment Delays during Natural Disasters Lessen Lung Cancer Patient Survival
Roselle De Guzman, Philippines

12:50 - 13:00
ES32.07 Live Q&A

12:00 – 13:00
ES33: Management of Oligometastatic and Multi-Focal Lung Cancer

Track: Locally Advanced Non-small Cell Lung Cancer - Oligometastatic

HALL C2

Chair: Alexander Louie, Canada

12:00 - 12:02
ES33.01 / ES33.02 Session Introduction
Alexander Louie, Canada

12:02 - 12:14
ES33.03 Role of Ablation in Multifocal or Oligometastatic Lung Carcinoma
Carole Ridge, United Kingdom

12:14 - 12:26
ES33.04 Surgery for Oligometastatic and Multi-Focal Lung Cancer
Loretta Erhunmwunsee, United States

12:26 - 12:38
ES33.05 Radiation for Oligometastatic Lung Cancer
Fiona Hegi Johnson, Australia

12:38 - 12:50
ES33.06 Multimodality Management of Multi-Focal Lung Cancer
Walter Weder, Switzerland

12:50 - 13:00
ES33.07 Live Q&A

12:00 – 13:00
ES34: Updates in Radiology, Pulmonology, and Staging

Track: Pulmonology, Radiology, and Staging

STRAUSS 1/2

Chair(s): Lynette Teo, Singapore, David Carbone, United States

12:00 - 12:02
ES34.01 / ES34.02 Session Introduction
Lynette Teo, Singapore, David Carbone, United States

12:02 - 12:14
ES34.03 Advances in Lung Cancer Imaging
Jin Mo Goo, South Korea

12:14 - 12:26
ES34.04 Diagnostic and Interventional Bronchoscopy: Updates and Future
Daniela Gompelmann, Austria

12:26 - 12:38
ES34.05 TNM Staging: Essential and Other Emerging Concepts
David Carbone, United States

12:38 - 12:50
ES34.06 Inclusion of Molecular/Genetic Factors in the TNM Staging System, Is It Possible?
David Carbone, United States
12:00 - 12:02
ES35.01 / ES35.02 Session Introduction
Martin Filipits, Austria, Caroline Dive, United Kingdom

12:02 - 12:14
ES35.03 Discovery of Predictive Biomarkers for Immunotherapy Using Deep Spatial Tissue Analysis in Lung Cancer
David Rimm, United States

12:14 - 12:26
ES35.04 Single-Cell Transcriptomics to Study Immunotherapy Responses in Resectable Non-small Cell Lung Cancer
Kellie Smith, United States

12:26 - 12:38
ES35.05 Computational Approaches to Analyze and Interpret High-Plex Spatial and Single-Cell Molecular Tumour Studies
Melissa Davies, Australia

12:38 - 12:50
ES35.06 A Multi-Omics Approach for Delineating Tissue Signatures of Immunotherapy Response in Lung Cancer
Arutha Kulasinghe, Australia

12:50 - 13:00
ES35.07 Live Q&A

12:00 - 12:02
MA13.01 / MA13.02 Session Introduction
Lorenza Landi, Italy, Jii Bum Lee, South Korea

12:02 - 12:07
MA13.03 Integrated Efficacy and Safety of Brigatinib Following Alectinib Treatment in the ALTA-2 and J-ALTA Studies
Sai-Hong Ou, United States

12:07 - 12:12
MA13.04 Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis
Yun Fan, China

12:12 - 12:17
MA13.05 TA0953/HM06, a Novel RET-specific Inhibitor Effective in Extracranial and CNS Disease Models of NSCLC with RETfusions
Romel Somwar, United States

12:17 - 12:27
MA13.06 Discussant
Lorenza Landi, Italy

12:27 - 12:32
MA13.07 TROPION-Lung02: Initial Results for Datopotamab Deruxtecan Plus Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC
Benjamin Levy, United States

12:32 - 12:37
MA13.08 A Phase 1 Trial of Sapanisertib and Telaglenastat (CB-839) in Patients With Advanced NSCLC (NCI 10327): Results from Dose Escalation
Jonathan Riess, United States

12:37 - 12:42
MA13.09 Time from Immune Checkpoint Inhibitor to Sotorasib Use Correlates with Risk of Hepatotoxicity in Non-small Cell Lung Cancer
Sagar Rakshit, United States

12:42 - 12:52
MA13.10 Discussant
Paolo Bironzo, Italy

12:52 - 13:00
MA13.11 Live Q&A
12:00 – 13:00
OA14: New Techniques to Improve Outcome in Early Stage NSCLC Patients Treated with Surgery or Radiotherapy

Track: Early Stage Non-small Cell Lung Cancer

HALL C8

Chair(s): Paul Van Schil, Belgium, Fabio Moraes, Canada

12:00 - 12:02
OA14.01 / OA14.02 Session Introduction
Paul van Schil, Belgium, Fabio Moraes, Canada

12:02 - 12:12
OA14.04 Chest Wall Toxicity after Individualized Stereotactic Ablative Radiotherapy for Lung Tumours
Brianna Lau, United States

12:12 - 12:22
OA14.05 Intraoperative Molecular Imaging Guided Resection of CEACAMS5+ Lung Tumours: First In-Human SGM-101 Lung Cancer Surgical Trial
Feredun Azari, United States

12:22 - 12:32
OA14.06 T-Cell Dynamics in Response to Neoadjuvant Atezolizumab in Early NSCLC by Antigen Response and T-Cell Receptor Sequencing
Filiz Oezkan, Germany

12:32 - 12:42
OA14.07 Discussant
Brendon Stiles, United States

12:42 - 13:00
OA14.08 Live Q&A

13:15 – 14:15
LA03: Lectureship Awards - Tuesday

HALL C1

Chair(s): Ross Soo, Singapore, David Carbone, United States

13:15 - 13:17
LA03.01 / LA03.02 Session Introduction
Ross Soo, Singapore, David Carbone, United States

13:17 - 13:32
LA03.03 Fred R. Hirsch Lectureship Award for Translational Research
Lukas Bubendorf, Switzerland

13:32 - 13:47
LA03.04 IASLC Lectureship Award for Nurses and Allied Health Professionals (NAHP)
Anne Fraser, New Zealand

13:47 - 14:02
LA03.05 Clifton F. Mountain Lectureship Award for Staging
Clarissa Mathias, Brazil

14:02 - 14:15
LA03.06 Live Q&A

14:30 – 15:30
ES36: Revisiting the Perioperative Management of NSCLC

Track: Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjutant Therapy

HALL C1

Chair(s): Yasushi Goto, Japan, Virginie Westeel, France

14:30 - 14:32
ES36.01 / ES36.02 Session Introduction
Yasushi Goto, Japan, Virginie Westeel, France

14:32 - 14:44
ES36.03 Reshaping Perioperative Treatment With the Emergence of Immunotherapy
Enriqueta Felip, Spain

14:44 - 14:56
ES36.04 Neoadjuvant versus Upfront Surgery - Which Surgical Endpoints Are Most Relevant?
Jonathan Spicer, Canada

14:56 - 15:08
ES36.05 Role of Perioperative Radiotherapy in the Era of Immunotherapy
Sameera Kumar, United States

15:08 - 15:20
ES36.06 Perioperative Targeted Therapy
Wen-Zhao Zhong, China

15:20 - 15:30
ES36.07 Live Q&A
14:30 – 15:30
ES37: What Lung Cancer Clinicians Need to Know about Tobacco

**Track:** Tobacco Control and Risk Reduction

[HAL C2](#)  [IASLC CME Accredited](#)

*Chair(s):* May Myat Cho, Thailand, Magdalena Cedzynska, Poland

14:30 - 14:32
ES37.01 / ES37.02 Session Introduction
May Myat Cho, France, Magdalena Cedzynska, Poland

14:32 - 14:44
ES37.03 Biologic Perturbations Induced by Tobacco Smoke
Srikumar Chellappan, United States

14:44 - 14:56
ES37.04 Does Quitting Smoking after a Diagnosis of Lung Cancer Improve Survival?
Jacek Jaszem, Poland

14:56 - 15:08
ES37.05 How Best to Talk With Your Patient About Tobacco Use
Joelle Fathi, United States

15:08 - 15:20
ES37.06 Implementing Smoking Cessation within Cancer Centers
William Evans, Canada

15:20 - 15:30
ES37.07 Smoking Cessation: A Component of High Quality Thoracic Surgery
Christian Finley, Canada

14:30 – 15:30
ES38: Optimising the Management of SCLC and Neuro-endocrine Tumours

**Track:** Small Cell Lung Cancer and Neuro-endocrine Tumours

[STRAUSS 1/2](#)  [IASLC CME Accredited](#)

*Chair(s):* Feng Ming Spring Kong, Hong Kong, Nevena Secen, Serbia

14:30 - 14:32
ES38.01 / ES38.02 Session Introduction
Feng-Ming Spring Kong, Hong Kong, Nevena Secen, Serbia

14:32 - 14:47
ES38.03 What’s the Best Management for CNS Metastases in the Era of IO?
Inga Grills, United States

14:47 - 15:02
ES38.04 Treatment of Relapsed/Refractory SCLC: Old and New Drugs
Charles Rudin, United States

15:02 - 15:17
ES38.05 How Should We Treat Pulmonary Large-Cell Neuro-endocrine Carcinomas?
Andrea Ardizzoni, Italy

15:17 - 15:30
ES38.06 Live Q&A

14:30 – 15:30
ES39: Role of Novel Biomarkers and Technologies in Optimal Diagnosis and Disease Management: Focus on Liquid Biopsies And Advanced Tissue Diagnostics

**Track:** Tumour Biology and Biomarkers

[LEHAR 1](#)  [IASLC CME Accredited](#)

*Chair(s):* Umberto Malapelle, Italy, Christian Rolfo, United States

14:30 - 14:32
ES39.01 / ES39.02 Session Introduction
Umberto Malapelle, Italy, Christian Rolfo, United States

14:32 - 14:44
ES39.03 Advances and Role of CTCs for Lung Cancer Diagnosis and Treatment (Early and Advanced: NSCLC and SCLC)
Caroline Dive, United Kingdom

14:44 - 15:08
ES39.04 Optimal Use of ctDNA Analysis Lung Cancer Diagnosis, Response Assessment and Monitoring
Christian Rolfo, United States

14:56 - 15:08
ES39.05 Biomarker Analysis of the Tumour Microenvironment and Tumour-Immune Cell Interactions Using High-Plex Spatial and Single-Cell Studies
Junko Tanizaki, Japan

15:08 - 15:20
ES39.06 Advanced Tumour-Based and Circulating Diagnostics in Early Stage Disease
Lillian Siu, Canada

15:20 - 15:30
ES39.07 Live Q&A
14:30 – 15:30
MA14: Palliative and Supportive Care - The Forgotten Trade

Track: Palliative and Supportive Care

STRAUSS 3

Chair(s): Maria Werner-Wasik, United States, Satoko Kono, Japan

14:30 - 14:32
MA14.01 / MA14.02 Session Introduction
Maria Werner-Wasik, United States, Satoko Kono, Japan

14:32 - 14:37
MA14.03 Effect of Mirtazapine on Energy Intake in Patients with Anorexia Associated with NSCLC
Oscar Arrieta, Mexico

14:37 - 14:42
MA14.04 Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study
Narjust Duma, United States

14:42 - 14:47
MA14.05 A Double-blind Phase III Trial of Denosumab Biosimilar QL1206 vs Denosumab in Bone Metastatic Tumour: Lung Cancer Cohort Data
Yan Huang, China

14:47 - 14:57
MA14.06 Discussant
Karin Dieckmann, Austria

14:57 - 15:02
MA14.07 The Use of Medical Cannabis Concomitantly with Immune-Check Point Inhibitors (ICI) in Non Small Cell Lung Cancer (NSCLC): A Sigh of Relief?
Barliz Waissengrin, Israel

15:02 - 15:07
MA14.08 Longitudinal Symptoms and Health Utility Scores (HUS) in Patients Receiving PD-1 Inhibitors for Metastatic NSCLC
Christopher Poletes, Ireland

15:07 - 15:12
MA14.09 Lower Paraspinous Muscle Index at First Thoracentesis is Associated with Poor Survival in Non-Small Cell Lung Cancer
Candice Wilshire, United States

15:12 - 15:22
MA14.10 Discussant
Devayani Niyogi, India

15:22 - 15:35
MA14.11 Live Q&A

14:30 – 15:30
OA15: Patient Selection in Advanced NSCLC Immunotherapy

Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy

HALL C7

Chair(s): Pilar Garrido, Spain, António Araújo, Portugal

14:30 - 14:32
OA15.01 / OA15.02 Session Introduction
Pilar Garrido, Spain, António Araújo, Portugal

14:32 - 14:42
OA15.03 Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis from JAVELIN Lung 100
Martin Reck, Germany

14:42 - 14:52
OA15.04 Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC
Solange Peters, Switzerland

14:52 - 15:02
OA15.05 HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed Phase 2 Study in NSCLC Patients Who Progressed on Anti-PD-(L)1 Therapy
Benjamin Besse, France

15:02 - 15:12
OA15.06 Pooled Analysis of Outcomes With Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer
Delvys Rodriguez-Abreu, Spain

15:12 - 15:22
OA15.07 Discussant
Puey Ling Chia, Singapore

15:22 - 15:30
OA15.08 Live Q&A
15:45 – 16:45
PL05: Closing Plenary 5: Access to Drugs

Chair(s): Yi-Long Wu, China, Clarissa Mathias, Brazil

15:45 - 15:47
PL05.01 / PL05.02 Session Introduction
Yi-Long Wu, China, Clarissa Mathias, Brazil

15:47 - 16:02
PL05.03 How to Double Lung Cancer Survival within 5 Years
Giorgio Scagliotti, Italy

16:02 - 16:17
PL05.04 Access to Drugs
Nir Peled, Israel

16:17 - 16:32
PL05.05 Drug Development in the 21st Century
Francesco Pignatti, Netherlands

16:32 - 16:45
PL05.06 Closing Remarks
**WS08: Joint IASLC-CSGO-CAALC Session: Liquid Biopsy in Oncogene Driven NSCLC**

**Chair(s):** Yi-Long, Wu, China, Chunxue Bai, China, Caicun Zhou, Karen Kelly, United States

10 mins
WS08.01 / WS08.02 / WS08.03 / WS08.04
**Session Introduction**
Yi-Long, Wu, China, Chunxue Bai, China, Caicun Zhou, Karen Kelly, United States

20 mins
WS08.05 Minimal Residual Disease (MRD) Negative: Potential for Cure in Resected Oncogene Driven NSCLC? Chinese Perspective
Jia-Tao, China

20 mins
WS08.06 Could MRD Change Our Clinical Practice? North American Perspective
Aadel A. Chaudhuri, United States

20 mins
WS08.07 How to Use Liquid Biopsy to Monitor Treatment Efficacy for Advanced Driven NSCLC
Jie Hu, China

20 mins
WS08.08 Liquid Biopsy for Advanced Oncogene Driven NSCLC. European Perspective
Martin Filipits, Austria

10 mins
WS08.09 Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naive Metastatic Non-small Cell Lung Cancer
Si-Yang Liu, China

10 mins
WS08.10 Toripalimab in Combination with CIK Cells in Patients with Advanced NSCLC: An Exploratory Study
Xuxinyi Ling, China

5 mins
WS08.11 Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp)
Yun Fan

20 mins
WS08.12 Discussant for Oral Abstracts
Sai-Hong Ou, United States

WS08.13 Activity of aPD1-MSLN-CART Cells Against Metastatic Lung Cancer in a Phase 1 Trial
Xiaorong Dong, China

WS08.14
Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-Negative NSCLC
Lin Wu, China

WS08.15 Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC
Jun Zhao, China

WS08.16
The Increase of Blood Intratumor Heterogeneity is Associated with Unfavorable Outcomes of ICIs Plus Chemotherapy in NSCLC
Juan Zhou, China

WS08.17 Utilization of Tumor Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer
Wenbin Li, China

15 mins
WS08.18 Discussant for Poster 1 – 5
Xiaorong Dong, China

WS08.19 Phase II Trial of Neoadjuvant Tislelizumab with Chemotherapy for Resectable Stage IIB-III Non-small Cell Lung Cancer
Yao-Bin Lin, China

WS08.20 Comprehensive Analysis of a Dendritic Cell Marker Genes Signature to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma
Yuan Li, China

WS08.21 Immune Evolution of Metastases & Underlying Molecular Mechanisms in Non-small Cell Lung Cancer
Wen-Fang Tang, China

WS08.22 Neoadjuvant Toripalimab Combination in Patients with Stage IIB-IIIB NSCLC: A Single-arm, Phase 2 Trial (Renaissance Study)
Shi Yan, China
WS08.23
Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer with Four Structure-Based EGFR-Mutation Subgroups
Shu Lu, China
15 mins
WS08.24 Discussant for Poster 6 – 10
Ming Fang Zhao, China

HOD01:
Highlights of the Day - Sunday

HOD02:
Highlights of the Day - Monday

HOD03:
Highlights of the Day – Tuesday
ON-DEMAND
15 mins
HOD03.01 Surgery + Early Stage
Aki Kobayashi, Japan
15 mins
HOD03.02 Pathology + Epidemiology
Fernando Lopez-Rios, Spain
15 mins
HOD03.03 Pulmonology
Joanna Chorostowska-Wynimko, Poland
15 mins
HOD03.04 Medical Oncology
Alexander Drilon, United States
8 POSTER SESSIONS
Poster will be displayed in the Exhibit Hall, Hall B, Messe Wien Exhibition and Congress Center starting Sunday, August 7 at 09:45 until Tuesday, August 9 at 14:15.

Poster Viewing Reception with Presenters in Attendance by Day

**POSTER SESSIONS - SUNDAY, AUGUST 7, 2022 17:00 – 19:00**

**P1.01 Early Detection and Screening – Biomarkers**

**P1.01-01** Comparison between Protein and Autoantibody Biomarkers for the Early Detection of Lung Cancer
Xiaoshuang Feng, France

**P1.02 Early Detection and Screening - Implementation**

**P1.02-02** Current Status, Challenges and Perspectives of Lung Cancer Screening in Low- and Middle-Income Countries
Milena Cavic, Serbia

**P1.02-03** Budget Impact Analysis of Volume CT Lung Cancer Screening Based on NELSON Study Outcomes in Europe
Xuanqi Pan, Netherlands

**P1.02-04** Spatial Access to Lung Screening in British Columbia, Canada
Stephen Lam, Canada

**P1.03 Early Detection and Screening - Pulmonary Nodule**

**P1.03-01** Do We Follow Incidental Lung Nodules Appropriately? A Retrospective Study
Jasleen Pannu, United States

**P1.04 Early Detection and Screening - Risk Stratification**

**P1.04-01** Risk Stratification for Personalised Screening Intervals: Performance of PLCom2012NoRace at Second Round of Manchester LHC
Patrick Bradley, United Kingdom

**P1.04-02** Optimizing Screening Frequency and Interval Using a Deep Learning Algorithm
Stephen Lam, Canada

**P1.04-03** Independent Validation of the Maisonneuve Lung Cancer Risk Model to Optimize Screening Interval in High-risk Individuals
Giulia Veronesi, Italy

**P1.05 Early Stage Non-small Cell - Biomarkers**

**P1.05-01** Phase II Study of ctDNA Directed Consolidation Durvalumab After Induction and Concurrent Durvalumab with SABR for Stage I NSCLC
Islam Mohamed, Canada

**P1.05-02** Mutations in CREBBP are Associated with Local Failure after Lung Stereotactic Body Radiation Therapy
Victor Ng, United States
<table>
<thead>
<tr>
<th>Program</th>
<th>IASLC 2022 World Conference on Lung Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P1.06 Early Stage Non-small Cell - Systemic Therapy</strong></td>
<td></td>
</tr>
</tbody>
</table>
| **P1.06-01** | Adjuvant Osimertinib vs Placebo in Completely Resected Stage IA2-IA3 EGFR-mutated NSCLC: The ADAURA2 Phase III Study  
Toon Van Der Gronde, United States |
| **P1.07 Epidemiology** |
| **P1.07-01** | Early Detection Plus Timely Surgery Remains the Standard despite Advances in Immunotherapy  
Emanuela Taioli, United States |
| **P1.07-02** | Personal and Family HiStory of CANcer in Patients with Non-small Cell Lung Cancer: Preliminary Data of the SCAN Study  
Juan Carlos Laguna, Spain |
| **P1.08 Global Health, Health Services Research, and Health Economics - Cost Issues** |
| **P1.08.01** | Updated Costs and Survival Expectations for Stage IV Lung Cancer in Australia  
Preston Ngo, Australia |
| **P1.09 Global Health, Health Services Research, and Health Economics - Support to Patients and Staff** |
| **P1.09-01** | The Lung Cancer Patient Experience and Care Pathway: A Multi-Country Survey  
Pauline Frank, Msc, Switzerland |
| **P1.09-02** | Real-world Clinical Characteristics and Treatment Patterns of METExon 14 Skipping Mutation in Advanced/Metastatic NSCLC  
Xiuning Le, United States |
| **P1.09-03** | Multidisciplinary Thoracic Tumours Board Survey in Spain  
Bartomeu Massutí, Spain |
| **P1.10 Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy** |
| **P1.10-01** | Phase 3 Study of Durvalumab Combined with Oleclumab or Monalizumab in Patients with Unresectable Stage III NSCLC (PACIFIC-9)  
Aarthi Gopinathan, United Kingdom |
| **P1.10-02** | ImmunoPET: A Phase 0/1 Study Characterising PD-L1 with 89Zr-Durvalumab (MEDI4736) PET/CT in Stage III NSCLC Patients Receiving Chemoradiation  
Fiona Hegi-Johnson, Australia |
| **P1.10-03** | A Deep Learning Auto-Segmentation Tool for Cardiac Substructures in 4D Radiotherapy Planning for Locally Advanced Lung Cancer  
Gerard Walls, United Kingdom |
| **P1.10-04** | Impact of Radiation Dose to the Immune Cells in Unresectable or Stage III Non-Small Cell Lung Cancer in the Durvalumab Era  
Neal Mccall, United States |
<table>
<thead>
<tr>
<th>P1.11</th>
<th>Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy</th>
</tr>
</thead>
</table>
| P1.11-01 | Cobolimab With Dostarlimab and Docetaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung  
*Hye Ryun Kim, South Korea* |
| P1.11-02 | Combined Regimen of Anlotinib and Trametinib for NSCLC Patients Harbouring Pan-KRAS Mutation without KRASG12C  
*Baohui Han, China* |

<table>
<thead>
<tr>
<th>P1.12</th>
<th>Management of Lung Cancer in the Era of COVID-19</th>
</tr>
</thead>
</table>
| P1.12-01 | Lung Cancer Screening in the COVID-19 Era: Understanding Program-Level Impact  
*Andrew Ciupek, United States* |
| P1.12-02 | The Impact of COVID-19 on Quality of Care for Lung Cancer - Analyses of Prospective Clinical Data from The EnRICH Cohort  
*Bea Brown, Australia* |
| P1.12-03 | Computed Tomography-based Artificial Intelligence System in the Diagnosis of COVID-19  
*Yusuf Kahya, Turkey* |
| P1.12-04 | The FLARE Score and Circulating Neutrophils Are Associated with Poor Covid-19 Outcomes in Patients with Thoracic Cancers  
*Laura Mezquita, Spain* |
| P1.12-05 | Prediction of Clinically Significant Pathological Upstaging in Resected Lung Cancer: Insight from COVID-19 Pandemic (1st Wave)  
*Yu Zhi Zhang, United Kingdom* |

<table>
<thead>
<tr>
<th>P1.13</th>
<th>Mesothelioma, Thymoma, and Other Thoracic Malignancies - Clinical</th>
</tr>
</thead>
</table>
| P1.13-01 | Preoperative Chemotherapy Induces Epithelial-Mesenchymal Transition Which Reduces Survival After Surgery for Mesothelioma  
*Luigi Ventura, United Kingdom* |
| P1.13-02 | Quantitative Assessment Using MR in Malignant Pleural Mesothelioma  
*Ritu Gill, United States* |

<table>
<thead>
<tr>
<th>P1.14</th>
<th>Mesothelioma, Thymoma, and Other Thoracic Malignancies - Preclinical</th>
</tr>
</thead>
</table>
| P1.14-01 | Transcriptomic Analysis of Malignant Pleural Mesothelioma (MPM) Reveals Insights for Basic Research and Preclinical Testing  
*Alexander Laure, Switzerland* |
| P1.14-02 | Implantable Cytokine Factories for Eradication of Malignant Pleural Mesothelioma (MPM) Tumours in Mice  
*Amanda Nash, United States* |
| P1.14-03 | Characterization of Tumour Immune Microenvironment and Its Prognostic Value in Patients with Surgically Resected Thymic Epithelial Tumours  
*Haojie Si, China* |
| P1.14-04 | Silencing ADAR1 Abrogates Mesothelioma Tumourogenicity  
*Robert Kratzke, United States* |
P1.15  Metastatic Non-small Cell Lung Cancer – Immunotherapy

P1.15-01  Differential Diagnosis of Pneumonitis in Metastatic NSCLC (Non-Small Cell Lung Cancer) Patients Receiving Immunotherapy With Radiomics
   Alberto Traverso, Netherlands

P1.15-02  Plasma microRNAs Modulation in Advanced NSCLC Patients Receiving Single Agent Immune Checkpoint Inhibitors
   Claudia Proto, Italy

P1.15-03  Clinical Outcomes Among Patients With Non-small Cell Lung Cancer Who Discontinued Immune Checkpoint Inhibitors Due to Toxicity
   Federica Pecci, United States

P1.15-04  Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer
   Giulia Mazzaschi, Italy

P1.15-05  Nintedanib in Combination with Nivolumab in Pretreated Patients with Advanced Adenocarcinoma of the Lung (AIO-TRK-0117 Phase IB/II Trial)
   Martin Reck, Germany

P1.15-06  Immune-Checkpoint Inhibitors-Related Colitis in Advanced Non-small Cell Lung Cancer Patients: A Real-World Analysis
   Martina Lorenzi, Italy

P1.15-07  Phase II Study of Pembrolizumab and Itacitinib for First Line Treatment of Metastatic NSCLC Expressing PD-L1
   Melina Marmarelis, United States

P1.15-08  Phase 1: IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as Monotherapy or in Combination with Atezolizumab, in Adults with Non-Small Cell Lung Cancer
   Michael Boyer, Australia

P1.15-09  First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study.
   Mariano Provencio-Pulla, Spain

P1.15-10  Chronic Obstructive Pulmonary Disease Patients Receiving Immunotherapy for Lung Cancer: A Population-Based Study in Canada
   Sze Wh Samuel Chan, Canada

P1.15-11  Durvalumab + Olaparib vs Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: Outcomes from the Phase 2 ORION Study
   Myung-Ju Ahn, South Korea

P1.15-12  Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1
   Saadettin Kilickap, Turkey

P1.15-13  Immune Escape Mechanisms Mediated by B-Catenin in Non-small Cell Lung Cancer
   Satoshi Muto, Japan
<table>
<thead>
<tr>
<th>P1.16</th>
<th><strong>Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments</strong></th>
</tr>
</thead>
</table>
| P1.16-01 | Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)  
*Byoung Chul Cho, South Korea* |
| P1.16-02 | Clinical Utility of ctDNA in Advanced NSCLC at Diagnosis or Where Insufficient Tissue Was Available, Based on the ESMO ESCAT Scale  
*Laura Mezquita, Spain* |
| P1.16-03 | Managing Cardiotoxicity in Metastatic Non-Small Cell Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors (TKIs)  
*Luis Raez, United States* |
| P1.16-04 | Phase 3 EVOKE-01 Study of Sacituzumab Govitecan vs Docetaxel in NSCLC After Prior Platinum and Checkpoint Inhibitors  
*Niels Reinmuth, Germany* |
**P2.01  Metastatic Non-small Cell Lung Cancer - Oligometastatic Disease**

**P2.01-01**  
Association Between Clinical Outcomes and Local Treatment in Stage IV Non-small Cell Lung Cancer Patients With Single Extrathoracic Metastasis  
Seung Joon Kim, South Korea

**P2.01-02**  
Delivery of Concurrent Extracranial Stereotactic Body Radiotherapy With Osimertinib for Oligoprogressive EGFR Mutated Stage IV NSCLC  
Eyal Tsur, Israel

**P2.02  Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy**

**P2.02-01**  
Value of Albumin-to-Globulin Ratio for Survival Prediction in Advanced Stage Non-Small Cell Lung Cancer Treated with Chemotherapy  
Chaichana Chantharakhit, Thailand

**P2.02-02**  
A Phase 2 Study of MLN4924 (Pevonedistat) in Combination with Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated with Immunotherapy  
Ralph Millett, United States

**P2.02-03**  
A Phase II Study of Metformin with Pemetrexed/Carboplatin in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer  
Saurav Verma, India

**P2.03  Metastatic Non-small Cell Lung Cancer - Palliative Radiotherapy**

**P2.03-01**  
Initial Biodistribution Data of ImmunoPET A Phase 0/1 Study Characterising PD-L1 with 89 Zr-Durvalumab (MEDI4736) PET/CT  
Fiona Hegi-Johnson, Australia

**P2.04  Nursing and Allied Health Professionals**

**P2.04-01**  
Lung Cancer Patient Experience Survey from Twelfth Central and Eastern Europe Countries  
Andreja Sajnic, Croatia

**P2.04-02**  
Psychosocial Burdens in Cancer Caregivership, an Updated Overview  
Csaba Dégi, Romania

**P2.04-03**  
Perceptions and Knowledge of Electronic Smoking Devices among Patients with Solid Tumours and their Care-Givers  
Paolo Bironzo, Italy

**P2.04-05**  
Is Opioid Use in the Management of Stage III Non-Small Cell Lung Cancer Patients Necessary?  
Ulrike Gorgens, United States
<table>
<thead>
<tr>
<th>Session</th>
<th>Topic</th>
<th>Poster Title</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.05</td>
<td>Palliative and Supportive Care</td>
<td>The Effect of Treadmill Training on Cardiopulmonary, Health-related Quality of Life in Lung Cancer with Lobectomy</td>
<td>Kyung-Lim Joa, South Korea</td>
</tr>
<tr>
<td>P2.06</td>
<td>Pathology - Tumour Diagnostics</td>
<td>Skip Hilar Lymph Node Metastasis in Non-Small Cell Lung Cancer Has Similar Survival to N0 Disease: Need for a change in the pN sub-classification?</td>
<td>Ismail Sarbay, Turkey</td>
</tr>
<tr>
<td>P2.07</td>
<td>Pathology - Tumour Genomics</td>
<td>Deep-Learning Based Prediction of c-MET Status from Digitized H&amp;E-Stained Non-Small Cell Lung Cancer Tissue Samples</td>
<td>Bahar Rahsepar, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC</td>
<td>Susana Hernandez, Spain</td>
</tr>
<tr>
<td>P2.08</td>
<td>Patient Advocacy</td>
<td>Real-world barriers to clinical trial enrollment as reported by U.S. lung cancer patients and community cancer centers</td>
<td>Andrew Ciuprek, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Burning the Candle at Both Ends-Sleep Quality Before and After Chemotherapy in Lung Cancer Patients - A Systematic Review and Meta-Analysis</td>
<td>Andrew Jeklin, Australia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patient Reported Lung Cancer Care Team Satisfaction and Treatment Dynamics, Based on the Online MyHealthTeams Survey</td>
<td>Dianna Cronin, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patient Reported Impact of Lung Cancer Symptoms and Treatment on Mental Health and Quality of Life, Based on the Online MyHealthTeams Survey</td>
<td>Dianna Cronin, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lung Cancer Patients' Willingness to Attend a Screening Appointment or Lung Health Check: Insights from a Global Patient Experience Survey</td>
<td>Jackie Fenemore, United Kingdom</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patient Involvement in Decision-Making around Their Treatment and Care: Findings from a Global Patient Experience Survey</td>
<td>Jackie Fenemore, United Kingdom</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Campaign to End Lung Cancer Stigma: The ACS National Lung Cancer Roundtable Efforts to Confront and Extinguish Lung Cancer Stigma</td>
<td>Dusty Donaldson, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Where Have All the Lung Cancer Support Groups Gone?</td>
<td>Maureen Rigney, United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adaptation of Empathic Communication Skills Training for Oncology Care Providers to Reduce Lung Cancer Stigma</td>
<td>Jamie Ostroff, United States</td>
</tr>
<tr>
<td>Session</td>
<td>Title</td>
<td>Details</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>P2.09</strong></td>
<td>Pulmonology, Radiology, and Staging</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P2.09-01</td>
<td>MRI-based Radiomic Signature to Predict Pathologic High-grade Pattern in Lung Adenocarcinoma</td>
<td>Harim Kim, South Korea</td>
<td></td>
</tr>
<tr>
<td>P2.09-02</td>
<td>Clinical Nodal (cN) Category Is Independently Prognostic for Overall Survival in Unresectable Advanced/Metastatic Lung Cancer</td>
<td>Navneet Singh, India</td>
<td></td>
</tr>
<tr>
<td>P2.09-03</td>
<td>A Radiomics Approach Using Baseline CT Can Predict Response to 1st-Line Pembrolizumab in Advanced NSCLC with High PD-L1</td>
<td>Ren Yuan, Canada</td>
<td></td>
</tr>
<tr>
<td><strong>P2.10</strong></td>
<td>Small Cell Lung Cancer and Neuro-endocrine Tumours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P2.10-01</td>
<td>Transcriptional Diversity of Emerging Cell Populations in Refractory Small Cell Lung Cancer Biopsies and Xenografts</td>
<td>C. Allison Stewart, United States</td>
<td></td>
</tr>
<tr>
<td>P2.10-02</td>
<td>EMERGE 402: Preliminary Real-world Characteristics and Safety of Lurbinectedin in Patients With Small-cell Lung Cancer</td>
<td>Balazs Halmos, United States</td>
<td></td>
</tr>
<tr>
<td>P2.10-03</td>
<td>High-dose Thoracic Radiotherapy Improves the Overall Survival of Oligo-Metastatic Extensive-Stage Small Cell Lung Cancer</td>
<td>Zhengfei Zhu, China</td>
<td></td>
</tr>
<tr>
<td>P2.10-04</td>
<td>Immunologic Subtype of Small Cell Lung Carcinoma Dictates Susceptibility to NK Cell-Mediated Cytotoxicity</td>
<td>Navin Mahadevan, United States</td>
<td></td>
</tr>
<tr>
<td>P2.10-05</td>
<td>Circulating CD3+CD56+ Cells as a Biomarker for Immunotherapy in SCLC.</td>
<td>Vito Longo, Italy</td>
<td></td>
</tr>
<tr>
<td><strong>P2.11</strong></td>
<td>Tobacco Control and Risk Reduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P2.11-01</td>
<td>Awareness of Lung Cancer Risk Factors in Palestine: Current Situation and Future Directions</td>
<td>Ahmad Mansour, Palestine</td>
<td></td>
</tr>
<tr>
<td>P2.11-02</td>
<td>New Assay for Smoking Status based on 3D Imaging of Pulmonary Macrophages</td>
<td>Michael Meyer, United States</td>
<td></td>
</tr>
<tr>
<td>P2.11-03</td>
<td>Smoking Prevention Intervention With School Classes in University Hospital by Thoracic Surgeon und Pulmonologist</td>
<td>Sven Hillinger, Switzerland</td>
<td></td>
</tr>
<tr>
<td><strong>P2.12</strong></td>
<td>Tumour Biology and Biomarkers - Immune Biology &amp; Immunotherapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P2.12-01</td>
<td>Intratumoural Conventional Type 1 Dendritic Cells (cDC1s) Predict Response to Immunotherapy in Human Non-small Cell Lung Cancer cancer (NSCLC)</td>
<td>Angelo Porciuncula, United States</td>
<td></td>
</tr>
<tr>
<td>P2.12-02</td>
<td>Immune-Cell Distribution Between Tumour Edge and Center Affects Lung Cancer Aggressiveness - Multiplex Immunofluorescence</td>
<td>Takashi Eguchi, Japan</td>
<td></td>
</tr>
</tbody>
</table>
| P2.12-03 | External Validation of a Novel CT-Based Prognostic Radiomic Signature in Patients With Metastatic NSCLC in SWOG S0819 Phase III Randomized Trial  
Laurent Dercle, United States |
| P2.12-04 | The Role of Serum Proteomic Signature in Predicting Survival in PD-L1 Low Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor (ICI)  
Youjin Oh, United States |
| P2.12-05 | Cancer and Atopy: Parallel Drivers? IL-4 Blockade Synergizes with PD-L1 Blockade to Reverse Type-2Mediated Immunosuppression  
Thomas Marron, United States |

| P2.13 | Tumour Biology and Biomarkers - Minimally Invasive Biomarkers |
| P2.13-01 | Low EV miR-30c Levels as Biomarker of Increased Tumour Autophagy and Chemoradiotherapy Resistance in Locally Advanced NSCLC  
Diego de Miguel Perez, United States |
| P2.13-02 | Dynamic Tracking of Bespoke Circulating Tumour DNA During Multi-Modality Therapy for Locally Advanced NSCLC (LA-NSCLC)  
Kevin Chua, Singapore |
| P2.13-03 | Plasma Profiling Unveils Transcriptional Signatures Associated with Resistance to Osimertinib in Non-Small Cell Lung Cancer  
Per Hydbring, Sweden |

| P2.14 | Tumour Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics |
| P2.14-01 | Clinical Utility of Reflex to Tissue-based Comprehensive Genomic Profiling (CGP) After Negative Liquid Biopsy (LBx) in NSCLC  
Khaled Tolba, United States |
| P2.14-02 | TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial  
Lorenza Landi, Italy |
| P2.14-03 | Restored Ubiquitination and Degradation of Exon 14 Skipped MET with Proteolysis Targeting Chimeras  
Aaron Mansfield, United States |
| P2.14-04 | Re-Definition of Lung Adenocarcinoma Transcriptional Subtypes Using Integrative Bioinformatics Approaches  
Sara Hijazo-Pechero, Spain |
| P2.15-01 | Digital Pathology Uncovers Multi-Omic Hallmarks of Lung Cancer in Histopathology Images  
Maria Guramare, United States |
JTO Clinical and Research Reports is the official open access journal of the International Association for the Study of Lung Cancer. It complements the Journal of Thoracic Oncology by offering authors a gold open access publication option and publishing the following article types in particular:

- Phase I trials
- Well performed single-arm phase II trials
- Subset analyses of published trials
- Impactful retrospective studies
- Database and registry analysis
- Large institutional series
- High-quality case reports
- Region-specific clinical trials
- Subspecialty specific thoracic oncology studies
- Selected high-quality meeting reports

Now indexed in PubMed Central

Visit jtocrr.org

Learn more at JTOCRR.org
Lace up your sneakers and get ready to Step it Up for Research by joining our First Annual IASLC Steps Challenge!

The Steps Challenge is a virtual walk-a-thon, held in conjunction with WCLC, to raise money for lung cancer research. Register Today!

Scan the QR code for information.

If you’re signed up, be sure to stop by the IASLC booth to grab your participant pin!
<table>
<thead>
<tr>
<th>Track: Early Detection and Screening – Biomarkers</th>
</tr>
</thead>
</table>
| **EP01.01-001** Circulating Tumour Cells-Based Radiobiological Model Improves the Indeterminate Pulmonary Solid Nodules Diagnosis  
Mengmeng Zhao, China |
| **EP01.01-002** Challenges in the Use of NLST Image Data for Quantitative Algorithm Development  
Artit Jirapatnakul, United States |
| **EP01.01-003** DELFI-L101: Development of a Blood-Based Assay That Evaluates Cell-Free DNA Fragmentation Patterns to Detect Lung Cancer  
Peter Bach, United States |
| **EP01.01-004** The Correlation Between Exhaled Volatile Organic Compounds Using Breath Analyzer and Interleukin-23 (IL-23) in Lung Cancer  
Ilona Urbarova, Norway |
| **EP01.01-005** Increased Levels of mRNAs and miRNAs Associated with Imminent and Advanced Lung Cancer  
Natalia Krzyzanowska, Poland |
| **EP01.01-006** Sensitive Detection of Lung Cancer Using a Multimomic Plasma Cell-Free DNA Sequencing Assay  
Jing Shan Lim, United States |
| **EP01.01-007** Incorporating cfDNA Detection to CT Scan Assessment in Post-Surgical Lung Cancer Patients  
Paul Dempsey, United States |
| **EP01.01-008** Expression of PD-L1 mRNA and Its Epigenetic Regulators: MicroRNA-17, -93 and -142 in Early Stages NSCLC Patients’ Plasma  
Artit Jirapatnakul, United States |
| **EP01.01-009** Common MicroRNAs in Pre-diagnostic Serum Associated with Lung Cancer in Two Cohorts up to Eight Years Before Diagnosis: A HUNT Study  
Oluf Røe, Norway |
| **EP01.01-010** Graphene Based Activity Sensors Detect All Stages of Lung Cancer Using an Evolutionary Machine Learning Algorithm Approach  
Lifeng Wang, China |
| **EP01.01-011** Utility of Arm-level cfDNA Fragment Size Distribution in the Early Detection of Lung Cancer and Pan Cancer  
Yongjie Wang, China |
| **EP01.01-012** Clinical and Molecular Features of Chinese Early-stage Multiple Primary Lung Cancer Patients  
Carina Behr, Netherlands |
| **EP01.02** Track: Early Detection and Screening - Dissemination  
Citizens’ Perspective on Combination Screening for Lung Cancer, COPD and CVD  
Jing Shan Lim, United States |

---

**EP01.02-001** Citizens’ Perspective on Combination Screening for Lung Cancer, COPD and CVD  
Jing Shan Lim, United States
<table>
<thead>
<tr>
<th>EP01.02-002</th>
<th>Awareness of Palestinians about Lung Cancer Symptoms: A National Cross-sectional Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hanan Abukmail, Palestine</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.02-003</th>
<th>Lung Cancer Screening: A Systematic Review of Knowledge Translation Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Dawkins, New Zealand</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.02-004</th>
<th>Education Messages and Strategies About Lung Cancer Screening: A Systematic Review</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rachael Dodd, Australia</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.02-005</th>
<th>Exploring Individuals’ Views on Invitation to Lung Cancer Screening: Developing a Tailored Approach</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rachael Murray, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.02-006</th>
<th>Excuse Me? Patient Perceptions of Lung Cancer Screening Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rayan Ihle, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.02-007</th>
<th>It’s Not How You Start, It’s How You Finish: Patient Motivators to Follow Low-Dose Screening Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rayan Ihle, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.02-008</th>
<th>Pocket Nodules, An Innovative Patient Education Tool to Explain Lung Nodules</th>
</tr>
</thead>
<tbody>
<tr>
<td>Theresa Roelke, United States</td>
<td></td>
</tr>
</tbody>
</table>

| EP01.03 | Track: Early Detection and Screening - Implementation |

<table>
<thead>
<tr>
<th>EP01.03-001</th>
<th>Māori Perspectives on a Potential Lung Cancer Screening Programme Aotearoa NZ: An Indigenous People’s Perspective</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anne Fraser, New Zealand</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.03-002</th>
<th>Implementation of the International Lung Screen Trial (ILST) in Catalonia: A Cost Analysis study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antoni Rosell, Spain</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.03-003</th>
<th>AI Detection of Emphysema in an Ultra-Low Dose CT Lung Cancer Screening Program</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chellan Kumarasamy, Australia</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.03-004</th>
<th>Should We Screen for Lung Cancer? A 10-Country Analysis Identifying Key Decision-Making Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charlotte Poon, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.03-005</th>
<th>Current status of High-risk Smokers Participating in Population-based National Lung Cancer Screening Program in Korea</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eunkyo Kang, South Korea</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.03-006</th>
<th>Potential Drivers of Lung Cancer Screening Participation in Australia: A Qualitative Study to Inform Future Implementation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emily Stone, Australia</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.03-007</th>
<th>Lung Cancer Screening Use Among Screening-Eligible Adults With Disability in the United States: Evidence From Population-Based Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hermine Poghosyan, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.03-008</th>
<th>Lung Cancer Screening Patients Experiences and Satisfaction: Quantitative and Qualitative Findings from a Survey Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jaileene Perez-Morales, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.03-009</th>
<th>Cost-effectiveness of Lung Cancer Screening in New Zealand Varies by Ethnicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Sandiford, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.03-010</th>
<th>China Lung Cancer Screening Study (CLUS) Version 2.0: Study Design and Baseline Screening Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fangfei Qian, China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.03-011</th>
<th>Clinical Features and Surgical Outcomes of Young Patients with Ground Glass Opacity Featured Lung Adenocarcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rirong Qu, China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.03-012</th>
<th>Acceptability and Feasibility of Lung Cancer Screening in Australia: The View of Key Stakeholders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rachael Dodd, Australia</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.03-013</th>
<th>A Pilot Study of Lung Cancer Screening with Low Dose CT in Georgia (One Centre Experience and Preliminary Data)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salome Kukava, Georgia</td>
<td></td>
</tr>
</tbody>
</table>

| EP01.04 | Track: Early Detection and Screening - Implementation Quality Control |

<table>
<thead>
<tr>
<th>EP01.04-001</th>
<th>A Programmatic Approach to Improve Efficiency in Lung Cancer Screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brendon Stiles, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.04-002</th>
<th>The Impact of Enforcing a Structure in Lung Cancer Screening Strategy on the Effectiveness and Efficiency of the Screening Program</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iakovos Toumazis, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.04-003</th>
<th>Effectiveness of Cloud-based Computer Aided Quality Control System in Korean National Lung Cancer Screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ji-Youn Song, South Korea</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.04-004</th>
<th>Overcoming the Barriers to Lung Cancer Screening using a Systemwide Approach</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Gieske, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.04-005</th>
<th>Quantitative Characteristics in Global CT Lung Cancer Screening Populations Using the ELIC Distributed Database and Computation Environment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Lam, Canada</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.04-006</th>
<th>Clinical Scores, Biomarkers and IT Tools in Lung Cancer Screening - Can an Integrated Approach Overcome Current Challenges?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wieland Voigt, Germany</td>
<td></td>
</tr>
</tbody>
</table>

| EP01.05 | Track: Early Detection and Screening - Pulmonary Nodule |

<table>
<thead>
<tr>
<th>EP01.05-001</th>
<th>Radiomics to Increase the Effectiveness of Lung Cancer Screening Programs. Radiolung Preliminary Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antoni Rosell, Spain</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP01.05-002</th>
<th>Role of the Lung Cancer Screening MDT in the Manchester Lung Health Check Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avik Ghoshal, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>
EP01.05-003 Changes of Repeated Lung Cancer Screening Results and Affected Factors; Analysis of Korean National Lung Cancer Screening Program
Eunkyo Kang, South Korea

EP01.05-004 Trial in Progress: An Observational Study for Management of Lung Nodules across Latin America (DOuBLED Study)
Felipe Da Costa, Brazil

EP01.05-005 The Accuracy of Baseline Low-dose CT Lung Cancer Screening: A Systematic Review and Meta-analysis
Lanwei Guo, China

EP01.05-006 Influenza Season Influence on Incidence and Outcome of Nodules in the NELSON Trial
Harriet Lancaster, Netherlands

EP01.05-007 Radiomics Based Machine Learning Model for Sub-cm Lung Nodule Malignancy Diagnosis in the PanCan Screening Study
Ian Janzen, Canada

EP01.05-008 Pre-Trial Validation of a Risk Prediction Model for Pulmonary Nodules Trained on a Nested Case-Control Study with No External Cohort
Michael Kammer, United States

EP01.05-009 Simulation-Based Sample Size Estimation for an Early Detection of Lung Cancer Clinical Utility Trial in Indeterminate Pulmonary Nodules
Michael Kammer, United States

EP01.05-010 Using a Pattern Submodel Approach to Predict Lung Cancer in High-Risk Lung Nodule Clinics
Valerie Welty, United States

EP01.05-011 Radiologic Features of Nodules Attached to the Mediastinal or Diaphragmatic Pleura
Yeqing Zhu, United States

EP01.06 Track: Early Detection and Screening - Risk Stratification

EP01.06-001 Lung Cancer after First Primary Breast Cancer: Risk Factors and Results of Treatment
Camilla Vanni, Italy

EP01.06-002 Impact of Immediate AI Enabled Patient Triage to Chest CT on the Lung Cancer Pathway: LungMPACT
David Baldwin, United Kingdom

EP01.06-003 Female Asian Nonsmoker Screening Study (FANSS): Exploring Lung Cancer Screening in a High Risk Population
Elaine Shum, United States

EP01.06-004 Eliciting Quantitative Smoking History by the Use of Natural Language Processing
John Ruckdeschel, United States

EP01.06-005 Assessment of Cardiovascular Risk in the Non Screening Radically Treated Lung Cancer Cohort
Marius Theiveehathasan, United Kingdom

EP01.06-006 Impact of Low Dose CT Screening on Cause of Death in Different Socio-Economic Groups
Michael Davies, United Kingdom

EP01.06-007 The Impact of Modified Screening Eligibility Criteria on Race and Sex Disparities in Lung Cancer Screening
Matthew Smeltzer, United States

EP01.06-008 Low Dose CT Screening in Asian Female-Never-Smokers is as Efficacious as in Asian Male-Ever-Smokers. A Systemic Review and Meta-Analysis
Natthaya Triphuridet, Thailand

EP01.06-009 Frequency of Lung Adenocarcinoma in Patients With Growing Nonsolid and Part-Solid Nodules With Solid Component ≤5 mm
Natthaya Triphuridet, Thailand

EP01.07 Track: Early Detection and Screening - Work Up

EP01.07-001 Surveillance with FDG PET/CT after Completion of Therapy for NSCLC: A Status Update on Inclusion in the SUPE_R Trial
Kasper Guldbrandsen, Denmark

EP01.07-002 Objectives and Design of the ACR Lung Cancer Screening CT Incidental Findings - Quick Reference Guide
Michael Gieske, United States

EP01.07-003 Accuracy of Cytological Diagnosis for Malignant Nodule in Participants With Nonsolid Nodules and Part-Solid Nodules With Solid Component≤5 mm
Natthaya Triphuridet, Thailand

EP01.07-004 FDG-PET-CT for Staging Screen Detected Lung Cancer
Renelle Meyers, Canada

EP01.07-005 Combined Diffusion-Weighted Imaging and Dynamic Contrast-Enhanced MRI for Diagnosing Indeterminate Pulmonary Nodules
Fang Wu, China

EP01.07-006 Incidence and Resource Burden for the Management of CT Detected Ground Glass Opacities at a Tertiary Lung Cancer Service in the United Kingdom
Muhammad Ashraf, United Kingdom

EP02.01 Track: Early Stage Non-small Cell Lung Cancer - Biomarkers

EP02.01-001 Plasma Cell-Free DNA as a Point-of-Care Wellbeing Biomarker for Early-Stage Non-Small Cell Lung Cancer Patients
Anna Mcguire, Canada

EP02.01-002 Development of Circulating and Tissue Biomarkers Predicting Immune Phenotype and Response to Immunotherapy in NSCLC.
Brian Henderson, Ireland

EP02.01-003 Predictive Role of Novel Grading System on Adjuvant Chemotherapy in Early Resected Lung Adenocarcinoma Based on EGFR Mutation Status
Yiming He, China
EP02.01-004 Application of a Genomic Assay for Risk Stratification of Resected NSCLC in a Community Cancer Center Setting, a Pilot Study
Hiroshi Yamagata, United States

EP02.01-005 The Efficacy of Platinum-Based Chemotherapy as Adjuvant Therapy in EGFR Mutant Lung Adenocarcinoma
Ken Onodera, Japan

EP02.01-006 Advances in the Treatment of Postoperative Recurrence of Non-Small Cell Lung Cancer and Their Real-World Impact on Survival
Kohei Hashimoto, Japan

EP02.01-007 Clinicopathologic and Prognostic Features of Early Resected Lung Adenocarcinoma Characterized With Uncommon EGFR Mutation
Shenghui Li, China

EP02.01-008 Clinicopathological Features of Rare but Targetable Mutations in Surgically Resected Lung Carcinomas
Luka Brcic, Austria

EP02.01-009 PD-L1 Expression in Biopsies and Surgical Specimens of Lung Cancer: Impact of Biopsy Methods and Neoadjuvant Therapy
Mir Alireza Hoda, Austria

EP02.01-010 Preoperative PET-SUVmax and Volume Based PET Metrics of the Tumour Fail to Predict Nodal Upstaging in Early-Stage Lung Cancer
Oezlem Okumus, Germany

EP02.01-011 Immune-related Histologic Phenotype in Pretreatment Tumour Biopsy Predicts Efficacy of Neoadjuvant Anti-PD-1 Treatment in Squamous Lung Cancer
Pei Yuan, China

EP02.01-012 PD-L1 Expression Predicts Prognosis in Completely Resected NSCLC Patients with an EGFR Mutation
Yi-Fan Qi, China

EP02.01-013 Real World Treatment Patterns, Prevalence and Outcomes in Patients with KRAS Mutated Non Small Cell Lung Cancer in Southwestern Ontario
Sara Kuruvilla, Canada

EP02.01-014 Prognostic Classification of Early-Stage Lung Cancer Using Preoperative Prealbumin and D-dimer Levels
Takashi Yamamichi, Japan

EP02.01-015 Computer-Aided Volumetry by Multidetector Computed Tomography is Efficient for Prognostic Prediction of Early-Stage Solid Lung Cancers
Taketo Kato, Japan

EP02.01-016 Molecular Alterations and Clinical Prognostic Factors in Resectable Non-Small Lung Cancer
Thanaporn Thamrongjirapat, Thailand

EP02.01-017 The Role of Adjuvant Chemotherapy for Stage II/III Lung Adenocarcinoma Based on Epidermal Growth Factor Receptor Mutation Status
Yasuhiro Tsutani, Japan

EP02.01-018 EGFR Mutations Promote Lung Adenocarcinoma From Adenocarcinoma in Situ to Minimally Invasive Carcinoma to Invasive Adenocarcinoma
Jianfei Zhu, China

EP02.02
Track: Early Stage Non-small Cell Lung Cancer - Radiotherapy

EP02.02-001 Genome-wide Analysis and Dynamic Changes of Human Non-small Cell Lung Carcinoma Cells After Radiation
Yajing Du, China

EP02.02-002 Increased Utilization of Stereotactic Body Radiotherapy Has Decreased Treatment Disparities for Early-Stage NSCLC
Ashwin Ganesh, United States

EP02.02-003 Mean Lung Dose Correlates with Volume of Radiation-Induced Lung Injury in Patients Treated with SABR for Lung Cancer
Angus Killean, United Kingdom

EP02.02-004 Clinical Outcomes Following Photon-Based and Proton-Based Stereotactic Body Radiation Therapy for Early Stage Lung Cancer
Bong Kyung Bae, South Korea

EP02.02-005 Changes in PFT Parameters and Correlation with Symptomatic Pulmonary Toxicity Following SBRT For Early Stage Lung Cancer
Bong Kyung Bae, South Korea

EP02.02-006 Differing Doses: The Effects of Radiation Dose Calculation Algorithms on Local Control in Early-Stage Lung Cancer
Bradley Ackerson, United States

EP02.02-007 Correlation between Biological Equivalent Dose and Radiological Changes after Lung Stereotactic Ablative Radiation Therapy
Carla Cases Copestake, Spain

EP02.02-008 Transbronchial Microwave Ablation of Lung Nodules - Good Safety Profile and Promising Mid-Term Results
Wing Yan Joyce Chan, China

EP02.02-009 Stereotactic Body Radiotherapy for Primary and Metastatic Lung Cancer, Cyberknife-M6 Experience
Süreyya Sarihan, Turkey

EP02.02-010 Histology Impacts Time-to-Treatment on Lung SBRT Outcomes
Gregory Videtic, United States

EP02.03
Track: Early Stage Non-small Cell Lung Cancer - Surgery

EP02.03-001 The Role of Completion Lobectomy Following Sublobar Resection in Patients with T1 Non-Small Cell Lung Cancer
Akif Turna, Turkey
Chiara Proli, United Kingdom

EP02.03-003 Survival of Patients with Interstitial Lung Disease Who Undergoing Lung Cancer Surgery: A Propensity Score Matching Study
Sang Hoon Lee, South Korea

EP02.03-004 Association Between Sarcopenia and Outcomes of Lung Cancer Surgery in Old-Age Patients: Interim Analysis of Prospective Cohort Study
Hyeok Sang Woo, South Korea

EP02.03-005 Perioperative Factors That Predict or Are Associated With Prolonged Air Leaks After Robotic-Assisted Pulmonary Lobectomy
Eric Toloza, United States

EP02.03-006 Oncological Outcome And Surgical Instruments in VATS Lobectomy For Early Stage Lung Cancer
Federico Femia, Italy

EP02.03-007 Seeds of Gold. Triple Contrast Marking in Hybrid Operative Room for All-in One Diagnostic and Therapeutic Precision Surgery
Francesco Guerrera, Italy

EP02.03-008 Combined Robotic Assisted Thoracic Surgery (CRATS)
Eric Anderson, United States

EP02.03-009 Real-world Disease-Free Survival as a Predictor of Overall Survival in Resected Early-Stage NonSmall Cell Lung Cancer
Howard West, United States

EP02.03-010 Intrapulmonary and Hilar Lymph Node Dissection Performed by the Surgical Team: Impact on Pathological Stage of NSCLC
Jefferso Gross, Brazil

EP02.03-011 Timeliness of Surgery for Early-Stage Lung Cancer: Perspectives from Surgeons and Patients
Jeffrey Zhu, United States

EP02.03-012 Perioperative and Oncologic Outcomes after Robotic-Assisted Segmentectomy at a NCI-designated Cancer Center
Jobelle Joyce Anne Baldonado, United States

EP02.03-013 Should Visceral Pleural Invasion Be Prognostic Factor in Early-Stage Lung Adenocarcinoma With Tumour Size 3cm or Less?
Kisung Park, South Korea

EP02.03-014 Pulmonary Segmentectomy via Minimally Invasive Open Surgery: An Analysis From a Japanese High-Volume Hospital
Kazuo Nakagawa, Japan

EP02.03-015 Fully Robotic Arm Robot Assisted Lung Surgery Exploration
Taiyang Liuru, China

EP02.03-016 Dynamics of Recurrence After Curative Resection of Non-small Cell Lung Cancer
Masaya Yotsukura, Japan

EP02.03-017 Novel Intraoperative CT-Guided Marking Using O-Arm in Video-Assisted Thoracoscopic Surgery
Yoshimitsu Hirai, Japan

EP02.03-018 Intermittent Chest Tube Clamping Shortens Chest Tube Duration After Lung Cancer Surgery: An Open-label, Randomized Controlled Trial
Nan Wu, China

Pietro Bertoglio, Italy

EP02.03-020 Patient Outcomes Following Salvage Lung Cancer Surgery Post Definitive Chemotherapy or Radiation
Riley Bowker, Canada

EP02.03-021 Uncertain Resection for Localized cN0M0 Non Small Cell-Lung Cancer: The Crucial Prognosis of Suboptimal Lymph Node Assessment
Romain Vergé, France

EP02.03-022 Evolution of Lung Cancer Resection Quality: A Prospective Staggered Implementation Quality Improvement Study
Ray Osarogiagbon, United States

EP02.03-023 Decreasing Time to Definitive Therapy with MIDAS: Minimally Invasive Diagnosis and Surgery
Patrick Ross, United States

EP02.03-024 Clinical and Prognostic Impact of Pleural Adhesions during Lung Cancer Surgery
Satoshi Shiono, Japan

EP02.03-025 Long-Term Oncological Outcomes and Risk Factors of Recurrence After Segmentectomy for Primary Lung Cancer
Shinsuke Uchida, Japan

EP02.03-026 Is Ratio of Surgical Margin to Nodule Size a Prognostic Factor in Stage 1 Adenocarcinoma?
Tiffany Melissa Ergin, Turkey

EP02.03-027 After Surgery Factors Affecting Relapse in Early Stage Non Small Cell Lung Cancer
Tiffany Ergin, Turkey

EP02.03-028 Pathologic Risk Factors for Recurrence in Early Stage Invasive Lung Adenocarcinoma with Tumour Spread through Air Spaces
Eunjue Yi, South Korea

EP02.03-029 Prognostic Factors in Curative Intent Stage I Lung Adenocarcinoma: Hospital’s Cancer Registry Based Analysis
Vinicius Silva, Brazil

EP02.04
Track: Early Stage Non-small Cell Lung Cancer - Systemic Therapy

EP02.04-001 Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-Positive NSCLC: ALNEO Phase II Trial (GOIRC-01-2020)
Alessandro Leonetti, Italy
EP02.04-002 Synergy of Local Treatment with Pulsed Electric Fields and Anti-PD1 Checkpoint Blockade
Chiara Pastori, United States

EP02.04-003 A Retrospective Comparison of Survival Outcomes in EGFR-mutated, NSCLC Patients on Osimertinib +/- Brain Metastases
Ishjot Litt, Canada

EP02.04-004 Time to Surgery After Neoadjuvant Immunotherapy: Not a Day Too Soon
Nathan Mynard, United States

EP02.04-005 Phase II NAUTIKA1 Study of Targeted Therapies in Stage I-II NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK+ NSCLC
Jay Lee, United States

EP02.04-006 Adjuvant Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Preoperative Chemotherapy
Lei Deng, United States

EP02.04-007 Phase 2 Trial of Neoadjuvant KRASG12C Directed Therapy with Adagrasib (MRTX849) With or Without Nivolumab in Resectable NSCLC (Neo-KAN)
Patrick Forde, United States

EP02.04-008 Efficacy and Safety of Neoadjuvant Chemoinmunotherapy in Resectable Non-small Cell Lung Cancer (NSCLC): a systematic review and meta-analysis
Sebawe Syaj, Jordan

EP02.04-009 Real World Survival Outcome Analysis of Adjuvant Therapies in Non-EGFR, Non-ALK Early Stage Resected NSCLC
Tedi Hoxha, Canada

EP02.04-010 Clinical Outcomes After Neoadjuvant Tisilizumab plus Chemotherapy in Resectable Stage IIIA-B NSCLC: A Retrospective Study
Xiangyang Cheng, China

EP03.01
Track: Epidemiology

EP03.01-001 Is Airflow Limitation a Causal Factor for Lung Squamous Cell Carcinoma? Evidence from Mendelian Randomization Analysis
Qing Zhang, China

EP03.01-002 Co-occurring Mutations, Smoking Status and Prognosis of Early-stage Resected NSCLCs with EGFR Mutations
Alison Moore, Canada

EP03.01-003 Clinical Features and Molecular Profile of Advanced Non-small Cell Lung Cancer in Latin America: LATINO Lung (LACOG 0116)
Clarissa Mathias, Brazil

EP03.01-004 Impact of Covid-19 Pandemic in Lung Cancer Patients in Albania
Daniela Xhemalaj, Albania

EP03.01-005 Clinicopathological Features of ROS1-rearranged Adenocarcinomas: A Single Institutional Experience Spanning Four Years From India
Aruna Nambirajan, India

EP03.01-006 Familial Aggregation in Non-small Cell Lung Cancer - An Observational Study
Sindhura Durga Chitikela, India

EP03.01-007 Comprehensive Genomic Profile of Advanced Lung Cancer in a Region With the Worst Human Development Index in Brazil
Eldsamira Mascarenhas, Brazil

EP03.01-008 Shift in Lung Cancer Stage at Diagnosis during the COVID-19 Pandemic in New York City
Emanuela Taioli, United States

EP03.01-009 BrainMets-Cross-Sectional Study To Identify The Presence Of Brain Metastasis At Diagnosis Of Advanced NSCLC EGFRm in Portuguese Patients
Maria Teixeira, Portugal

EP03.01-010 Clinicopathological Characteristics of Non-Small Cell Lung Cancer patients in the United Arab Emirates and Correlation with Their Outcomes
Fathi Azribi, United Arab Emirates

EP03.01-011 Prevalence of KRASMutations in Treatment-naive Non-small Cell Lung Cancer Patients in Hong Kong
James Ho, China

EP03.01-012 Characterization of Lung Cancer in Patients With High Familial Aggregation of Cancer: Preliminary Data From the SCAN Study
Juan Carlos Laguna, Spain

EP03.01-013 Improving the Risk Estimation for Second Primary Lung Cancer after Lung Cancer by Taking Histologic Subtype into Account
Marian Eberl, Germany

EP03.01-014 Results From the BEWELL Study: Black Raspberry Nectar for the Prevention of Lung Cancer (NCT04267874)
Marisa Bittoni, United States

EP03.01-015 Disease-Free Survival and Clinical Characteristics in Early-Stage NSCLC Patients From a Danish Cohort
Peter Meldgaard, Denmark

EP03.01-016 The Canadian Small Cell Lung Cancer Database (CASCADE): Results from a Multi-Institutional Real-World Evidence Collaboration
Sara Moore, Canada

EP03.01-017 Epidemiology of Lung Cancer in Northern Serbia During the Past Ten Years
Tomi Kovacevic, Serbia

EP04.01
Track: Global Health, Health Services Research, and Health Economics - Cost Issues

EP04.01-001 Prevalence And Outcomes of EGFR Exon 20 Insertion Mutation in NSCLC: Princess Margaret Cancer Center Experience
Abhenil Mittal, Canada

EP04.01-002 Costs of Locoregional and Metastatic Recurrences in Patients with Resectable Stage II-III NSCLC in Spain
Amelia Insa, Spain
EP04.01-003 Is It Time for a New Paradigm in Care of Young Cancer Patients? A Retrospective Study
Andreina Vasconcelos, Portugal

EP04.01-004 Interim Feedback on Pilot Public Facing Website for Cancer Clinical Trial Patient-Reported Symptom Data: Project Patient Voice
Bellinda King-Kallimanis, United States

EP04.01-005 Lung Cancer Diagnosis Following Emergency Admission: Diagnostic and Therapeutic Pathways and Outcomes Within an Italian Cancer Center
Carlo Genova, Italy

EP04.01-006 A Systematic Review (SR) of Cost-effectiveness Analysis (CEA) of ALK Inhibitors (iALK) in Advance Non-small Cell Lung Cancer (NSCLC)
Carolina Gabay, Argentina

EP04.01-007 Impact of Precision Medicine Methods on First-Line Therapies in Metastatic Non-Small-Cell Lung Cancer
Chetan Vakkalagadda, United States

EP04.01-008 Factors Impacting Time from Biopsy to Initiation of Treatment for Advanced NSCLC at an Academic Hospital and Affiliate Hospitals
Chetan Vakkalagadda, United States

EP04.01-009 Performance Indicators of Lung Cancer MDT at a Regional Center: Disagreements Between Trust and NLCA Data
Qudratullah Qudratullah, United Kingdom

EP04.01-010 Addressing Barriers to Lung Cancer Care for Diverse Populations through Patient Navigation: The University of Miami Experience
Estelamari Rodriguez, United States

EP04.01-011 Diagnostic Approach and Treatment of Lung Cancer Patients in Portugal: Portuguese Lung Cancer Study Group Survey
Fernanda Estevinho, Portugal

EP04.01-012 Sex and Age-Related Guideline-Adherence Disparities in Non-Small-Cell Lung Cancer Treatment Patterns: Real-World Data
Heidi Andersén, Finland

EP04.01-013 Frailty Index Predicts Treatment Outcomes in Older Adults with Lung Cancer
James Fletcher, Australia

EP04.01-014 Adherence to Treatment Recommendations From Multidisciplinary Tumour Boards
Julia Roeper, Germany

EP04.01-015 Lung Cancer after Solid Organ Transplantation - A Claims Data Analysis
Julia Walter, Germany

EP04.01-016 First Comprehensive Lung Cancer Long-Term Survivorship Analysis - Late Toxicities and Overall Survival
Martin Metzenmacher, Germany

EP04.01-017 Cost-Effectiveness of Atezolizumab for Adjuvant Treatment of Patients with Stage II-IIIA PD-L1+ Non-small Cell Lung Cancer
Millie Das, United States

EP04.01-018 Medical Oncology and Radiation Oncology Consultation in Non-small Cell Lung Cancer (NSCLC). A Population-Based Study Using Administrative Data
Michela Febbraro, Canada

EP04.01-019 Into the Wild: Assessing Acute Care for Lung Cancer Patients, A Cohort Study to Improve Cancer Care at Emergency Department
Mariano Provencio, Spain

EP04.01-020 Impact of Next-Generation Sequencing on Treatment Choice Among Patients with Metastatic NSCLC from the CHUM University Center
Myriam Nait Ajjou, Canada

EP04.01-021 Cancer Clinical Quality Registries: A Systematic Review of the Utilisation and Effectiveness of Knowledge Translation Interventions
Paul Dawkins, New Zealand

EP04.01-022 Real-world Evidence of Durvalumab for Stage III NSCLC: Survival Outcomes and Patterns of Care Post-progression
Pedro Aguiar Jr, Brazil

EP04.01-023 Development of an Australia and New Zealand Lung Cancer Clinical Quality Registry (ANZLCR)
Rob Stirling, Australia

EP04.01-024 Influence of Lung Diagnostic Assessment Program on Health Resource Utilization in Lung Cancer in Southeastern Ontario, Canada
Shahad Alghamdi, Canada

EP04.01-025 Implementation of Electronic Patient Reported Outcomes in Routine Cancer Care
Shalini Vinod, Australia

EP04.01-026 Cone-Beam CT Guided Navigation Bronchoscopy: a Cost-Effective Modality for the Diagnosis of Pulmonary Nodules
Stephan Kops, Netherlands

EP04.01-027 Pain and Interventions in Stage IV Non-Small Cell Lung Cancer: A Province-Wide Analysis
Vivian Tan, Canada

EP04.01-029 Reduction of ER Visits of Lung Cancer Patients Through Care Interventions in Day-To-Day Clinical Service: Experience of a Thoracic Unit in México
Saul Campos-Gomez, Mexico

EP04.02 Track: Global Health, Health Services Research, and Health Economics - Support to Patients and Staff

EP04.02-001 Sex as a Potential Independent Prognostic Factor in Non-Small Cell Lung Cancer Survival
Chelsea Ford-Sahibzada, Canada

EP04.02-002 International Consensus on Actions to Improve Lung Cancer Survival: Delphi Method in the International Cancer Benchmarking Partnership
Christian Finley, Canada
EP04.02-003 Improving Supportive Care for Patients with Thoracic Cancer
Lakedia Banks, United States

EP04.02-004 The Patient Impact of Liquid Biopsy - Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer
Lucy Corke, Canada

EP04.02-005 First Comprehensive Lung Cancer Long-Term Survivorship Program - Late Toxicities and Overall Survival
Martin Metzenmacher, Germany

EP04.02-006 Burn-Out Syndrome: Neglected Syndrome Among Health Care Professionals Managing Lung Cancer Patients
Tomi Kovacevic, Serbia

EP04.02-007 First Comprehensive Lung Cancer Long-Term Survivorship Program - Competing Risks
Sascha Nadjm, Germany

EP05.01 Track: Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy

EP05.01-001 Hispanic Patients with Unresectable Stage III NSCLC under PACIFIC Protocol: Evidence of Interior Outcomes and Health Inequity
Andres Cardona, Colombia

EP05.01-002 Real World Treatment Patterns and Outcomes among Unresectable Stage III Non-Small Cell Lung Cancer Patients Initiating Chemoradiotherapy
Ashwini Arunachalam, United States

EP05.01-003 First Real-World Data on Unresectable Stage III NSCLC Patients Treated with Durvalumab after Chemoradiotherapy in Asia Area
Chihhsi Kuo, Taiwan

EP05.01-004 Induction Chemoimmunotherapy before Definitive Chemoradiotherapy for Large-Volume Unresectable Locally Advanced NSCLC
Yu Wang, China

EP05.01-005 Impact of Antibiotic Use Before Definitive Concurrent Chemoradiation in Patients With Locally Advanced Non Small Cell Lung Cancer
Youling Gong, China

EP05.01-006 Population Kinetic Assessment of Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
David Stewart, Canada

EP05.01-007 CONCORDE – A Phase Ib Platform Study of Novel Agents in COMbinatioN with Conventional RaDiOTherapy in Non-small Cell Lung Cancer (NSCLC)
Gerard Walls, United Kingdom

EP05.01-008 The Scottish Inflammatory Prognostic Score predicts survival in non-small cell lung cancer treated with chemoradiotherapy
Grace Ball, United Kingdom

EP05.01-009 A Clinical Outcome Comparison of IMRT and VMAT in Stage II and III NSCLC Irradiated with Radical Intent
José Belderbos, Netherlands

EP05.01-010 External Validation of Two Prediction Models for Severe Radiation-induced Lymphopenia during Concurrent Chemoradiotherapy for Lung Cancer
José Belderbos, Netherlands

EP05.01-011 Real World Outcomes of Durvalumab after Chemoradiotherapy in unresectable advanced Non-Small Cell Lung Cancer: The Mayo Clinic Experience.
Joel Rivera Concepcion, United States

EP05.01-012 Avoiding Cardiac Toxicity in Lung Cancer Radiotherapy (ACcoLade) Trial - Initial Results
Kathryn Banfill, United Kingdom

EP05.01-013 Increased C-reactive Protein after Chemoradiotherapy and Immunotherapy in Locally Advanced Non-small Lung Cancer Indicates Worse Survival
Karmen Stanic, Slovenia

EP05.01-014 Circulating Tumour DNA to Identify Genomic Biomarkers of Radiation Sensitivity in Locally Advanced Non-Small Cell Lung Cancer
Emily Lebow, United States

EP05.01-015 Validate Radiomics Features and XGBoost Model in Radiation Pneumonitis (RP) Prediction in Patients with Primary Lung Cancer: A MultiCenter Study
Jiali Liu, China

EP05.01-016 Radiation Recall Pneumonitis (RP) Induced by Immune Checkpoint Inhibitors (ICIs) after Thoracic Radiotherapy for Lung Cancer
Xiaotong Lu, China

EP05.01-017 Exploring the Benefits of Adaptive Radiotherapy in NSCLC-patients
Marie Tvilum, Denmark

EP05.01-018 Chemoradiotherapy Followed by Durvalumab in Unresectable Locally Advanced NSCLC- A Single Institution Experience in Croatia
Marko Jakopović, Croatia

EP05.01-019 4D CT Ventilation Image-Guided Lung Functional Avoidance Radiotherapy: A Single-Arm Prospective Pilot Clinical Trial
Megan Daly, United States

EP05.01-020 Unanticipated Radiation Re-planning for Stage III Non-small Cell Lung Cancer
Melinda Mushonga, Canada

EP05.01-021 Radiation Dose to Cardiac Substructures and the Incidence of Cardiac Events in Patients with Stage III NSCLC Receiving CCRT
Meng Welliver, United States

EP05.01-022 Evaluation of the Management of Stage III NSCLC at Mohamed IV Center for Cancer Treatment Casablanca
Maryam Zaouit, Morocco

EP05.01-023 Feasibility of Functional Lung Avoidance using Ga-68 4D Ventilation Perfusion PET/CT: The HI-FIVE Trial
Nicholas Bucknell, Australia
EP05.01-024 Real-life Management of Stage III NSCLC Patients in Italy: The BE-PACIFIC Observational Study
Paolo Bironzo, Italy

EP05.01-025 Planned Interim Analysis of a Phase II Trial of Concurrent Durvalumab and Radiation Therapy for Locally Advanced Lung Cancer
Andreas Rimner, United States

EP05.01-026 Carboplatin Dose Calculations for Patients with Lung Cancer: Significant Dose Differences Found Depending on Dosing Equation
Seckin Akgül, Australia

EP05.01-027 Uncertain Resection of pN2 NSCLC Patients-survival Analysis of Postoperative Radiotherapy and Driver Gene Mutations
Qianyue Deng, China

EP05.01-028 Thoracic Radiotherapy of Baseline Severe Pulmonary Dysfunction NSCLC Patients and Predictive Analysis for Acute Radiation Pneumonitis
Qianyue Deng, China

EP05.01-029 Association between DNA Repair Gene Pathway SNPs and Tumour Response in NSCLC Patients Receiving Radiotherapy: A Meta-Analysis
Timothy Shun Man Chu, United Kingdom

EP05.01-030 CRISP: First Real-World Evidence of NSCLC Stage I, II and III in Germany - AIO-TRK-0315
Wilfried Eberhardt, Germany

EP05.01-031 Lysimachia Capillipes Capilliposide C Enhances the Radiosensitivity of Lung Cancer by Promoting ERRFI1 via Inhibiting Phosphorylation of STAT3
Kan Wu, China

EP05.01-032 The Incidence of Brain Metastasis and Radiation Pneumonitis With Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC
Yeonsil Kim, South Korea

EP05.01-033 Stimulation CT-Based Radiomics Predict Radiation Pneumonitis after Chemoradiotherapy in Locally Advanced NSCLC
Haihua Yang, China

EP05.01-036 Role of Nanoparticle Polymeric Micellar Paclitaxel in Reducing Toxicity and Enhancing Efficacy in Non-small Cell Lung Cancer
Baohui Han, China

EP05.02 Track: Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy

EP05.02-003 Durvalumab after Chemoradiotherapy (CRT) in Unresectable Stage III NSCLC. Comparative Study of Two Cohorts in the Real-World Setting.
Blanca Tavara, Spain

EP05.02-004 Could Fifty Percent Tumour Viability Be a Good Prognostic Factor?
Ezgi Cesur, Turkey

EP05.02-005 Is Immunotherapy Safer Than Radiotherapy in Combination With Chemotherapy in Neoadjuvant Therapy?
Ezgi Cesur, Turkey

EP05.02-006 Neoadjuvant DS-8201 for Stage III Non-small Cell Lung Cancer with HER2 20ins
Huizhao Hong, China

EP05.02-007 Impact Of Fibrinogen Levels and mGPS on Survival of Stage III/N2 NSCLC Patients Treated with Neoadjuvant Therapy and Radical Surgery
Katharina Sinn, Austria

EP05.02-008 Phase II Trial of Neoadjuvant Icotinib Plus Chemotherapy for Stage II-IIIB EGFR-mutant Non-small-Cell Lung Cancer
Fang-Liang Lu, China

EP05.02-009 Aumolertinib Versus Erlotinib/Chemotherapy for Neoadjuvant Treatment of Stage IIIA EGFR-mutant NSCLC (ANSWER)
Wenhua Liang, China

EP05.02-010 Robotic-Assisted Thoracic Surgery Following Neoadjuvant Chemotherapy in Patients with Stage III Non-small Cell Lung Cancer
Min Li, China

EP05.02-011 Phase II Trial of Neoadjuvant Tislelizumab with Chemotherapy for Resectable Stage IIB-III Non-small Cell Lung Cancer
Yao-Bin Lin, China

EP05.02-012 Chemoradiotherapy versus Chemotherapy in Neoadjuvant Settings for Stage III-N2MO Non-Small Cell Lung Cancer (NSCLC) Patients
Marah Akhdar, Jordan

EP05.02-013 Immune-Related Adverse Effects and Durvalumab Treatment Patterns in VHA Patients with Unresectable Stage III NSCLC
Amanda Moore, United States

EP05.02-014 Neoadjuvant Toripalimab Combination in Patients with Stage IIB-IIIB NSCLC: A Single-Arm, Phase 2 Trial (Renaissance Study)
Shi Yan, China

EP05.02-015 Neoadjuvant Prehabilitation Therapy for Locally Advanced Non-small-Cell Lung Cancer: Optimizing Outcomes throughout the Trajectory of Care.
Severin Schmid, Germany

EP05.02-016 Aumolertinib after Adjuvant Chemotherapy/Radiotherapy in Stage pIIIA-N2 Non-Small-Cell Lung Cancer with EGFR Mutation
Yu Zhang, China

EP05.02-017 Prognostic Factors Following Induction Therapy for N2 Lung Cancer
Takashi Inoue, Japan
**Program | IASLC 2022 World Conference on Lung Cancer**

**EP05.02-019** Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Surgical Outcomes in a Regionalized Pulmonary Oncology Network
Yohann Pilon, Canada

**EP05.02-020** IL-9Stimulates Anti-tumour Immune Response and Facilitates Checkpoint Blockade in Lung Cancer
Yuqian Feng, Hong Kong

**EP05.02-021** An Updated Analysis of Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable NSCLC
Yongchang Zhang, China

**EP05.02-022** Thoracic Radiotherapy May Increase the Risk of Treatment-induced Pneumonitis after Immune Checkpoint Inhibitors: A Meta-Analysis
Feng-Ming Kong, Hong Kong

**EP05.03** Track: Locally Advanced Non-small Cell Lung Cancer - Surgery

**EP05.03-001** Impact of Neoadjuvant Chemo/radiation Therapy Followed by Surgical Resection on T4N0-1 Non-Small Cell Lung Cancer
Akin Turna, Turkey

**EP05.03-002** Pulmonary Artery Reconstruction for Lung Cancer With N1 Vessel Infiltration: Is It Justified?
Camilla Vanni, Italy

**EP05.03-003** Superior Sulcus (Pancoast) Tumours: A 11-Year Single-Centre Experience
Catarina Moita, Portugal

**EP05.03-004** Risk Prediction of Multiple-station N2 Metastasis in Patients with Clinical Single-station N2 Non-small Cell Lung Cancer
Joon Young Kim, South Korea

**EP05.03-005** Clinical Impact of Histologic Type in Patients with Surgically Resected Stage II and III Non-small Cell Lung Cancer
Hyeong Ryul Kim, South Korea

**EP05.03-006** Real-World Treatment Pathways In Stage III Non-Small Cell Lung Cancer in Portugal (PICTuRE): An Interim Analysis Of Surgical Patients
Maria Teixeira, Portugal

**EP05.03-007** Comparison of Surgical Methods in Patients Receiving Neoadjuvant Treatment; Thoracoscopy vs. thoracotomy
Ezgi Cesur, Turkey

**EP05.03-008** Surgery after First-Line Alectinib for (Locally) Advanced ALK-rearranged NSCLC: Pathological Response and Peri-Operative Results
Filippo Lococo, Italy

**EP05.03-009** Prognostic Impact of Tumour Volume Doubling Time for Resected Squamous Cell Carcinoma of the Lung
Kenta Nakashima, Japan

**EP05.03-010** Extended Resection of Non-small Cell Lung Cancer with Superior Vena Cava Involvement: A Systematic Review and Meta-analysis
Shadi Hamouri, Jordan

**EP05.03-011** Bilateral Orthotopic Lung Transplantation for a Patient with Advanced Invasive Mucinous Adenocarcinoma
Young Kwang Chae, United States

**EP05.03-012** Deep Learning-based Classifier to Predict Intensified Locoregional Approach Need in Stage III Non-Small Cell Lung Cancer
Chenchen Zhang, China

**EP06.01** Track: Management of Lung Cancer in the Era of COVID-19

**EP06.01-001** The Longitudinal Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Centre: A Retrospective Chart Review
Angelo Rizzolo, Canada

**EP06.01-002** Cancer Care in a Time of COVID: Lung Cancer Patient’s Experience of Telehealth and Connectedness.
Anne Fraser, New Zealand

**EP06.01-003** Impact of COVID-19 on Lung Cancer Patients; The Patients’ Perspective
Desiree Hao, Canada

**EP06.01-004** Lung Cancer Resection During the Covid-19 Pandemic: A Single Centre Study
Tunde Oyebanji, United Kingdom

**EP06.01-005** COVID-19 and Post-COVID Outcomes in Lung Cancer Patients: Experience from an Indian Cancer Center
Debapriya Mondal, India

**EP06.01-006** Multidisciplinary Team during the COVID-19 Pandemic: The BE-PACIFIC Italian Observational Study Analysis.
Enrica Capelletto, Italy

**EP06.01-007** Fate of Pneumonectomy Patients During Covid-19 Pandemic
Gökberk Güler, Turkey

**EP06.01-008** COVID-Protected Pathways for Image Guided Lunc Cancer Intervention during the COVID-19 Pandemic: A Cohort Study
Alexander Sheeka, United Kingdom

**EP06.01-009** Maintaining Thoracic Services During COVID-19 - A Single Centre Experience
Hasanali Walji, United Kingdom

**EP06.01-010** Clinical Outcomes after Hypofractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer During The Covid-19 Pandemic
Meriem Cherkaoui, Morocco

**EP06.01-011** COVID-19 Impact in Thoracic Surgery: a Comparison Between Public and Private Care in a Single-Center Facility
Maria Teresa Tsukazan, Brazil

**EP06.01-012** Impact of COVID-19 on the Stage of Lung Cancer Diagnosis at the Mohamed VI Center for Cancer Treatment in Morocco
Souleymane Panandtigri, Morocco
EP06.01-013 Differences of Oncology Treatment for Lung Cancer Patients in Pandemic COVID-19 Year- Our Clinical Experience
Simonida Crvenkova, North Macedonia

EP06.01-014 Lung Resections After COVID: Short-term Outcomes
Srinivas Kodaganur Gopinath, India

EP06.01-015 Will Virtual Care Stand the Test of Time; One Site’s Perspective on the Continuity of Virtual Care Post-Pandemic
Suheon Lee, Canada

EP06.01-016 Nationwide Activity of Lung Cancer Surgery Before and During the COVID-19 Pandemic
Tanis Laisaar, Estonia

EP06.01-017 Clinical Impact of SARS-CoV2 Pandemic in the Diagnosis of Early-Stage Thoracic Tumours
Yago Garitaonaindia Diaz, Spain

EP07.01 Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies - Clinical

EP07.01-001 Molecular Profiling Predicts Outcomes in Patients With Resected Malignant Pleural Mesothelioma
Christian Rolfo, United States

Qian Wang, United States

EP07.01-003 Metadata-Oriented Data Engineering Approach for Integration of Medical Data: A Pilot Study
Yusuf Kahya, Turkey

EP07.01-004 Long Survivor Epithelioid Pleural Mesotheliomas Are Characterized by Tertiary Lymphoid Structures: An Update to the MATCH Study
Federica Grosso, Italy

EP07.01-005 Second Primary Cancers in a Population-Based Mesothelioma Registry
Giovanni Ceresoli, Italy

EP07.01-006 Clinicopathologic Determinants of Survival in Thoracic NUT Carcinoma (TNUT): Analysis of a Pooled Database
Philip Haddad, United States

EP07.01-007 Is Extended Resection for Tracheobronchial Adenoid Cystic Carcinoma Warranted?
Jérôme Estephan, France

EP07.01-008 Perturbation of Warburg Effect by Dichloroacetate and Niclosamide in Malignant Pleural Mesothelioma in Vitro and in Vivo
James Chung-Man Ho, China

EP07.01-009 Solitary Fibrous Tumours of the Pleura, Clinical and Surgical Dilemma. Single-Center Experience
Krzysztof Kurowski, Spain

EP07.01-010 Results of Multimodal Treatment in Patients with Malignant Pleural Mesothelioma Undergoing Pleurectomy/Decortication
Kubra Alphan Kavak, Turkey

EP07.01-011 Integrating PD-L1 Expression to the CALGB Prognostic Scoring System in Malignant Pleural Mesothelioma
Luis Cabrera, Mexico

EP07.01-012 Ipilimumab and Nivolumab in Pretreated Patients with Malignant Pleural Mesothelioma
Marko Jakopovic, Croatia

EP07.01-013 Physical Function, Symptom Burden, and Quality of Life in Patients with Malignant Pleural Mesothelioma
Meng Wu, United States

EP07.01-014 Mesothelioma-Associated Fibroblasts Enhance Mesothelioma Aggressiveness and Modulate Drug Response
Michael Grusch, Austria

EP07.01-015 Multimodality Imaging for Characterization, Classification, and Staging of Malignant Pleural Mesothelioma, Focusing on MR Imaging
Mi Young Kim, South Korea

EP07.01-016 Role of Neoadjuvant Chemotherapy in Thymic Tumours
Riad Abdeljalil, Jordan

EP07.01-017 Malignant Fibrous Solitary Tumour of the Pleura Is Not All the Same: Evaluation of Risk Stratification Models in a Large Single Centre Series
Sara Ricciardi, Italy

EP07.01-018 Phase III Randomized Trial on Surgery, Chemo and Pleural Radiation (IMPRINT) for Resectable Pleural Mesothelioma (NRG LU-006)
Andreas Rimner, United States

EP07.01-019 Multiinstitutional Patterns of Use and Compliance with Tumour Treating Fields for Patients with Unresectable Malignant Pleural Mesothelioma
Rupesh Kotecha, United States

EP07.01-020 Pulmonary MALT Lymphoma: Detailed CT Findings
Kyongmin Beck, South Korea

EP07.01-021 Clinical and Biochemical Profiling of Pleural Mesothelioma Patients Treated With Immunotherapy
Sara Manglaviti, Italy

EP07.01-022 Analysis of Second Surgery for Recurrence in Malignant Pleural Mesothelioma (MPM) Patients (P)
Susana Cedres, Spain

EP07.01-023 Family History of Cancer in a Series of Malignant Pleural Mesothelioma (MPM) Patients (P)
Susana Cedres, Spain

EP07.01-024 Preclinical Investigation of Immune Checkpoint Blockade and Anti-Angiogenic Therapy in Malignant Pleural Mesothelioma
Sophie Rovers, Belgium
EP07.01-025 Survival Advantage of Pulmonary Metastasectomy in Advanced Melanoma Patients: A Population-Based Study
Sebawe Syaj, Jordan

EP07.01-026 Primary Pulmonary Ewing’s Sarcoma: Post Hoc Analysis From Two International Multicenter Prospective Randomized Trials
Theresa Stork, Germany

EP08.01
Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy

EP08.01-001 Update Analysis of Sintilimab With Two Cycles Chemotherapy for Untreated Advanced Squamous Non-small-Cell Lung Cancer
Huijuan Wang, China

EP08.01-002 Real-World Survival Outcomes of Patients with High PD-L1 Advanced NSCLC Who Received Chemo-Immunotherapy vs Immunotherapy
Junipearl Cheng, Australia

EP08.01-003 Efficacy of Immune Checkpoint Inhibitors in Pulmonary Sarcomatoid Carcinoma, A Multicenter Retrospective Study
Zhimin Zeng, China

EP08.01-004 Pattern of Subsequent Treatment and Outcomes in Relapsed PD-L1 high NSCLC Pre-treated with Pembrolizumab
Anifat Elegbede, Canada

EP08.01-005 A Multicenter Prospective Observational Study of Atezolizumab in Unresectable Advanced or Metastatic NSCLC in Japan: J-TAIL
Akito Hata, Japan

EP08.01-006 Using Real World data to build effective predictive machine learning models for NSCLC patients treated with immune-based therapy
Alessandro de Toma, Italy

EP08.01-007 Real-World Outcomes of Patients with Advanced Lung Adenocarcinoma Treated with First-Line Chemo-Immunotherapy in Italy
Alessandro Leonetti, Italy

EP08.01-008 Immune Checkpoint Inhibitors in Oncogenic Driven Non-small Cell Lung Cancer
Ana Fonseca, Portugal

EP08.01-009 TRBV Haplotype Profile Was Related to Immune-Induced Adverse Events in Chinese Patients With Advanced NSCLC
Xiaomin Niu, China

EP08.01-010 Troponin Elevation and the Risk of Myocarditis among NSCLC Patients Treated with Immune Checkpoint Inhibitors
Barliz Waissengrin, Israel

EP08.01-011 Diabetes Mellitus (DM) is Associated with Poor Outcome in Pembrolizumab-treated Non-Small Cell Lung Cancer (NSCLC) Patients
Barliz Waissengrin, Israel

EP08.01-012 First-line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer with 0-49% PD-L1: A Real-world Experience
Beatrice Benetti, Italy
EP08.01-013 Ramucirumab plus Atezolizumab in Patients with Stage IV NSCLC Previously Treated with Immune Checkpoint Blockade
Brett Herzog, United States

EP08.01-014 Tislelizumab versus Docetaxel in Previously Treated Advanced Non-Small Cell Lung Cancer: Final Analysis of RATIONALE-303
Caicun Zhou, China

EP08.01-015 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Anti-oxMIF Antibody ON203 in Malignant Solid Tumours
Christine Landlinger-Schubert, Austria

EP08.01-016 A Review Of Real-World Treatment Outcomes Of mNSCLC Patients Following Progression On Or After Platinum-Based Chemotherapy
Cloe Koh, United States

EP08.01-017 Evaluation of Blood Tumour Mutation Burden for Efficacy of Second-Line Atezolizumab Treatment in Non-small Cell Lung Cancer
Cheol-Kyu Park, South Korea

EP08.01-018 Patterns of Failure in Metastatic NSCLC Treated with First Line Pembrolizumab and Impact of Local Therapy in Patients with Oligoprogression
Cole Friedes, United States

EP08.01-019 Modifiable biomarkers of response to immune checkpoint inhibitor treatment in non-small cell lung cancer
Daniel Spakowicz, United States

EP08.01-020 Phase 2 Platform Trial of Anti-TIGIT GSK'859A/EOS-448 + Anti-PD-1 Dostarlimab in Non-small Cell Lung Cancer (NSCLC)
David Spigel, United States

EP08.01-021 Phase 2 Study Evaluating Inupadenant in Combination with Chemotherapy in Adults with NSCLC who Progressed on Immunotherapy
Shouryadeep Srivastava, United States

EP08.01-022 Treatment Outcomes of Second-Line Immune Modulators in Steroid Refractory/Resistant Immune Related Adverse Events
Yasar Ahmed, Ireland

EP08.01-023 Factors Associated with Survival and Refusal of Physician Recommended Immunotherapy in Metastatic Non Small Cell Lung Cancer
Iktej Jabbal, United States

EP08.01-024 Multicenter Real Life Clinical Outcomes of PD-L1 Tested Patients with Non Small Cell Lung Cancer (NSCLC) in Turkey
Ozan Yazici, Turkey

EP08.01-025 PD-L1 Tumour Tissue Expression and Its Relation with Clinico-pathological Profile in Advanced NSCLC
Sindhu Kilaru, India

EP08.01-026 Influence of Brain Metastases on Survival of KRASG12C Mutated Stage IV Immune Checkpoint Inhibitor Treated Non-small Cell Lung Cancer Patients
Esther Swart, Netherlands

EP08.01-027 Durvalumab (D) ± Tremelimumab (T) + Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON
Edward Garon, United States

EP08.01-028 Overestimation with Cox HR - Cox-TEL-Adjusted Associations of PD-L1 Expression with Immune Checkpoint Inhibitor Survival Benefit in Lung Cancer
Emily Lin, Taiwan

EP08.01-029 NIVIPi-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases
Ernest Nadal, Spain

EP08.01-030 Nivolumab+Ipilimumab Vs Platinum-Based CT+Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial
Federico Cappuzzo, Italy

EP08.01-031 Blood Gene Expression Changes in Metastatic Lung Cancer under second-line Immunotherapy according to Clinical Response
Fabienne Lusky, Germany

EP08.01-032 Sintilimab in Combination with Anlotinib in NSCLC Patients with Uncommon EGFR Mutations: A Phase II, Single-arm, Prospective Study
Yun Fan, China

EP08.01-033 ML40471: Preliminary Analysis of Atezolizumab in Previously Treated Patients With Locally Advanced or Metastatic NSCLC
Yun Fan, China

EP08.01-034 Association of Sarcopenia with Survival in Advanced NSCLC Patients Receiving Concurrent Immunotherapy and Chemotherapy
Fabian Bolte, United States

EP08.01-035 Personalized ctDNA Detection to Monitor Outcome and Predict Immunotherapy Benefit in Locally Advanced and Metastatic NSCLC
Guanghui Gao, China

EP08.01-036 Low-dose EGFR-TKIs Directly Induce Maturation and Functional Activity of Human Dendritic Cells in an EGFR-independent manner
Hiroyuki Inoue, Japan

EP08.01-037 Association of Baseline NLR and BMI with Clinical Outcomes in NSCLC Patients Treated with Immunotherapy Alone Versus Chemo-Immunotherapy
Hita Moudgalya, United States

EP08.01-038 Clinical Predictors of Treatment Efficacy in Patients with Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors
Fang Hu, China

EP08.01-039 Impact of Pulmonary Function Indexes on Immunotherapy Efficacy in Lung Adenocarcinoma Patients and the Potential Prognostic Factors
Fang Hu, China

EP08.01-040 Peripheral Blood Cells as Predictors for Efficacy of Immunotherapy in Patients with Advanced Non-small Cell Lung Cancer
Jacobo Rogado, Spain
EP08.01-041 Impact of Gender on Response to Immune Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer
Jae Cheol Lee, South Korea

EP08.01-042 NEPTUNE China Cohort: First-Line Durvalumab + Tremelimumab versus Chemotherapy in Chinese Patients with Metastatic NSCLC
Ying Cheng, China

EP08.01-043 Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced Non-small Cell Lung Cancer (NSCLC)
Joao Alessi, United States

EP08.01-044 A Phase 2 Multi-Cohort Study of Tiragolumab, Atezolizumab and Bevacizumab in Advanced Non-Squamous Non-small Cell Lung Cancer
Joshua Reuss, United States

EP08.01-045 The Impact of Current Smoking Status at Initiation of Immune Checkpoint Inhibitor Therapy on Tumour Mutation Burden and Survival
Julie Wu, United States

EP08.01-046 Examination of Long-Term Administration of Pembrolizumab in Patients with Non-small Cell Lung Cancer at Our Institution
Kazuhito Nii, Japan

EP08.01-047 Chemo-immunotherapy is Associated With Better Survival Than Chemotherapy Alone in Stage IV Non-small Cell Lung Cancer
Krishna Patel, United States

EP08.01-048 Spanish Immunotherapy Registry of Cardiovascular Toxicity (SIR-CVT): Preliminary Analysis of the Lung Cancer Cohort
Laura Gutiérrez Sainz, Spain

EP08.01-049 Unscheduled Hospitalizations in Patients With Thoracic Tumours in the Era of Immunotherapy
Laura Gutiérrez-Sainz, Spain

EP08.01-050 Survival Outcome of Metastatic Pulmonary Sarcomatoid Carcinoma Treated with Immunotherapy: An Analysis of National Cancer Database (NCDB)
Lei Deng, United States

EP08.01-051 Clinical Characterization and Outcomes of Non Small Cell Lung Cancer with HER2 Alterations in the Era of Immunotherapy
Shenduo Li, United States

EP08.01-052 Toripalimab in Combination with CIK Cells in Patients with Advanced NSCLC: An Exploratory Study
Xuxinyi Ling, China

EP08.01-053 PD-1 Inhibitors Plus Chemotherapy in Patients with Brain Metastasis and EGFR/ALK-positive Non-small Cell Lung Cancer after EGFR/ALK-TKIs
Yutao Liu, China

EP08.01-054 ICIs combined with Single-agent Chemotherapy in Two or More Lines Treatment for Advanced Non-Small Cell Lung Cancer
Yutao Liu, China

EP08.01-055 Utilization of Tumour Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer
Wenbin Li, China

EP08.01-056 Pemetrexed-Based Chemotherapy Plus ICIs or Bevacizumab as First-Line Strategy for Patients with Lung Adenocarcinoma in Real-World Setting
Xin Li, China

EP08.01-057 Pembrolizumab Maintenance in Patients with Metastatic Squamous Non-Small Cell Lung Cancer (sNSCLC) - AIO-TRK-0115/PRIMUS
Martin Reck, Germany

EP08.01-058 Access to Immunotherapy in Control Arms of Pivotal First Line Immunotherapy Trials in Metastatic Non-Small Cell Lung Cancer
Maham Bakhtyar, Pakistan

EP08.01-059 Safety, Tolerability and Clinical Activity of Selinexor in Combination with Pembrolizumab in Metastatic Non-small Cell Lung Cancer
Mehmet Altan, United States

EP08.01-060 Long-term Survival Outcomes in NSCLC Patients with Targeted Therapy and Immunotherapy: An IASLC Analysis of ASCO CancerLinQ Discovery Data
Madhusmita Behera, United States

EP08.01-061 A Pilot Study of Avelumab and SABR in Non-Responding and Progressing NSCLC Patients Previously Treated with a Checkpoint Inhibitor
Megan Daly, United States

EP08.01-062 Body Mass Index, Immune Related Adverse Events, and Survival in Patients with Metastatic Non-small Cell Lung Cancer Treated with Immunotherapy
Mingjia Li, United States

EP08.01-063 Chemoimmunotherapy versus Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer with a PD-L1 Score of 50-100%
Mohsin Shah, United States

EP08.01-064 Serum NY-ESO-1 and XAGE1 Antibodies Predict and Monitor Clinical Responses to Immune Checkpoint Therapy for NSCLC
Mikio Oka, Japan

EP08.01-065 Prevalence of Non-driver Mutations and Characterization of Patients with Advanced or Metastatic Non-small Cell Lung Cancer
Mariano Provencio, Spain

EP08.01-066 Assessing Immunotherapy in Real Life: Have We Transferred the Increase in Overall Survival in Stage IV NSCLC from Trials to Clinical Practice?
Mariano Provencio, Spain

EP08.01-067 Rechallenging with PD-1 Inhibitors: Incidence and Management of Immune-Related Adverse Events in Metastatic NSCLC
Tuan Hoang, Canada

EP08.01-068 Going for the Ligand After a Stint With the Receptor: Can Switching Target From PD-1 to PD-L1 (Or Vice-Versa) Be Beneficial?
Nida Khan, United States
EP08.01-069 A Retrospective Study of Immune Checkpoints Rechallenge/Retreatment in Metastatic NSCLC Progressing after Previous ICIs
Nuria Mederos Alfonso, Switzerland

EP08.01-070 Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC
Jun Zhao, China

EP08.01-071 Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC
Jun Zhao, China

EP08.01-072 Clinical Value of Patras Immunotherapy Score (PIOS) Formula in Patients With Advanced NSCLC Treated With Immunotherapy/Chemotherapy
Petros Christopoulos, Germany

EP08.01-073 AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC
Rajiv Kumar, New Zealand

EP08.01-074 ‘Long Responders’ Compared to ‘Non-Responders’ to a First Line Immune Checkpoint Inhibitor in Incurable Non-Small Cell Lung Cancer
Rebekah Rittberg, Canada

EP08.01-075 Combination of Baseline Disease and Smoking Pack-Years Can Guide The 1st-line Treatment Decision in Advanced NSCLC with High PD-L1 Expression
Ren Yuan, Canada

EP08.01-076 KEYNOTE B36: A Pilot Study of First-line Tumour Treating Fields (150 kHz) Plus Pembrolizumab for Advanced or Metastatic Non-small Cell Lung Cancer
Rupesh Kotecha, United States

EP08.01-077 Predicting Response to Checkpoint Inhibitors Using Complex Molecular Characteristics and Immunoprofiling in Patients With NSCLC
Simona Borilova, Czech Republic

EP08.01-078 Clinical Outcomes in Metastatic Non-small Cell Lung Cancer Harboring BRAF Mutations Treated With Immune Checkpoint Inhibitors
Susana Cedres, Spain

EP08.01-079 Long Term Use of Immune Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer (NSCLC) and Abnormal Marrow Pathology: A Case Series
Shane Wing, United States

EP08.01-080 Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced NSCLC in Patients aged ≥ 70
Bo Shen, China

EP08.01-081 A Phase I Dose-Escalation Study of HBM4003, an anti-CTLA-4 Heavy Chain Only Monoclonal Antibody, in Combination with Pembrolizumab
Shun Lu, China

EP08.01-082 Therapeutic Resistance and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients: A Prospective Study
Shun Lu, China

EP08.01-083 Real-World PD-(L)1 Inhibitor Treatment Pattern and Outcomes in Advanced Non-Small Cell Lung Cancer in Sweden
Simon Ekman, Sweden

EP08.01-084 Non-Invasive Detection of Predictive Biomarkers for PD-1 Inhibitor Treated Non-Small Cell Lung Cancer Patients
Simone Stensgaard, Denmark

EP08.01-085 Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naive Metastatic Non-small Cell Lung Cancer
Si-Yang Liu, China

EP08.01-086 Pooled Mutant KRAS-Targeted Peptide Vaccine with Nivolumab and Ipilimumab in Advanced KRAS Mutated Non-Small Cell Lung Cancer
Samuel Rosner, United States

EP08.01-087 First-Line Pembrolizumab-Combination Therapy for Advanced Squamous NSCLC: Real-World Outcomes at US Oncology Practices
Stephen Liu, United States

EP08.01-088 Direct Acting Antivirals (DAA) and Immune Checkpoint Inhibitors (ICIs) Therapy in Patients with Lung Cancer and Hepatitis C
Marco Tagliamento, Italy

EP08.01-089 Efficacy and Safety of Immune Checkpoint Inhibitors in Treating Brain Metastases in Patients With Non-small Cell Lung Cancer
Fei Teng, China

EP08.01-090 Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront.
Teresa Gorria, Spain

EP08.01-091 Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront
Teresa Gorria, Spain

EP08.01-092 ICI in Combination With Chemotherapy or Anti-angiogenic Agents as Second-Line Orbettermentreatment for Advanced Non-small Cell Lung Cancer
Lin Wu, China

EP08.01-093 A Phase II Study of Camrelizumab combined with Apatinib and Albumin Paclitaxel in Advanced Non-squamous NSCLC (CAPAP-lung)
Lin Wu, China

EP08.01-094 Efficacy and Safety of Combining Endostar with Camrelizumab plus Chemotherapy in Advanced NSCLC Patients: A Multi-Center Retrospective Study
Lin Wu, China

EP08.01-095 Lung Immune Prognostic Index is Prognostic in Patients Treated with PD-1 Inhibitor with Chemotherapy for Non-small Cell Lung Cancer
Anning Xiong, China
| EP08.01-097 | Landscape and Dynamic Changes of Peripheral Immune Cells in Non-small Cell Lung Cancer Patients with First-line Immunotherapy | Xiangling Chu, China |
| EP08.01-098 | Evaluating Risk Factors for Pneumonitis in Stage III NSCLC Patients Receiving Durvalumab after Definitive Chemoradiation | Xiaokui Mo, United States |
| EP08.01-099 | Activity of aPD1-MSLN-CART Cells against Metastatic Lung Cancer in a Phase 1 Trial | Xiaorong Dong, China |
| EP08.01-100 | Unlocking Primary Resistance to Checkpoint Inhibitors in Non-small Cell Lung Cancer by Metagenomic and Metabolomic | Xiaorong Dong, China |
| EP08.01-101 | Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Asian Patients with Advanced NSCLC | Yiqing Huang, Singapore |
| EP08.01-102 | Aumolertinib Combined with PD-1 Inhibitors May Benefit Advanced Non-small Cell Lung Cancer Patients After Failure of EGFR-TKI Therapy | Lian Yu, China |
| EP08.01-103 | Combination of Aumolertinib and PD-1/PD-L1 Inhibitors as Second-line and Subsequent Therapy in Advanced Small-cell Lung Cancer | Lian Yu, China |
| EP08.01-104 | Baseline Tumour Size and Survival Outcomes among Patients with Advanced NSCLC treated with First-Line Immunotherapy | Yuji Uehara, Japan |
| EP08.01-105 | Efficacy of First-Line Immune Checkpoint Inhibitors in Patients with Advanced NSCLC harboring KRAS, MET, FGFR, RET, BRAF, and HER2 Alterations | Yuji Uehara, Japan |
| EP08.01-106 | PD-1/PD-L1 Inhibitors Increase Myocardial Infarction in Osimertinib-Treated Patients with Non-Small Cell Lung Cancer | Lucheng Zhu, China |
| EP08.01-107 | The Increase of Blood Intratumour Heterogeneity Is Associated with Unfavorable Outcomes of ICIs Plus Chemotherapy in NSCLC | Juan Zhou, China |
| EP08.01-108 | Real-Life Costs and Benefit of First-Line Pembrolizumab for Advanced NSCLC - A Propensity-Score Matched Case-Control Study | Vanessa Rambousek, Austria |
| EP08.01-109 | TACTI-002: A Phase II Study of Eftilagimid Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC | Martin Forster, United Kingdom |
| EP08.01-110 | Trial in Progress: A Phase 2 Multicenter Study (IOV-LUN-202) of Autologous Tumour-infiltrating Lymphocyte (TIL) Cell Therapy (LN-145) in mNSCLC | Jason Chesney, United States |

| EP08.02 | Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments |
| EP08.02-001 | Concurrent Aumolertinib and Cerebral Radiotherapy as First-Line Treatment for EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases | Ying Wang, China |
| EP08.02-002 | Aumolertinib in the Treatment of Activated EGFR Mutation Advanced NSCLC Patients with Interstitial Pneumonia | Jie Tan, China |
| EP08.02-003 | Aumolertinib Plus Chemotherapy as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation andctDNA Cleared Analysis | Yanwei Li, China |
| EP08.02-004 | Aumolertinib in Treatment-Naïve EGFR-mutant NSCLC Patients With Brain Metastases: Primary Efficacy and Safety Data from the ARTISTRY | Huijuan Wang, China |
| EP08.02-005 | A Prospective Non-randomized Observational Study on Efficacy and Its Relative Factors of Pemetrexed Combined With EGFR-TKIs in NSCLC | Huijuan Wang, China |
| EP08.02-006 | Data from Real World to Evaluate the Efficacy of Almonertinib in EGFR-mutant NSCLC Patients | Huijuan Wang, China |
| EP08.02-007 | Disease Burden and Clinical Outcomes of Advanced ROS1 Positive NSCLC with Different Fusion Partners | Zihua Zou, China |
| EP08.02-008 | Tumour Invasiveness and Clinical Outcomes between Metastatic ROS-1 and ALK Positive NSCLC | Zihua Zou, China |
| EP08.02-009 | Progression Pattern, Resistance Mechanism and Subsequent Therapy for ALK Positive NSCLC in the Era of Second—Generation ALK—TKIs | Zihua Zou, China |
| EP08.02-010 | Low-Dose Dacomitinib as First-Line Therapy for Driver-Positive Advanced Non-small Cell Lung Cancer: A Multicenter Real-World Study in China | Liang Gong, China |
| EP08.02-011 | Design of a Phase I Trial (TOTEM) to Test Repotrectinib in Combination with Osimertinib in Advanced, Metastatic EGFR-Mutant NSCLC | Andrés Aguilar, Spain |
| EP08.02-012 | Real-world Analysis of the Efficacy and Safety of lorlatinib in Patients with ALK-Positive Non-small Cell Lung Cancer in Korea | Beung-Chul Ahn, South Korea |
| EP08.02-013 | Prognostic Utility of the ALI (Advanced Lung Index) in Crizotinib-Treated ALK and ROS1Fusion-Positive NSCLC | Amanda Gibson, Canada |
EP08.02-014 Impact of East Asian Ancestry on Response to First-Line Osimertinib: A Real-World Canadian Cohort
Amanda Gibson, Canada

EP08.02-015 The Utility of Liquid Biopsies for Management of Stage IV Non-small Cell Lung Cancer (NSCLC) in an Academic Community Medical Center
Alisha Maity, United States

EP08.02-016 Frontline and Post-Osimertinib Therapy for EGFR-mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs
Benjamin Besse, France

EP08.02-017 Time on Treatment for Patients Treated With Anti-EGFR Tyrosine Kinase Therapy for Metastatic NSCLC: Real-World Experience Data
Lior Apter, Israel

EP08.02-018 Phase 1/2 Study of BLU-451, a Small Molecule Inhibitor of EGFR, in EGFR Exon 20 Insertion-Mutant Incurable Advanced Cancers
Alexander Spira, United States

EP08.02-019 Phase 1/2 Study of BLU-701, a Highly Selective EGFR Inhibitor, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Alexander Spira, United States

EP08.02-020 Preclinical Activity of NVL-655 in a Patient-Derived NSCLC Model with Lorlatinib-Resistant ALK G1202R/T1151M Mutation
Anupong Tangpeerachaikul, Thailand

EP08.02-021 A Phase II Trial of Upfront Aumolertinib (HS-10296) plus Radiotherapy for EGFR Mutated Non-small-cell Lung Cancer Patients with Brain Metastases
Yi Tang, China

Bengisu Uluata Dayanc, Turkey

EP08.02-023 Differentiation Syndrome in a Patient with Non-Small-Cell Lung Cancer Harboring IDH2 Mutation Treated with Enasidenib.
Bhoomika Sukhadia, United States

EP08.02-024 Research Efforts in Systemic Therapy of Lung Cancer With Brain Metastasis From 2015-21: A clinicaltrial.gov Registry Analysis
Bindu Venugopal, Canada

EP08.02-025 Lazertinib as a Frontline Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer: Results from the Phase I/II Trial
Byoung Chul Cho, South Korea

EP08.02-026 Real-world Efficacy of EGFR-TKI in Advanced NSCLC and Clinical Predictors of Outcome in Maharaj Nakorn Chiangmai Hospital in Thailand.
Chaiyut Charoentum, Thailand

EP08.02-027 T790M Detection Rate After First-Line Treatment with Bevacizumab Plus 1st or 2nd Generation EGFR-TKI in Advanced NSCLC
Chao-Chi Ho, Taiwan

EP08.02-028 Germline HRR Mutations in Metastatic NSCLC and Impact on Progression-Free Survival: A Single-Center Retrospective Study
Chetan Vakkalagadda, United States

EP08.02-029 Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment
James Chih-Hsin Yang, Taiwan

EP08.02-030 Tusamitamab Rattansine in Patients with NSQ NSCLC and Negative or Moderate CEACAM5 Expression Tumours and High Circulating CEA
Christine Soufflet, France

EP08.02-031 NRF2 Pathway Signature Predicts KEAP1/ NFE2L2 Mutations and Reveals Alternative Pathway-Activating Mutations in NSCLC
Christoph Arolt, Germany

EP08.02-032 High Efficiency Multiplex Detection of Molecular Alterations in Supernatants of Pleural Effusion and Cerebrospinal Fluid
Clara de las Casas, Spain

EP08.02-033 Anlotinib in Elderly Patients With Advanced Non-squamous NSCLC Who Had Not Received Systemic Chemotherapy: A Single-Arm, Phase II Study
Da Zhao, China

EP08.02-034 OCELOT - Osimertinib then Chemotherapy in EGFR+ Lung Cancer with Osi Third-line Rechallenge and Osimertinib for Uncommon EGFRm in 1L
Daniel Breadner, Canada

EP08.02-035 Clinical Utility of Liquid Biopsy After Progression to First and Second-Generation TKIs in Advanced EGFR Mutant NSCLC Patients
David Heredia, Mexico

EP08.02-036 Selpercatinib Striking Response in a Case of Cerebral and Auditory Canal Metastasis of RET Fusion-Positive Non-Small-Cell Lung Cancer
Diana Sousa, Portugal

EP08.02-037 Small Cell Transformation in a Patient with RET Fusion Positive Lung Adenocarcinoma on Pralsetinib.
Anastasios Dimou, United States

EP08.02-038 Study of First-Line Aumolertinib Plus Bevacizumab and Pemetrexed Treated NSCLC with EGFR Mutation and Brain Metastasis
Shuai Fu, China

EP08.02-039 An Effective Treatment for EGFR-mutated Lung Adenocarcinoma with Symptomatic Leptomeningeal Metastases Using Aumolertinib
Xinyong Zhang, China

EP08.02-040 Dacomitinib Induced Febrile Neutropenia: a Rare Serious Adverse Event
Debapriya Mondal, India

EP08.02-041 NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumours: The Phase 1/2 ARROS-1 Study
Alexander Drilon, United States
<table>
<thead>
<tr>
<th>Presentation ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP08.02-042</td>
<td>EGFR-TKI +/- Antiangiogenics for EGFR-mutated Advanced NSCLC</td>
<td>Laercio Da Silva, United States</td>
</tr>
<tr>
<td>EP08.02-043</td>
<td>The Current State of Biomarker Testing in Lung Cancer as Seen by Health Care Providers</td>
<td>Daniel Saez, United States</td>
</tr>
<tr>
<td>EP08.02-044</td>
<td>Adding Alectinib Rescues Progression on Osimertinib Due to Acquired ALK p.R1275Q Variant in EGFR p.L858R-mutated NSCLC</td>
<td>Edyta Urbanska, Denmark</td>
</tr>
<tr>
<td>EP08.02-045</td>
<td>Phase 1/2 Study of BLU-945 in Patients With Common Activating EGFR-Mutant Non-Small Cell Lung Cancer</td>
<td>Elaine Shum, United States</td>
</tr>
<tr>
<td>EP08.02-046</td>
<td>Activity of Osimertinib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)</td>
<td>Elio Gregory Pizzutilo, Italy</td>
</tr>
<tr>
<td>EP08.02-047</td>
<td>The Impact of CPG on the Decision-making Process in ALK+ aNSCLC After Failure of 2nd/3rd-Generation ALK TKIs</td>
<td>Elizabeth Dudnik, Israel</td>
</tr>
<tr>
<td>EP08.02-048</td>
<td>Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial</td>
<td>Federico Capuzzo, Italy</td>
</tr>
<tr>
<td>EP08.02-049</td>
<td>A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, in Patients With Advanced Solid Tumours With HER2 Aberrations</td>
<td>Frans Opdam, Netherlands</td>
</tr>
<tr>
<td>EP08.02-050</td>
<td>A Retrospective Study of Aumolertinib in Combination with Bevacizumab for EGFR-mutated NSCLC with the Presence of Leptomeningeal Metastasis</td>
<td>Shencun Fang, China</td>
</tr>
<tr>
<td>EP08.02-051</td>
<td>High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC</td>
<td>Yun Fan, China</td>
</tr>
<tr>
<td>EP08.02-052</td>
<td>Safety and Efficacy of Dabrafenib Plus Trametinib in Chinese Patients With BRAF V600E-Mutation Positive Metastatic NSCLC</td>
<td>Yun Fan, China</td>
</tr>
<tr>
<td>EP08.02-053</td>
<td>Non-small Cell Lung Cancer withMETExon14 Skipping Mutation: Literature Review of Real-World Evidence Data</td>
<td>Fernanda Estevinho, Portugal</td>
</tr>
<tr>
<td>EP08.02-054</td>
<td>Efficacy and Safety of TKI Dose Reduction - Can Less Mean More?</td>
<td>Fernanda Pereira Da Silva, Portugal</td>
</tr>
<tr>
<td>EP08.02-055</td>
<td>Targeting Lung Adenocarcinoma Cells with a Novel Disulfide Reductase Inhibitor</td>
<td>Fraser Johnson, Canada</td>
</tr>
<tr>
<td>EP08.02-056</td>
<td>Coexisting MET Exon 14 Skipping Mutation and MET Amplification in a Patient with Complete Response to MET Inhibitors</td>
<td>Flávia Duarte, Brazil</td>
</tr>
<tr>
<td>EP08.02-057</td>
<td>Mechanism of Resistance to Second-Line Aumolertinib and Therapeutic Regime after Resistance</td>
<td>Lingxin Feng, China</td>
</tr>
<tr>
<td>EP08.02-058</td>
<td>A Case Series of Patients With Kras KRAS G12C Mutation Treated With Sotorasib - Croatian Experience</td>
<td>Fran Seiwerth, Slovenia</td>
</tr>
<tr>
<td>EP08.02-059</td>
<td>EGFR Tyrosine Kinase Inhibitors and Combination Strategies in First-line Treatment of Advanced NSCLC: A Network Meta-analysis</td>
<td>Gilberto de Castro, Brazil</td>
</tr>
<tr>
<td>EP08.02-060</td>
<td>How Do Oncologists Treat Patients With EGFR Exon-20 Mutant NSCLC Outside of Clinical Trials? Updated Analysis From the European EXOTIC Registry</td>
<td>Giannis Mountzios, Greece</td>
</tr>
<tr>
<td>EP08.02-061</td>
<td>Treatment Sequences in ALK-rearranged Non-small Cell Lung Cancer; What Happens in the Real World?</td>
<td>Grace Chazan, Australia</td>
</tr>
<tr>
<td>EP08.02-062</td>
<td>Evaluation of In Silico Tools to Determine Potential Actionability of Missense Variants with Experimental Therapies for NSCLC</td>
<td>Lena Chae, United States</td>
</tr>
<tr>
<td>EP08.02-063</td>
<td>SANNO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC</td>
<td>Qing Zhou, China</td>
</tr>
<tr>
<td>EP08.02-064</td>
<td>ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)</td>
<td>Qing Zhou, China</td>
</tr>
<tr>
<td>EP08.02-065</td>
<td>Response to Systemic Anti-Cancer Therapy in Uncommon EGFR Mutations</td>
<td>Hazel O’Sullivan, United Kingdom</td>
</tr>
<tr>
<td>EP08.02-066</td>
<td>Real-World Data on the Side Effects of Alectinib, Brigatinib and Lorlatinib</td>
<td>Debra Montague, United Kingdom</td>
</tr>
<tr>
<td>EP08.02-067</td>
<td>Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases</td>
<td>Meijuan Huang, China</td>
</tr>
<tr>
<td>EP08.02-068</td>
<td>ALK-Dependent Resistance Mechanism to Ensartinib Differs Between the ALK Fusion Subtypes Variant 1 (V1) and Variant 3 (V3)</td>
<td>Jie Huang, China</td>
</tr>
<tr>
<td>EP08.02-069</td>
<td>A Retrospective Study of Aumolertinib Monotherapy or Combination Therapy Treated EGFR-mutated NSCLC Patients with Leptomeningeal Metastases</td>
<td>Siyuan Huang, China</td>
</tr>
<tr>
<td>EP08.02-070</td>
<td>High Incidence of Peridagnosis Thromboembolic Events In Patients with BRAF Mutant Lung Cancer</td>
<td>Inmaculada Aparicio Salcedo, Spain</td>
</tr>
</tbody>
</table>
EP08.02-071 Brain Metastases in EGFR-mutant NSCLC: Outcome of Osimertinib +/- Radiation Therapy in a Real-World Canadian Cohort
Ishjot Litt, Canada

EP08.02-072 The Predictive Value of Longitudinal Monitoring of Mutated EGFR in Plasma of Advanced NSCLC Patients on First-Line EGFR-TKIs
Joanna Chorostowska-Wynimko, Poland

EP08.02-073 Clinical and Genomic Analysis of Primary and Secondary MET Fusions with Intact Kinase Domain in Lung Cancer
Bo Jin, China

EP08.02-074 Impact of Germline BRCA1/2 Alterations on EGFR Mutant Advanced Non-small Cell Lung Cancer Outcomes
Jyoti Patel, United States

EP08.02-075 Maintained Complete Response for 8+ Years with Erlotinib Alone in Advanced Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion
Jens Sørensen, Denmark

EP08.02-076 Efficacy and Safety Evaluations of Anlotinib in Patients with Advanced Non-small Cell Lung Cancer Treated with Bevacizumab
Fenge Jiang, China

EP08.02-077 Two Phase III Trials of Aumolertinib Plus Chemotherapy for NSCLC with EGFR and Concomitant non-EGFR Driver Genes /Tumour Suppressor Genes
Jie Wang, China

EP08.02-078 Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy (TRACES)
Yan Li, China

EP08.02-079 The Use of Lung Adenocarcinoma Patient-Derived Xenografts and Organoids to Study GDP-KRAS G12C Inhibitor Resistance
Joshua Rosen, Canada

EP08.02-080 EGFR Testing Practices, Treatment Choice and Clinical Outcomes in Advanced NSCLC in a Real-World Setting
Janakiram Subramanian, United States

EP08.02-081 Cabozantinib Plus Atezolizumab in First or Second-Line Advanced NSCLC and Previously-Treated EGFR Mutant Advanced NSCLC
Joel Neal, United States

EP08.02-082 Treatment Patterns and Outcomes of First-line Osimertinib-treated Advanced EGFR Mutated NSCLC Patients: A Real-world Study
Jae Yun Lee, Canada

EP08.02-083 Real World Treatment and Outcomes in EGFR-mutated Advanced Non-small Cell Lung Cancer Patients: A Nationwide Cohort for 1,932 Thai Patients
Kakanan Tienchai, Thailand

EP08.02-084 Evaluation of Tumour Heterogeneity (TH) as a Prognostic Biomarker in Osimertinib treated Non-Small Cell Lung Cancer Patients
Karthikeyan Murugesan, United States

EP08.02-085 In vitro Activity and Potential Resistance Mutations Against BI-4020, a 4th-generation EGFR-TKI
Kenichi Suda, Japan

EP08.02-086 Randomized Double-blind Placebo-controlled trial of Nicotinamide and EGFR-TKIs for EGFR-mutated Lung Adenocarcinoma
Young-Chul Kim, South Korea

EP08.02-087 A 28-Years Old Pregnant Woman Diagnosed as ALK-Rearrangement Lung Adenocarcinoma With Multiple Brain Metastasis - Case Report
Simona Laštíkova, Slovakia

EP08.02-088 Mutational Status of KRAS, STK11 and CDKN2A Genes as Predictors of Response to Antiangiogenic Agents in Non-small Cell Lung Cancer Patients
Laura Gutiérrez Sainz, Spain

EP08.02-089 Toxicity of Sequential Tyrosine Kinase Inhibitors After Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer
Lauren Jones, Canada

EP08.02-090 Sotorasib Drug-Drug Interactions: Essential Guidance Requested by Physicians Worldwide
Leila-Sophie Otten, Netherlands

EP08.02-091 Disease Monitoring of EGFR-mutated NSCLC Patients Treated with TKIs via EGFR Status in Circulating ctDNA
Yan Li, China

EP08.02-092 Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib
Na Li, China

EP08.02-093 Loss of Tumour Endothelial QKI Expression Results in Pronounced Reductions in Metastasis and Remodeling of the Tumour Microenvironment
Lincy Edatt, United States

EP08.02-094 Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma (ARISE): A Multicenter, Open-Label, Single-Arm Trial
Gen Lin, China

EP08.02-095 Successful Treatment of EGFR Exon 19 Deletion with TP53 and ERBB2 20ins Mutation in Stage IVB NSCLC Patient with Aumolertinib
Chunling Liu, China

EP08.02-096 Different Epidermal Growth Factor Receptor Inhibitor Generations Plus Antiangiogenic for EGFR-Mutated NSCLC: A Meta-Analysis
Leen Al-Kraimeen, Jordan

EP08.02-097 Prevalence, Clinical Characteristics and Survival of Patients With Brain Metastases and KRAS Mutation Lung Cancer in Argentina
Luis Basbus, Argentina

EP08.02-098 Phase 2 EVOKE-02 Study of Sacituzumab Govitecan and Pembrolizumab±Platinum in First-Line Metastatic NSCLC
Martin Reck, Germany
**EP08.02-099** Liquid Biopsies as a Tool for Monitoring Patients with Metastatic ALK-positive NSCLC
Maiken Ulhøi, Denmark

**EP08.02-100** Combination of Bevacizumab and Continuation of EGFR-TKIs in NSCLC Patients beyond Gradual Progression
Ziyi Xu, China

**EP08.02-101** Real-world Data from KRAS-mutant Advanced NSCLC: the ATLAS Multicenter Cohort Study
Maristella Bungaro, Italy

**EP08.02-102** Feasibility and Clinical Utility of ctDNA for Detection of Sensitizing and Resistance EGFR Mutations in Patients with Non-small Cell Lung Cancer
Marta García de Herreros, Spain

**EP08.02-103** Lorlatinib for ALK+ NSCLC Patients: Pretreated with Second-generation ALK Inhibitors: Canadian Real-world Experience
Martin Rupp, Canada

**EP08.02-104** Osimertinib in Untreated EGFR-Mutant Non-small Cell Lung Cancers: Overall Survival and Budget Impact Analysis in Real-world
Martina Lorenzi, Italy

**EP08.02-105** KRAS p.G12 Mutated Advanced Non-small Cell Lung Cancer. Characteristics and Outcomes from a Danish Nationwide Observational Study
Matilde Frost, Denmark

**EP08.02-106** KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations
Matthias Scheffler, Germany

**EP08.02-107** Molecular Biomarker Testing and Initiation of Targeted Therapy in Minority Patients with Stage IV Non-small Cell Lung Cancer
Matthew Villanueva, PharmD, United States

**EP08.02-108** Osimertinib Long-Term Tolerability in Patients with EGFRm NSCLC Enrolled in the AURA Program or FLAURA Study
Marina Garassino, United States

**EP08.02-109** A Drug-Drug Interaction Study of Mobocertinib and Midazolam in Patients With Advanced Non-small Cell Lung Cancer
Michael Hanley, United States

**EP08.02-110** Plasma-based Molecular Profiling to Guide Treatment Decisions in Patients with Advanced NSCLC and Limited Tissue Biopsy
Miguel Garcia, Canada

**EP08.02-111** RMC-4630, a SHP2 Inhibitor, in Combination with Sotorasib for Advanced KRASG12C NSCLC After Failure of Prior Standard Therapies: A Phase 2 Trial
Melissa Johnson, United States

**EP08.02-112** Precision Treatment of Non-small Cell Lung Cancer Has a Profound Impact on Outcomes in a Canadian Province
Michelle Dean, Canada

**EP08.02-113** Clinico-genomic Characteristics of Patients with Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Masanobu Okahisa, Japan

**EP08.02-114** Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients
Moritz Glaser, Germany

**EP08.02-115** A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan
Motoho Tamiya, Japan

**EP08.02-116** Design of a Phase 1 Study of AMG 193, an MTA-Cooperative PRMT5 Inhibitor, in Patients with Advanced MTAP-Null Solid Tumours
Miguel Villalona Calero, United States

**EP08.02-117** Online CME Improves Clinicians’ Ability to Identify and Manage Patients with NSCLC and EGFR Exon 20 Insertion Mutations
Michelle Worst, United States

**EP08.02-118** TRUST-II: A Global Phase II Study for Taletrectinib in ROS1fusion Positive Lung Cancer and Other Solid Tumours
Nagasaka Misako, United States

**EP08.02-119** RNA Sequencing to Characterize Pathways in EGFR-mutated Non-Small Cell Lung Cancer
Nicole Yun, United States

**EP08.02-120** MET Alterations at Presentation in NSCLC Patients Harboring EGFR Mutations and ALK, RET and ROS1 fusions
Núria Jordana, Spain

**EP08.02-121** The Landscape of Anti-neoplastic Drugs for Malignant Pleural Effusion in Non-small Cell Lung Cancer: A Systematic Review of Clinical Trials
Obada Ababneh, Jordan

**EP08.02-122** Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP)
Oliver Illini, Austria

**EP08.02-123** First Line Osimertinib in Lung Cancer Patients with Postoperative Recurrence
Atsushi Osoegawa, Japan

**EP08.02-124** Lorlatinib Treatment Related Adverse Events: Single Centre Real-World Experience in ALK and ROS1-driven NSCLC
Parvin Begum, United Kingdom

**EP08.02-125** Tumour Suppressor Gene Alterations Identified at Disease Progression Impact Outcomes in Patients with EGFR-mutant Lung Cancer
Paul Stockhammer, United States

**EP08.02-126** The MOMENT Disease Registry of Patients with Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping
Petros Christopoulos, Germany
EP08.02-127 Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study
Bin-Chi Liao, Taiwan

EP08.02-128 Long Term Efficacy of SNK01 Plus Pembrolizumab for NSCLC: Expanded Observation from a Phase I/II A Randomized Controlled Trial
Hyungjun Park, South Korea

EP08.02-129 Closing the Gaps with Blood-Based Next Generation Sequencing
Pratik Shah, United States

EP08.02-130 Tegavivint Exhibits Antitumour Activity and Modulates Macrophage Phenotype in the Non-small Cell Lung Cancer Tumour Microenvironment
Raghad Chandra, United States

EP08.02-131 Alectinib after Crizotinib Failure in Patients with Advanced ALK-Positive NSCLC: Results from the Spanish Early Access Program
Reyes Bernabé-Caro, Spain

EP08.02-132 Fatal Interstitial lung disease induced by Osimertinib: a case report
Ricardo Cordeiro, Portugal

EP08.02-133 Sequential Afatinib to Osimertinib in EGFR-mutant NSCLC: A Prospective Observational Study, Gio-Tag Japan Interim Report
Ryo Morita, Japan

EP08.02-134 Real-world Efficacy of Dacomitinib in Patients with Previously EGFR-TKI Treated Non-small Cell Lung Cancer
Chien-Yeh Chi, Taiwan

EP08.02-135 Anti-EGF Antibodies Significantly Improve the Activity of MET and KRAS Inhibitors in Preclinical Models of Non-small Cell Lung Cancer (NSCLC)
Silvia García-Roman, Spain

EP08.02-136 Final Analysis of a Phase II Study: Alectinib Plus Docetaxel in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer
Juan Shen, China

EP08.02-137 Prospective Study of Aumolertinib in NSCLC Patients with EGFR Sensitive Mutations Who Are Intolerant to Osimertinib Treatment
Shun Lu, China

EP08.02-138 SAFFRON: Ph3 Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib
Shun Lu, China

EP08.02-139 A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs
Shun Lu, China

EP08.02-140 MET Biomarker-based Preliminary Efficacy Analysis in SAVANAH: savolitinib+ osimertinib in EGFRm NSCLC Post-Osimertinib
Myung-Ju Ahn, South Korea

EP08.02-141 ‘Our’ EGFR population - experience in a secondary center
Sofia Silva, Portugal

EP08.02-142 Effects of Afatinib on the Treatment and Prognosis of Brain Metastasis in Advanced EGFR Mutation (+) NSCLC
Sung Yong Lee, South Korea

EP08.02-143 Shortening of the Turn around time (TAT) in the Examination of Rapid On-Site cytologic Evaluation (ROSE) at transbronchial biopsy.
Yoshihiro Taguchi, Japan

EP08.02-144 The Impact of CNS Recurrence on Post-recurrence Survival in Patients with EGFR-mutation-positive Non-small-cell Lung Cancer
Tatsuro Okamoto, Japan

EP08.02-145 An Efficacy Analysis of Advanced Non Small Cell Lung Cancer With MET Exon 14 Skipping in the Real World
Fei Teng, China

EP08.02-146 Proposal of Foretinib as Second-Line TKI after Capmatinib/Tepotinib Treatment Failure in NSCLC with MET Exon 14 Mutation
Toshio Fujino, Japan

EP08.02-147 Clinical Outcomes in Patients with or without Cell Cycle Gene Alterations in EGFR mutated Non-Small Cell Lung Cancer
Turja Chakrabarti, United States

EP08.02-148 Extended Follow-up of Efficacy and Safety of Larotrectinib in Patients With TRK Fusion Lung Cancer
Victor Moreno, Spain

EP08.02-149 Spanish Multicenter Retrospective Study of Real-Life Experience of Advanced NSCLC with EGFR Exon 20 Insertions Treated With Amivantamab
Víctor Albarrán-Artahona, Spain

EP08.02-150 Molecular Heterogeneity of Compound Epidermal Growth Factor Receptor (EGFR) Mutations in Lung Adenocarcinoma (LAC)
Ramesh Bulusu, United Kingdom

EP08.02-151 A Real World Evidence of Lorlatinib for Taiwanese with advanced ALK Positive Non-Small Cell Lung Cancer
Wade Fang, Taiwan

EP08.02-152 Long-Term Survival With Anlotinib in a Patient With Advanced Undifferentiated Large-Cell Lung Cancer and Rare Tonsillar Metastasis
Zhaoxia Wang, China

EP08.02-153 The Efficacy and Safety of EGFR-TKIs plus Anlotinib in Maintenance Therapy for Oligoprogressive Advanced or Metastatic EGFR Mutant NSCLC
Zhaoxia Wang, China

EP08.02-154 Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II Trial
Hualin Chen, China

EP08.02-155 The Difference in Clinical Outcomes Between Osimertinib and EGFR-TKI plus Anti-angiogenic Agent in EGFR-mutant NSCLC Patients
Yen Hsiang Huang, Taiwan
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP08.02-156</td>
<td>Real-World Treatment Patterns and Impact of Comorbidity Burden on Treatment Duration for Patients with ALK+ NSCLC in the US</td>
<td>Yin Wan, United States</td>
</tr>
<tr>
<td>EP08.02-157</td>
<td>Acquired EGFR Exon 19 Deletion Is a Resistance Mechanism to BRAF/ MRK Inhibition in BRAF V600Emutant NSCLC</td>
<td>Fang Wu, China</td>
</tr>
<tr>
<td>EP08.02-158</td>
<td>Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-negative NSCLC</td>
<td>Lin Wu, China</td>
</tr>
<tr>
<td>EP08.02-159</td>
<td>Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study</td>
<td>Lin Wu, China</td>
</tr>
<tr>
<td>EP08.02-160</td>
<td>A Pooled Efficacy and Safety Analysis of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Immunotherapy</td>
<td>Lin Wu, China</td>
</tr>
<tr>
<td>EP08.02-161</td>
<td>An Exploratory Study on Biomarkers Related to Primary Resistance Of EGFR-TKIs Therapy in Lung Cancer</td>
<td>Lin Wu, China</td>
</tr>
<tr>
<td>EP08.02-162</td>
<td>Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series</td>
<td>Xiuning Le, China</td>
</tr>
<tr>
<td>EP08.02-163</td>
<td>Real-World Case Series on Efficacy and Safety of Amivantamab for EGFR-mutant Non-small Cell Lung Cancer</td>
<td>Xiuning Le, China</td>
</tr>
<tr>
<td>EP08.02-164</td>
<td>The Effect of Metformin on Survival Outcomes of Advanced-egfr-mutant NSCLC Patients Treated with EGFR TKIs in Thailand</td>
<td>Siriwimon Saichaemchan, Thailand</td>
</tr>
<tr>
<td>EP08.02-165</td>
<td>Small Cell Transformation After Lorlatinib ALK Resistance - A Case Report with Clonal Evolution</td>
<td>Xiaoling Xu, China</td>
</tr>
<tr>
<td>EP08.02-166</td>
<td>Brain Metastases in Patients with ALK-rearranged or ROSI-fusion Non-small-Cell Lung Cancers in China</td>
<td>Shaoyu Yang, China</td>
</tr>
<tr>
<td>EP08.02-167</td>
<td>Diverse Effects of Radiotherapy for Osimertinib Acquired Resistance Non-small Cell Lung Cancer: Gene Matters</td>
<td>Yasi Xu, China</td>
</tr>
<tr>
<td>EP08.02-168</td>
<td>Efficacy, Safety and Treatment Courses for Patients with ALK Oncogene Positive NSCLC; Retrospective Data in Single Institute</td>
<td>Yuki Akazawa, Japan</td>
</tr>
<tr>
<td>EP08.02-169</td>
<td>Research of Aumolertinib Combined with Bevacizumab for Advanced NSCLC Lung Cancer with EGFR Sensitive Mutation</td>
<td>Dian Sheng Zhong, China</td>
</tr>
<tr>
<td>EP08.02-171</td>
<td>PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)</td>
<td>Maria García Campelo, Spain</td>
</tr>
<tr>
<td>EP08.02-172</td>
<td>Effect of EGFR Inhibition on Bone Health in NSCLC Patients without Skeletal Metastasis</td>
<td>Marcella Mandruzzato, Italy</td>
</tr>
<tr>
<td>EP08.03</td>
<td>Track: Metastatic Non-small Cell Lung Cancer - Oligometastatic Disease</td>
<td></td>
</tr>
<tr>
<td>EP08.03-001</td>
<td>A Clinical Study on the Safety and Efficacy of Aumolertinib Combined with SBRT in the EGFR-mutant NSCLC with Brain Parenchymal Oligometastases</td>
<td>Chunyu He, China</td>
</tr>
<tr>
<td>EP08.03-002</td>
<td>Local Ablative Therapy in Oligoprogressive NSCLC - Results from a Tertiary Cancer Center of India</td>
<td>Anil Tibdewal, India</td>
</tr>
<tr>
<td>EP08.03-003</td>
<td>Surgery for Primary Tumour is Associated with Prolonged Overall Survival in Patients with Oligometastatic NSCLC</td>
<td>Jose Corona-Cruz, Mexico</td>
</tr>
<tr>
<td>EP08.03-004</td>
<td>Outcomes of Oligometastatic Non-Small Cell Lung Cancer Patients Undergoing Surgical Resection: A Single Center Experience</td>
<td>Fulden Gorguner, Turkey</td>
</tr>
<tr>
<td>EP08.03-005</td>
<td>HALT - Targeted Therapy with or without Dose-Intensified Radiotherapy in Oligo-Progressive Disease in Oncogene Addicted Lung Tumours</td>
<td>Fiona Mcdonald, United Kingdom</td>
</tr>
<tr>
<td>EP08.03-006</td>
<td>Survival After Radical Treatment of Oligometastatic Non-small Cell Lung Cancer: A Multicenter Analysis</td>
<td>Isabelle Opitz, Switzerland</td>
</tr>
<tr>
<td>EP08.03-007</td>
<td>Spontaneous Regression in Metastatic Non-small Cell Lung Cancer: A Case Report</td>
<td>Maria La Mantia, Italy</td>
</tr>
<tr>
<td>EP08.03-008</td>
<td>Whether Immunotherapy Should Be Maintained or Not After Acquired Resistance in Advanced Nsclc</td>
<td>Shun Lu, China</td>
</tr>
<tr>
<td>EP08.04</td>
<td>Track: Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy</td>
<td></td>
</tr>
<tr>
<td>EP08.04-001</td>
<td>Weekly versus 3-Weekly Regimens of Carboplatin and Paclitaxel in Metastatic NSCLC: A Real-World Data</td>
<td>Barliz Waissengrin, Israel</td>
</tr>
<tr>
<td>EP08.04-002</td>
<td>Australian Vinorelbine Use in Advanced Lung cancer (The AVAL Study)</td>
<td>Ben Markman, Australia</td>
</tr>
<tr>
<td>EP08.04-003</td>
<td>A Simple Clinical Prediction Score to Determine Response to First Line Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients</td>
<td>Chawalit Chayangsu, Thailand</td>
</tr>
<tr>
<td>EP08.04-004</td>
<td>Impact of Comorbidity Scores on Overall Survival in Advanced Non-Small Cell Lung Cancer Patients - A Real-World Experience from Eastern India</td>
<td>Srikanth Mamidi, India</td>
</tr>
<tr>
<td>EP08.04-005</td>
<td>Phase II Study of Ramucirumab and Docetaxel for NSCLC Patients with Malignant Pleural Effusion</td>
<td>Shinnosuke Takemoto, Japan</td>
</tr>
<tr>
<td>EP08.04-006</td>
<td>Risk Factors of Chemotherapy-Induced Severe Neutropenia in Elderly Lung Cancer: Data From a Regional Hospital in Thailand</td>
<td>Sunee Neesanun, Thailand</td>
</tr>
</tbody>
</table>

**EP08.05**

**Track: Metastatic Non-small Cell Lung Cancer - Palliative Radiotherapy**

| EP08.05-001 | Evaluation of Pneumonitis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Receiving Osimertinib and Thoracic Radiation | David Mak, Canada |
| EP08.05-002 | Sequencing of T cell Receptor Revealed Radiotherapeutic Efficacy and Prognosis in Non-small Cell Lung Cancer Patients with Brain Metastasis | Xiaorong Dong, China |
| EP08.05-003 | Evaluation of Dose Changes in Different Periods after 125I Seed Implantation in Lung Cancer | Haihua Yang, China |
| EP08.05-004 | The Optimal Intervention Timing of Hypofractionated Stereotactic Radiotherapy for EGFR Mutated NSCLC Patients with Limited Brain Metastases | Lin Zhou, China |

**EP09.01**

**Track: Nursing and Allied Health Professionals**

| EP09.01-001 | International Collaboration for Thoracic Oncology Education | Beth Sandy, United States |
| EP09.01-002 | Patient with Immune-associated Dermatomyositis Caused by Advanced NSCLC Treated with ICIs | Yuanyong Wang, China |

**EP10.01**

**Track: Palliative and Supportive Care**

| EP10.01-001 | Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Lung Cancer: Dose-Response Effect and Toxicity | Kaicheng Pan, China |
| EP10.01-002 | The Effect of Group Rehabilitation Training in the Ward on the Psychological Status and Quality of Life of Lung Cancer Patients | Li Li, China |
| EP10.01-003 | Non-Small Cell Lung Cancer Treatment Preferences Among EGFR Mutation Patients and Physicians in Japan | Akira Inoue, Japan |
| EP10.01-004 | Perspectives of Patients with Metastatic Lung Cancer on Symptom Screening and Patient-Reported Symptom Trajectory Data | Amir H. Safavi, Canada |
| EP10.01-005 | Australian Lung Cancer Survivors Experiences of Novel Treatments, Healthcare, and Ongoing Physical and Psychological Needs | Bea Brown, Australia |
| EP10.01-006 | Differences In Toxicity Among Platinum-Based Combinations As Reported By Non-Small Cell Lung Cancer (NSCLC) Patients | Christie Lagogianni, United Kingdom |
| EP10.01-007 | Real World Data Comparing Lung Cancer Side-Effects Between Past/Current Smokers And Never Smokers | Christie Lagogianni, United Kingdom |
| EP10.01-008 | Examining Social Determinants of Health Among Newly Diagnosed Lung Cancer Patients Contacted for Early Specialist Palliative Care Consultation | Desiree Hao, Canada |
| EP10.01-009 | The Impact of the COVID-19 Pandemic on Palliative Care for Cancer: A Preliminary Cross-Country Survey of Clinical Oncologists | Yu Wang, China |
| EP10.01-010 | Real-world Study of the Incidence and Risk Factors of Venous Thromboembolism in Chinese Lung Cancer (RIVAL) | Zhen Wang, China |
| EP10.01-011 | Prognostic Impact of Body Composition Phenotypes in Non-small Cell Lung Cancer Patients Receiving First-Line Pembrolizumab | Ilaria Trestini, Italy |
| EP10.01-012 | Geriatric Assessment in Patients Undergoing Lung Cancer Surgery and Their Family Caregivers | Jae Kim, United States |
| EP10.01-013 | Erector Spinae Plane Block for Post-thoracotomy Analgesia; Comparison with Intercostal Block; Preliminary Results | Kubra Alphan Kavak, Turkey |
| EP10.01-014 | A Multidisciplinary Team to Manage Patients with Lung Cancer and Opioid Use Disorder | Lawrence Feldman, Md, United States |
| EP10.01-015 | The Role of CT-Scan as a Body Composition Tool in Oncogene-Addicted Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients. | Maristella Bungaro, Italy |
| EP10.01-016 | Cachexia’s Impact on Immunotherapy  
Dose Reduction, Treatment Discontinuation, and Survival: a Systematic Review  
Richard Skipworth, United Kingdom |
| EP10.01-017 | Use of Lalaby in Lung Cancer Patients to Trace Performance from Phone Sensors and Reported Outcomes Involving Quality of Life  
Teresa Soria-Comes, Spain |
| EP10.01-018 | Thromboprophylaxis for Lung Cancer Patients: Results From ACT4CAT Trial  
Nikolaos Tsoukalas, Greece |
| EP10.01-019 | Rowing Against Cancer: From a Support Project to a Research Program. Perspectives and Challenges of Rowing in Metastatic Lung Cancer Patients  
Veronica Franchina, Italy |
| EP10.01-020 | Nutrition assessment for With Common Cancer Patients in a Cancer Hospital of China  
Mengting Chen, China |
| EP11.01-001 | Training Increases Concordance in Classifying Pulmonary Adenocarcinomas According to the Novel IASLC Grading System  
Jiani Gao, China |
| EP11.01-002 | Malignant Pleural Effusion Cell Blocks Are Reliable Resources for PD-L1 Analysis in Advanced Lung Adenocarcinomas  
Aruna Nambirajan, India |
| EP11.01-003 | Advanced Non Small Cell Lung Cancer With EGFR Exon 20 Insertion Gene Mutation  
Nguyen Lam, Viet Nam |
| EP11.01-004 | An Effective Two-step Reflex Test for 10 Biomarkers Analysis in Non-small Cell Lung Cancer  
Giachino Pelizzari, Italy |
| EP11.01-005 | Ultra-Fast Gene Fusion Assessment as a Reflex Testing in Daily Clinical Practice for Advanced Non-small Cell Lung Cancer Patients  
Paul Hofman, France |
| EP11.01-006 | Setting Up an Ultra-Fast Next-Generation Sequencing Approach as a Reflex Testing at Diagnosis in Non-squamous Non-small Cell Lung Cancer  
Paul Hofman, France |
| EP11.01-007 | Tracking ROS1 Fusions in NSCLC - Mirage or Truth When Screening the Desert  
Johanna Mattsson, Sweden |
| EP11.01-008 | Discrepancy in MET Exon 14 Skipping Mutation Measurement Between ArcherMET and Oncomine Dx Target Test System  
Kanako Shinada, Japan |
| EP11.01-009 | Amplicon-Based Next-Generation Sequencing Rescues “Quantity Not Sufficient” NSCLC Samples and Provides Clinical Information  
Matthew Beer, United States |
| EP11.01-010 | A Prospective Validation Study of Lung Cancer Gene Panel Testing Using Cytological Specimens  
Kei Morikawa, Japan |
| EP11.01-011 | Clinical Application of Liquid Biopsy for Assessing Early EGFR Mutation Detection in Non-Small Cell Lung Carcinoma  
Amber Rathor, India |
| EP11.01-012 | Genomic Landscape of Liquid Biopsy in Advanced Lung Cancer Patients, an Indian Experience  
Shivani Sharma, India |
| EP11.01-013 | Genomic Landscape of Pulmonary Sarcomatoid Carcinoma  
Hyun Jung Kwon, South Korea |
| EP11.01-014 | Optimizing Targetable Gene Screening by Sequential Multi-platform Detection Applied to Driver-negative mNSCLC Patients Detected by DNA-NGS  
Yaxi Wang, China |

**EP11.02**

**Track: Pathology - New Technology**

| EP11.02-001 | Natural Language Processing to Abstract Preneoplastic and Incidental Pulmonary Lesions from Pathology Reports  
Jessica Petricca, Canada |
| EP11.02-002 | A Comparative Study of PD-L1 Scoring: Humans versus AI  
Luka Brcic, Austria |

**EP11.03**

**Track: Pathology - Tumour Biology**

| EP11.03-001 | Loss of SUSD2 Expression in Lung Adenocarcinoma Correlates with Solid Pattern, Higher Histological Grading and Higher Ki-67 Cycling Index  
Hangjun Wang, Canada |
| EP11.03-002 | Prognostic Significance of YAP1 and Its Association with Neuro-endocrine Markers in Pulmonary Large Cell Neuro-endocrine Carcinoma (LCNEC)  
Xu Jie Sun, China |
| EP11.03-003 | Adenocarcinoma Grade Correlates with PD-L1 and TP53, but not EGFR/KRAS Status and Diagnostic Yield: Analysis of 346 Cases  
Yu Zhi Zhang, United Kingdom |
| EP11.03-004 | Identification of Filigree Pattern Increases Diagnostic Accuracy of Micropapillary Pattern on Frozen Section for Lung Adenocarcinoma  
Shengnan Zhao, China |

**EP11.04**

**Track: Pathology - Tumour Diagnostics**

| EP11.04-001 | Cytokeratin 5-Positive Pulmonary Adenocarcinoma: A Study with Resected Specimens  
Akihiko Yoshizawa, Japan |
EP11.04-002 The Histopathological Reasons for Better Survival of Patients with Lepidic Pattern Dominant Adenocarcinoma
Ismail Sarbay, Turkey

EP12.01
Track: Patient Advocacy
EP12.01-001 What Do Patients Want - a European Study Into ALK-Positive Patients Perspectives
Jamie Gibbard, United Kingdom

EP13.01
Track: Pulmonology, Radiology, and Staging
EP13.01-001 The Burden of Incidental Extra-thoracic Positron Emission Tomography-CT (PET-CT) Findings in Thoracic Malignancies
Dana Li, United Kingdom
EP13.01-002 Radiomic Signature on CT Images: A Noninvasive Biomarker for Pretreatment Discrimination of EGFR Mutations in NSCLC Patients
Yusuf Kahya, Turkey
EP13.01-003 Diagnostic Yield of Radial Probe Endobronchial Ultrasonography without Fluoroscopic guidance in Peripheral Pulmonary Lesions
Joonhee Han, South Korea
EP13.01-004 Accuracy of Clinical Stage in Resectable Non-small Cell Lung Cancer (NSCLC)
Hye Ran Gwon, South Korea
EP13.01-005 Role of Artificial Intelligence on Chest Radiographs for Detecting Resectable Early Lung Cancer
Eunhye Lee, South Korea
EP13.01-006 Safety of Image Guided Research Biopsies in Patients with Thoracic Malignancies
Jia Luo, United States
EP13.01-007 Differentiation between heterogeneous GGNs and part solid nodules using histogram on thin-section CT.
Hirofumi Koike, Japan
Yeon Wook Kim, South Korea
EP13.01-009 A Modified T Categorization for Pathological Stage I Lung Adenocarcinoma with Lepidic Component in Chinese Population
Shenghui Li, China
EP13.01-010 Effect of Perioperative Respiratory Muscle Training with Gamification for Lung Cancer
Masao Saito, Japan
EP13.01-011 Combining Automated Malignancy Risk Estimation with Lung Nodule Detection May Reduce Physician Effort and Increase Diagnostic Accuracy
Michael Calhoun, United States
EP13.01-012 Exploring Factors Affecting Variability in Lung Cancer Outcomes Across Southeastern Ontario, Canada
Shahad Alghamdi, Canada

EP13.01-013 Determination of the Timing of Bevacizumab Administration in Osimertinib and Bevacizumab Combination Therapy
Fei Teng, China
EP13.01-014 Evaluation of Malignancy and Survival in Patients Operated With a Preliminary Diagnosis of Interstitial Lung Disease
Tiffany Ergin, Turkey
EP13.01-015 Correlation Between CT Signs and Ki67 Expression in Non-small Cell Lung Cancer
Yuanyong Wang, China
EP13.01-016 Are Follow-up Tests Useful in NSCLC? Experience of a Tertiary Hospital
Yago Garitaonaindia Díaz, Spain
EP13.01-017 Assessing Variance Between Radiology versus Multidisciplinary Clinic Recommendations in the Pulmonary Nodule and Lung Screening Clinic
Inga Lennes, United States

EP14.01
Track: Small Cell Lung Cancer and Neuro-endocrine Tumours - Informing ES-SCLC
EP14.01-001 SCLC Transformation from ALK-rearranged Lung Adenocarcinoma after Alectinib Resistance and Response to Atezolizumab: Case Report
Guohao Xia, China
EP14.01-002 Efficacy and Safety of Tiselizumab Combined with Anlotinib and 2-cycle Irinotecan as Second-line Treatment of Small Cell Lung Cancer
Xian Chen, China
EP14.01-003 Parotid Metastases from Primary Lung Cancer: Case Series and Systematic Review on the Clinical Features
Xian Chen, China
EP14.01-005 Weekly Sequential ACOCEV Chemotherapy (ADR, CTX, CBDCA, VP16, VCR) for Elderly - Poor PS SCLC Patients: An Observational Study
Antonio Santo, Italy
EP14.01-006 CeLEBrATE: Phase II trial of Carboplatin, Etoposide, Bevacizumab and Atezolizumab in Patients with extensive-Stage SCLC-GOIRC-01-2019
Giuseppe Lamberti, Italy
EP14.01-007 Next-Generation Sequencing to Dynamically Detect Mechanisms of Resistance to ALK Inhibitors in ALK-positive SCLC Patient: A Case Report
Renhong Guo, China
EP14.01-008 Checkpoint Inhibitors Prevent New Onset of Brain Metastases in Relapsed Extensive Disease Small-Cell Lung Cancer
Jan Stratmann, Germany
EP14.01-009 A Comparative Study of Histological Predictors of Outcome in Patients with Lung Typical and Atypical Carcinoids
Joana Rei, Portugal
EP14.01-010 CAN: A Phase II Trial of Combination of Niraparib and Anlotinib in Patients with Recurrent Small Cell Lung Cancer
Ying Cheng, China

Lovorka Batelja Vuletic, Croatia

EP14.01-012 A Case Report of Lung Large Cell Neuro-endocrine Carcinoma with Carcinoid Morphology
Lovorka Batelja Vuletic, Croatia

EP14.01-013 First-Line Chemotherapy vs Chemoimmunotherapy in Stage IV Large Cell Neuro-endocrine Carcinoma of the Lung, a Retrospective Study
Lingbin Meng, United States

EP14.01-014 Risk Factors for Brain Metastasis in Patients with Small Cell Lung Cancer: A Systematic Review and Meta-analysis
Lizza Hendriks, Netherlands

EP14.01-015 IMforte: A Phase III Study of Lurbinectedin and Atezolizumab Versus Atezolizumab as Maintenance Therapy in ES-SCLC
Luis Paz-Ares, Spain

EP14.01-016 Anlotinib Plus Toripalimab as Maintenance Treatment in Extensive-Stage Small Cell Lung Cancer: a Single-Arm Phase II Study
Dongqing Lv, China

EP14.01-018 Small Cell Lung Carcinoma in Morocco
Ouassima Erefai, Morocco

EP14.01-019 Identifying Circulating DNA Methylation Patterns in Small Cell Lung Cancer Patients
Sami Ul Haq, Canada

EP14.01-020 Trial in Progress: [177Lu]Lu-DOTA-TATE Combination Treatment in Treatment-Naïve Extensive Stage Small Cell Lung Cancer
Stephen Liu, United States

EP14.01-021 Anlotinib Plus Irinotecan or Docetaxel in Small-Cell Lung Cancer (SCLC) Relapsed within Six Months: a Single-Arm Phase II Study
Bing Xia, China

EP14.01-022 Immune Thrombocytopenia in a Patient with Large Cell Neuro-endocrine Carcinoma Under Dual Immune Checkpoint Inhibition
Ioannis Gkiozos, Greece

EP14.01-023 A Randomized Phase II Study of Irinotecan Plus Cisplatin With or Without Simvastatin in Ever-Smoking Small Cell Lung Cancer
Youngjoo Lee, South Korea

EP14.01-024 Transformation of SCLC to Lung Squamous Cell Carcinoma after First-Line Chemotherapy and Response to Sintilimab: A Case Report
Zhiseng Liu, China

EP14.01-025 Anlotinib Plus Standard Chemotherapy as First-line Treatment in Extensive-Stage Small Cell Lung Cancer Patients
Wei Zhang, China

EP14.02 Track: Small Cell Lung Cancer and Neuro-endocrine Tumours - Preclinical/Translational

EP14.02-001 Could the Oxidative Stress Be Used as a Marker for Neuro-endocrine Lung Tumours?
Luigi Andriolo, Italy

EP14.02-002 Cisplatin in Combination with Entinostat exerts Synergistic Antineoplastic Activity in Small Cell Lung Cancer
Anna Schwendenwein, Austria

EP14.02-003 Clinical Significance of MYC Family Members in Surgically Resected Limited-Stage Small Cell Lung Cancer: A Multicenter Study
Christian Lang, Austria

EP14.02-004 Barasertib Inhibits the Growth of SCLC Cell Lines and Transformed SCLC Patient Derived Model In Vitro and In Vivo
Jin Soo Kim, South Korea

EP14.02-005 Therapeutic targeting Mevalonate-Geranylgeranyl Diphosphate Pathway with Statins Overcomes Chemotherapy-resistance in SCLC
Chenchen Guo, China

EP14.02-006 Subtype-specific Hypersensitivity to Oxidative Phosphorylation Inhibition in Small Cell Lung Cancer
Kristiina Boettiger, Austria

EP14.02-007 Hes1 Protein Expression and Its Significance in Resected Small Cell Lung Cancers
Xujie Sun, China

EP14.03 Track: Small Cell Lung Cancer and Neuro-endocrine Tumours - RT

EP14.03-001 DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive Stage Small Cell Lung Cancer
Aditya Juloori, United States

EP14.03-002 Low-Dose Radiotherapy Plus Sugemalimab in Second-Line Treatment for Advanced-Stage Small-Cell Lung Cancer: Initial Results of a Phase I Study
Youling Gong, China

EP14.03-003 Phase I Study of Palliative Radiotherapy with Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer
Neal Mccall, United States

EP14.03-004 Neuro-cognitive Effect of HS-PCI in LS-SCLC
Suryakanta Acharya, India

EP14.03-005 Role of Radiotherapy Fraction in Limited-Stage SCLC: a Meta-Analysis of 8585 Reconstructed Individual Patient Data
Jingjing Zhao, China
WCLC 2022 | ePOSTERS

EP14.04
Track: Small Cell Lung Cancer and Neuro-endocrine Tumours - RW

EP14.04-001 Treatment and Outcomes of Patients with Limited-Stage Small-cell Lung Cancer in the Canadian SCLC Database (CASCADE)
Sara Moore, Canada

EP14.04-002 The Impact of Response on Survival in Extensive-Stage Small-Cell Lung Cancer in the CASPIAN Study
Sukhvinder Johal, United Kingdom

EP14.05
Track: Small Cell Lung Cancer and Neuro-endocrine Tumours - RW/SOC

EP14.05-001 Chemoimmunotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer and ECOG Performance Status of 2 or 3
Muskan Agarwal, United States

EP14.05-002 Impact of Body Mass Index on Survival in Patients with Small Cell Lung Cancer
Alejandro Rios-Hoyo, Spain

EP14.05-003 Recent Stage Shifts and Changes in the Treatment of Stage I Small Cell Lung Cancer in the United States
Chinmay Haridas, India

EP14.05-004 Temozolomide and Atezolizumab as Second Line Treatment for Extensive Stage Small Cell Lung Cancer: A Randomized, Multi-Cohort Phase 2 Trial
Dwight Owen, United States

EP14.05-005 Survival of Small Cell Lung Cancer in Relation to Chemotherapy Dose Intensity
Elisa Fernández Pérez, Spain

Philip Haddad, United States

EP14.05-007 A Study of the Best Reduction in Target Lesion Size and Treatment Duration in the Durvalumab plus Platinum-Etoposide Regimen for ES-SCLC
Kageaki Watanabe, Japan

EP14.05-008 Development of a Prognostic Model for High-Grade Neuro-endocrine Carcinoma of the Lung Using Next-Generation Sequencing
Hye Sook Kim, South Korea

Niels Reinmuth, Germany

EP14.05-010 Real-World Eligibility for Clinical Trials in Extensive Stage Small Cell Lung Cancer Patients
Navdeep Dehar, Canada

EP14.05-011 Real-World Impact of Platinum Sensitivity and Disease Stage on Survival Among Medicare Patients with Small Cell Lung Cancer
Paul Cockrum, United States

EP14.05-012 Comparing Costs for Medicare FFS Patients Treated with Etoposide or Irinotecan for Extensive Stage Small Cell Lung Cancer
Paul Cockrum, United States

Paul Cockrum, United States

Paul Cockrum, United States

EP14.05-015 Quantifying Recent Trends in Real-World Treatment Patterns Among Adults Diagnosed with Small Cell Lung Cancer in the U.S. from 2013-2021
Paul Cockrum, United States

Rob Stirling, Australia

EP14.05-017 Real World Eligibility of Immune Checkpoint Inhibitors with Platinum-Doublet in Extensive Stage Small Cell Lung Cancer
Rebekah Rittberg, Canada

EP14.05-018 Major Lung Resection for Carcinoid Tumour; Does It Affect Quality of Life?
Riad Abdeljalil, Jordan

Robert Ramirez, United States

EP14.05-020 Population-based Outcomes for Patients with Extensive-Stage Small-cell Lung Cancer from the Canadian SCLC Database (CASCADE)
Sara Moore, Canada

EP14.05-021 Promising Long-Term Survival after Surgical Resection of Early Stage Small Cell Lung Cancer in a Modern Single-Center Cohort
Sora Ely, United States

EP14.05-022 The Drug Induced Interstitial Lung Disease in Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer
Rei Takamiya, Japan

EP14.05-023 Characterization of Real-World Use of Lurbinectedin in Adult Small Cell Lung Cancer Patients in the United States
Xue Wang, United States

Rob Stirling, Australia

EP15.01
Track: Tobacco Control and Risk Reduction

EP15.01-001 Ask, Advise, Help (AAH) Smoking Cessation Brief Advice Delivery in Patients with Diagnosed Lung Cancer: A Retrospective Audit
John Lau, Australia
EP15.01-002 Lowering Rates of Smoking after Cancer Diagnosis: Use Social Networks
Melissa Neumann, United States

EP16.01-001 Transforming Growth Factor-inhibits Interferon-mediated Immune Resistance in Lung Cancer
Ye Fan, China

EP16.01-002 T Cell Receptor Diversity among Non-Small Cell Lung Cancer Patients Treated with Pembrolizumab Alone or in Combination with Chemotherapy.
Afaf Abed, Australia

EP16.01-003 The Dynamic Immune Signature of Patients with Advanced Non-small Cell Lung Cancer in Prediction of Infection After Receiving Immunotherapy
Chia-I Shen, Taiwan

EP16.01-004 Pleural Mesotheliomas Related with Geographical Asbestos Exposure Show Higher PD-L1 Expression
Yusuf Kahya, Turkey

EP16.01-005 Cilia-related mRNA Profile Predicts Clinical Response to PD-1 Blockade in Lung Adenocarcinoma
Guanghui Gao, China

EP16.01-006 CD47 Inhibition Impairs the Growth of Orthotopic, Immune Competent Lung Tumour Models
Kelsie Thu, Canada

EP16.01-007 Molecular Characterization by Next-Generation Sequencing (NGS) of Patients with Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy
Laura Gutiérrez Sainz, Spain

EP16.01-008 The Effect of Cytochrome P450 Family 4 Subfamily B Member 1 (CYP4B1) on Lung Adenocarcinoma (LUAD) Immune Microenvironment
Leen Al-Kraimeen, Jordan

Tong Lu, China

EP16.01-010 PD-L1 Expression on Cytological Imprints and Circulating Tumour Cells versus Standardized Immunohistochemistry in NSCLC
Martin Reck, Germany

EP16.01-011 Immunophenotyping of Lung Adenocarcinoma in situ Based on CD8-positive T Cell Infiltration
Yu Ma, China

EP16.01-012 The Diagnostic Accuracy of Tumour Mutational Burden in Advanced NSCLC: An Individual Patient Data Meta-Analysis
Maria La Mantia, Italy

EP16.01-013 Characterisation of Circulating Immune Cells in a Cohort of Non-small Cell Lung Cancer Patients Treated with Immunotherapy
Marta Gascón-Ruiz, Spain

EP16.01-014 Introducing “BiomeOne” a Microbiome-based bBiomarker to Predict Immune Checkpoint Inhibitor Response in NSCLC Ipatients
Maximilian Hochmair, Austria

EP16.01-015 Tumour Treating Fields (TTFields) Application Promotes a Pro-inflammatory Phenotype in Macrophages
Moshe Giladi, Israel

EP16.01-016 T-cell Repertoire Heterogeneity and Homogeneity in Synonymous Multiple Primary Lung Cancers
Naixin Liang, China

EP16.01-017 SAKK 16/14 -Peripheral Immune Cell Populations Inresponse to Neoadjuvant Durvalumab in Patients with Stage IIIA(N2) NSCLC
Sacha Rothschild, Switzerland

EP16.01-018 The Role of the Pregnancy Associated Protein Glycodelin and Its Influence on the Immune System in Non-small-Cell Lung Cancer
Sarah Richtmann, Germany

EP16.01-019 Predictive Effect of Spatial Protein Signature in Advanced NSCLC Receiving Immunotherapy with a Bispecific Antibody
Xinyu Song, China

EP16.01-020 Less Immune Cell Infiltration and Worse Prognosis for NSCLC Patients with XPO1 Copy Number Alterations
Xuanzong Li, China

EP16.01-021 A Signature of B Cells-Related Gene Pairs Predicts Oncologic Outcomes and Response to Immunotherapy in NSCLC Patients
Xuanzong Li, China

EP16.01-022 Comprehensive Analysis of a Dendritic Cell Marker Genes Signature to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma
Yuan Li, China

EP16.01-023 Differential Efficacy of Combined GITR Co-stimulation with PD-1 Blockade in Preclinical Non-small Cell Lung Cancer Models
Sheng Yan, Hong Kong

EP16.01-024 Immune Evolution of Metastases & Underlying Molecular Mechanisms in Non-small Cell Lung Cancer
Wen-Fang Tang, China

EP16.01-025 MIF Improves Immune Microenvironmentof Lewis Lung Cancer Brain Metastases after Radiotherapy ViaReducing M2 Macrophages
Xiaorong Dong, China

EP16.01-026 Immunomodulatory Effects of Cryoablation Combined With Immune Checkpoint Inhibitors in a Murine Lung Cancer Model
Yoshikane Yamauchi, Japan
EP16.01-029 Inter-tumour Heterogeneity of PD-L1 Expression in Non-small Cell Lung Cancer
Yuichi Saito, Japan

EP16.01-030 Peripheral T-Cell Receptor Repertoire Profiling in Non-small Cell Lung Cancer Using an Amplicon-Based Sequencing Assay
Zi Yi Wan, Singapore

EP16.01-031 Association Between Programmed Death Ligand-1 (PD-L1) Expression and Clinicopathological Features in Non-small Cell Lung Cancer (NSCLC)
Sena Valcárcel González, Spain

EP16.01-032 Guiding Monotherapy with Docetaxel or Atezolizumab via the Tumour Mutation Index in Non-small Cell Lung Cancer Patients
Baohui Han, China

EP16.01-033 Characterisation of T Cell Receptor Repertoire in Non-small Cell Lung Cancer Patients Treated with Immunotherapy
Andrea Goñi, Spain

EP16.02
Track: Tumour Biology and Biomarkers - Minimally Invasive Biomarkers

EP16.02-001 Integration of Primer Exchange Reaction and DNAzyme for Electrochemical Detection of PD-L1-Expressing Exosomes in Lung Cancer
Bing Bo, China

EP16.02-002 Circulating Tumour DNA (ctDNA) Changes in Patients With Lung Cancer from a Real-World Prospective Clinico-Genomic (PCG) Study
Anne Chiang, United States

EP16.02-003 Real World Experience and Feasibility of Tissue Informed CGP and ctDNA Testing in a Cohort of NSCLC Patients
Georges Azzi, United States

EP16.02-004 Clinical Significance and Genomic Characteristics of CD56+ Circulating Tumour Cells in Small Cell Lung Carcinoma
Charles Ricordel, France

EP16.02-005 Liquid Biopsy Detects Genomic Drivers in Non-small Cell Lung Cancer without EGFR Mutations by Single-plex Testing; WJOG13620L
Daisuke Hazama, Japan

EP16.02-006 Evaluation of Carcinoembryonic Antigen (CEA) as Predictive Marker in Patients with Metastatic Non-small Cell Lung Cancer
Debapiya Mondal, India

EP16.02-007 Detection of Clinically Relevant Fusions and Exon Skipping Alterations in Non Small Cell Lung Cancer Patients Liquid Biopsies
Estela Sánchez-Herrero, Spain

EP16.02-008 Cerebrospinal Fluid as a Liquid Biopsy for Molecular Characterization of Brain Metastases in Patients With Non-small Cell Lung Cancer
Georgios Tsakonas, Sweden

EP16.02-009 Psychobiological Stress Responses to a Lung Cancer Diagnosis.
Hronn Hardardottir, Iceland

EP16.02-010 Predictive Value of Serum Reactive Oxygen Species Modulator 1 for Surgically Resected Lung Adenocarcinoma
Seung Hyeun Lee, South Korea

EP16.02-011 Liquid Biopsies in the Setting of Early-Stage Lung Cancer for the Detection of Actionable Mutations
Joana Espiga de Macedo, Portugal

EP16.02-012 cfDNA Analysis Implementation in Early Stage Lung Cancer
Joana Espiga de Macedo, Portugal

EP16.02-013 Retrospective Analysis of BRCA1/2 Alterations in Advanced NSCLC Using An Amplicon-based NGS Liquid Biopsy Assay
Jonathan Poh, Singapore

EP16.02-014 A Comparative Analysis of Gene Alteration Detected With NGS in Tumour Tissue and Peripheral Blood in Lung Cancer
Laura Gutiérrez-Sainz, Spain

EP16.02-015 Phenotyping Malignant Pleural Effusions with Mass Cytometry: Evidence of EMT and MET States in Late-Stage NSCLC
Loukia Karacosta, United States

Guomin Lin, China

EP16.02-017 Predictive Value of Peripheral Blood Immune Cell Profiling in EGFR-T790M Mutant Lung Adenocarcinoma
Yutao Liu, China

EP16.02-018 Liquid Biopsies First to Make Treatment Decisions in Patients With Metastatic Non-small Cell Lung Cancer (NSCLC)
Luis Raez, United States

Naseer Ahmed, Canada

Oleg Kshivets, Russian Federation

EP16.02-021 The Expression of CEACAMs and Serum CEA Levels as Biomarkers of Postoperative Cancer Recurrence in Non-small Cell Lung Cancer
Bubse Na, South Korea

EP16.02-022 Circulating Tumour DNA Minimal Residual Disease Assay Predicts Outcome in Lung Cancer Patients Who Had Curative Treatments
Youjin Oh, United States
<table>
<thead>
<tr>
<th>EP16.02-023</th>
<th>Extracellular Vesicles Long RNA Sequencing as Diagnostic Biomarkers for Lung Adenocarcinoma Patients with Tumour Size Smaller than 2cm</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fangfei Qian,</strong> China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.02-024</th>
<th>Plasma ctDNA Organ-Specific Genomic Patterns and Origination Analysis in Advanced Non-Small Cell Lung Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rui Fu,</strong> China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.02-025</th>
<th>Serum Tumour Markers as a Surrogate for Radiographic Assessment of Non-Small Cell Lung Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Scott Strum,</strong> Canada</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.02-026</th>
<th>Dynamic Change of Indoleamine 2,3-dioxygenase Activity Predicts Survival in Radiotherapy-Received Unresectable Stage III NSCLC</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Linfang Wu,</strong> China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.02-027</th>
<th>Targeted Methylation Analysis of Circulating Cell-Free DNA to Predict Outcomes in Clinical Stage I NSCLC Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Yohan Bossé,</strong> Canada</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.02-028</th>
<th>Schwann Cell Exosomes Promote Lung Cancer Progression via miRNA-21-5P Cargo</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Yan Zhou,</strong> China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.02-029</th>
<th>Plasma-Based Next Generation Sequencing for Molecular Characterization of Lung Adenocarcinoma: A Multicentric Cohort From Argentina</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Martina Spotti,</strong> Argentina</td>
<td></td>
</tr>
</tbody>
</table>

**EP16.03**

**Track: Tumour Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics**

<table>
<thead>
<tr>
<th>EP16.03-001</th>
<th>High Frequency of KRAS Mutation, Uncommon EGFR Mutation and TMB-H in Xuanwei Female Patients With Lung Adenocarcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Heng Li,</strong> China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.03-002</th>
<th>Mechanisms of Resistance to First-line Osimertinib in Hispanic Patients with EGFR mutant Non-Small Cell Lung Cancer (FRESTON-CLiCaP)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Andres Cardona,</strong> Colombia</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.03-003</th>
<th>Systematic Population-based Identification of NTRK Fusion Genes Among Hispanic Patients with Non-Small Cell Lung Cancer (NSCLC)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Andres Cardona,</strong> Colombia</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.03-004</th>
<th>Targeting SHP2 Reverts Oncogenic Mediated Resistance to KRAS-G12C Inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alicia Tüns,</strong> Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ben Markman,</strong> Australia</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.03-006</th>
<th>Genetic Characteristics of EGFR Concurrent Variants with RB1 and TP53 in NCSLC Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hui Chen,</strong> China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.03-007</th>
<th>Comprehensive Analysis of m6A-Related Gene Mutation Characteristics and Prognosis in Lung Adenocarcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Jinghua Chen,</strong> China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.03-008</th>
<th>The Landscape of NFE2L2 Alteration in Chinese Lung Cancer Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Xuejun Dou,</strong> China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.03-009</th>
<th>Patterns of KEAP1 Genomic Co-alterations in Advanced Non-small Cell Lung Cancer Identified by Plasma-Based Genotyping</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dwight Owen,</strong> United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.03-010</th>
<th>Molecular and Clinical Characterization of Lung Adenocarcinoma With Respect to Patient Age at Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Elsa Arbajian,</strong> Sweden</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.03-011</th>
<th>The European Program for ROUTine Testing of Patients with Advanced Lung Cancer (EPROPA) 1 Year Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Francesco Passiglia,</strong> Italy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.03-012</th>
<th>Novel Human-derived EML4-ALK Fusion cell lines identify ribonucleotide reductase RRM2 as a Target of Activated ALK in NSCLC</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ganesh Umapathy,</strong> Sweden</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.03-013</th>
<th>Psychological Distress and Beta-2 Adrenergic Receptor Expression in Non-small Cell Lung Cancer Cells</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hronn Hardardottir,</strong> Iceland</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Joanna Chorostowska-Wynimko,</strong> Poland</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.03-015</th>
<th>Centrosome Amplification Is a Prognostic Indicator and Potential Therapeutic Vulnerability in Non-small Cell Lung Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Kelsie Thu,</strong> Canada</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.03-016</th>
<th>Targetable Alterations in Non-Small Cell Lung Cancer According to Age and Sex</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Erin Kimbrough,</strong> United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.03-017</th>
<th>Spatial Heterogeneity of Tumour Microenvironment of Lung Adenocarcinoma Associated With Genomic Alterations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Kwon Joong Na,</strong> South Korea</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.03-018</th>
<th>Molecular Features of Subtypes Classified Based on Predominance and Components in Chinese Patients with Lung Adenocarcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Guomin Lin,</strong> China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.03-019</th>
<th>Landscape of EGFR Extracellular Domain Mutations in Advanced Non Small Cell Lung Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lesli Kiedrowski,</strong> United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.03-020</th>
<th>High Tumour Mutational Burden by Whole-Genome Sequencing in Resected NSCLC in Never Smokers is Associated with Worse Prognosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Louis-Jacques Ruel,</strong> Canada</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP16.03-021</th>
<th>Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Luis Raez,</strong> United States</td>
<td></td>
</tr>
</tbody>
</table>
EP16.03-022 Endobronchial Ultrasound Guided Transbronchial Needle Aspiration Sampling Is Sufficient for Lung Cancer Molecular Profiling
Luis Raez, United States

EP16.03-023 KRAS Alterations, Clinicopathological Features and Co-occurring Drivers Associated with Prognosis in Advanced NSCLC Patients
Maritza Ramos-Ramirez, Mexico

EP16.03-024 Cellworks Singula™ Therapy Response Index (TRI) Identifies Superior OS Outcomes for NSCLC Patients: myCare-203A
Mark Klein, United States

EP16.03-025 Immunogenomics of Clinical Resistance to KRAS G12C Inhibition
Mark Woodcock, United States

EP16.03-026 Metastasis Sites and Genomic Alterations in Advanced Non Small Cell Lung Cancer: A Retrospective Study
Juan Martínez-Valenciano, Mexico

EP16.03-027 Routine Molecular Testing Using the TSO500+ NGS Panel in a Cohort of Patients with NSCLC
Miguel Mosteiro Lamas, Spain

EP16.03-028 Cancer Cells May be Re-sensitized to Tumour Treating Fields (TTFields) Through Inhibition of the PI3K/AKT/mTOR Pathway
Moshe Giladi, Israel

EP16.03-029 SLIT2 Expression in NSCLC With Long-Term Response to Pemetrexed
Eiji Nakajima, Japan

EP16.03-030 AKT Inhibition as a Therapeutic Strategy to Constrain Histological Transdifferentiation in EGFR-mutant Lung Adenocarcinoma.
Alvaro Quintanal-Villalonga, United States

EP16.03-031 Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer Harboring Different EGFR Exon 19 Del/Delins Variants
Shun Lu, China

EP16.03-032 Structure-Based Classification of Chinese Patients with Non-Canonical EGFR-Mutant Non-Small Cell Lung Cancer
Shun Lu, China

EP16.03-033 Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer with Four Structure-Based EGFR-Mutation Subgroups
Shun Lu, China

EP16.03-034 Differential Prognostic Effect of EGFR Mutation According to Smoking Status and Pathologic Stage in Non-mucinous Lung Adenocarcinoma
Sukki Cho, South Korea

EP16.03-035 Driver Mutations on Metastatic NSCLC - Experience in a Secondary Center
Sofia Silva, Portugal

EP16.03-036 Clinical and Genomic Features of HER2 exon 20 Insertion Mutations in East Asian NSCLC
Stephanie Saw, Singapore

EP16.03-037 Poor Prognosis of Patients with EGFR Mutations Left behind by Selective Detection in NSCLC
Taisuke Matsubara, Japan

EP16.03-038 Single-cell Analyses Reveal Tumour Microenvironment Differences between EGFR 19del and LB58R mutations in Lung Adenocarcinoma
Tao Wang, China

EP16.03-039 Characterizing SHPRH as a Novel Tumour Suppressor Gene in Lung Adenocarcinoma
Tianna Sihota, Canada

EP16.03-040 Biomarkersatlas.com: the Italian NSCLC Precision Medicine Knowledge Data Base
Umberto Malapelle, Italy

EP16.03-041 Single Cell RNA Sequencing Reveals Phenotypic Predispositions to Developing Lung Cancer in Never-Smokers
Venessa Chin, Australia

EP16.03-042 BET Inhibitors Stimulate NK Cytotoxic Activity in NSCLC through Attenuation of YAP/TAZ and SMAD3 Transcriptional Programs
Valentina Sancisi, Italy

EP16.03-043 Comprehensive Genomic Profiling of Tumour Mutational Burden-high in Chinese Lung Cancer Patients
Wei Li, China

EP16.03-044 Genomic Evidence Depicting Clonal Evolution of Lung Adenosquamous Carcinoma
Yuchen Han, China

EP16.03-045 The Effect of Vascular Endothelial Growth Factor Gene Polymorphisms in the Clinical Outcome of Patients with Lung Cancer
Younes El Founini, Morocco

EP16.03-046 Tumour Grade Associated Genomic Mutations in Chinese Patients with Lung Cancer
Min Zheng, China

EP16.03-047 Genomic Landscape of Squamous Cell Carcinoma Lung in an Indian Cohort
Ullas Batra, India

EP16.04
Track: Tumour Biology and Biomarkers - Tumour Biology & Preclinical Studies

EP16.04-001 The Role of Stromal PDGFR-activation in NSCLC
Amanda Lindberg, Sweden

EP16.04-002 Combining Patient-Derived Xenografts and Barcoding Technology to Evaluate Response to Targeted Therapies in ALK+NSCLC
Anne Petzold, Germany

EP16.04-003 High Dimensional Spatial Profiling of the NSCLC Tumour Microenvironment
Arutha Kulasinghe, Australia

EP16.04-004 Impact of Gender on Cellular Response to Cigarette Smoke Extract
Anne-Marie Baird, Ireland
EP16.04-005 Investigating the Side Effects of Docetaxel on Rat Lung and Heart
Berna Komurcuoglu, Turkey

EP16.04-006 A Novel Orthotopic Xenograft Mouse Model to Study Lung Cancer-Associated Fibroblasts and Lymphangiogenesis
Caoyang Chen, China

EP16.04-007 ALDH2 Downregulation, Aberrant DNA Methylation, and Loss of Stemness Pathways as an Enhanced Biomarker in Lung Adenocarcinoma
Thi-Oanh Tran, Taiwan

EP16.04-008 Cytotoxic Effects of Carnosic Acid Are Mediated by Induction of Autophagy and Activation of Sestrin-2/LKB1/AMPK Signalling in H1299 NSCLC Cells
Eric O'Neill, Canada

EP16.04-009 The Proliferative Effect of 27-Hydroxycholesterol as a Selective Estrogen Receptor Modulator on Pathology of NSCLC
Ikki Takada, Japan

EP16.04-010 Histological and Genetic Parental Tumour Characteristics are Conserved in Patient-derived Non-small Cell Lung Cancer Organoids
Isabelle Opitz, Switzerland

EP16.04-011 Sex Hormone Signalling in Lung Adenocarcinoma Limits Tumour Virulence
John Le Quesne, United Kingdom

EP16.04-012 Retrospective Analysis of Non-Small Cell Lung Cancer with Mucinous Histology Subtype
Katherine Garcia, United States

Kwon Joong Na, South Korea

EP16.04-014 NTRK in Lung Cancer Patients with History of Hodgkin's Lymphoma
Mariola Blanco Clemente, Spain

Maryam Khalil, Canada

EP16.04-016 Overexpression of CEACAM6 Activates Src-FAK Signaling and Inhibits Anoikis, through Homophilic Interactions in Lung Adenocarcinomas
Eun Young Kim, South Korea

EP16.04-017 Lineage Switching and Tumour Microenvironment Roles of Tumour Suppressors in Autochthonous Lung Cancer Models
Nisitha Sengottuvel, United States

EP16.04-018 DNA Mismach Repair in Lung Adenocarcinoma in Morocco
Ouassima Erefai, Morocco

EP16.04-019 Impact of Chemotherapy on Tridimensional Multicellular Non-Small Cell Lung Cancer Spheroids With Microenvironment Cells
Pauline Hulo, France

EP16.04-020 Dysregulation of 14-3-3 Signaling Adapters in Lung Adenocarcinoma, New Insights Into the Impact on Cancer Cell Biology
Rhys Hamon, Australia

EP16.04-021 Chromatin Remodeling Drives Lung Premalignancy and is a Target for Prevention
Steven Belinsky, United States

EP16.04-022 Prognosis of Epithelial-Mesenchymal Transition-Related IncRNA Profile in LUSC Patients
Shanshan Xiao, China

EP16.04-023 Development and Validation of a Necroptosis-related Prognostic Model for Lung Adenocarcinoma
Tao Wang, China

EP16.04-024 HMGB1-mediated Autophagy Promotes Gefitinib Resistance in Human Non-small Cell Lung Cancer
Zhaoxia Wang, China

EP16.04-025 Statins Suppress SOAT1 Expression & Reduce Cholesterol Esterification in Statin-sensitive Lung Cancer Cells
Katsuhiko Warita, Japan

EP16.04-026 Effectiveness of Atorvastatin and SR-12813 Combination in Statin-resistant and Statin-sensitive Lung Cancer Cell Lines
Tomoko Warita, Japan

EP16.04-027 Identification of Optimal Internal Reference Gene to Analyze the Anticancer Effects of Statins in Lung Cancer Cells
Tomoko Warita, Japan

EP16.04-028 PHLPP2 Regulates Ferroptosis Through Nrf2 Pathway to Affected Cell Cycle and Apoptosis in Lung Squamous Cell Carcinoma
Haihua Yang, China

EP16.04-029 Downregulation of PHLPP2 Induced by Radiation Promotes GPX4-mediated Ferroptosis Defense and Radioresistance in Lung Cancer
Haihua Yang, China

EP16.04-030 Cancer-Associated Fibroblasts Attenuate DNA Damage Repair by Promoting Glycolysis in Non-small Cell Lung Cancer
Hongfang Zhang, China

EP16.04-031 Connexin 43 Overexpression Induces Angiogenesis in Vitro Following Phosphorylation at Ser279 in its C Terminus
Zizi Zhou, China

EP16.04-032 Indoleamine 2,3-dioxygenase 1 (IDO1) Blood Metabolites May Improve Predictive Accuracy for Radiation Pneumonitis
Fengming Kong, Hong Kong
Editor-in-Chief:
Alex A. Adjei, MD, PhD, FACP
Chairman, Taussig Cancer Institute - Cleveland Clinic, Cleveland, OH USA

The Journal of Thoracic Oncology (JTO) is the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of thoracic malignancies. JTO emphasizes a multidisciplinary approach, and includes original research (clinical trials, and translational or basic research), reviews, and opinion pieces. The audience consists of epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonary specialists, radiologists, pathologists, and research scientists with a special interest in thoracic oncology.
<table>
<thead>
<tr>
<th>Program</th>
<th>IASLC 2022 World Conference on Lung Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brunström, Hans</td>
<td>EP08.01-083, EP11.01-007, EP16.04-001, MA05.04</td>
</tr>
<tr>
<td>Bruns, Rolf</td>
<td>MA03.05, E05.04</td>
</tr>
<tr>
<td>Brustugun, Odd Terje</td>
<td>P08.02-072</td>
</tr>
<tr>
<td>Bryl, Maciej</td>
<td>EP10.01-004</td>
</tr>
<tr>
<td>Bryson, Emily</td>
<td>LA03.03, MA12.07</td>
</tr>
<tr>
<td>Bubendorf, Lukas</td>
<td>P11.05-005</td>
</tr>
<tr>
<td>Buheite, Leslie</td>
<td>EP08.02-028, EP08.02-074, EP16.03-009, MA07.07</td>
</tr>
<tr>
<td>Bucknell, Nicholas W.</td>
<td>P05.01-023</td>
</tr>
<tr>
<td>Budach, v. Fried</td>
<td>MA04.03, P12.10-005</td>
</tr>
<tr>
<td>Buderi, Silviu</td>
<td>P13.05-003, P11.05-005</td>
</tr>
<tr>
<td>Budhiani, Irfan A.</td>
<td>EP01.04-004</td>
</tr>
<tr>
<td>Buduhan, Gordon</td>
<td>EP16.02-019</td>
</tr>
<tr>
<td>Bueno, Raphael</td>
<td>P15.03-005</td>
</tr>
<tr>
<td>Buffoni, Lucio</td>
<td>EP16.03-011</td>
</tr>
<tr>
<td>Buglioni, Simonetta</td>
<td>EP01.03-030</td>
</tr>
<tr>
<td>Bulusu, Ramesh</td>
<td>P08.02-002</td>
</tr>
<tr>
<td>Bulut, Halil I.</td>
<td>EP05.03-001, P12.05-005</td>
</tr>
<tr>
<td>Bulutay, Pinar</td>
<td>EP05.02-004, EP02.02-048, EP02.02-101, EP10.01-015, P2.04-03</td>
</tr>
<tr>
<td>Bungaro, Maristella</td>
<td>EP02.02-094, P02.02-095, LA01.02, P04.03-004, OA06.03</td>
</tr>
<tr>
<td>Bunn, Becky</td>
<td>EP01.02-016</td>
</tr>
<tr>
<td>Bunn, Paul</td>
<td>EP01.02-029, OA02.01, OA04.06</td>
</tr>
<tr>
<td>Bunn Jr, Paul A.</td>
<td>OA06.03</td>
</tr>
<tr>
<td>Buño, Antonio</td>
<td>EP01.02-048</td>
</tr>
<tr>
<td>Burger, David</td>
<td>EP02.02-090</td>
</tr>
<tr>
<td>Burgers, Jacobus A.</td>
<td>OA04.06</td>
</tr>
<tr>
<td>Burioni, Silvia</td>
<td>EP11.01-004</td>
</tr>
<tr>
<td>Burn, Kenly</td>
<td>P2.08-07</td>
</tr>
<tr>
<td>Burns, Timothy F.</td>
<td>OA03.06, EP16.03-002</td>
</tr>
<tr>
<td>Burotto, Mauricio</td>
<td>P14.02-002</td>
</tr>
<tr>
<td>Burt, Bryan</td>
<td>MA02.07</td>
</tr>
<tr>
<td>Burtness, Barbara</td>
<td>EP05.01-011</td>
</tr>
<tr>
<td>Bush, Aaron</td>
<td>EP05.02-028, P02.10-002</td>
</tr>
<tr>
<td>Bushonid, Peter</td>
<td>P02.10-002</td>
</tr>
<tr>
<td>Bustamante Alvarez, Jean</td>
<td>P07.01-019, EP06.01-013, EP02.01-012</td>
</tr>
<tr>
<td>Busuito, Giulia</td>
<td>P08.01-017, P05.01-012, P15.05-004</td>
</tr>
<tr>
<td>But-Hadžić, Jasna</td>
<td>P15.05-004</td>
</tr>
<tr>
<td>Buti, Sebastiano</td>
<td>P15.05-004</td>
</tr>
<tr>
<td>Butler, John</td>
<td>EP04.02-002, P10.01-005</td>
</tr>
<tr>
<td>Butow, Phyllis</td>
<td>EP05.01-007</td>
</tr>
<tr>
<td>Butterworth, Karl</td>
<td>P10.01-003</td>
</tr>
<tr>
<td>Butterworth, Karl T.</td>
<td>P15.01-003</td>
</tr>
<tr>
<td>Buttligeri, Alessandro</td>
<td>EP03.03-007, EP02.03-031, P02.10-002, P02.13-002, P02.13-016, E05.05-006, MA01.03, P12.10-001, P02.08-009, P05.01-023</td>
</tr>
<tr>
<td>Butts, Emily</td>
<td>EP05.01-011</td>
</tr>
<tr>
<td>Buyukceran, Emre Utkan</td>
<td>EP13.01-002</td>
</tr>
<tr>
<td>Byers, Lauren</td>
<td>EP02.02-016, ES05.06, MA01.03, P12.10-001</td>
</tr>
<tr>
<td>Byers, Lauren A.</td>
<td>P02.10-001</td>
</tr>
<tr>
<td>Byers, Stephen</td>
<td>P13.01-006, P08.02-001, E05.03-003, WS07.04</td>
</tr>
<tr>
<td>Byrne, Keelan</td>
<td>EP08.02-001, EP08.02-032, E05.03-003, WS07.04</td>
</tr>
<tr>
<td>Cabrera, Carlos</td>
<td>E05.01-008, ES05.06</td>
</tr>
<tr>
<td>Cabrera, Luis A.</td>
<td>EP08.02-035, MA09.09, EP08.03-003</td>
</tr>
</tbody>
</table>
Gall, Giulia EP01.02-09, MA01.07
Gallo, Martina EP02.03-006
Galpin, Kirsty P1.12-02
Galvan, Patricia EP08.02-102
Galvano, Antonio EP08.03-007, EP16.01-013
Galbar, Ema V EP16.03-002, EP16.03-003
Gamez, Tatiana EP08.01-085, WSO8.09
Gan, Bin EP14.03-001
Gan, Gregory EP08.01-081
Gan, Xin EP08.02-049
Gandara, David R. ESI07.02, MA13.08, OA03.02
Gandara, David R. P2.12-03
Gandhi, Yash EP16.03-002
Gangieddy, Mounika P. EP08.02-015
Ganguly, Sandip EP16.03-024
Ganz, Xin EP08.01-081
Gao, Zhuolin EP08.02-032
Gao, Yanfei EP05.02-001
Gao, Boning EP08.02-130
Gao, Shugeng EP05.01-025, P1.05-02
Gao, Robert W. EP05.01-011
Gao, Grace EP08.01-006, MA01.07
Gao, Jin EP08.01-001
Gao, Rong EP08.01-080
Gao, Rang EP08.01-073
Gao, Robert W. EP05.01-011
Gao, Shugeng EP08.01-055, P1.16-04
Garci, P.2.07-02
Garcia, Miguel EP16.04-012
Garcia, Carmen P03.12
Garcia Campbello, Maria R. EP02.02-171
Garcia Campbello, Rosario EP08.02-060
Garcia- Campello, Maria del Rosario OA02.03
Garcia-Campello, Mos Rosario P1.09-03
Garcia-Campello, Rosario EP08.02-131
Garcia-Campello, Rosario OA07.06
Garcia Casabal, Florencia EP08.02-032
Garcia de Herreros, Marta MA07.07, OA13.04, P16.02
Garcia-Diaz, Abel P2.13-01
Garcia-Gomez, Juan M. EP10.01-017
Garcia Gonzalez, Guillermo EP14.05-005
Garcia-Illanes, David EP07.01-022, EP08.01-078
Garcia Palomo, Andres EP05.02-002, EP05.02-003
Garcia-Pelaez, Beatriz EP08.02-032
Garcia-Reina, Samuel EP01.03-002, EP16.01-007
Garcia-Robledo, Juan B. EP16.03-002
Garcia-Robledo, Juan E. EP16.03-003
Garcia Rodriguez, Sonia EP14.05-005
Garcia-Román, Silvia EP08.02-120
Garcia-Sastre, Adolfo OA06.03
Gard, Grace EP08.04-002, EP16.03-005
Garde-Noguera, Javier EP02.03-019
Garell, Elena EP03.01-010
Garrido Lopez, Pilar EP15.03, 08.02-070
Garrido Lopez, Pilar EP11.01
Garrido Lopez, Pilar OA02.07, OA15.01
Garrido Lopez, Pilar OA07.02, OA15.01
Garrido Lopez, Pilar OA15.05, P2.07-02
Garrido, Pilar OA07.02, OA15.01
Garrido, Pilar OA07.02, OA15.01
Garroto, Pamela EP03.02-007
Gardon-Pelham, Claudia EP16.01-018
García-Vázquez, Mónica EP08.02-032
Gasche, Nikolaus EP16.01-015
Gascon- Ruiz, Marta EP16.01-014
Gaspar, Bernard MA08.07
Gastala, MD, Nicole EP10.01-014
Gauthier, Nathalie EP16.02-027, OA06.05
Gauthier, Nathalie EP16.02-027
Gavilan, Pedro EP08.02-049
Gee, Harriet EP16.02-074
Gelblum, Daphna Y. EP05.01-025, P1.05-02
Geleff, Silvana EP02.01-09
Gelleniter, Alain EP08.01-007
Gelleniter, Alain J. EP08.02-046
Gelsomino, Francesco EP02.04-001, EP08.01-007, EP14.01-006
Gemmill, Akio EP08.01-005
Gencheva, Radosveta EP02.03-005
Geng, di EP08.02-069
Genova, Carlo EP04.01-001, EP04.01-005, EP08.01-007, EP08.02-046, EP08.02-101, EP01.06-006
EP16.03-040
Gensheimer, Michael OA14.04
Gerard, Ian J. OA06.07
Gerard, Roger L. EP02.03-005
Gerber, David E. OA06.03
Gerke, Oke EP01.07-001
Gesualdo, Monica P2.10-05
Gethling, Scott EP08.02-125
Ghanim, Obeda OA02.02, P1.11-02
Ghanita, Ravi P14.02
Ghantous, Akram MA01.09
Gharaibeh, azza EP07.01-016
Ghatsis, Christian P1.03-01
Ghefter, Mario MA11.09, WSO7.05
Ghos, Atyy EP16.03-024
Ghos, Joyce EP06.01-005, EP08.02-040, MA10.05, OA14.05
Ghos, Sudip EP04.04-004
Ghosal, Avik EP10.05-002
Giacometti, Valentina P1.03-03
Gianetta, Martina P2.04-03
Giannino, Nicole P2.12-01
Giannarelli, Diana EP08.01-030, EP08.02-048, P2.14-02
Giannetta, Laura G. EP14.01-006
Giannetta, Laura G. EP12.01-001
Gibbard, Jamie EP08.04-002, EP16.03-005
Gibbs, Peter EP08.02-049
Gibbs, Peter EP16.03-005
Gibson, Amanda EP02.04-003, EP04.02-001, EP05.02-001, EP08.02-004, EP02.03-018, EP08.02-013, EP08.02-014, EP08.02-071
Gibson, Amanda EP08.02-112
Gibson, Neil EP02.04-09
Gierard, David EP01.01-002
Gieske, Michael R. EP01.04-004, EP01.07-002
Gil, Debora EP05.01-008, EP04.01-001
Gil, Nuno EP01.03-009
Giladi, Moshe EP16.03-016
Gial, Osami EP08.02-071, MA06.08
Gilibert, Marianna EP06.01-017
Gibert, Ignacio EP08.02-070, MA02.08
Gilbert, Alexandre EP05.01-007
Gilbert, Christopher R. MA14.09
Glja, Shivee OA02.04
Gill, Ritu ES18.04, P13102
Gill, Ritu EP07.01-018
Gilligan, David EP08.02-150
Gimenez Capitán, Ana EP08.02-032
Gimenez-Capitán, Ana EP08.02-135
Giribaldi, Beatrice EP08.02-147
Ginsberg, Michelle S. EP01.05-025
Ginzinger, David EP11.04-009
La, Jennifer EP08.01-045
Labbé, Catherine EP16.03-020
Laber, Damian EP14.01-013
Lacroix, Ludovic MA10.08
Lacroix, Ludovic Lacroix P1.16-02
Ladanyi, Marc EP04.01-013, EP08.04-002
Ladwa, Rahul MA12.05
Lafeuille, Marie-Hélène MA05.04
La Fleur, Linnéa MA10.08
Lafluer, Francois MA02.03, MA03.05
Lagani, Vincenzo EP01.01-009, MA11.04
Lage Alfranca, Yolanda EP08.02-070
Lager, Joanne EP01.01-021, EP10.01-006, EP10.01-007
Lagogianni, Christie EP08.02-149
Laguna, Juan C. EP03.01-012, MA07.07, OA13.04, P1.07-02
Laguna, Juan Carlos EP16.03-036, P12.03-02
Lai, Jia-li EP08.05-004, OA12.05
Lai, Victoria MA13.08
Lai, Wei-Chu V. EP16.03-012
Lai, Wei-Yun P12.13-05
Lai, Yi P12.13-01
Lai, Zhongyu OA15.01, MA15.03
Laidisaar-Powell, Rebekah P10.01-005
Laisaar, Tanel EP06.01-016
Lakhan, Dhairya EP01.05-008
Lakhanpal, Shaily EP16.02-002
Lala, Deepak A. EP16.03-024
Lalezari, Ferry OA04.06
Lalvée, Salomé EP11.01-006, EP11.01-003
LAM, NGUYEN S. EP12.04-005
Lam, Stephen EP01.05-007, EP01.07-004, EP08.01-075, MA03.04, MA11.07, MA11.08, OA12.03, P1.02-02, P12.04-04, P1.04-02, P2.09-03, WSO2.04, WSO2.08, WSO2.17, WS02.23
Lam, Sze Kwan EP05.02-020, EP07.01-009, EP16.04-005
Lam, Vincent EP02.04-007, EP08.01-086
Lam, Wan L. EP16.03-015
Lam, Wei-Sen EP08.02-162
La Mantia, Maria EP08.03-007, EP16.01-013
LaMarche, Nelson M. EP12.02-05
Lamarre, Neil EP14.05-014
Lamaze, Fabien EP16.02-027
Lamberg, Kristina EP11.01-007, MA05.04
Lamberti, Giuseppe EP08.01-043, EP14.01-006, MA01.08, MA02.09, P15.15-03
Lambin, Philippe ES09.03, MA10.08
Lambotte, Olivier EP10.01-007
Lammers, Philip EP12.02-010
Lamot, Sebastian EP01.05-004
Lampaki, Sofia EP08.02-060
Lamprecht, Bernd EP08.01-108
Lancaster, Harriet L. EP13.02-00, P13.02-04, MA13.01, MA13.06, P2.14-02
Land, Lotte H. EP16.03-020
Landi, Lorenzo EP08.01-015
Landi, Maria T. EP16.03-020
Landlinder-Schubert, Christine EP01.05-008
Landman, Bennett EP03.01-006
Landreneau, Rodney P1.04-06
Lane, Jordan EP01.06-007
Lang, David EP08.01-108
Lang, Joshua EP02.02-02
Langdon, Robert EP08.02-111
Lang, Corey J. EP03.01-011, MA01.05, P1.01-01
Langer, Deanna EP14.05-001, EP16.03-014
Langleben, Adrian EP04.02-004
Langeveld, Adrian EP04.12-003, MA01.04
Lanterneau, Sylvie ES21.02, MA01.07, MA01.09, MA02.03, MA12.07, OA04.05
Lanza, Ian MA13.08
La Porta, Marilina EP02.03-019, MA13.08
Lara, Primo N. EP08.02-075
Lara-Mejia, Luis EP07.01-011
Lara-Mejia, Luis MA04.01
Lara-Mejia, Luis EP08.02-035
Lara-Mejia, Luis EP16.03-023
Lara-Mejia, Luis MA09.09
Lara-Mejia, Luis OA13.04, WSO7.03
Lardón, Filip EP07.01-024
Larson, Timothy EP02.11-002
Laskin, Janessa EP04.02-004, EP04.02-018, EP11.01-005, EP11.01-006
Lassen, Ulrik N. EP08.02-048
Lastra, Rodrigo MA01.04
Laszlo, Viktoria EP08.02-087
Lazikova, Simona EP16.01-006
Lau, Asa P. OA14.04
Lau, Brianna EP16.03-036
Lau, Dawn EP15.01-001
Lau, John EP02.02-008
Lau, Rainbow WH EP08.01-067, MA14.08
Lau, Sally C. EP08.01-010, MA14.08
Lauer, Andrew EP08.02-071
Laure, Alexander EP01.07-001, P14.01-01
Laure, MSc, Julie EP01.09-001
Lauricella, Calogero EP04.02-004
Laure, Scott EP02.03-006, EP02.03-007
Laursen, Christian B. EP04.02-004
Lausi, Paolo Olivo OA12.03
Law, Jennifer EP04.01-023
Lawler, William LM20.07
Mandal, Nabanita
Mandiblatt, Jeanne
Mander, Kimberley
Manders, Peter M.
Mandlekia, Sandhya
Maneenil, Kunalatida
Mangiamei, Giuseppe
Mangiante, Lise
Manglavit, Sara
Marianas, Midlands, Deborah
Mansur, Ahmad
Mansour, Ahmad A.
Manst, MD, MPH, Deborah
Mar, Brenton G.
Marcini, Sergio
Marconi, Silvia
Marco, Elly
Mardanzai, Khaled
Marech, Illaria
Marfia, Ivett
Margaritora, Stefano
Margolis, Marc
Mariamidze, Elene
Marinas, Michael
Marin, Elba
Marin, Elba
Marin, Reba
Marinacci, Roberto
Marin-Acevedo, Julian A.
Marinato, Gianmarco
Markaki, Maria
Markman, Ben
Marko-Varga, Gyorgy
Markowitsch, Geoffrey
Marks, Jennifer
Marks, Randolph
Marmarelis, Melina
Marmarelis, Melina E.
Markman, Edith
Marques, Édouard
Marquette, Charles-Hugo
Márquez Rodas, Iván
Marron, Thomas U.
Marrone, Kristen
Marrone, Kristen A.
S

Saad, Akram EP08.02-122
Saafeld, Felix C. EP14.01-008
Saar, Annika EP06.01-016
Saavedra Armero, Victoria EP16.02-027
Sabari, Joshua EP08.02-016
Sabouhanian, Amir EP02.04-009,
EP03.01-002, EP04.01-001
Sabourin, Jean-Christophe EP11.01-005
Sacco, Gianluca EP08.01-088
Sacadlan, Danielle EP14.01-019
Sachdeva, Ashutosh EP07.01-001
Sachdeva, Robin EP12.01-013
Sacher, Adrian EP02.04-009,
EP03.01-002, EP08.02-067,
EP08.02-082, EP08.02-116, OA03.04
Sacher, Adrian G. MA08.05
Saeid, Daniel MA08.05
Saeid, Daniel A. EP08.02-043,
P2.02-01
Safavi, Amir H. EP10.01-004
Safavi, Farnoush EP08.02-098
Sahghir, Zaigham EP01.07-001
Saha, Jayati EP08.02-074
Sahnoouri, Souha EP06.01-010,
EP06.01-012, EP06.03-024
Sahu, Diwyanshu EP08.02-164
Saichachman, Sirivimol EP01.03-002,
OA06.04
Saig, Maria EP02.02-070
Saig, Rogeria Maria EP02.02-070
Salim, Heba EP07.03-005
Saliz, Cristina EP16.01-009
Saito, Hanhiro EP01.01-007,
EP01.01-008, OA15.04
Saito, Masao EP13.01-010
Saito, Yuichi EP16.01-028,
EP16.01-029
Sajin, Hisashi EP16.01-028,
EP16.01-029
Sajjnic, Andreja P2.04-01
Sakaeda, Kanako EP08.01-064
Sakai, Hiroshi OA03.05
Sakai, Tetsuya EP08.02-113
Sakai, Yumiko EP08.01-064
Sakao, Yukinori EP16.01-028,
EP16.01-029
Salah, Myriam EP01.01-006
Salam, Ömer Faruk P2.06-01
Salas, Clara EP16.01-028,
EP16.01-029
Saleh, Mohamed M. EP08.02-106
Saleh, Sara EP08.02-121
Salemi, Ahmed EP05.01-012
Salerno, Domenico EP03.03-007
Sales Santos, Ricardo P1.03-002,
P1.03-003
Sales Santos, Ricardo EP08.02-106
Salomonsson, Stina EP01.01-007,
EP01.01-008
Salvadori, Lorenzo EP07.01-017
Sam, Janette P1.02-04
Samanta, Epaminondas EP12.01-013
Samaraweera, Lelesha EP08.02-081
Samarzija, Miroslav EP07.01-012
Samelis, Georgios EP10.01-008
Samitas, Konstantinos EP08.02-060
Samkari, Ayman EP02.03-009,
OA04.07
Sammini, Sunil EP06.01-003
Samnani, Suraj EP06.01-009
Samuel, Evangeline EP14.05-016
Sanatan, Michael EP02.01-013
Sánchez, Alfredo EP08.01-029,
PI09-03, PI15-09
Sánchez, Enrique EP05.02-002,
EP05.02-003, EP05.02-006
Sánchez, José Miguel EP01.01-005,
P15-09
Sánchez, Leire EP07.01-022
Sánchez-Cabrero, Dario EP08.01-049
Sanchez del Corral, Maria EP04.01-019
Sanchez del Corral, Maria Matilde EP06.01-017, EP13.01-016
Sanches-García, Ángel EP10.01-017
Sánchez-Gastaldo, Amparo EP02.02-149
Sánchez González, Juan Cristóbal EP04.01-019,
EP08.01-066, EP16.04-014
Sánchez-González, Marcelo EP02.02-007
Sánchez-Herrero, Estela EP06.01-007
Sánchez-Mauriño, Pedro EP08.01-048
Sánchez-Pablo, Clara EP08.01-048
Sánchez-Ramos, Carles EP05.01-001
Sánchez Torres, José Miguel EP08.02-070,
EP08.02-131
Sancis, Valentina EP16.03-042
Sandanger, Torkel M. EP01.01-005
Sandanger, Torkel Manning EP01.01-009
Sandiford, Peter EP01.03-009
Sands, Jacob EP14.05-003
Sandy, Beth EP09.01-001
Sangiovanni, Sara EP02.02-104
Saugnusai, Sunatee EP08.02-083
Sanmamed, Miguel F. OA09.04
Sansano, Irene P2.07-02
Santana, María EP01.01-008
Santarpia, Mariacarmela EP08.02-104
Santini, Fernando C. EP05.01-025
Santo, Antonio EP11.01-005
Santoni-Rugiu, Eric EP08.02-044,
EP08.02-075
Santoro, Alessandra EP03.01-007
Santoro, Armando EP08.02-081
Santos, Edgardo S. EP16.02-018
Santos, Ricardo EP10.04-005,
MA11.07
Santos, Ricardo S. MA11.09, WS05.07
Santojano, Nicolás EP16.03-002,
EP16.03-003
Sanz-Moreno, Sandra EP06.02-007
Sarachai, Nidchakarn EP02.01-016
Sarina, Bruno EP06.01-016
Saravia, Diana EP08.01-023
Sarbay, Ismail EP05.03-001,
EP05.03-001, EP05.03-001,
EP14.04-002, P2.06-01
Sardo, Delia EP16.01-001
Sarich, Peter MA11.03
Sarihan, Suiyya EP02.02-009
Sarkar, Subho EP08.04-004
Sarris, Ahmad EP02.08-117
Sart, Joan OA13.04
Sartore-Bianchi, Andrea EP02.02-146
Sasaki, Takuya EP05.03-009
Sathyam, Neha G. OA10.06
Sato, Keiyu EP02.01-015
Sato, Yuki MA06.04
Wang, Qichuan  
EP08.01-001

Wang, Qiming  
EP08.01-073

Wang, Qiu Ming  
EP08.02-078

Wang, Qun  
EP05.02-018

Wang, Renwei  
P1.01-01

Wang, Ruhua  
EP08.01-073

Wang, Rulan  
EP14.01-003

Wang, Runsheng  
EP07.01-021

Wang, Sai  
EP01.01-012

Wang, Shouzheng  
EP01.01-011

Wang, Tao  

Wang, XiaoZhe  
EP14.01-003

Wang, Xiangcai  
MA14.05

Wang, Wenchen  
MA06.07

Watanabe, Hirokazu  
EP08.01-001

Waszak, Angela  
P1.01-01

Watanabe, Kageaki  
EP08.01-105, EP14.05-007

Watanabe, Masayuki  
P15.13

Watanabe, Shun-ichi  
EP02.03-014, EP02.03-016, MA04.04

Watkins, Neil  
EP16.03-041

Watson, Drew  
EP16.03-024

Watt, Colleen  
P1.03-06

Wawryko, Paul  
OA06.07

Webb, Maxine  
EP03.01-014

Weber, Jan-Philip  
EP02.01-016, MA10.04

Weber, Marianne  
MA11.03, P108.01

Weder, Walter  
ES33.06

Wei, Chenchen  
EP08.01-001, EP08.02-153, EP08.04-024

Wei, Hao  
EP14.01-003

Wei, Li  
EP05.02-009

Wei, Shihong  
MA14.05

Wei, Yu-Feng  
MA16.04

Wei, Zihan  
MA04.04

Wel, Stefan  
MA06.08

Welte, Valerie F.  
EP01.05-010

Wen, Lu  
EP08.01-099, MA09.04, W508.13

Wen, Xiaoping  
EP08.01-094

Wen, Lu  
EP08.02-158, W508.14

Weng, Wei  
EP08.01-027, MA14.04

Welker, Lutz  
EP16.01-011

Welch, Connor  
MA02.08

Weluver, M. X.  
EP05.01-021, EP08.01-098

Weis, Jessica  
EP08.01-067, EP08.02-079, EP16.03-016

Weikens, Anthonie v.  
EP02.02-162

Welch, Conch  
MA02.08

Welker, Lutz  
EP08.02-045

Weininger, Tessa  
EP02.01-008, EP08.12-22

Weininger, Christoph  
EP02.01-008, EP08.12-22

Weimpert, Caroline  
EP08.02-074

Weiss, Jessica  
EP08.01-067, EP08.02-079, EP16.03-016

Weijts, Willem  
EP08.01-098

Weinberg, Tessa  
EP02.01-008, EP08.12-22

Weller, M. X.  
EP05.01-021, EP08.01-098

Weltner, Mirjana  
OA12.06

Welte, Stefan  
MA06.08

Weisz, Valentin  
EP02.01-008, EP08.12-22

Welte, Valerie F.  
EP01.05-010

Welflein, Stefan  
ES39.06, MA14.01

Wen, Xiaoping  
EP08.01-094

Wendt, Walter  
MA02.08

Wendling, Tessa  
EP02.01-008, EP08.12-22

Wen, Zhi  
EP01.03-014

Wenger, Waldek  
P1.01-01

Wen, Lu  
EP08.01-099, MA09.04, W508.13

Wenger, Pawia  
EP08.01-086

Werner, Raphael S.  
EP08.03-006, EP16.04-010

Werner-Wasik, Maria  
ES39.06, MA14.01

Werth, Michael  
PI01.01

Werutsky, Gustavo  
EP03.01-003

Wesalman, Abdul  
P2.11-01

Wesolowski, Robert  
EP14.05-004, OA12.04

Wesolowski, Robert  
EP14.05-004, OA12.04

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard (Jack)  
ES20.06

Westeel, Virginia  
ES36.02, MA12.07

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009

West, Howard  
EP02.03-009
<table>
<thead>
<tr>
<th>Author</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zheng, Li</td>
<td>EP08.02-029</td>
</tr>
<tr>
<td>Zheng, Liqing</td>
<td>EP16.03-038</td>
</tr>
<tr>
<td>Zheng, Min</td>
<td>EP16.03-046</td>
</tr>
<tr>
<td>Zheng, Xin</td>
<td>EP16.02-016</td>
</tr>
<tr>
<td>Zheng, Xinyu</td>
<td>EP16.02-016</td>
</tr>
<tr>
<td>Zheng, Yating</td>
<td>MA05.05</td>
</tr>
<tr>
<td>Zheng, zhiqing</td>
<td>P2.10-03</td>
</tr>
<tr>
<td>Zhi, Xiuyi</td>
<td>EP08.02-139</td>
</tr>
<tr>
<td>Zhong, Chenghua</td>
<td>EP05.02-009</td>
</tr>
<tr>
<td>Zhong, Dian Sheng</td>
<td>EP08.02-169</td>
</tr>
<tr>
<td>Zhong, Diangsheng</td>
<td>EP08.01-073, EP08.02-063</td>
</tr>
<tr>
<td>Zhong, Hu</td>
<td>EP05.01-36, EP08.01-102, EP16.01-032, EP16.02-028, OA05.05</td>
</tr>
<tr>
<td>Zhong, Runbo</td>
<td>EP08.01-052, EP08.01-0103, W508.10</td>
</tr>
<tr>
<td>Zhong, Wen-Zhao</td>
<td>EP01.02-025, EP16.02-024, EP16.03-007, ES36.06, W508.21</td>
</tr>
<tr>
<td>Zhong, Wenzhao</td>
<td>EP05.02-006, LA01.04, MA06.09</td>
</tr>
<tr>
<td>Zhong, Yifan</td>
<td>EP02.01-012</td>
</tr>
<tr>
<td>Zhong, Wen-Zhao</td>
<td>P2.11-01</td>
</tr>
<tr>
<td>Zhou, Cai-Cun</td>
<td>EP08.02-064</td>
</tr>
<tr>
<td>Zhou, Caicun</td>
<td>EP05.02-021, EP08.01-014, EP08.01-035, EP08.02-171, EP16.01-005, ES05.01, PL03.09, W508.03</td>
</tr>
<tr>
<td>Zhou, Chao</td>
<td>EP05.01-033, EP08.05-003</td>
</tr>
<tr>
<td>Zhou, Fei</td>
<td>EP16.01-005</td>
</tr>
<tr>
<td>Zhou, Hongrui</td>
<td>EP16.02-016</td>
</tr>
<tr>
<td>Zhou, Jianying</td>
<td>EP08.02-029, EP08.02-139, OA03.07</td>
</tr>
<tr>
<td>Zhou, Juan</td>
<td>EP08.01-097, EP08.01-107, W508.16</td>
</tr>
<tr>
<td>Zhou, Lin</td>
<td>EP08.05-004, EP14.03-002</td>
</tr>
<tr>
<td>Zhou, Ming</td>
<td>EP02.04-010</td>
</tr>
<tr>
<td>Zhou, Qing</td>
<td>EP08.01-042, EP08.01-085, EP08.02-063, EP08.02-064, EP10.01-010, OA02.05, W508.09</td>
</tr>
<tr>
<td>Zhou, Qinghua</td>
<td>EP14.01-003</td>
</tr>
<tr>
<td>Zhou, Xiangdong</td>
<td>EP08.02-159</td>
</tr>
<tr>
<td>Zhou, Yan</td>
<td>EP16.02-028</td>
</tr>
<tr>
<td>Zhou, Yanwu</td>
<td>EP05.02-010</td>
</tr>
<tr>
<td>Zhou, Yuling</td>
<td>EP05.02-021</td>
</tr>
<tr>
<td>Zhou, Yuxi</td>
<td>MA02.05</td>
</tr>
<tr>
<td>Zhou, Zhipeng</td>
<td>EP16.01-017</td>
</tr>
<tr>
<td>Zhou, Zichao</td>
<td>EP16.02-006</td>
</tr>
<tr>
<td>Zhou, Zhi</td>
<td>EP16.04-031</td>
</tr>
<tr>
<td>Zhu, Chuan</td>
<td>OA02.05</td>
</tr>
<tr>
<td>Zhu, Haohua</td>
<td>EP07.03-003</td>
</tr>
<tr>
<td>Zhu, Hongge</td>
<td>EP08.02-095</td>
</tr>
<tr>
<td>Zhu, Jeffrey</td>
<td>EP02.03-011</td>
</tr>
<tr>
<td>Zhu, Jian</td>
<td>EP01.02-018, EP16.01-012, MA06.07</td>
</tr>
<tr>
<td>Zhu, Jiang</td>
<td>EP08.05-004, EP14.03-002</td>
</tr>
<tr>
<td>Zhu, Kai</td>
<td>EP09.01-002</td>
</tr>
<tr>
<td>Zhu, Lei</td>
<td>MA05.07</td>
</tr>
<tr>
<td>Zhu, Lucheng</td>
<td>EP08.01-106, EP08.02-021, EP08.02-167, EP10.01-001</td>
</tr>
<tr>
<td>Zhu, Qian</td>
<td>EP02.04-005</td>
</tr>
</tbody>
</table>
11 MAPS & FLOOR PLANS
Messe Wien Exhibition and Congress Center

HALL B | Exhibition Hall
       Refreshments
       Posters
       Delegate Lounge
       Internet Cafe
       Charging Station

HALL C | Session Rooms

Hall A

Hall B

Hall C

Hall D

Congress Center | Session Rooms
                Press & Media Room
                Sponsor Meeting Rooms

Foyer D | Registration & Coat Check

Recommended U-Bahn Station
Closed to Registration
MAPS & FLOOR PLANS

Foyer D and Hall C

FOYER D | REGISTRATION, HELP DESK, COAT & BAGGAGE CHECK
HALL C | SESSION ROOMS
VIP LOUNGE D | SPEAKER PREVIEW ROOM & LOUNGE
EXHIBIT & SUPPORTER INFORMATION
EXHIBIT & SUPPORTER INFORMATION

Conference Supporters

Diamond Level

AstraZeneca
Daiichi-Sankyo

Gold Level

AMGEN
Janssen Oncology

Silver Level

Lilly
Novartis

Bronze Level

Bristol Myers Squibb
MSD
Mirati Therapeutics
Sanofi
Destination Supporter

IASLC 2022 WCLC Official Mobile App

Charging Station Supporter

Collaborator Meeting Space Supporter

Delegate Lounge Supporter

Exhibit Information Desk Supporter

Patient Advocacy Lounge Supporter

Poster Supporter

Welcome Reception Supporter

International Lung Cancer Foundation Benefit Supporting Early Career Researchers Supporter
### EXHIBITORS LISTINGS

#### Exhibitors By Name

<table>
<thead>
<tr>
<th>SPONSOR</th>
<th>BOOTH #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amgen Inc</td>
<td>410</td>
</tr>
<tr>
<td>Amoy Diagnostics Co., Ltd.</td>
<td>307</td>
</tr>
<tr>
<td>Arcus Biosciences</td>
<td>310</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>300</td>
</tr>
<tr>
<td>Blueprint Medicines</td>
<td>313</td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td>319</td>
</tr>
<tr>
<td>Caris Life Sciences</td>
<td>503</td>
</tr>
<tr>
<td>Context Flow / RevealDx</td>
<td>404</td>
</tr>
<tr>
<td>Coreline Soft Co., Ltd.</td>
<td>408</td>
</tr>
<tr>
<td>Daiichi Sankyo, Inc.</td>
<td>200</td>
</tr>
<tr>
<td>DaSH Global</td>
<td>305</td>
</tr>
<tr>
<td>Eli Lilly And Company</td>
<td>401</td>
</tr>
<tr>
<td>Exelixis</td>
<td>406</td>
</tr>
<tr>
<td>Global Lung Cancer Coalition</td>
<td>507</td>
</tr>
<tr>
<td>GSK</td>
<td>308</td>
</tr>
<tr>
<td>IASLC</td>
<td>423</td>
</tr>
<tr>
<td>Janssen Pharmaceuticals</td>
<td>309</td>
</tr>
<tr>
<td>KRAS Kickers</td>
<td>403</td>
</tr>
<tr>
<td>Lung Ambition Alliance</td>
<td>301</td>
</tr>
<tr>
<td>Lung Cancer Europe</td>
<td>409</td>
</tr>
<tr>
<td>Medscape LLC</td>
<td>312</td>
</tr>
<tr>
<td>Merck KGaA Darmstadt, Germany</td>
<td>303</td>
</tr>
<tr>
<td>Mesothelioma UK</td>
<td>306</td>
</tr>
<tr>
<td>MeVis Medical Solutions AG</td>
<td>405</td>
</tr>
<tr>
<td>Mirati Therapeutics</td>
<td>315</td>
</tr>
<tr>
<td>MSD</td>
<td>311</td>
</tr>
<tr>
<td>Novartis</td>
<td>314</td>
</tr>
<tr>
<td>Novocure Inc.</td>
<td>201</td>
</tr>
<tr>
<td>Optellum</td>
<td>506</td>
</tr>
<tr>
<td>Pfizer</td>
<td>500</td>
</tr>
<tr>
<td>Sanofi</td>
<td>400</td>
</tr>
<tr>
<td>Sanofi Genzyme</td>
<td>400</td>
</tr>
<tr>
<td>Scanlan International, Inc.</td>
<td>402</td>
</tr>
<tr>
<td>Spectrum Pharmaceuticals, Inc.</td>
<td>504</td>
</tr>
<tr>
<td>Takeda</td>
<td>502</td>
</tr>
<tr>
<td>Thermo Fisher Scientific</td>
<td>322</td>
</tr>
<tr>
<td>Turning Point Therapeutics (TP)</td>
<td>501</td>
</tr>
<tr>
<td>Wisepress Ltd</td>
<td>600</td>
</tr>
</tbody>
</table>

#### Exhibitors By Booth Number

<table>
<thead>
<tr>
<th>SPONSOR</th>
<th>BOOTH #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daiichi Sankyo, Inc.</td>
<td>200</td>
</tr>
<tr>
<td>Novocure Inc.</td>
<td>201</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>300</td>
</tr>
<tr>
<td>Lung Ambition Alliance</td>
<td>301</td>
</tr>
<tr>
<td>Merck KGaA Darmstadt, Germany</td>
<td>303</td>
</tr>
<tr>
<td>DaSH Global</td>
<td>305</td>
</tr>
<tr>
<td>Mesothelioma UK</td>
<td>306</td>
</tr>
<tr>
<td>Amoy Diagnostics Co., Ltd.</td>
<td>307</td>
</tr>
<tr>
<td>GSK</td>
<td>308</td>
</tr>
<tr>
<td>Janssen Pharmaceuticals</td>
<td>309</td>
</tr>
<tr>
<td>Arcus Biosciences</td>
<td>310</td>
</tr>
<tr>
<td>Merck (MSD)</td>
<td>311</td>
</tr>
<tr>
<td>Medscape LLC</td>
<td>312</td>
</tr>
<tr>
<td>Blueprint Medicines</td>
<td>313</td>
</tr>
<tr>
<td>Novartis</td>
<td>314</td>
</tr>
<tr>
<td>Mirati Therapeutics</td>
<td>315</td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td>319</td>
</tr>
<tr>
<td>Thermo Fisher Scientific</td>
<td>322</td>
</tr>
<tr>
<td>Sanofi</td>
<td>400</td>
</tr>
<tr>
<td>Sanofi Genzyme</td>
<td>400</td>
</tr>
<tr>
<td>Eli Lilly And Company</td>
<td>401</td>
</tr>
<tr>
<td>Scanlan International, Inc.</td>
<td>402</td>
</tr>
<tr>
<td>KRAS Kickers</td>
<td>403</td>
</tr>
<tr>
<td>Context Flow / RevealDx</td>
<td>404</td>
</tr>
<tr>
<td>MeVis Medical Solutions AG</td>
<td>405</td>
</tr>
<tr>
<td>Exelixis</td>
<td>406</td>
</tr>
<tr>
<td>Coreline Soft Co., Ltd.</td>
<td>408</td>
</tr>
<tr>
<td>Novartis</td>
<td>409</td>
</tr>
<tr>
<td>Lung Cancer Europe</td>
<td></td>
</tr>
<tr>
<td>Amgen Inc</td>
<td>410</td>
</tr>
<tr>
<td>IASLC</td>
<td>423</td>
</tr>
<tr>
<td>Pfizer</td>
<td>500</td>
</tr>
<tr>
<td>Turning Point Therapeutics (TP)</td>
<td>501</td>
</tr>
<tr>
<td>Takeda</td>
<td>502</td>
</tr>
<tr>
<td>Caris Life Sciences</td>
<td>503</td>
</tr>
<tr>
<td>Spectrum Pharmaceuticals, Inc.</td>
<td>504</td>
</tr>
<tr>
<td>Optellum</td>
<td>506</td>
</tr>
<tr>
<td>Global Lung Cancer Coalition</td>
<td>507</td>
</tr>
<tr>
<td>Wisepress Ltd</td>
<td>600</td>
</tr>
</tbody>
</table>
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Amoy Diagnostics Co., Ltd. (SZSE: 300685) is a pioneer and globally leading company in the field of molecular diagnostics for precision oncology, focusing on companion diagnostics product development and commercialization. A rich product portfolio has been established with more than twenty products approved by China NMPA, EU authority, Japan MHLW, South Korea MFDS, etc. Patients in more than 60 countries are benefiting from AmoyDx products. With multiple technological platforms and full capability for companion diagnostics product development and commercialization, AmoyDx has become an important diagnostics partner of many pharmaceutical companies over the globe. For more information, please visit www.amoydiagnostics.com.

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. The company has six investigational medicines in clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2a. For more information about its clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company’s focus is on some of the most challenging cancers. Through persistent innovation, AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

For information, please visit our website: www.abbvie.com/our-science/therapeutic-focus-areas/oncology.html
Bayer is committed to delivering **SCIENCE FOR A BETTER LIFE** by advancing a portfolio of innovative treatments. The company has the passion and determination to develop innovative medicines that help improve and extend the lives of people living with cancer. The oncology franchise at Bayer includes six marketed products across various indications and several compounds in different stages of clinical development. Bayer focuses its research activities on first-in-class innovations across the following scientific platforms: Precision Molecular Oncology, Targeted Alpha Therapies, and Immuno-Oncology. The company’s approach to research prioritizes targets and pathways with the potential to impact the way that cancer is treated.

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide.

Blueprint Medicines is a global precision therapy company that aims to invent medicines for people with cancer and hematologic disorders.

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients’ lives through science.

Caris Life Sciences® (Caris) is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. With a primary focus on cancer, Caris’ suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit [www.CarisLifeSciences.com](http://www.CarisLifeSciences.com) or follow us on Twitter (@CarisLS).

Contextflow is your comprehensive solution for all things lung CT: ILD, COPD, and lung cancer. Its clinical decision support system (SEARCH Lung CT), offers quantitative and qualitative analysis of 8 key image patterns and lung nodule detection, segmentation and quantification. By integrating new technology from partner RevealDx, nodules can be further characterized, detecting lung cancer earlier and reducing costs (publication forthcoming).

Contextflow SEARCH Lung CT includes a TIMELINE feature that even quantifies and visualizes nodules over time, allowing physicians to follow treatment progress easily and efficiently. Fully integrated into the radiologist’s workflow, our preliminary research shows average reading time is 31% shorter when Contextflow SEARCH Lung CT is available for use (publication forthcoming). See beyond a single case at [contextflow.com](http://contextflow.com).
Coreline Soft Ltd. was founded in the year 2012 and has its headquarters in Seoul, South Korea.

In September 2020, we founded Coreline Europe in Frankfurt, Germany in order to support the fast-growing European business. Coreline develops AI-based thorax specialized imaging diagnosis package, lung cancer screening (LCS), COPD quantification, and coronary artery calcification (CAC). These modules, so-called “Big3”, cover the three big diseases of thoracic imaging.

More complex lung modules are part of our portfolio as well, such as texture analysis for ILD/IPF and unique pneumonia detection software including COVID-19. Coreline became an official solution provider of 4-IN-THE-LUNG-RUN (4ITLR) project, initiated and led by the Nelson Team (Erasmus MC and IDNA in the Netherlands). 4-IN-THE-LUNG-RUN has set up the goal to establish strategies that lead to cost-efficient lung cancer screening within reach for Europe. Coreline also became the official solution provider for the largest German LCS Study, HANSE Study in Germany initiated by Medizinische Hochschule Hannover- MHH. Besides MHH, there are two additional hospitals taking part in this study: Lungenclinic Grosshansdorf and University Hospital Schleswig-Holstein am Campus Lübeck.

Another remarkable reference where Coreline’s software was chosen is K-LUKAS, Korean Lung Cancer Screening Project. Korea is the second country, followed by USA to adopt the national lung cancer screening program. The Full-Out Screening, started in 2019, involves 270 thousand examinees per year and 300 hospitals.

Most recent achievement for Coreline is beginning to work for the Italian Lung Screening Project (ILSP). Coreline’s goal is not only to contribute to the field of treatment and management, but ideally to the area of prevention and diagnosis also.

With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.”

DaSH Global supports the drug approval process through the power of delivering cost-efficient, timely and precise evidence from unique real-world research methodologies. Specialising in MedTech strategies & products through our vision of building collaborative ‘disruptive’ transformational research platforms from ‘joined up’ health care.

DaSH Global has launched the Digital Assessment Xchange (DAX) research platform in Lung Cancer & Mesothelioma

www.dash-global.com
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world.

To learn more about Lilly’s commitment to people with cancer, please visit www.LillyOncology.com.

Exelixis is an oncology-focused biotechnology company striving to accelerate discovery, development, and commercialization of new products for difficult-to-treat cancers. Clinical development focuses on continued evaluation of approved products and investigational pipeline. Exelixis continues to invest in expansion of our product pipeline through internal drug discovery and strategic business development opportunities.

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.

Roche is also the world leader in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.

For more information, please visit roche.com.

The Global Lung Cancer Coalition promotes global understanding of the burden of lung cancer and the right of patients to effective early detection, better treatment and supportive care. Serving as the international voice of lung cancer patients, the Global Lung Cancer Coalition is committed to improving disease outcomes for all.

GSK is focused on maximising patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, cell therapy, tumor cell targeting therapies and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilising modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination. International Association for the Study of Lung Cancer

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association’s membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
At Janssen Oncology, our purpose is to make cancer a manageable and, ultimately, curable condition. We understand that the power to change the lives of those living with cancer begins with a very considered step forwards. Whether it’s finding a novel solution, a new indication approval, or even just reaching one more patient. That’s The Power of Purpose™.

KRAS Kickers is a patient founded organization that connects people to current research, resources, and community to kick cancer’s KRAS. KRAS Kickers operates under the Dusty Joy Foundation, a 501(c)(3) nonprofit organization with the mission of advancing education, early detection, optimal care, and empathy to people impacted by lung cancer and other cancers triggered by specific biomarkers.

Terri Conneran, who has been battling lung cancer since 2017, founded KRAS Kickers to create a network for patients and families in search of KRAS information and support. KRAS Kickers focuses on people with any KRAS oncogene cancer including patients, survivors, and all who care. Within KRAS Kickers, members engage with leading doctors, researchers, and advocates, build community, and share their stories to give hope to all with a KRAS biomarker.

The KRAS Kickers community believes that hope shared is hope multiplied. The organization actively monitors and shares KRAS-related research developments, information, and clinical trials to help patients find answers, explore treatment options, and connect with others on a similar journey.

To learn more about KRAS Kickers, visit KRASKickers.org, connect on Facebook, or join the conversation on Twitter.

LuCE is the voice of Europeans impacted by lung cancer with a core purpose to Represent common interests of the lung cancer patient community in Europe.

We Collaborate with members and other stakeholders to Strengthen the voice of the lung cancer patient community and work to destigmatising the disease to ensure that those impacted by lung cancer get the care they need to achieve the best possible outcomes. We Act to address common problems by mobilising and leading collective action together with LuCE members, empowering them to ensure strong and effective lung cancer patient advocacy and to Amplify the patient voice by collaborating with all stakeholders with the power to improve the lives of people affected by lung cancer across Europe.

As a community we prioritise the needs and interests of those living with lung cancer, by working together to drive the changes needed to improve lung cancer outcomes. Our solidarity creates a strong community that is committed to helping each other achieve our common goals and to be as representative as possible of the European lung cancer patient community.

Our organizational values ensure that we work in a professional, respectful, ethical manner with integrity and are accountable for all that we do.
Medscape is the leading source of clinical news, health information, medical education and point-of-care tools for health care professionals across more than 30 specialty areas. Medscape offers specialists, primary care physicians, and other health professionals the most robust and integrated medical information and educational tools.

Merck KGaA, Darmstadt, Germany is a science-led organization dedicated to delivering transformative medicines with the goal of making a meaningful difference in the lives of people affected by cancer. Our oncology research efforts aim to leverage our synergistic portfolio in oncogenic pathways, immuno-oncology, and DNA Damage Response (DDR) to tackle challenging tumor types in gastrointestinal, genitourinary, and thoracic cancers. Our curiosity drives our pursuit of treatments for even the most complex cancers, as we work to illuminate a path to scientific breakthroughs that transform patient outcomes. Learn more at www.merckgrouponcology.com.

Mesothelioma UK is the national charity for anyone affected by mesothelioma. We exist to support people with mesothelioma to live better and live longer and to prevent mesothelioma happening to future generations. We will do this by advocating for better treatment and care, enhancing quality of life, supporting research and amplifying the patient’s voice.

The focus of our charitable activity since our foundation has been to provide access to specialist nurses at the point of need, in local hospitals across the UK. Mesothelioma Clinical Nurse Specialists provide a large range of benefits including; specialist expertise available to patients, increased access to clinical trials, an increase in the number of patients accessing treatment, a lower rate of unplanned admissions, better management of symptoms and an overall increase in the quality of life for patients.

At Mesothelioma UK, we also provide a number of other services to support anyone affected by mesothelioma. These include a Freephone Support Line, three specialist benefits advisors, a travel grant to support the cost of accessing clinical trials, a dedicated research centre at Sheffield University and a comprehensive information service accredited by the Patient Information Forum. Services such as this helped us directly support 1900 patients or carers in 2020/21 and reach a further ~500 people indirectly.

We understand that people diagnosed with mesothelioma feel very strongly about preventing future cases. That is why we work closely with partner organisations to raise awareness of asbestos and to shine a light on the devastating impact of mesothelioma.

MeVis Medical Solutions AG develops software for the analysis and processing of medical imaging data. Focus is the image-based early detection of cancer. Its state-of-the-art software solutions support the image-based early detection of lung cancer with dedicated reading software and how it can be used in lung cancer screening settings.
Mirati Therapeutics, Inc. is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer.

At MSD, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, MSD is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields, TTFields. TTFields are electric fields that disrupt cancer cell division. Novocure’s commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Optellum is a commercial-stage lung health company providing Artificial Intelligence decision support software that assists physicians in early diagnosis and optimal treatment for their patients. The company was founded so that every lung disease patient is diagnosed and treated at the earliest possible stage, when chances of cure are the highest. Optellum’s roadmap extends beyond lung cancer diagnosis and treatment to other deadly diseases of the lungs, including interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD). Optellum has headquarters at the Oxford Centre for Innovation in Oxford, United Kingdom and a U.S. office at the Texas Medical Center in Houston, TX. Optellum has received grant funding from InnovateUK, the National Institute for Health Research (NIHR), the NHS AI Lab, The Accelerated Access Collaborative (AAC), MedCity and EIT Health. For more information, visit optellum.com, or follow us LinkedIn and Twitter.
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications. Going forward, we are focused on delivering a next wave of breakthroughs in breast cancer, genitourinary cancer, hematology and precision medicine.

RMEI Medical Education, LLC (RMEI) is an established US-based provider of accredited continuing education, founded in 2005. With an emphasis on rigorous learner data analytics to inform course design, delivery, and assessment, RMEI works to elevate the dialogue on what makes for effective education. By creating original and evidence-based educational designs, such as Clinical Convergence®, Clinical Consults®, and the Care Team Forum®, RMEI seeks to foster greater collaboration within multidisciplinary care teams and a stronger commitment to patient engagement. RMEI is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Sanofi’s Specialty Care business is committed to meeting significant unmet medical needs. In oncology, we are building on a rich legacy with a strong pipeline and a continued commitment to contribute meaningful solutions for patients with cancer. Through rigorous drug discovery and development rooted in cutting-edge science and innovative technologies, we are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at www.sanofi.com.

Since 2007, Sanofi and Regeneron have collaborated to help people with conditions that are often difficult to diagnose and treat, using innovative technology platforms. Sanofi is an innovative global healthcare company that provides potentially life-changing treatment options and life-saving vaccine protection to millions of people globally. Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions.

Celebrating 100 Years of Excellence ...and Our Journey Continues! The highest quality surgical instruments have been designed and manufactured by the Scanlan Family since 1921.

Experience the Scanlan Difference at Exhibit #402

Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit www.sppirx.com.
Takeda Oncology is structured to ensure a tight connection from research to development to commercialization and rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to market. Built on a legacy foundation and structured for agility, our leaders have proven experience to drive future growth.

We've demonstrated leadership in the treatment of hematologic cancers and solid tumors, and we're now leveraging that expertise to advance cutting-edge science through multiple platforms, partnerships and therapeutic approaches. We are focused on collaborating with leading scientific teams around the globe to accelerate remarkable innovation, including by leveraging the power of innate immunity to enhance and broaden the impact of immunotherapy.

We complement our deep in-house expertise with a network of symbiotic external partnerships to unlock the most promising science wherever it emerges. We fuel our relationships with academic, biotechnology and pharmaceutical partners with mutual respect, shared knowledge, scientific rigor and agility to find the best way to attack cancer. We are structured to ensure a tight connection from research to development to commercialization to rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to patients.

Takeda Oncology: We aspire to cure cancer with inspiration from patients and innovation from everywhere.

For more information, visit www.takedaoncology.com

Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner, and safer. Our clinical next-generation sequencing (NGS) division focuses on delivering simple, fast and cost effective NGS technology for a range of applications. We are enabling precision oncology with easily implementable Oncomine™ assays. Our latest development, the Ion Torrent™ Genexus™ system, provides a highly automated end-to-end workflow allowing laboratories to deliver NGS results in as little as one day.

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational drugs designed to address key limitations of existing cancer therapies. Its lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. The company’s current pipeline of drug candidates also includes elzovantinib, targeting MET, CSF1R and SRC; TPX-0046, targeting RET; and TPX-0131, a next-generation ALK inhibitor. To learn more, visit www.tptherapeutics.com.

Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.
13 | INDUSTRY SYMPOSIAS
**INDUSTRY SYMPOSIA - SATURDAY, AUGUST 6, 2022**

**Saturday, August 6, 2022**

**10:45 - 11:45**
**IS01 Industry Sponsored Symposium by Abbvie Global: c-Met Dysregulation: Targeted Agents and Their Emerging Role in Advanced NSCLC**

**HALL C7**

Chair: Jair Bar, Israel

**10:45 - 10:50**
**IS01.01 Introduction and Opening Remarks**
Jair Bar, Israel

**10:50 - 11:05**
**IS01.02 c-Met Testing and Challenges Associated with Biomarker Testing in NSCLC Patients**
Jair Bar, Israel

**11:05 - 11:20**
**IS01.03 Role of c-MET Dysregulation in NSCLC**
Shobhit Baijal, United Kingdom

**11:20 - 11:35**
**IS01.04 Clinical Data Available on Agents Targeting c-Met Dysregulation in NSCLC**
Alona Zer, Israel

**11:35 - 11:40**
**IS01.05 Live Q&A**

**11:40 - 11:45**
**IS01.06 Conclusion and Evaluation**
Jair Bar, Israel

**12:00 - 13:00**
**IS03 Industry Sponsored Symposium by Mirati Therapeutics: Future Directions in NSCLC: Tailoring Treatment Options**

**HALL C2**

Chair: David Planchard, France

**12:00 - 12:05**
**IS03.01 Welcome and Program Overview**
Barbara Melosky, Canada

**12:05 - 12:20**
**IS03.02 The Changing Landscape in NSCLC**
Riyaz Shah, United Kingdom

**12:20 - 12:35**
**IS03.03 New Approaches for Overcoming CPI Resistance in NSCLC**
Giorgio Scagliotti, Italy

**12:35 - 12:50**
**IS03.04 Panel Discussion: How to Break New Ground with Anti-TIGIT Combinations**

**12:50 - 13:00**
**IS03.05 Q&A Session**

**13:15 - 14:15**
**IS05 Industry Sponsored Symposium by Merck KGaA Darmstadt: Decisive Moments in the Treatment of MET Exon 14 Skipping NSCLC**

**HALL C7**

Chair: Sanjay Popat, United Kingdom

**13:15 - 13:20**
**IS05.01 A Moment to Welcome You**
Sanjay Popat, United Kingdom

**13:20 - 13:25**
**IS05.02 Take A Moment to Consider Identification and Treatment**
Sanjay Popat, United Kingdom, Sonja Loges, Germany, Paul Paik, United States, Enriqueta Felip, Spain

**12:30 - 12:50**
**IS03.04 Targeting KRAS: Novel Opportunities for KRASG12C-Driven NSCLC**
Marina Garassino, United States

**12:55 - 13:00**
**IS03.05 Summary and Q&A**
13: 25 - 13:40
IS05.03 A Moment of Clarity: Has Our VISION1 for Metex14 Skipping Become a Reality?
Sanjay Popat, United Kingdom, Sonja Loges, Germany, Paul Paik, United States, Enriqueta Felip, Spain

13:40 - 13:55
IS05.04 Seize The Moment: The Benefits of Early Treatment
Sanjay Popat, United Kingdom, Sonja Loges, Germany, Paul Paik, United States, Enriqueta Felip, Spain

13:55 - 14:10
IS05.05 Make Every Moment Matter: Optimising Treatment
Sanjay Popat, United Kingdom, Sonja Loges, Germany, Paul Paik, United States, Enriqueta Felip, Spain

14:10 - 14:15
IS05.06 A Moment to Reflect on METex14 Skipping
Sanjay Popat, United Kingdom

13:15 - 14:15
IS06 Industry Sponsored Symposium by Takeda: Precision Medicine in Lung Cancer: Learnings from Established and Emerging Targets

14:30 - 15:30
IS07 Satellite CME Symposium by Liberum IME, supported by Bayer, Eli Lilly and Illumina: Optimizing Biomarker-Driven Therapy in NSCLC
Chair: Fernando López-Ríos, Spain

14:30 - 14:35
IS07.01 Welcome, Pre-activity Information & Pre-assessment
Fernando López-Ríos, Spain

14:35 - 14:45
IS07.02 Implementation and Interpretation of Biomarker Testing in NSCLC
Fernando López-Ríos, Spain

14:45 - 14:55
IS07.03 Biomarker-driven Approaches: Combined Prevalence and Individual Outcomes
Robin Cornelissen, Netherlands

14:55 - 15:00
IS07.04 How to Use Classroom to Clinic™
Fernando López-Ríos, Spain

15:00 - 15:15
IS07.05 Workshop: Applying Guideline Best Practice to Case Studies
Fernando López-Ríos, Spain

15:15 - 15:18
IS07.06 Post-assessment and Commitment to Change
Fernando López-Ríos, Spain

14:30 - 15:30
IS08 Industry Sponsored Symposium by Pfizer: Is it Time to Raise the Bar for ALK+ NSCLC Patients?
Chair: Justin Gainor, United States

14:30 - 14:35
IS08.01 Welcome and Introduction
Justin Gainor, United States

14:35 - 14:45
IS08.02 New Data and Updated Expectations for First-Line Therapy
Alessandra Bearz, Italy
14:45 - 14:55
IS08.03 Managing AEs and Keeping Patients on Treatment
Rosario Garcia Campelo, Spain

14:55 - 15:05
IS08.04 What Next? Options After Progression on 2nd- and 3rd-Generation TKIs
Alessandra Bearz, Italy

15:05 - 15:15
IS08.05 The Future of ALK+ NSCLC
Justin Gainor, United States

15:15 - 15:25
IS08.06 Live Q&A

15:25 - 15:30
IS08.07 Summary and Close
Justin Gainor, United States

15:45 - 16:45
IS09 Industry Sponsored Symposium by AstraZeneca: Embarking on The Next Chapter in SCLC: Challenges and Opportunities
Chair: Lauren Byers, United States

15:45 - 15:50
IS09.01 Introduction
Lauren Byers, United States

15:50 - 16:05
IS09.02 Current Treatment Landscape for ES-SCLC and the Unmet Need
Andrea Ardizzoni, Italy

16:05 - 16:25
IS09.03 Panel Discussion: Improving Outcomes for Patients with SCLC – Today and Tomorrow
Lauren Byers, United States, Andrea Ardizzoni, Italy, Taofeek Owonikoko, United States, Keunchil Park, South Korea

16:25 - 16:40
IS09.04 Audience Q&A

16:40 - 16:45
IS09.05 Closing Remarks
Lauren Byers, United States
**3:00 PM - 4:00 PM**

**IS11 Industry Sponsored Symposium by Amgen Inc.: Driving Advancements in the Treatment of Lung Cancer**

**Hall C8**

Chair: Luis Paz-Ares, Spain

13:15 - 13:30

IS11.01 Welcome and Introduction to Innovative Treatments for New Targets in Lung Cancer

Luis Paz-Ares, Spain

13:30 - 14:00

IS11.02 A Step Forward: KRASG12C Inhibitors in NSCLC Today and in the Future

Natasha Leighl, Canada

14:00 - 14:15

IS11.04 Panel Discussion and Q&A

**13:15 - 14:15**

**IS12 Industry Sponsored Symposium by AstraZeneca: Expanding Horizons in Metastatic NSCLC: Unmet Need and Future Directions**

**Hall C7**

Chair: John Heymach, United States

13:15 - 13:20

IS12.01 Welcome and Introduction

John Heymach, United States

13:20 - 13:35

IS12.02 Biomarker Identification of Hard-to-treat Patients: Shining a Spotlight on Unmet Need

Niels Reinmuth, Germany

13:35 - 13:50

IS12.03 Seeing the Unseen: Techniques and Practical Strategies for Broad Molecular Profiling

Elena Guerini-Rocco, Italy

13:50 - 14:15

IS12.04 Panel Discussion and Q&A

**13:15 - 14:15**

**IS13 Industry Sponsored Symposium by Janssen Pharmaceuticals: Expanding Horizons for the Targeted Management of EGFR-Mutant NSCLC**

**Hall C3**

Chair: Martin Reck, Germany

13:15 - 13:17

IS13.01 Welcome and Introduction

Martin Reck, Germany

13:17 - 13:32

IS13.02/IS13.03 What’s New in Molecular Diagnostics for EGFR-Mutant NSCLC?

Umberto Malapelle, Italy, Sabine Merkelbach-Bruse, Germany

13:32 - 13:47

IS13.04 EGFR Exon 20 Insertion Mutations: A New Target for an Old Mutation

Maximilian Hochmair, Austria

13:47 – 14:02

IS13.04 Novel Approaches in Treatment-Resistant Advanced EGFR-Mutant NSCLC

Jordi Remon, Spain

14:02 – 14:12

IS13.06 Live Q&A

14:12 – 14:15

IS13.07 Key Learnings and Closing Remarks

Martin Reck, Germany

**18:00 - 19:00**

**IS14 - Industry Sponsored Symposium by RMEI, Supported by Regeneron and Sanofi: Harnessing the Full Potential of Immunotherapy in Frontline Treatment of Locally Advanced or Metastatic NSCLC**

**Hall C7**

Chair: Jared Weiss, United States

18:00 - 18:05

IS14.01 Opening Ceremonies

Jared Weiss, United States

18:05 - 18:20

IS14.02 Use of Biomarker Testing in Advanced NSCLC

Aleš Ryška, Czech Republic

18:20 - 18:35

IS14.03 Selecting Frontline Immunotherapy in Advanced NSCLC

Jared Weiss, United States

18:35 - 18:50

IS14.04 Managing Immunotherapy-Related Adverse Events in NSCLC

Mihaela Aldea, France

18:50 - 19:00

IS14.05 Closing Ceremonies

Jared Weiss, United States
Monday, August 8, 2022

13:30 - 14:30
IS20 Industry Sponsored Symposium by AstraZeneca: Current and Future Management of Patients with Advanced EGFRm NSCLC Progressing on Third-generation EGFR-TKIs

Chair: Pasi Jänne, United States

13:30 - 13:33
IS20.01 Welcome and Introductions
Pasi Jänne, United States

13:33 - 13:43
IS20.02 Current Management of Patients Progressing on Third-Generation EGFR-TKIs
Myung-Ju Ahn, South Korea

13:43 - 13:58
IS20.03 Evolving Treatment Landscape for Patients with Advanced EGFRm NSCLC and c-MET Driven Resistance to Third-Generation EGFR-TKIs
Pasi Jänne, United States

13:58 – 14:13
IS20.04 Optimal Biomarker Testing to Identify Patients with MET-Driven Resistance
Michelle Shiller, United States

14:13 – 14:28
IS20.05 Panel Discussion and Live Q&A

14:28 – 14:30
IS20.06 Summary and Close
Pasi Jänne, United States

13:30 - 14:30
IS21 Industry Sponsored Symposium by Daiichi Sankyo, Inc.: The Expanding Toolbox: Key Updates for ADCs in Lung Cancer

Chair: Michael Thomas, Germany

13:30 - 13:35
IS21.01 Welcome and Introductions
Federico Cappuzzo, Italy

13:35 - 13:50
IS21.02 Focusing on the Challenge of Squamous Lung Cancer
Jürgen Wolf, Netherlands

13:50 - 14:05
IS21.03 Immunotherapy Outcomes for Advanced Squamous Cancers of the Lung
Johan Vansteenkiste, Belgium

14:05 - 14:30
IS21.04 Case Study Panel Discussion, Ask the Faculty and Concluding Remarks

18:00 - 19:00
IS23 Satellite CME Symposium by Medscape Oncology Global, supported by Daiichi Sankyo: The Potential of Antibody-Drug Conjugates in Non-Small Cell Lung Cancer - From Mechanism to Action

Chair: Hossein Borghaei, United States
18:00 - 18:18
IS23.02 Mechanism of Action and Targets of ADCs in NSCLC
Antonio Passaro, Italy

18:18 - 18:35
IS23.03 ADCs in NSCLC: What Do the Data Show?
Hossein Borghaei, United States

18:35 - 18:50
IS23.04 ADCs in the Clinic: Challenges and Perspectives
Ticiana Leal, United States

18:50 - 18:59
IS23.05 Audience Q&A

18:59 - 19:00
IS23.06 Concluding Remarks
Hossein Borghaei, United States

18:00 - 19:00
IS24 Industry Sponsored Symposium by MSD: New Frontiers in the Management of NSCLC

HALL C7 | LIGHT REFRESHMENTS PROVIDED

Chair: Solange Peters, Switzerland

18:00 - 18:05
IS24.01 Welcome and Introductions
Solange Peters, Switzerland

18:05 - 18:15
IS24.02 Evolving Treatment Landscape in Metastatic NSCLC
Solange Peters, Switzerland

18:15 - 18:30
IS24.03 Emergence of Immuno-Oncology in Early Stage Operable NSCLC
Benjamin Besse, France

18:30 - 18:45
IS24.04 A Surgeon’s Perspective on Treatment in Early-Stage Operable NSCLC
David J. Finey, United States

18:45 - 18:59
IS24.05 Panel Discussion and Q&A

18:59 - 19:00
IS24.06 Closing Remarks
Solange Peters, Switzerland
The Queen, in chess, holds the most versatile range of possible strategic moves.

Solid tumor treatment calls for an innovative versatile modality. TTFields are electric fields that disrupt multiple cellular processes critical for cancer cell viability and tumor progression.

Please visit tumortreatingfieldstherapy.com to discover more.